U.S. patent application number 15/423447 was filed with the patent office on 2017-05-25 for cyclic thienouracil-carboxamides and use thereof.
The applicant listed for this patent is BAYER PHARMA AKTIENGESELLSCHAFT. Invention is credited to Martina DELBECK, Michael HARTER, Bernd KALTHOF, Raimund KAST, Niels LINDNER, Klemens LUSTIG, Frank SU MEIER, Pierre WASNAIRE.
Application Number | 20170145029 15/423447 |
Document ID | / |
Family ID | 51655757 |
Filed Date | 2017-05-25 |
United States Patent
Application |
20170145029 |
Kind Code |
A1 |
HARTER; Michael ; et
al. |
May 25, 2017 |
CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF
Abstract
The present application relates to novel
2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxamide
derivatives ("thienouracil"-carboxamides), to processes for their
preparation, to their use alone or in combinations for the
treatment and/or prevention of diseases and to their use for the
preparation of medicaments for the treatment and/or prevention of
diseases, in particular for the treatment and/or prevention of
pulmonary and cardiovascular disorders.
Inventors: |
HARTER; Michael;
(Leverkusen, DE) ; DELBECK; Martina;
(Heiligenhaus, DE) ; KALTHOF; Bernd; (Wuppertal,
DE) ; LUSTIG; Klemens; (Wuppertal, DE) ;
LINDNER; Niels; (Wuppertal, DE) ; KAST; Raimund;
(Wuppertal, DE) ; WASNAIRE; Pierre; (Dusseldorf,
DE) ; SU MEIER; Frank; (Munchen, DE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
BAYER PHARMA AKTIENGESELLSCHAFT |
Berlin |
|
DE |
|
|
Family ID: |
51655757 |
Appl. No.: |
15/423447 |
Filed: |
February 2, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15027519 |
Apr 6, 2016 |
9604996 |
|
|
PCT/EP2014/071113 |
Oct 2, 2014 |
|
|
|
15423447 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 9/00 20180101; C07D
495/04 20130101; A61K 45/06 20130101; A61P 7/06 20180101; A61K
31/519 20130101; A61P 9/12 20180101; A61P 11/06 20180101; C07D
519/00 20130101; A61P 11/00 20180101; A61P 11/08 20180101 |
International
Class: |
C07D 495/04 20060101
C07D495/04; A61K 31/519 20060101 A61K031/519; C07D 519/00 20060101
C07D519/00; A61K 45/06 20060101 A61K045/06 |
Foreign Application Data
Date |
Code |
Application Number |
Oct 7, 2013 |
EP |
13187487.7 |
Jan 24, 2014 |
EP |
14152518.8 |
Claims
1-12. (canceled)
13. A method of making the compound of formula (I), ##STR00408## in
which R.sup.1 represents hydrogen, methyl or ethyl, where methyl
and ethyl may be substituted up to three times by fluorine, R.sup.2
represents methyl, ethyl, n-propyl, isopropyl, cyclopropyl,
cyclopropylmethyl, 2,2-difluorovinyl, 3,3-difluoroallyl or
propargyl or represents a group of the formula ##STR00409## in
which * denotes the point of attachment to the CH.sub.2 group, Ar
represents phenyl or 5- or 6-membered heteroaryl having up to two
ring nitrogen atoms, where phenyl and heteroaryl may be mono- or
disubstituted by identical or different radicals selected from the
group consisting of fluorine, chlorine, methyl, trifluoromethyl,
methoxy and trifluoromethoxy, R.sup.4A represents hydrogen,
fluorine or methyl, R.sup.4B represents hydrogen, fluorine, methyl,
trifluoromethyl, hydroxy or methoxy, or R.sup.4A and R.sup.4B are
attached to one another and together with the carbon atom to which
they are attached form a cyclopropyl or cyclobutyl ring, R.sup.8
represents methyl or trifluoromethyl, and R.sup.9A and R.sup.9B
independently of one another represent hydrogen, methyl or
trifluoromethyl, R.sup.3 represents (C.sub.1-C.sub.6)-alkyl,
(C.sub.2-C.sub.6)-alkenyl, (C.sub.3-C.sub.7)-cycloalkyl or
[(C3-CT)-cycloalkyl]methyl, where alkyl and alkenyl may be
substituted up to three times and cycloalkyl may be substituted up
to two times by fluorine and where in alkyl and cycloalkyl up to
two CH.sub.2 groups may be replaced by --O-- or --S--, with the
proviso that there are at least two carbon atoms between such
heteroatoms including the uracil N.sup.1-atom, and the ring A
represents a mono- or bicyclic aza heterocycle of the formula
##STR00410## in which ** denotes the point of attachment to the
carbonyl group, R.sup.5 represents hydrogen, methyl,
trifluoromethyl, hydroxymethyl or ethyl, R.sup.6A and R.sup.6B each
independently of one another represent hydrogen, methyl or ethyl,
R.sup.10A represents methyl, ethyl, hydroxy or methoxy, and
R.sup.10B represents hydrogen, methyl or ethyl, and their salts,
solvates and solvates of the salts; characterized in that either
[A-1] a compound of the formula (II) ##STR00411## in which R.sup.1
and R.sup.2 have the meanings given above and T.sup.1 represents
(C.sub.1-C.sub.4)-alkyl or benzyl is alkylated in the presence of a
base with a compound of the formula (III) ##STR00412## in which
R.sup.3 has the meaning given above and X.sup.1 represents a
leaving group, for example chlorine, bromine, iodine, mesylate,
triflate or tosylate, to give a compound of the formula (IV)
##STR00413## in which R.sup.1, R.sup.2, R.sup.3 and T.sup.1 have
the meanings given above, then the ester radical T.sup.1 is cleaved
off and the carboxylic acid of the formula (V) obtained in this
manner ##STR00414## in which R.sup.1, R.sup.2 and R.sup.3 have the
meanings given above is then coupled with activation of the
carboxyl function with an amine of the formula (VI) ##STR00415## in
which the ring A has the meaning given above, or [A-2] the compound
of the formula (II) ##STR00416## in which R.sup.1, R.sup.2 and
T.sup.1 have the meanings given above is initially converted by
cleavage of the ester radical T.sup.1 into the carboxylic acid of
the formula (VII) ##STR00417## in which R.sup.1 and R.sup.2 have
the meanings given above, then coupled with activation of the
carboxyl function with an amine of the formula (VI) ##STR00418## in
which the ring A has the meaning given above to give a compound of
the formula (VIII) ##STR00419## in which R.sup.1, R.sup.2 and the
ring A have the meanings given above and this is then alkylated in
the presence of a base with a compound of the formula (III)
##STR00420## in which R.sup.3 and X.sup.1 have the meanings given
above or [B] initially an N.sup.3 protected compound of the formula
(IX) ##STR00421## in which R.sup.1 and T.sup.1 have the meanings
given above and R.sup.7A and R.sup.7B independently of one another
represent hydrogen or methoxy is alkylated in the presence of a
base with a compound of the formula (III) ##STR00422## in which
R.sup.3 and X.sup.1 have the meanings given above to give a
compound of the formula (X) ##STR00423## in which R.sup.1, R.sup.3,
R.sup.7A, R.sup.7B and T.sup.1 have the meanings given above, the
N.sup.3-benzyl group and the ester radical T.sup.1 are then cleaved
off simultaneously by treatment with a strong Lewis acid such as
aluminium trichloride, the carboxylic acid of the formula (XI)
obtained in this manner ##STR00424## in which R.sup.1 and R.sup.3
have the meanings given above, is then coupled with activation of
the carboxyl function with an amine of the formula (VI)
##STR00425## in which the ring A has the meaning given above to
give a compound of the formula (XII) ##STR00426## in which R.sup.1,
R.sup.3 and the ring A have the meanings given above and the latter
is then either reacted (a) in the presence of a base with a
compound of the formula (XIII) ##STR00427## in which R.sup.2 has
the meaning given above and X.sup.2 represents a leaving group, for
example chlorine, bromine, iodine, mesylate, triflate or tosylate,
or (b) in the presence of a suitable phosphine and an
azodicarboxylate with a compound of the formula (XIV) ##STR00428##
in which R.sup.2 has the meaning given above, and the compounds of
the formula (I) prepared in this manner are optionally converted
with the appropriate (i) solvents and/or (ii) acids into their
solvates, salts and/or solvates of the salts.
14. A method of making the compound of the formula (II-C)
##STR00429## in which R.sup.2 has the meaning given in claim 13
R.sup.1F represents difluoromethyl or trifluoromethyl and T.sup.1
represents (C.sub.1-C.sub.4)-alkyl or benzyl, characterized in that
a compound of the formula (XIX) ##STR00430## in which R.sup.2 has
the meaning given above, is converted with phosphorus oxychloride
into a compound of the formula (XXIV) ##STR00431## in which R.sup.2
has the meaning given above, then in the presence of excess
pyridine is reacted with an anhydride of the formula (XXV)
##STR00432## in which R.sup.1F has the meaning given above to give
a betaine compound of the formula (XXVI) ##STR00433## in which
R.sup.1F and R.sup.2 have the meanings given above and these are
then condensed in the presence of a base with an
.alpha.-mercaptoacetic ester of the formula (XXI) ##STR00434## in
which T.sup.1 has the meaning given above to give the compound
(II-C).
15. A method for treatment and/or prevention of diseases using the
compound of claim 13.
16. A method for the treatment and/or prevention of idiopathic
pulmonary fibrosis, pulmonary hypertension, Bronchiolitis
obliterans syndrome, chronic-obstructive pulmonary disease, asthma,
cystic fibrosis, myocardial infarction, heart failure and sickle
cell anemia using the compound of claim 13.
17. A method of making a medicament for the treatment and/or
prevention of idiopathic pulmonary fibrosis, pulmonary
hypertension, Bronchiolitis obliterans syndrome,
chronic-obstructive pulmonary disease, asthma, cystic fibrosis,
myocardial infarction, heart failure and sickle cell anemia using
the compound of claim 13.
18. A medicament comprising the compound of claim 13 in combination
with one or more inert, nontoxic, pharmaceutically suitable
excipients.
19. A medicament comprising the compound of claim 13 in combination
with one or more further active compounds selected from the group
of PDE 5 inhibitors, sGC activators, sGC stimulators, prostacyclin
analogs, endothelin antagonists, antifibrotic agents, the
antiinflammatory, immunomodulating, immunosuppressive agents,
cytotoxic agents, and signal transduction cascade-inhibiting
compounds.
20. A method for the treatment and/or prevention of idiopathic
pulmonary fibrosis, pulmonary hypertension, Bronchiolitis
obliterans syndrome, chronic-obstructive pulmonary disease, asthma,
cystic fibrosis, myocardial infarction, heart failure and sickle
cell anemia using the medicament of claim 18.
21. A method for the treatment and/or prevention of idiopathic
pulmonary fibrosis, pulmonary hypertension, Bronchiolitis
obliterans syndrome, chronic-obstructive pulmonary disease, asthma,
cystic fibrosis, myocardial infarction, heart failure and sickle
cell anemia in humans and animals by administration of an effective
amount of the compound of claim 13.
22. A method for the treatment and/or prevention of idiopathic
pulmonary fibrosis, pulmonary hypertension, Bronchiolitis
obliterans syndrome, chronic-obstructive pulmonary disease, asthma,
cystic fibrosis, myocardial infarction, heart failure and sickle
cell anemia in humans and animals by administration of an effective
amount of the medicament of claim 18.
Description
[0001] The present application relates to novel
2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxamide
derivatives ("thienouracil"-carboxamides), to processes for their
preparation, to their use alone or in combinations for the
treatment and/or prevention of diseases and to their use for the
preparation of medicaments for the treatment and/or prevention of
diseases, in particular for the treatment and/or prevention of
pulmonary and cardiovascular disorders.
[0002] The endogenous purine nucleoside adenosine is formed
ubiquitously and modulates, as important signal molecule, a large
number of physiological and pathophysiological processes. Most of
it is formed during the intra- and extracellular degradation of
adenine nucleotides, and a smaller amount is formed during the
intracellular hydrolysis of S-adenosyl homocysteine. Under
physiological conditions, extracellular adenosine can be
re-phosphorylated by adenosine kinase to adenosine monophosphate
(AMP) or rearranged by adenosine deaminase to inosine. The
extracellular concentration is between 30 and 300 nM. As a result
of tissue damage caused, for example, by hypoxia, in inflammation
reaction and during oxidative stress, there is an increased
formation and accumulation of adenosine, such that the
extracellular concentration may increase to up to 15 .mu.M.
[0003] The biological actions of adenosine are mediated via
G-protein-coupled receptors located at the plasma membrane.
Currently, four adenosine receptor subtypes have been demonstrated:
A1 adenosine receptor (A1R), A2a adenosine receptor (A2aR), A2b
adenosine receptor (A2bR) and A3 adenosine receptor (A3R). From
among the adenosine receptors mentioned above, the A2b receptor has
the weakest affinity for adenosine. For this reason, in contrast to
the other adenosine receptors, it is not activated under normal
physiological conditions. A1 and A3 receptors are coupled to Gi
proteins which inhibit adenylate cyclase, whereas A2a and A2b
receptors, via Gs proteins, stimulate adenylate cyclase, thus
causing an intracellular increase of cAMP. Via Gq proteins, both
the A1, the A3 and the A2b receptor activate phospholipase C which
cleaves membrane-bound phosphatidylinositol-4,5-bisphosphate into
inositol-1,4,5-triphosphate and diacylglycerol. This in turn leads
to an increase of the intracellular calcium concentration and
activation of further target proteins such as protein kinase C and
the MAP kinases.
[0004] A2b receptors are expressed on pulmonary epithelial and
smooth muscle cells, vascular endothelial and smooth muscle cells,
fibroblasts and also inflammatory cells. Expression of the A2b
receptor at the cell surface is a dynamic process and is greatly
enhanced, for example, by hypoxia, inflammatory factors and free
radicals. The adenosine-activated A2b receptors lead to formation
and release of pro-inflammatory and pro-fibrotic cytokines such as,
for example, IL-6, IL-4 and IL-8. Studies have shown that the A2b
receptor plays an important role at the chronic stage of pulmonary
disorders during tissue remodelling and promotes inter alia
differentiation of fibroblasts in myofibroblasts, resulting in
enhanced synthesis and deposition of collagen.
[0005] In pulmonary tissue samples of patients suffering from
idiopathic pulmonary fibrosis, COPD and pulmonary hypertension
associated with COPD [Zhou et al., PLoS One 5, e9224 (2010);
Selmann et al., PLoS One 2, e482 (2007)] and various animal models
of fibro-proliferative pulmonary disorders [Karmouty-Quintana et
al., Am. J. Respir. Cell. [mol %] Biol., publ. online, 15. July
2013; Karmouty-Quintana et al., Faseb J. 26, 2546-2557 (2012); Sun
et al., J. Clin. Invest. 116, 2173-2182 (2006)], it was possible to
detect an increased expression of the A2b receptor. In the animal
model of bleomycin-induced pulmonary fibrosis and pulmonary
hypertension in the mouse, a genetic knock-out of the A2b receptor
resulted both in inhibition of the progression of pulmonary
fibrosis and pulmonary vascular remodeling and the resulting
pulmonary hypertension [Karmouty-Quintana et al., Faseb J. 26,
2546-2557 (2012)]. It is assumed that the release of inter alia
endothelin-1 (ET-1) and interleukin-6 (IL-6) from vascular cells,
which is modulated by the A2b receptor, plays a role during the
development of pulmonary hypertension associated with pulmonary
fibrosis. Stimulation of human pulmonary arterial endothelial and
smooth muscle cells with 5'-(N-ethylcarboxamido)adenosine (NECA),
an adenosine analog, results in the release of ET-1 and IL-6, which
can be prevented by A2b receptor inhibition [Karmouty-Quintana et
al., Faseb J. 26, 2546-2557 (2012)]. Elevated endothelin-1- and
IL-6 concentrations were found in lung tissue and serum of patients
suffering from pulmonary hypertension [Giaid et al., N. Engl. J.
Med. 329, 1967-1968 (1993); Steiner et al., Circ. Res. 104, 236-244
(2009)]. Furthermore, it is assumed that the A2b receptor-mediated
release of inter alia IL-6 and other profibrotic mediators and
stimulation of the differentiation of fibroblasts in myofibroblasts
in the lung leads to induction of fibrosis. Stimulation of human
fibroblasts with NECA leads to the release of IL-6 which is
increased by hypoxia and can be prevented by inhibiting the A2b
receptor. It was possible to demonstrate an increased IL-6
expression in patients suffering from idiopathic pulmonary fibrosis
and in animal models of pulmonary fibrosis [Zhong et al., Am. J.
Respir. Cell. [mol %] Biol. 32, 2-8 (2005); Cavarra et al., Am. J.
Physiol. Lung Cell. [mol %] Physiol. 287, L1186-L1192 (2004)].
[0006] The A2b receptor also plays an important role in tissue
remodelling after myocardial infarction. In the animal model of the
permanent ligature of the coronary artery in the mouse, inhibition
of the A2b receptor resulted in a reduction of caspase-1 activity
and the invasion of inflammatory cells in heart tissue and the
cytokines and adhesion molecules in plasma and in an improvement of
systolic and diastolic heart function [Toldo et al., J. Pharmacol.
Exp. Ther. 343, 587-595 (2012)].
[0007] It is therefore assumed that the A2b receptor plays an
important role in many disorders, injuries and pathological changes
whose aetiology and/or progression is associated with inflammatory
events and/or proliferative and fibro-proliferative tissue and
vessel remodelling. These can be in particular disorders of and/or
damage to the lung, the cardiovascular system or the kidney, or it
can be a blood disorder, a neoplastic disease or other inflammatory
disorders.
[0008] Disorders of and damage to the lung which may be mentioned
in this context are in particular idiopathic pulmonary fibrosis,
pulmonary hypertension, the bronchiolitis obliterans syndrome
(BOS), chronic-obstructive pulmonary disease (COPD), asthma and
cystic fibrosis. Disorders of and damage to the cardiovascular
system in which the A2b receptor is involved are, for example,
tissue changes following myocardial infarction and associated with
heart failure. Renal disorders are, for example, renal
insufficiency and kidney failure. A blood disorder is, for example,
sickle cell anaemia. Examples of tissue degradation and remodelling
during neoplastic processes are the invasion of cancer cells into
healthy tissue (formation of metastases) and neovascularization
(neoangiogenesis). Another inflammatory disease where the A2b
receptor is involved is, for example, multiple sclerosis.
[0009] Idiopathic fibrosis of the lung or idiopathic pulmonary
fibrosis (IPF) is a progressive lung disease which, left untreated,
results in death on average within 2.5 to 3.5 years after
diagnosis. At the time of diagnosis, the patients are in most cases
more than 60 years old, men being slightly more frequently affected
than women. Onset of IPF is insidious and characterized by
increasing shortness of breath and dry tickly cough. IPF belongs to
the group of idiopathic interstitial pneumonias (IIP), a
heterogeneous group of pulmonary disorders characterized by
fibrosis and inflammation of varying severity which can be
distinguished using clinical, imaging and fine tissue criteria.
Within this group, the idiopathic pulmonary fibrosis is of
particular significance owing to its frequency and aggressive
progression [Ley et al., Am. J. Respir. Crit. Care Med. 183,
431-440 (2011)]. IPF may either occur sporadically or be
hereditary. As yet, the causes are unknown.
[0010] However, in recent years there have been numerous
indications that chronic damage of the alveolar epithelium leads to
the release of profibrotic cytokines/mediators followed by
increased fibroblast proliferation and increased collagen fibre
formation, resulting in a patchy fibrosis and the typical honeycomb
structure of the lung [Strieter et al., Chest 136, 1364-1370
(2009)]. The clinical sequelae of fibrotization are a decrease in
the elasticity of the pulmonary tissue, a reduced diffusing
capacity and the development of severe hypoxia. With regard to lung
function, a corresponding worsening of the forced vital capacity
(FVC) and the diffusing capacity (DLCO) can be detected.
[0011] Essential and prognostically important comorbidities of IPF
are acute exacerbation and pulmonal hypertension [Beck et al.,
Pneumologe 10, 105-111 (2013)]. The prevalence of pulmonary
hypertension in interstitial pulmonary disorders is 10-40%
[Lettieri et al., Chest 129, 746-752 (2006); Behr et al., Eur.
Respir. J. 31, 1357-1367 (2008)]. Currently, there is no curative
treatment for IPF--except for lung transplantation.
[0012] Pulmonary hypertension (PH) is a progressive lung disease
which, left untreated, leads to death on average within 2.8 years
after diagnosis. By definition, the mean pulmonary aterial pressure
(mPAP) in case of chronic pulmonary hypertension is >25 mmHg at
rest or >30 mmHg during exertion (normal value<20 mmHg). The
pathophysiology of pulmonary hypertension is characterized by
vasoconstriction and remodelling of the pulmonary vessels. In
chronic PH there is neomuscularization primarily of unmuscularized
pulmonary vessels, and the vascular muscles of the already
muscularized vessels increase in circumference. This increasing
obliteration of the pulmonary circulation results in progressive
stress on the right heart, which leads to a reduced output from the
right heart and eventually ends in right heart failure [M. Humbert
et al., J. Am. Coll. Cardiol. 2004, 43, 13S-24S]. Idiopathic (or
primary) pulmonary arterial hypertension (IPAH) is a very rare
disorder, whereas secondary pulmonary hypertension (non-PAH PH,
NPAHPH) is very common, and it is thought that the latter is
currently the third most common group of cardiovascular disorders
after coronary heart disease and systemic hypertension [Naeije, in:
A. J. Peacock et al. (Eds.), Pulmonary Circulation. Diseases and
their treatment, 3.sup.rd edition, Hodder Arnold Publ., 2011, p.
3]. Since 2008, pulmonary hypertension is classified in accordance
with the Dana Point classification into various sub-groups
according to the respective aetiology [D. Montana and G. Simonneau,
in: A. J. Peacock et al. (Eds.), Pulmonary Circulation. Diseases
and their treatment, 3.sup.rd edition, Hodder Arnold Publ., 2011,
pp. 197-206].
[0013] Despite all the advances in the therapy of PH there is as
yet no prospect of cure of this serious disorder. Standard
therapies available on the market (for example prostacyclin
analogues, endothelin receptor antagonists, phosphodiesterase
inhibitors) are able to improve the quality of life, the exercise
tolerance and the prognosis of the patients. These are therapeutic
principles which are administered systemically and act primarily
heamodynamically by modulating vessel tone. The applicability of
these medicaments is limited owing to side effects, some of which
are serious, and/or complicated administration forms. The period
over which the clinical situation of the patients can be improved
or stabilized by specific monotherapy is limited (for example owing
to the development of tolerance). Eventually the therapy escalates
and thus a combination therapy is applied, where a plurality of
medicaments must be given concurrently. Currently, these standard
therapeutics are approved only for the treatment of pulmonary
arterial hypertension (PAH). In the case of secondary forms of PH
such as PH-COPD, these therapeutic principles (for example
sildenafil, bosentan) fail in clinical studies since, as a result
of non-selective vasodilatation, they lead to a reduction
(desaturation) of the arterial oxygen content in the patients. The
probable reason for this is an unfavourable effect on the
ventilation-perfusion adaptation in the lung in heterogeneous lung
disorders owing to the systemic administration of non-selective
vasodilatators [I. Blanco et al., Am. J. Respir. Crit. Care Med.
2010, 181, 270-278; D. Stolz et al., Eur. Respir. J. 2008, 32,
619-628].
[0014] Novel combination therapies are one of the most promising
future therapeutic options for the treatment of pulmonary
hypertension. In this connection, the finding of novel
pharmacological mechanisms for the treatment of PH is of particular
interest [Ghofrani et al., Herz 2005, 30, 296-302; E. B.
Rosenzweig, Expert Opin. Emerging Drugs 2006, 11, 609-619; T. Ito
et al., Curr. Med. Chem. 2007, 14, 719-733]. In particular novel
therapeutic approaches which can be combined with the therapy
concepts already on the market may form the basis of a more
efficient treatment and thus be of great advantage for the
patients.
[0015] In the context of the present invention, the term "pulmonary
hypertension" includes both primary and secondary sub-forms
(NPAHPH) as defined according to the Dana Point classification in
accordance with their respective aetiology [D. Montana and G.
Simonneau, in: A. J. Peacock et al. (Eds.), Pulmonary Circulation.
Diseases and their treatment, 3.sup.rd edition, Hodder Arnold
Publ., 2011, pp. 197-206; Hoeper et al., J. Am. Coll. Cardiol.,
2009, 54 (1), Suppl. S, p85-p96]. These include in particular in
group 1 pulmonary arterial hypertension (PAH), which, among others,
embraces the idiopathic and the familial forms (IPAH and FPAH,
respectively). Furthermore, PAH also embraces persistent pulmonary
hypertension of the newborn and the associated pulmonary arterial
hypertension (APAH) associated with collagenoses, congenital
systemic pulmonary shunt lesions, portal hypertension, HIV
infections, the intake of certain drugs and medicaments (for
example of appetite suppressants), with disorders having a
significant venous/capillary component such as pulmonary
venoocclusive disorder and pulmonary capillary haemangiomatosis, or
with other disorders such as disorders of the thyroid, glycogen
storage diseases, Gaucher disease, hereditary teleangiectasia,
haemoglobinopathies, myeloproliferative disorders and
splenectomy.
[0016] Group 2 of the Dana Point classification comprises PH
patients having a causative left heart disorder, such as
ventricular, atrial or valvular disorders. Group 3 comprises forms
of pulmonary hypertension associated with a lung disorder, for
example with chronic obstructive lung disease (COPD), interstitial
lung disease (ILD), pulmonary fibrosis (IPF), and/or hypoxaemia
(e.g. sleep apnoe syndrome, alveolar hypoventilation, chronic
high-altitude sickness, hereditary deformities). Group 4 includes
PH patients having chronic thrombotic and/or embolic disorders, for
example in the case of thromboembolic obstruction of proximal and
distal pulmonary arteries (CTEPH) or non-thrombotic embolisms (e.g.
as a result of tumour disorders, parasites, foreign bodies). Less
common forms of pulmonary hypertension, such as in patients
suffering from sarcoidosis, histiocytosis X or lymphangiomatosis,
are summarized in group 5.
[0017] The bronchiolitis obliterans syndrome (BOS) is a chronic
rejection reaction after a lung transplantation. Within the first
five years after a lung transplantation, about 50-60% of all
patients, within the first nine years more than 90% of the patients
are affected [Estenne et al., Am. J. Respir. Crit. Care Med. 166,
440-444 (2003)]. The cause of the disease has not been elucidated.
In spite of numerous improvements in the treatment of
transplantation patients, the number of BOS cases has hardly
changed over the last years. BOS is the most important long-term
complication in lung transplantations and is considered to be the
main reason for the fact that survival rates are still markedly
below those for other organ transplantations. BOS is an
inflammatory event which is associated with changes in the lung
tissue affecting primarily the small respiratory passages. Damage
and inflammatory changes of the epithelial cells and the
subepithelial structures of the smaller respiratory passages lead,
owing to ineffective regeneration of the epithelium and aberrant
tissue repair, to excessive fibroproliferation. There is scarring
and finally destruction of the bronchi and also clots of
granulation tissue in the small respiratory passages and alveolae,
occasionally with vascular involvement. The diagnosis is based on
the lung function. In BOS, there is a worsening of the FEV1
compared to the average of the two best values measured
postoperatively. Currently, there is no curative treatment of BOS.
Some of the patients show improvements during more intensive
immunosuppression, patients not showing any response experience
persistent worsening such that retransplantation is indicated.
[0018] Chronic obstructive pulmonary disease (COPD) is a slowly
progressing pulmonary disease characterized by an obstruction of
respiratory flow which is caused by pulmonary emphysema and/or
chronic bronchitis. The first symptoms of the disease generally
manifest themselves during the fourth or fifth decade in life. In
the subsequent years of life, the shortness of breath frequently
worsens and cough becomes manifest, associated with plentiful and
in some cases purulent expectoration and stenosis breathing up to
breathlessness (dyspnoea). COPD is primarily a disease of smokers:
Smoking is the cause of 90% of all cases of COPD and of 80-90% of
all COPD-related deaths. COPD is a big medicinal problem and
constitutes the sixth most frequent cause of death world-wide. Of
people over the age of 45, about 4-6% are affected. Although the
obstruction of the respiratory flow may only be partial and
temporal, COPD can not be cured. Accordingly, the aim of the
treatment is to improve the quality of life, to alleviate the
symptoms, to prevent an acute worsening and to slow the progressive
impairment of lung function. Existing pharmacotherapies, which have
hardly changed over the last two or three decades, are the use of
bronchodilators to open blocked respiratory passages, and in
certain situations corticosteroids to control the inflammation of
the lung [P. J. Barnes, N. Engl. J. Med. 343, 269-280 (2000)]. The
chronic inflammation of the lung, caused by cigarette smoke or
other irritants, is the driving force of the development of the
disease. The basic mechanism comprises immune cells which, during
the inflammatory reaction of the lung, release proteases and
various cytokines which cause pulmonary emphysema and remodelling
of the bronchi.
[0019] It is therefore an object of the present invention to
provide novel substances which act as potent and selective
antagonists of the adenosine A2b receptor and are suitable as such
for treatment and/or prevention in particular of pulmonary and
cardiovascular disorders.
[0020] WO 98/54190-A1 and WO 00/12514-A1 disclose
thieno[2,3-d]pyrimidinediones (thienouracils) having
immunosuppressive activity. WO 02/064598-A1 and WO 2004/014916-A1
describe bicyclic pyrimidine derivatives as inhibitors of matrix
metalloproteinases (MMPs), in particular of MMP-13. Further
bicyclic pyrimidine derivatives are disclosed in WO 2005/117890-A2
as CCR2 antagonists in particular for the treatment of inflammatory
disorders, and EP 1 847 541-A1 claims bicyclic pyrimidine
derivatives as GnRH antagonists for the treatment of
hormone-dependent disorders. U.S. Pat. No. 7,928,111-B2 describes
thienopyrimidinone derivatives having taste-enhancing properties.
WO 2007/103776-A2 discloses thieno[2,3-d]pyrimidinediones as
antagonists of the adenosine A2a receptor which are suitable in
particular for the treatment of CNS disorders and addictions. WO
2013/071169-A1 claims thieno[2,3-d]pyrimidinediones as ACC
inhibitors for the treatment of infections and metabolic
disorders.
[0021] The present invention provides compounds of the general
formula (I)
##STR00001##
in which [0022] R.sup.1 represents hydrogen, methyl or ethyl, where
methyl and ethyl may be substituted up to three times by fluorine,
[0023] R.sup.2 represents methyl, ethyl, n-propyl, isopropyl,
cyclopropyl, cyclopropylmethyl, 2,2-difluorovinyl,
3,3-difluoroallyl or propargyl or represents a group of the
formula
[0023] ##STR00002## in which * denotes the point of attachment to
the CH.sub.2 group, [0024] Ar represents phenyl or 5- or 6-membered
heteroaryl having up to two ring nitrogen atoms, [0025] where
phenyl and heteroaryl may be mono- or disubstituted by identical or
different radicals selected from the group consisting of fluorine,
chlorine, methyl, trifluoromethyl, methoxy and trifluoromethoxy,
[0026] R.sup.4A represents hydrogen, fluorine or methyl, [0027]
R.sup.4B represents hydrogen, fluorine, methyl, trifluoromethyl,
hydroxy or methoxy, [0028] or [0029] R.sup.4A and R.sup.4B are
attached to one another and together with the carbon atom to which
they are attached form a cyclopropyl or cyclobutyl ring, [0030]
R.sup.8 represents methyl or trifluoromethyl [0031] and [0032]
R.sup.9A and R.sup.9B independently of one another represent
hydrogen, methyl or trifluoromethyl, [0033] R.sup.3 represents
(C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl,
(C.sub.3-C.sub.7)-cycloalkyl or
[(C.sub.3-C.sub.7)-cycloalkyl]methyl, [0034] where alkyl and
alkenyl may be substituted up to three times and cycloalkyl may be
substituted up to two times by fluorine [0035] and [0036] where in
alkyl and cycloalkyl up to two CH.sub.2 groups may be replaced by
--O-- or --S--, with the proviso that there are at least two carbon
atoms between such heteroatoms including the uracil N.sup.1-atom,
and the ring A represents a mono- or bicyclic aza heterocycle of
the formula
[0036] ##STR00003## [0037] in which ** denotes the point of
attachment to the carbonyl group, [0038] R.sup.5 represents
hydrogen, methyl, trifluoromethyl, hydroxymethyl or ethyl, [0039]
R.sup.6A and R.sup.6B each independently of one another represent
hydrogen, methyl or ethyl, [0040] R.sup.10A represents methyl,
ethyl, hydroxy or methoxy, [0041] and [0042] R.sup.10B represents
hydrogen, methyl or ethyl, and their salts, solvates and solvates
of the salts.
[0043] Compounds according to the invention are the compounds of
the formula (I) and their salts, solvates and solvates of the
salts, the compounds encompassed by formula (I) of the formulae
mentioned below and their salts, solvates and solvates of the salts
and the compounds encompassed by formula (I) and mentioned below as
working examples, and their salts, solvates and solvates of the
salts, if the compounds encompassed by formula (I) and mentioned
below are not already salts, solvates and solvates of the
salts.
[0044] Preferred salts in the context of the present invention are
physiologically acceptable salts of the compounds according to the
invention. Also encompassed are salts which are not themselves
suitable for pharmaceutical applications but can be used, for
example, for the isolation, purification or storage of the
compounds according to the invention.
[0045] Physiologically acceptable salts of the compounds according
to the invention include acid addition salts of mineral acids,
carboxylic acids and sulphonic acids, for example salts of
hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric
acid, methanesulphonic acid, ethanesulphonic acid, benzenesulphonic
acid, toluenesulphonic acid, naphthalenedisulphonic acid, formic
acid, acetic acid, trifluoroacetic acid, propionic acid, succinic
acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic
acid, citric acid, gluconic acid, benzoic acid and embonic
acid.
[0046] Solvates in the context of the invention are described as
those forms of the compounds according to the invention which form
a complex in the solid or liquid state by coordination with solvent
molecules. Hydrates are a specific form of the solvates in which
the coordination is with water. Solvates preferred in the context
of the present invention are hydrates.
[0047] The compounds according to the invention may, depending on
their structure, exist in different stereoisomeric forms, i.e. in
the form of configurational isomers or else optionally as
conformational isomers (enantiomers and/or diastereomers, including
those in the case of atropisomers). The present invention therefore
encompasses the enantiomers and diastereomers, and the respective
mixtures thereof. The stereoisomerically homogeneous constituents
can be isolated from such mixtures of enantiomers and/or
diastereomers in a known manner; chromatography processes are
preferably used for this purpose, especially HPLC chromatography on
an achiral or chiral phase.
[0048] Where the compounds according to the invention can occur in
tautomeric forms, the present invention encompasses all the
tautomeric forms.
[0049] The present invention also encompasses all suitable isotopic
variants of the compounds according to the invention. An isotopic
variant of a compound according to the invention is understood here
as meaning a compound in which at least one atom within the
compound according to the invention has been exchanged for another
atom of the same atomic number, but with a different atomic mass
than the atomic mass which usually or predominantly occurs in
nature. Examples of isotopes which can be incorporated into a
compound according to the invention are those of hydrogen, carbon,
nitrogen, oxygen, phosphorus, sulphur, fluorine, chlorine, bromine
and iodine, such as .sup.2H (deuterium), .sup.3H (tritium),
.sup.13C, .sup.14C, .sup.15N, .sup.17O, .sup.18O, .sup.32P,
.sup.33P, .sup.33S, .sup.34S, .sup.35S, .sup.36S, .sup.18F,
.sup.36Cl, .sup.82Br, .sup.123I, .sup.124I, .sup.129I and
.sup.131I. Particular isotopic variants of a compound according to
the invention, especially those in which one or more radioactive
isotopes have been incorporated, may be beneficial, for example,
for the examination of the mechanism of action or of the active
compound distribution in the body; due to comparatively easy
preparability and detectability, especially compounds labelled with
.sup.3H or .sup.14C isotopes are suitable for this purpose. In
addition, the incorporation of isotopes, for example of deuterium,
can lead to particular therapeutic benefits as a consequence of
greater metabolic stability of the compound, for example to an
extension of the half-life in the body or to a reduction in the
active dose required; such modifications of the compounds according
to the invention may therefore in some cases also constitute a
preferred embodiment of the present invention. Isotopic variants of
the compounds according to the invention can be prepared by
generally customary processes known to those skilled in the art,
for example by the methods described below and the procedures
reported in the working examples, by using corresponding isotopic
modifications of the particular reagents and/or starting compounds
therein.
[0050] In addition, the present invention also encompasses prodrugs
of the compounds according to the invention. The term "prodrugs"
refers here to compounds which may themselves be biologically
active or inactive, but are converted while present in the body,
for example by a metabolic or hydrolytic route, to compounds
according to the invention.
[0051] In the context of the present invention, unless specified
otherwise, the substituents and radicals are defined as
follows:
[0052] (C.sub.1-C.sub.6)-Alkyl and (C.sub.2-C.sub.4-alkyl in the
context of the invention represent a straight-chain or branched
alkyl radical having 1 to 6 and 2 to 4 carbon atoms, respectively.
A straight-chain or branched alkyl radical having 2 to 4 carbon
atoms is preferred. Preferred examples include: methyl, ethyl,
n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl,
n-pentyl, 2-pentyl, 3-pentyl, neopentyl, n-hexyl, 2-hexyl and
3-hexyl.
[0053] (C.sub.2-C.sub.6)-Alkenyl and (C.sub.2-C.sub.4)-alkenyl in
the context of the invention represent a straight-chain or branched
alkenyl radical having a double bond and 2 to 6 and 2 to 4 carbon
atoms, respectively. A straight-chain or branched alkenyl radical
having 2 to 4 carbon atoms is preferred. Preferred examples
include: vinyl, prop-1-en-1-yl, prop-2-en-1-yl (allyl),
prop-1-en-2-yl (isopropenyl), 2-methylprop-2-en-1-yl,
but-1-en-1-yl, but-1-en-2-yl, but-2-en-1-yl, but-2-en-2-yl,
but-3-en-1-yl, pent-2-en-1-yl, pent-3-en-1-yl, pent-4-en-1-yl,
3-methylbut-2-en-1-yl and 4-methylpent-3-en-1-yl.
[0054] (C.sub.3-C.sub.7)-Cycloalkyl and
(C.sub.3-C.sub.6)-cycloalkyl in the context of the invention
represent a monocyclic saturated cycloalkyl group having 3 to 7 and
3 to 6 carbon atoms, respectively. A cycloalkyl radical having 3 to
6 carbon atoms is preferred. Preferred examples include:
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and
cycloheptyl.
[0055] 5-membered heteroaryl in the definition of the group Ar
represents an aromatic heterocycle (heteroaromatic radical) having
a total of 5 ring atoms which contains one or two ring nitrogen
atoms and is attached via a ring carbon atom or a ring nitrogen
atom. Examples include: pyrrolyl, pyrazolyl and imidazolyl.
Preference is given to imidazolyl.
[0056] 6-membered heteroaryl in the definition of the group Ar
represents an aromatic heterocycle (heteroaromatic radical) having
a total of 6 ring atoms which contains one or two ring nitrogen
atoms and is attached via a ring carbon atom. Examples include:
pyridyl, pyrimidinyl, pyridazinyl and pyrazinyl. Preference is
given to pyridyl.
[0057] In the context of the present invention, it is the case that
for all radicals which occur more than once, their meaning is
independent of the others. When radicals in the compounds according
to the invention are substituted, the radicals may be mono- or
polysubstituted, unless specified otherwise.
[0058] Substitution by one or two identical or different
substituents is preferred. Particular preference is given to
substitution by one substituent.
[0059] In a particular embodiment, the present invention
encompasses compounds of the formula (I) in which [0060] R.sup.1
represents hydrogen, methyl, difluoromethyl, trifluoromethyl or
ethyl, [0061] R.sup.2 represents methyl, ethyl, n-propyl,
isopropyl, cyclopropyl, cyclopropylmethyl or propargyl or
represents a group of the formula
[0061] ##STR00004## [0062] in which * denotes the point of
attachment to the CH.sub.2 group, [0063] Ar represents phenyl or 5-
or 6-membered heteroaryl having up to two ring nitrogen atoms,
[0064] where phenyl and heteroaryl may be mono- or disubstituted by
identical or different radicals selected from the group consisting
of fluorine, chlorine, methyl, trifluoromethyl, methoxy and
trifluoromethoxy, [0065] R.sup.4A represents hydrogen, fluorine or
methyl, [0066] R.sup.4B represents hydrogen, fluorine, methyl,
trifluoromethyl, hydroxy or methoxy, [0067] or [0068] R.sup.4A and
R.sup.4B are attached to one another and together with the carbon
atom to which they are attached form a cyclopropyl or cyclobutyl
ring, [0069] R.sup.8 represents methyl or trifluoromethyl [0070]
and [0071] R.sup.9A and R.sup.9B independently of one another
represent hydrogen, methyl or trifluoromethyl, [0072] R.sup.3
represents (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl,
(C.sub.3-C.sub.7)-cycloalkyl or
[(C.sub.3-C.sub.7)-cycloalkyl]methyl, [0073] where alkyl and
alkenyl may be substituted up to three times and cycloalkyl may be
substituted up to two times by fluorine [0074] and [0075] where in
alkyl and cycloalkyl up to two CH.sub.2 groups may be replaced by
--O-- or --S--, with the proviso that there are at least two carbon
atoms between such heteroatoms including the uracil N.sup.1-atom,
and the ring A represents a mono- or bicyclic aza heterocycle of
the formula
[0075] ##STR00005## [0076] in which ** denotes the point of
attachment to the carbonyl group, [0077] R.sup.5 represents
hydrogen, methyl, trifluoromethyl, hydroxymethyl or ethyl, [0078]
R.sup.6A and R.sup.6B each independently of one another represent
hydrogen, methyl or ethyl, [0079] R.sup.10A represents methyl or
ethyl, [0080] and [0081] R.sup.10B represents hydrogen, methyl or
ethyl, and their salts, solvates and solvates of the salts.
[0082] In a further embodiment, the present invention encompasses
compounds of the formula (I) in which [0083] R.sup.1 represents
hydrogen, methyl, difluoromethyl or trifluoromethyl, [0084] R.sup.2
represents methyl, ethyl, n-propyl or isopropyl or represents a
group of the formula
[0084] ##STR00006## in which * denotes the point of attachment to
the CH.sub.2 group, [0085] Ar represents phenyl or 6-membered
heteroaryl having up to two ring nitrogen atoms, [0086] where
phenyl and heteroaryl may be mono- or disubstituted by identical or
different radicals selected from the group consisting of fluorine,
chlorine, methyl, trifluoromethyl, methoxy and trifluoromethoxy,
[0087] R.sup.4A represents hydrogen, fluorine or methyl, [0088]
R.sup.4B represents hydrogen, fluorine, methyl or methoxy, [0089]
or [0090] R.sup.4A and R.sup.4B are attached to one another and
together with the carbon atom to which they are attached form a
cyclopropyl or cyclobutyl ring, [0091] R.sup.3 represents
(C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl,
(C.sub.3-C.sub.7)-cycloalkyl or
[(C.sub.3-C.sub.7)-cycloalkyl]methyl, [0092] where alkyl and
alkenyl may be substituted up to three times and cycloalkyl may be
substituted up to two times by fluorine [0093] and [0094] where in
alkyl and cycloalkyl up to two CH.sub.2 groups may be replaced by
--O-- or --S--, with the proviso that there are at least two carbon
atoms between such heteroatoms including the uracil N.sup.1-atom,
and the ring A represents a mono- or bicyclic aza heterocycle of
the formula
[0094] ##STR00007## [0095] in which ** denotes the point of
attachment to the carbonyl group, [0096] R.sup.5 represents
hydrogen, methyl, trifluoromethyl or hydroxymethyl, [0097] and
[0098] R.sup.6A and R.sup.6B each independently of one another
represent hydrogen, methyl or ethyl, and their salts, solvates and
solvates of the salts.
[0099] Preference is given in the context of the present invention
to compounds of the formula (I) in which [0100] R.sup.1 represents
methyl, difluoromethyl, trifluoromethyl, ethyl or 1-fluoroethyl,
[0101] R.sup.2 represents methyl, ethyl, n-propyl, isopropyl,
3,3-difluoroallyl or propargyl or represents a group of the
formula
[0101] ##STR00008## [0102] in which * denotes the point of
attachment to the CH.sub.2 group, [0103] Ar represents phenyl or
pyridyl, [0104] where phenyl and pyridyl may be substituted by
fluorine, chlorine, methyl or methoxy, [0105] R.sup.4A represents
hydrogen, fluorine or methyl, [0106] R.sup.4B represents hydrogen,
fluorine, methyl, hydroxy or methoxy, [0107] or [0108] R.sup.4A and
R.sup.4B are attached to one another and together with the carbon
atom to which they are attached form a cyclopropyl ring, [0109] and
[0110] R.sup.9A represents hydrogen, methyl or trifluoromethyl,
[0111] R.sup.3 represents (C.sub.2-C.sub.4)-alkyl,
(C.sub.2-C.sub.4)-alkenyl, (C.sub.3-C.sub.6)-cycloalkyl or
[(C.sub.3-C.sub.6)-cycloalkyl]methyl, [0112] where alkyl and
alkenyl may be substituted up to three times and cycloalkyl may be
substituted up to two times by fluorine [0113] and [0114] where in
alkyl and cycloalkyl one CH.sub.2 group may be replaced by --O-- or
--S--, with the proviso that there are at least two carbon atoms
between such a heteroatom and the uracil N.sup.1-atom, and the ring
A represents an aza heterocycle of the formula
[0114] ##STR00009## [0115] in which ** denotes the point of
attachment to the carbonyl group, [0116] R.sup.5 represents
hydrogen, methyl, trifluoromethyl, hydroxymethyl or ethyl, [0117]
R.sup.6A and R.sup.6B independently of one another represent
hydrogen, methyl or ethyl, [0118] and [0119] R.sup.10A represents
methyl or ethyl, and their salts, solvates and solvates of the
salts.
[0120] In a further preferred embodiment, the present invention
encompasses compounds of the formula (I) in which [0121] R.sup.1
represents methyl, difluoromethyl, trifluoromethyl or ethyl, [0122]
R.sup.2 represents methyl, ethyl, n-propyl, isopropyl or propargyl
or represents a group of the formula
[0122] ##STR00010## [0123] in which * denotes the point of
attachment to the CH.sub.2 group, [0124] Ar represents phenyl or
pyridyl, [0125] where phenyl and pyridyl may be substituted by
fluorine, chlorine, methyl or methoxy, [0126] R.sup.4A represents
hydrogen, fluorine or methyl, [0127] R.sup.4B represents hydrogen,
fluorine, methyl, hydroxy or methoxy, [0128] or [0129] R.sup.4A and
R.sup.4B are attached to one another and together with the carbon
atom to which they are attached form a cyclopropyl ring, [0130] and
[0131] R.sup.9A represents hydrogen, methyl or trifluoromethyl,
[0132] R.sup.3 represents (C.sub.2-C.sub.4)-alkyl,
(C.sub.2-C.sub.4)-alkenyl, (C.sub.3-C.sub.6)-cycloalkyl or
[(C.sub.3-C.sub.6)-cycloalkyl]methyl, [0133] where alkyl and
alkenyl may be substituted up to three times and cycloalkyl may be
substituted up to two times by fluorine [0134] and [0135] where in
alkyl and cycloalkyl one CH.sub.2 group may be replaced by --O-- or
--S--, with the proviso that there are at least two carbon atoms
between such a heteroatom and the uracil N.sup.1-atom, and the ring
A represents an aza heterocycle of the formula
[0135] ##STR00011## [0136] in which ** denotes the point of
attachment to the carbonyl group, [0137] R.sup.5 represents
hydrogen, methyl, trifluoromethyl, hydroxymethyl or ethyl, [0138]
R.sup.6A and R.sup.6B independently of one another represent
hydrogen, methyl or ethyl, [0139] and [0140] R.sup.10A represents
methyl or ethyl, and their salts, solvates and solvates of the
salts.
[0141] In a further preferred embodiment, the present invention
encompasses compounds of the formula (I) in which [0142] R.sup.1
represents methyl or trifluoromethyl, [0143] R.sup.2 represents
methyl, ethyl, n-propyl or isopropyl or represents a group of the
formula
[0143] ##STR00012## in which * denotes the point of attachment to
the CH.sub.2 group, [0144] Ar represents phenyl or pyridyl, [0145]
where phenyl and pyridyl may be substituted by fluorine, chlorine,
methyl or methoxy, [0146] R.sup.4A represents hydrogen, fluorine or
methyl, [0147] R.sup.4B represents hydrogen, fluorine, methyl or
methoxy, [0148] or [0149] R.sup.4A and R.sup.4B are attached to one
another and together with the carbon atom to which they are
attached form a cyclopropyl ring, [0150] R.sup.3 represents
(C.sub.2-C.sub.4)-alkyl, (C.sub.2-C.sub.4)-alkenyl,
(C.sub.3-C.sub.6)-cycloalkyl or
[(C.sub.3-C.sub.6)-cycloalkyl]methyl, [0151] where alkyl and
alkenyl may be substituted up to three times and cycloalkyl may be
substituted up to two times by fluorine [0152] and [0153] where in
alkyl and cycloalkyl one CH.sub.2 group may be replaced by --O-- or
--S--, with the proviso that there are at least two carbon atoms
between such a heteroatom and the uracil N.sup.1-atom, and the ring
A represents an aza heterocycle of the formula
[0153] ##STR00013## [0154] in which ** denotes the point of
attachment to the carbonyl group, [0155] R.sup.5 represents
hydrogen, methyl, trifluoromethyl or hydroxymethyl, [0156] and
[0157] R.sup.6A and R.sup.6B each independently of one another
represent hydrogen, methyl or ethyl, and their salts, solvates and
solvates of the salts.
[0158] A particular embodiment of the present invention relates to
compounds of the formula (I) in which [0159] R.sup.1 represents
methyl or ethyl, and their salts, solvates and solvates of the
salts.
[0160] A further particular embodiment of the present invention
relates to compounds of the formula (I) in which [0161] R.sup.1
represents difluoromethyl or trifluoromethyl and their salts,
solvates and solvates of the salts.
[0162] A further particular embodiment of the present invention
relates to compounds of the formula (I) in which [0163] R.sup.2
represents methyl, ethyl or isopropyl, and their salts, solvates
and solvates of the salts.
[0164] A further particular embodiment of the present invention
relates to compounds of the formula (I) in which [0165] R.sup.2
represents propargyl, and their salts, solvates and solvates of the
salts.
[0166] A further particular embodiment of the present invention
relates to compounds of the formula (I) in which [0167] R.sup.2
represents a group of the formula
[0167] ##STR00014## in which * denotes the point of attachment to
the CH.sub.2 group, [0168] Ar represents phenyl which may be
substituted by fluorine, chlorine, methyl or methoxy, [0169]
R.sup.4A represents hydrogen [0170] and [0171] R.sup.4B represents
hydrogen, fluorine, methyl or methoxy, and their salts, solvates
and solvates of the salts.
[0172] A further particular embodiment of the present invention
relates to compounds of the formula (I) in which [0173] R.sup.2
represents a group of the formula
[0173] ##STR00015## in which * denotes the point of attachment to
the CH.sub.2 group, [0174] Ar represents phenyl which may be
substituted by fluorine, chlorine, methyl or methoxy, [0175]
R.sup.4A represents hydrogen or methyl, [0176] and [0177] R.sup.4B
represents hydroxy, and their salts, solvates and solvates of the
salts.
[0178] A further particular embodiment of the present invention
relates to compounds of the formula (I) in which [0179] R.sup.2
represents a group of the formula
[0179] ##STR00016## in which * denotes the point of attachment to
the CH.sub.2 group, [0180] Ar represents phenyl which may be
substituted by fluorine, chlorine, methyl or methoxy, [0181] and
[0182] R.sup.4A and R.sup.4B each represent fluorine or are
attached to one another and together with the carbon atom to which
they are attached form a cyclopropyl ring, and their salts,
solvates and solvates of the salts.
[0183] A further particular embodiment of the present invention
relates to compounds of the formula (I) in which [0184] R.sup.2
represents a group of the formula
[0184] ##STR00017## in which * denotes the point of attachment to
the CH.sub.2 group, [0185] Ar represents pyridyl [0186] and [0187]
R.sup.4A and R.sup.4B both represent hydrogen, and their salts,
solvates and solvates of the salts.
[0188] A further particular embodiment of the present invention
relates to compounds of the formula (I) in which [0189] R.sup.2
represents a group of the formula
[0189] ##STR00018## in which * denotes the point of attachment to
the CH.sub.2 group [0190] and [0191] R.sup.9A represents hydrogen,
methyl or trifluoromethyl, and their salts, solvates and solvates
of the salts.
[0192] A further particular embodiment of the present invention
relates to compounds of the formula (I) in which [0193] R.sup.3
represents (C.sub.2-C.sub.4)-alkyl, (C.sub.2-C.sub.4)-alkenyl or
(C.sub.3-C.sub.6)-cycloalkyl, [0194] where alkyl and alkenyl may be
substituted up to three times by fluorine [0195] and [0196] where
in alkyl and cycloalkyl one CH.sub.2 group may be replaced by --O--
or --S--, with the proviso that there are at least two carbon atoms
between such a heteroatom and the uracil N.sup.1-atom, and their
salts, solvates and solvates of the salts.
[0197] A further particular embodiment of the present invention
relates to compounds of the formula (I) in which [0198] R.sup.3
represents 2,2,2-trifluoroethyl or (trifluoromethoxy)methyl, and
their salts, solvates and solvates of the salts.
[0199] A further particular embodiment of the present invention
relates to compounds of the formula (I) in which
the ring A represents an aza heterocycle of the formula
##STR00019## [0200] in which ** denotes the point of attachment to
the carbonyl group, [0201] and [0202] R.sup.5 represents hydrogen,
methyl, trifluoromethyl, hydroxymethyl or ethyl, and their salts,
solvates and solvates of the salts.
[0203] A further particular embodiment of the present invention
relates to compounds of the formula (I) in which
the ring A represents an aza heterocycle of the formula
##STR00020## [0204] in which ** denotes the point of attachment to
the carbonyl group, [0205] and [0206] R.sup.6A and R.sup.6B each
independently of one another represent hydrogen, methyl or ethyl,
and their salts, solvates and solvates of the salts.
[0207] In the context of the present invention, particular
preference is given to compounds of the formula (I) in which [0208]
R.sup.1 represents methyl, difluoromethyl, trifluoromethyl or
ethyl, [0209] R.sup.2 represents methyl, ethyl, isopropyl or
propargyl or represents a group of the formula
[0209] ##STR00021## [0210] in which * denotes the point of
attachment to the CH.sub.2 group, [0211] Ar represents phenyl,
3-pyridyl or 4-pyridyl, [0212] where phenyl may be substituted in
the meta- or para-position by fluorine or in the ortho-position by
fluorine, chlorine or methyl, [0213] R.sup.4A represents hydrogen,
fluorine or methyl, [0214] R.sup.4B represents hydrogen, fluorine,
methyl, hydroxy or methoxy, [0215] or [0216] R.sup.4A and R.sup.4B
are attached to one another and together with the carbon atom to
which they are attached form a cyclopropyl ring, [0217] and [0218]
R.sup.9A represents methyl or trifluoromethyl, [0219] R.sup.3
represents 2,2,2-trifluoroethyl, 3,3-difluoroprop-2-en-1-yl,
methoxymethyl, (trifluoromethoxy)methyl or
[(trifluoromethyl)sulphanyl]methyl, and the ring A represents an
aza heterocycle of the formula
[0219] ##STR00022## [0220] in which ** denotes the point of
attachment to the carbonyl group [0221] and [0222] R.sup.5
represents hydrogen, methyl, trifluoromethyl, hydroxymethyl or
ethyl, and their salts, solvates and solvates of the salts.
[0223] In a further particularly preferred embodiment, the present
invention encompasses compounds of the formula (I) in which [0224]
R.sup.1 represents methyl, difluoromethyl, trifluoromethyl or
ethyl, [0225] R.sup.2 represents methyl, ethyl, isopropyl or
propargyl or represents a group of the formula
[0225] ##STR00023## in which * denotes the point of attachment to
the CH.sub.2 group, [0226] Ar represents phenyl, 3-pyridyl or
4-pyridyl, [0227] where phenyl may be substituted in the meta- or
para-position by fluorine or in the ortho-position by fluorine,
chlorine or methyl, [0228] R.sup.4A represents hydrogen or
fluorine, [0229] R.sup.4B represents hydrogen, fluorine, methyl,
hydroxy or methoxy, [0230] or [0231] R.sup.4A and R.sup.4B are
attached to one another and together with the carbon atom to which
they are attached form a cyclopropyl ring, [0232] R.sup.3
represents 2,2,2-trifluoroethyl, 3,3-difluoroprop-2-en-1-yl,
methoxymethyl, (trifluoromethoxy)methyl or
[(trifluoromethyl)sulphanyl]methyl, and the ring A represents an
aza heterocycle of the formula
[0232] ##STR00024## [0233] in which ** denotes the point of
attachment to the carbonyl group [0234] and [0235] R.sup.5
represents hydrogen, methyl, trifluoromethyl, hydroxymethyl or
ethyl, and their salts, solvates and solvates of the salts.
[0236] In a further particularly preferred embodiment, the present
invention encompasses compounds of the formula (I) in which [0237]
R.sup.1 represents methyl, [0238] R.sup.2 represents methyl, ethyl
or isopropyl or represents a group of the formula
[0238] ##STR00025## in which * denotes the point of attachment to
the CH.sub.2 group, [0239] Ar represents phenyl or 3-pyridyl,
[0240] where phenyl may be substituted in the ortho-position by
fluorine, chlorine or methyl, [0241] R.sup.4A represents hydrogen
[0242] and [0243] R.sup.4B represents hydrogen, methyl or methoxy,
[0244] R.sup.3 represents 2,2,2-trifluoroethyl,
3,3-difluoroprop-2-en-1-yl, methoxymethyl or
(trifluoromethoxy)methyl, and the ring A represents an aza
heterocycle of the formula
[0244] ##STR00026## [0245] in which ** denotes the point of
attachment to the carbonyl group [0246] and [0247] R.sup.5
represents hydrogen, methyl or hydroxymethyl, and their salts,
solvates and solvates of the salts.
[0248] The individual radical definitions specified in the
particular combinations or preferred combinations of radicals are,
independently of the particular combinations of the radicals
specified, also replaced as desired by radical definitions of other
combinations.
[0249] Very particular preference is given to combinations of two
or more of the abovementioned preferred ranges.
[0250] The invention further provides a process for preparing the
compounds according to the invention of the formula (I),
characterized in that either
[A-1] a compound of the formula (II)
##STR00027## [0251] in which R.sup.1 and R.sup.2 have the meanings
given above [0252] and [0253] T.sup.1 represents
(C.sub.1-C.sub.4)-alkyl or benzyl, [0254] is alkylated in the
presence of a base with a compound of the formula (III)
[0254] ##STR00028## [0255] in which R.sup.3 has the meaning given
above [0256] and [0257] X.sup.1 represents a leaving group, for
example chlorine, bromine, iodine, mesylate, triflate or tosylate,
[0258] to give a compound of the formula (IV)
[0258] ##STR00029## [0259] in which R.sup.1, R.sup.2, R.sup.3 and
T.sup.1 have the meanings given above, [0260] then the ester
radical T.sup.1 is cleaved off and the carboxylic acid of the
formula (V) obtained in this manner
[0260] ##STR00030## [0261] in which R.sup.1, R.sup.2 and R.sup.3
have the meanings given above [0262] is then coupled with
activation of the carboxyl function with an amine of the formula
(VI)
[0262] ##STR00031## [0263] in which the ring A has the meaning
given above or--in a changed order of the above reaction steps--
[A-2] the compound of the formula (II)
[0263] ##STR00032## [0264] in which R.sup.1, R.sup.2 and T.sup.1
have the meanings given above [0265] is initially converted by
cleavage of the ester radical T.sup.1 into the carboxylic acid of
the formula (VII)
[0265] ##STR00033## [0266] in which R.sup.1 and R.sup.2 have the
meanings given above, [0267] then coupled with activation of the
carboxyl function with an amine of the formula (VI)
[0267] ##STR00034## [0268] in which the ring A has the meaning
given above [0269] to give a compound of the formula (VIII)
[0269] ##STR00035## [0270] in which R.sup.1, R.sup.2 and the ring A
have the meanings given above [0271] and this is then alkylated in
the presence of a base with a compound of the formula (III)
[0271] ##STR00036## [0272] in which R.sup.3 and X.sup.1 have the
meaning given above or [B] initially an N.sup.3 protected compound
of the formula (IX)
[0272] ##STR00037## [0273] in which R.sup.1 and T.sup.1 have the
meanings given above [0274] and [0275] R.sup.7A and R.sup.7B
independently of one another represent hydrogen or methoxy [0276]
is alkylated in the presence of a base with a compound of the
formula (III)
[0276] ##STR00038## [0277] in which R.sup.3 and X.sup.1 have the
meanings given above [0278] to give a compound of the formula
(X)
[0278] ##STR00039## [0279] in which R.sup.1, R.sup.3, R.sup.7A,
R.sup.7B and T.sup.1 have the meanings given above, [0280] the
N.sup.3-benzyl group and the ester radical T.sup.1 are then cleaved
off simultaneously by treatment with a strong Lewis acid such as
aluminium trichloride, the carboxylic acid of the formula (XI)
obtained in this manner
[0280] ##STR00040## [0281] in which R.sup.1 and R.sup.3 have the
meanings given above, [0282] is then coupled with activation of the
carboxyl function with an amine of the formula (VI)
[0282] ##STR00041## [0283] in which the ring A has the meaning
given above [0284] to give a compound of the formula (XII)
[0284] ##STR00042## [0285] in which R.sup.1, R.sup.3 and the ring A
have the meanings given above [0286] and the latter is then either
reacted (a) in the presence of a base with a compound of the
formula (XIII)
[0286] ##STR00043## [0287] in which R.sup.2 has the meaning given
above [0288] and [0289] X.sup.2 represents a leaving group, for
example chlorine, bromine, iodine, mesylate, triflate or tosylate,
[0290] or (b) in the presence of a suitable phosphine and an
azodicarboxylate with a compound of the formula (XIV)
[0290] ##STR00044## [0291] in which R.sup.2 has the meaning given
above, and the compounds of the formula (I) prepared in this manner
are optionally converted with the appropriate (i) solvents and/or
(ii) acids into their solvates, salts and/or solvates of the
salts.
[0292] In the processes described above, it may optionally be
required or advantageous to protect temporarily a hydroxyl group
present in the amine compound of the formula (VI) during the
coupling of this amine [reactions (V)+(VI).fwdarw.(I),
(VII)+(VI).fwdarw.(VIII) and (XI)+(VI).fwdarw.(XII)] and/or during
the subsequent alkylation reactions [(VIII)+(III).fwdarw.(I) and
(XII)+(XIII) or (XIV).fwdarw.(I)] and only to deprotect again at
the end of the reaction sequence. Suitable for this purpose are
customary hydroxyl-protective groups such as acetyl, pivaloyl,
benzoyl, tert-butyl, 2-(trimethylsilyl)ethyl, benzyl,
triphenylmethyl, methoxymethyl, 2-(trimethylsilyl)ethoxymethyl,
tetrahydropyran-2-yl, trimethylsilyl, triisopropylsilyl or
tert-butyldimethylsilyl. The hydroxyl-protective group used is
preferably acetyl.
[0293] It may also be expedient to block temporarily an amidic NH
group present in the compound (VI) to avoid selectivity problems in
subsequent alkylation reactions in the uracil moiety of the
molecule [see reactions (VIII)+(III).fwdarw.(I) and (XII)+(XIII) or
(XIV).fwdarw.(I)]. Suitable for this purpose are known amide
protective groups such as allyl, 2-(trimethylsilyl)ethyl,
4-methoxybenzyl, 2,4-dimethoxybenzyl, methoxymethyl or
benzyloxymethyl.
[0294] Introduction and removal of the protective groups mentioned
are carried out by generally customary methods [see, for example,
T. W. Greene and P. G. M. Wuts, Protective Groups in Organic
Synthesis, Wiley, New York, 1999].
[0295] Suitable inert solvents for the alkylation reactions
(II)+(III).fwdarw.(IV), (VIII)+(III).fwdarw.(I),
(IX)+(III).fwdarw.(X) and (XII)+(XIII).fwdarw.(I) are in particular
ethers such as diethyl ether, diisopropyl ether, methyl tert-butyl
ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane or
bis(2-methoxyethyl) ether, or polar aprotic solvents such as
acetonitrile, butyronitrile, acetone, methyl ethyl ketone, ethyl
acetate, N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA),
dimethyl sulphoxide (DMSO), N,N'-dimethylpropyleneurea (DMPU) or
N-methylpyrrolidinone (NMP). It is also possible to use mixtures of
these solvents. Preference is given to using
N,N-dimethylformamide.
[0296] Suitable bases for these alkylation reactions are in
particular customary inorganic bases. These include alkali metal
hydroxides such as lithium hydroxide, sodium hydroxide or potassium
hydroxide, alkali metal bicarbonates such as sodium bicarbonate or
potassium bicarbonate, alkali metal carbonates such as lithium
carbonate, sodium carbonate, potassium carbonate or caesium
carbonate, or alkali metal hydrides such as sodium hydride or
potassium hydride. Preference is given to using caesium
carbonate.
[0297] The reactions mentioned are generally carried out in a
temperature range of from +20.degree. C. to +100.degree. C.
[0298] Cleavage of the ester group T.sup.1 in the process steps
(IV).fwdarw.(V) and (II).fwdarw.(VII) is carried out by customary
methods by treating the ester in an inert solvent with an acid or a
base, where in the latter variant the salt, initially formed, of
the carboxylic acid is converted by subsequent treatment with acid
into the free carboxylic acid. In the case of the tert-butyl
esters, ester cleavage is preferably carried out using an acid.
Methyl and ethyl ester are preferably cleaved using a base.
Alternatively, benzyl ester can also be cleaved by hydrogenation
(hydrogenolysis) in the presence of a suitable catalyst such as,
for example, palladium on activated carbon.
[0299] Suitable inert solvents for these reactions are water and
the organic solvents customary for ester cleavage. These include in
particular alcohols such as methanol, ethanol, n-propanol,
isopropanol, n-butanol or tert-butanol, ethers such as diethyl
ether, tetrahydrofuran, 1,4-dioxane or 1,2-dimethoxyethane, or
other solvents such as dichloromethane, acetonitrile,
N,N-dimethylformamide or dimethyl sulphoxide. It is equally
possible to use mixtures of these solvents. In the case of a basic
ester hydrolysis, preference is given to using mixtures of water
with tetrahydrofuran, 1,4-dioxane, methanol and/or ethanol. In the
case of the reaction with trifluoroacetic acid, preference is given
to using dichloromethane, and in the case of the reaction with
hydrogen chloride 1,4-dioxane, in each case under anhydrous
conditions.
[0300] Suitable bases for a hydrolysis reaction are the customary
inorganic bases. These include in particular alkali metal or
alkaline earth metal hydroxides, for example lithium hydroxide,
sodium hydroxide, potassium hydroxide or barium hydroxide, or
alkali metal or alkaline earth metal carbonates, such as sodium
carbonate, potassium carbonate or calcium carbonate. Preference is
given to using lithium hydroxide.
[0301] Suitable acids for the ester cleavage are generally
sulphuric acid, hydrogen chloride/hydrochloric acid, hydrogen
bromide/hydrobromic acid, phosphoric acid, acetic acid,
trifluoroacetic acid, toluenesulphonic acid, methanesulphonic acid
or trifluoromethanesulphonic acid, or mixtures thereof, optionally
with addition of water. Preference is given to using hydrogen
chloride or trifluoroacetic acid.
[0302] The ester cleavage is effected generally within a
temperature range of from -20.degree. C. to +100.degree. C.,
preferably at from 0.degree. C. to +50.degree. C.
[0303] The coupling reactions (V)+(VI).fwdarw.(I),
(VII)+(VI).fwdarw.(VIII) and (XI)+(VI).fwdarw.(XII) [amide
formation] can be carried out with the aid of a condensing or
activating agent, or via the intermediate stage of the
corresponding carboxylic acid chlorides.
[0304] Suitable such condensing or activating agents are, for
example, carbodiimides such as N,N'-diethyl-, N,N'-dipropyl-,
N,N'-diisopropyl-, N,N'-dicyclohexylcarbodiimide (DCC) or
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC),
phosgene derivatives such as N,N'-carbonyldiimidazole (CDI) or
isobutyl chloroformate, 1,2-oxazolium compounds such as
2-ethyl-5-phenyl-1,2-oxazolium 3-sulphate or
2-tert-butyl-5-methylisoxazolium perchlorate, acylamino compounds
such as 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline,
.alpha.-chloroenamines such as
1-chloro-2-methyl-1-dimethylamino-1-propene, phosphorus compounds
such as propanephosphonic anhydride, diethyl cyanophosphonate,
bis(2-oxo-3-oxazolidinyl)phosphoryl chloride,
benzotriazol-1-yloxytris(dimethylamino)phosphonium
hexafluorophosphate or
benzotriazol-1-yloxytris(pyrrolidino)phosphonium
hexafluorophosphate (PyBOP), or uronium compounds such as
O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
tetrafluoroborate (TBTU),
O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (HBTU),
2-(2-oxo-1-(2H)-pyridyl)-1,1,3,3-tetramethyluronium
tetrafluoroborate (TPTU),
O-(7-azabenzotriazol-1-yl)-N,N,N,N'-tetramethyluronium
hexafluorophosphate (HATU) or
O-(1H-6-chlorobenzotriazol-1-yl)-1,1,3,3-tetramethyluronium
tetrafluoroborate (TCTU), optionally in combination with further
auxiliaries such as 1-hydroxybenzotriazole (HOBt) or
N-hydroxysuccinimide (HOSu), and also as base alkali metal
carbonates, for example sodium carbonate or potassium carbonate, or
tertiary amine bases such as triethylamine, N-methylmorpholine
(NMM), N-methylpiperidine (NMP), N,N-diisopropylethylamine,
pyridine or 4-N,N-dimethylaminopyridine (DMAP). Preference is given
to using O-(7-azabenzotriazol-1-yl)-N,N,N,N'-tetramethyluronium
hexafluorophosphate (HATU) in combination with
N,N-diisopropylethylamine, or
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC)
in combination with 1-hydroxybenzotriazole (HOBt) and
triethylamine.
[0305] In the case in which the reaction is carried out in two
steps via the corresponding carboxylic acid chlorides, coupling
with the amine component (VI) is carried out in the presence of a
customary auxiliary base such as sodium carbonate, potassium
carbonate, triethylamine, N-methylmorpholine (NMM),
N-methylpiperidine (NMP), N,N-diisopropylethylamine, pyridine,
2,6-dimethylpyridine, 4-N,N-dimethylaminopyridine (DMAP),
1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or
1,5-diazabicyclo[4.3.0]non-5-ene (DBN); preference is given to
using N,N-diisopropylethylamine. For their part, the carboxylic
acid chlorides are prepared in a customary manner by treating the
carboxylic acid (V), (VII) or (XI) with thionyl chloride or oxalyl
chloride in an inert solvent such as dichloromethane.
[0306] Inert solvents for the coupling reactions mentioned are, for
example, ethers such as diethyl ether, diisopropyl ether, methyl
tert-butyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane
or bis(2-methoxyethyl) ether, hydrocarbons such as benzene,
toluene, xylene, pentane, hexane or cyclohexane, halogenated
hydrocarbons such as dichloromethane, trichloromethane, carbon
tetrachloride, 1,2-dichloroethane, trichloroethylene or
chlorobenzene, or polar aprotic solvents such as acetone, methyl
ethyl ketone, acetonitrile, butyronitrile, ethyl acetate, pyridine,
dimethyl sulphoxide (DMSO), N,N-dimethylformamide (DMF),
N,N'-dimethylpropyleneurea (DMPU) or N-methylpyrrolidinone (NMP).
It is also possible to use mixtures of such solvents. Preference is
given to using dichloromethane, tetrahydrofuran,
N,N-dimethylformamide or mixtures of these solvents.
[0307] The couplings are generally carried out within a temperature
range of from -20.degree. C. to +60.degree. C., preferably at from
0.degree. C. to +40.degree. C.
[0308] Simultaneous removal of the N.sup.3-benzyl protective group
and the ester radical T.sup.1 in process step (X).fwdarw.(XI) is
expediently carried out by treating (X) with a strong Lewis acid
such as, in particular, excess aluminium trichloride, in an inert
solvent such as toluene, xylene or chlorobenzene in a temperature
range of from +20.degree. C. to +120.degree. C., preferably in a
temperature range of from +40.degree. C. to +70.degree. C.
[0309] The reaction (XII)+(XIV).fwdarw.(I) is carried out under the
customary conditions of a Mitsunobu reaction in the presence of
triphenylphosphine and an azodicarboxylate such as diethyl
azodicarboxylate (DEAD) or diisopropyl azodicarboxylate (DIAD)
[see, for example, D. L. Hughes, Org. Reactions 42, 335 (1992); D.
L. Hughes, Org. Prep. Proced. Int. 28 (2), 127 (1996)]. The
preferred inert solvent used for this reaction is
tetrahydrofuran.
[0310] The process steps described above can be carried out at
atmospheric, elevated or reduced pressure (for example in the range
from 0.5 to 5 bar); in general, the reactions are each carried out
at atmospheric pressure.
[0311] Compounds of the formula (II) in which R.sup.1 represents
methyl or ethyl can be prepared by reacting a compound of the
formula (XV)
##STR00045##
in which T.sup.1 has the meaning given above, [0312] R.sup.1A
represents methyl or ethyl and T.sup.2 represents methyl or ethyl
in the presence of a base either (a) initially with a phosgene
equivalent such as N,N'-carbonyldiimidazole and then with an amine
of the formula (XVI)
##STR00046##
[0312] in which R.sup.2 has the meaning given above, or (b) with an
isocyanate of the formula (XVII)
##STR00047##
in which R.sup.2 has the meaning given above, to give a compound of
the formula (XVIII)
##STR00048##
in which R.sup.1A, R.sup.2, T.sup.1 and T.sup.2 have the meanings
given above and then cyclizing this by treatment with a base to
give the compound of the formula (II-A)
##STR00049##
in which R.sup.1A, R.sup.2 and T.sup.1 have the meanings given
above.
[0313] Inert solvents for the conversion of the aminothiophene (XV)
into the urea derivative (XVIII) with the aid of
N,N'-carbonyldiimidazole and the amine (XVI) or using the
isocyanate (XVII) are, for example, ethers such as diethyl ether,
diisopropyl ether, methyl tert-butyl ether, tetrahydrofuran,
1,4-dioxane, 1,2-dimethoxyethane or bis(2-methoxyethyl) ether,
hydrocarbons such as benzene, toluene, xylene, pentane, hexane or
cyclohexane, halogenated hydrocarbons such as dichloromethane,
trichloromethane, carbon tetrachloride, 1,2-dichloroethane,
trichloroethylene or chlorobenzene, or polar aprotic solvents such
as acetone, methyl ethyl ketone, acetonitrile, butyronitrile, ethyl
acetate, pyridine, dimethyl sulphoxide (DMSO),
N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA),
N,N'-dimethylpropyleneurea (DMPU) or N-methylpyrrolidinone (NMP).
It is also possible to use mixtures of these solvents. Preference
is given to using dichloromethane or tetrahydrofuran.
[0314] Preferred auxiliary bases used for these reactions are
tertiary amine bases such as triethylamine, N-methylmorpholine
(NMM), N-methylpiperidine (NMP), N,N-diisopropylethylamine,
pyridine or 4-N,N-dimethylaminopyridine (DMAP); preference is given
to triethylamine.
[0315] As alternative phosgene equivalents, in addition to
N,N'-carbonyldiimidazole, trichloromethyl chloroformate
("diphosgene"), bis(trichloromethyl) carbonate ("triphosgene") or
similar reagents may be considered.
[0316] The reactions are generally carried out in a temperature
range from 0.degree. C. to +100.degree. C., preferably at from
+20.degree. C. to +60.degree. C.
[0317] The base-induced cyclization reaction (XVIII).fwdarw.(II-A)
is preferably carried out with the aid of an alkali metal alkoxide
such as sodium methoxide or potassium methoxide, sodium ethoxide or
potassium ethoxide or sodium tert-butoxide or potassium
tert-butoxide in the alcohol in question as solvent or with the aid
of an alkali metal hydride such as sodium hydride or potassium
hydride in tetrahydrofuran or N,N-dimethylformamide as inert
solvent; preference is given to using sodium ethoxide in ethanol.
The reaction is generally carried out in a temperature range of
from 0.degree. C. to +100.degree. C., preferably at from
+20.degree. C. to +60.degree. C. [for the synthesis sequence
(XV).fwdarw.(XVIII).fwdarw.(II-A) generally cf., for example, also
the processes described in EP 1 847 541-A1 for preparing other
thienouracil derivatives].
[0318] For their part, the compounds of the formula (XV) can be
obtained by a route known from the literature via the 3-component
reaction of an acetoacetic acid or .beta.-ketovaleric acid ester
(for R.sup.A=methyl or ethyl) using a .alpha.-cyanoacetic ester and
elemental sulphur [Gewald reaction; see, for example, B. P.
McKibben et al., Tetrahedron Lett. 40, 5471-5474 (1999) and the
literature cited therein].
[0319] Compounds of the formula (II) in which R.sup.1 represents
hydrogen can be prepared by converting a compound of the formula
(XIX)
##STR00050##
in which R.sup.2 has the meaning given above, with a mixture of
phosphorus oxychloride and N,N-dimethylformamide into a compound of
the formula (XX)
##STR00051##
in which R.sup.2 has the meaning given above, and then condensing
this in the presence of a base with an .alpha.-mercaptoacetic ester
of the formula (XXI)
##STR00052##
in which T.sup.1 has the meaning given above to give the compound
of the formula (II-B)
##STR00053##
in which R.sup.2 and T.sup.1 have the meanings given above.
[0320] The conversion of the barbituric acid derivative (XIX) into
the 6-chloro-5-formylpyrimidinedione (XX) is carried out via a
regioselective Vilsmaier-Haack reaction by treating (XIX) with a
pre-formed mixture of phosphorus oxychloride and
N,N-dimethylformamide which is used in a large excess and
simultaneously also serves as solvent [cf., for example, K. Tanaka
et al., Chem. Pharm. Bull. 35 (4), 1397-1404 (1987)]. The reaction
is carried out in a temperature range of from +20.degree. C. to
+120.degree. C.
[0321] Bases suitable for the subsequent condensation reaction
(XX)+(XXI).fwdarw.(II-B) are in particular alkali metal carbonates
such as lithium carbonate, sodium carbonate, potassium carbonate or
caesium carbonate, alkali metal alkoxides such as sodium methoxide
or potassium methoxide, sodium ethoxide or potassium ethoxide or
sodium tert-butoxide or potassium tert-butoxide, or alkali metal
hydrides such as sodium hydride or potassium hydride; sodium
carbonate or potassium carbonate are preferably used [cf. also K.
Hirota et al., J. Heterocycl. Chem. 27 (3), 717-721 (1990)].
[0322] The reaction is preferably carried out in an alcoholic
solvent such as methanol, ethanol, isopropanol or tert-butanol, or
in an inert polar-aprotic solvent such as N,N-dimethylformamide
(DMF), N,N'-dimethylpropyleneurea (DMPU) or N-methylpyrrolidinone
(NMP), in a temperature range of from +20.degree. C. to
+150.degree. C., and it has been found to be advantageous to carry
out the reaction under microwave irradiation. The solvent used is
preferably ethanol.
[0323] For their part, the compounds of the formula (XIX) can be
prepared by a customary process by base-induced condensation of a
malonic ester of the formula (XXII)
##STR00054##
in which T.sup.3 represents methyl or ethyl with a urea derivative
of the formula (XXIII)
##STR00055##
in which R.sup.2 has the meaning given above.
[0324] The condensation (XXII)+(XXIII).fwdarw.(XIX) is usually
carried out with the aid of an alkali metal alkoxide such as sodium
methoxide or potassium methoxide, sodium ethoxide or potassium
ethoxide or sodium tert-butoxide or potassium tert-butoxide in the
alcohol in question as solvent or with the aid of an alkali metal
hydride such as sodium hydride or potassium hydride in
tetrahydrofuran or N,N-dimethylformamide as inert solvent;
preference is given to using sodium ethoxide in ethanol. The
reaction is generally carried out in a temperature range of from
+20.degree. C. to +100.degree. C.
[0325] Using the process described above (for R.sup.1=methyl, ethyl
or hydrogen), it is not possible to obtain compounds of the formula
(II) in which R.sup.1 represents difluoromethyl or trifluoromethyl,
or only in low yields (<10%). Accordingly, the present invention
furthermore provides a novel process for preparing compounds of the
formula (II-C)
##STR00056##
in which R.sup.2 has the meaning given above, R.sup.1F represents
difluoromethyl or trifluoromethyl and T.sup.1 represents
(C.sub.1-C.sub.4)-alkyl or benzyl, characterized in that a compound
of the formula (XIX)
##STR00057##
in which R.sup.2 has the meaning given above, is converted with
phosphorus oxychloride into a compound of the formula (XXIV)
##STR00058##
in which R.sup.2 has the meaning given above, then in the presence
of excess pyridine is reacted with an anhydride of the formula
(XXV)
##STR00059##
in which R.sup.1F has the meaning given above to give a betaine
compound of the formula (XXVI)
##STR00060##
in which R.sup.1F and R.sup.2 have the meanings given above and
these are then condensed in the presence of a base with an
.alpha.-mercaptoacetic ester of the formula (XXI)
##STR00061##
in which T.sup.1 has the meaning given above to give the compound
(II-C).
[0326] The conversion of the barbituric acid derivative (XIX) into
the 6-chloropyrimidinedione (XXIV) is carried out with the aid of
excess phosphorus oxychloride in an aqueous alcohol such as
methanol or ethanol as solvent in a temperature range of from
0.degree. C. to +100.degree. C.
[0327] Subsequent conversion into the pyridinium enolate betaine
(XXVI) is carried out analogously to a method described in the
literature for the synthesis of 3-substituted chromone derivatives
[I. Yokoe et al., Chem. Pharm. Bull. 42 (8), 1697-1699 (1994)] by
treating the 6-chloropyrimidinedione (XXIV) in the presence of a
relatively large excess of pyridine (about ten-fold) with the
anhydride (XXV). The reaction is generally carried out in a
temperature range of from 0.degree. C. to +40.degree. C., and the
inert solvent used is preferably acetonitrile.
[0328] Finally, the condensation of the betaine (XXVI) with the
mercaptoacetic ester (XXI) to give the target compound (II-C) is
carried out in a manner analogous to that described above for the
reaction (XX)+(XXI).fwdarw.(II-B), and here, too, it is
advantageous to carry out the reaction under microwave
irradiation.
[0329] The intermediates of the formula (IX) from process [B],
which are protected temporarily at the uracil N.sup.3 atom, can be
obtained in an analogous manner with the aid of the reaction
sequences described above by employing, instead of the compounds
(XVI), (XVII) or (XXIII), the corresponding benzyl derivatives, for
example compounds of the formula (XXVII) or (XXVIII)
##STR00062##
in which R.sup.7A and R.sup.7B have the meanings given above.
[0330] Compounds of the formula (IV) in which R.sup.1 represents
difluoromethyl can also be obtained by initially preparing,
starting with a compound of the formula (IV-A)
##STR00063##
in which R.sup.2, R.sup.3 and T.sup.1 have the meanings given
above, by treatment with N-bromosuccinimide (NBS) in the presence
of catalytic 2,2'-azobis(2-methylpropionitrile) (AIBN), the
bromomethyl compound (XXIX)
##STR00064##
in which R.sup.2, R.sup.3 and T.sup.1 have the meanings given
above, then oxidizing this by known methods to the formyl compound
(XXX)
##STR00065##
in which R.sup.2, R.sup.3 and T.sup.1 have the meanings given
above, and then fluorinating to give the difluoromethyl compound
(IV-B)
##STR00066##
in which R.sup.2, R.sup.3 and T.sup.1 have the meanings given
above.
[0331] The oxidation in reaction step (XXIX).fwdarw.(XXX) is
preferably carried out with the aid of N-methylmorpholine N-oxide
(NMO) in the presence of molecular sieve [cf., for example, D. R.
Levine et al., J. Am. Chem. Soc. 2014, 136 (19), 7132-7139]. The
reaction is generally carried out in a temperature range of from
-20.degree. C. to +25.degree. C. in an inert solvent such as, for
example, acetonitrile.
[0332] Suitable for the deoxyfluorination in process step
(XXX).fwdarw.(IV-B) are known agents such as diethylaminosulphur
trifluoride (DAST), morpholinosulphur trifluoride (Morpho-DAST) or
bis(2-methoxyethyl)aminosulphur trifluoride (Deoxo-Fluor.RTM.). The
reaction is usually carried out in a temperature range of from
-10.degree. C. to +25.degree. C. in an inert solvent such as, for
example, dichloromethane or tetrahydrofuran.
[0333] Compounds of the formula (IV) in which R.sup.1 represents
fluoromethyl, i.e. compounds of the formula (IV-C)
##STR00067##
in which R.sup.2, R.sup.3 and T.sup.1 have the meanings given
above, can be prepared in a simple manner by a substitution
reaction of the bromomethyl compound (XXIX) described above with a
fluoride such as, for example potassium fluoride, caesium fluoride
or tetra-n-butylammonium fluoride (TBAF). The reaction is generally
carried out in a temperature range of from 0.degree. C. to
+60.degree. C. in an inert solvent such as acetone, acetonitrile,
N,N-dimethylformamide (DMF) or tetrahydrofuran or mixtures
thereof.
[0334] Compounds of the formula (IV) in which R.sup.1 represents
1-fluoromethyl, i.e. compounds of the formula (IV-D)
##STR00068##
in which R.sup.2, R.sup.3 and T.sup.1 have the meanings given above
can be obtained by converting the formyl compound (XXX) described
above with methylmagnesium bromide under customary conditions at
about 0.degree. C. into the 1-hydroxyethyl compound (XXXI)
##STR00069##
in which R.sup.2, R.sup.3 and T.sup.1 have the meanings given above
and then treating this in a manner analogous to that described
above for the transformation (XXX).fwdarw.(IV-B) with a
fluorinating agent such as diethylaminosulphur trifluoride (DAST)
or bis(2-methoxyethyl)aminosulphur trifluoride
(Deoxo-Fluor.RTM.).
[0335] The intermediates of the formulae (IV-B), (IV-C) and (IV-D)
which can be obtained in this manner are then converted further
according to the reaction sequence (IV).fwdarw.(V) and
(V)+(VI).fwdarw.(I) described above under [A-1] into the
corresponding compounds of the formula (I) according to the
invention.
[0336] An alternative process for the preparation of compounds of
the formula (V-A)
##STR00070##
in which R.sup.2 and R.sup.3 have the meanings given above and
R.sup.1A represents methyl or ethyl consists in initially
converting a compound of the formula (XXXII)
##STR00071##
in which R.sup.1A has the meaning given above and T.sup.2
represents methyl or ethyl analogously to the reaction sequence
(XV).fwdarw.(XVIII).fwdarw.(II-A) and (II).fwdarw.(IV) described
above into a compound of the formula (XXXIII)
##STR00072##
in which R.sup.1A, R.sup.2 and R.sup.3 have the meanings given
above, then formylating these with a mixture of
N,N-dimethylformamide and phosphorus oxychloride to give a compound
of the formula (XXXIV)
##STR00073##
in which R.sup.1A, R.sup.2 and R.sup.3 have the meanings given
above, and finally oxidizing to the carboxyl compound of the
formula (V-A).
[0337] The transformation (XXXIII).fwdarw.(XXXIV) is carried out
under the customary conditions of a Vilsmaier-Haack reaction using
a mixture of N,N-dimethylformamide and phosphorus oxychloride which
is employed in a large excess and simultaneously also serves as
solvent. The reaction is generally carried out in a temperature
range of from 0.degree. C. to +120.degree. C.
[0338] The oxidizing agent used for the transformation
(XXXIV).fwdarw.(V-A) is preferably sodium chlorite in the presence
of hydrogenphosphate-buffered sulfaminic acid [cf., for example, WO
2008/115912-A1, Example 2; M. O. Anderson et al., J. Med. Chem.
2012, 55 (12), 5942-5950]. The reaction is usually carried out in a
temperature range of from -10.degree. C. to +20.degree. C. in a
mixture of water with acetone or 1,4-dioxane as inert solvent.
[0339] The compounds of the formulae (III), (VI), (XIII), (XIV),
(XVI), (XVII), (XXI), (XXII), (XXIII), (XXV), (XXVII), (XXVIII) and
(XXXII) are either commercially available or described as such in
the literature, or they can be prepared from other commercially
available compounds by methods familiar to the person skilled in
the art and known from the literature. Numerous detailed procedures
and further literature references can also be found in the
Experimental Part, in the section on the preparation of the
starting compounds and intermediates.
[0340] The preparation of the compounds according to the invention
can be illustrated by the following reaction schemes:
##STR00074##
##STR00075##
##STR00076## ##STR00077##
##STR00078##
##STR00079##
##STR00080##
##STR00081##
##STR00082##
##STR00083##
##STR00084##
[0341] The compounds according to the invention have valuable
pharmacological properties and can be used for prevention and
treatment of diseases in humans and animals.
[0342] The compounds according to the invention are potent and
selective antagonists of the adenosine A2b receptor and are
therefore suitable in particular for the treatment and/or
prevention of disorders and pathological processes, especially
those where the A2b receptor is involved in the course of an
inflammatory event and/or tissue or vessel reconstruction.
[0343] In the context of the present invention, these include in
particular disorders such as the group of the interstitial
idiopathic pneumonias which includes idiopathic pulmonary fibrosis
(IPF), acute interstitial pneumonia, non-specific interstitial
pneumonias, lymphoid interstitial pneumonias, respiratory
bronchiolitis with interstitial lung disease, cryptogenic
organizing pneumonias, desquamative interstitial pneumonias and
non-classifiable idiopathic interstitial pneumonias, furthermore
granulomatous interstitial lung diseases, interstitial lung
diseases of known aetiology and other interstitial lung diseases of
unknown aetiology, pulmonary arterial hypertension (PAH) and other
forms of pulmonary hypertension (PH), bronchiolitis obliterans
syndrome (BOS), chronic-obstructive pulmonary disease (COPD), acute
respiratory distress syndrome (ARDS), acute lung injury (ALI),
alpha-1-antitrypsin deficiency (AATD), pulmonary emphysema (for
example pulmonary emphysema induced by cigarette smoke), cystic
fibrosis (CF), inflammatory and fibrotic disorders of the kidney,
chronic intestinal inflammations (IBD, Crohn's disease, ulcerative
colitis), peritonitis, peritoneal fibrosis, rheumatoid disorders,
multiple sclerosis, inflammatory and fibrotic skin disorders,
sickle cell anaemia and inflammatory and fibrotic eye
disorders.
[0344] The compounds according to the invention can additionally be
used for treatment and/or prevention of asthmatic disorders of
varying severity with intermittent or persistent characteristics
(refractive asthma, bronchial asthma, allergic asthma, intrinsic
asthma, extrinsic asthma, medicament- or dust-induced asthma), of
various forms of bronchitis (chronic bronchitis, infectious
bronchitis, eosinophilic bronchitis), of bronchiectasis, pneumonia,
farmer's lung and related disorders, coughs and colds (chronic
inflammatory cough, iatrogenic cough), inflammation of the nasal
mucosa (including medicament-related rhinitis, vasomotoric rhinitis
and seasonal allergic rhinitis, for example hay fever) and of
polyps.
[0345] In addition, the compounds according to the invention can be
used for the treatment and/or prevention of cardiovascular
disorders such as, for example, high blood pressure (hypertension),
heart failure, coronary heart disease, stable and unstable angina
pectoris, renal hypertension, peripheral and cardiac vascular
disorders, arrhythmias, atrial and ventricular arrhythmias and
impaired conduction such as, for example, atrioventricular blocks
degrees I-III, supraventricular tachyarrhythmia, atrial
fibrillation, atrial flutter, ventricular fibrillation, ventricular
flutter, ventricular tachyarrhythmia, Torsade de pointes
tachycardia, atrial and ventricular extrasystoles, AV-junctional
extrasystoles, sick sinus syndrome, syncopes, AV-nodal re-entry
tachycardia, Wolff-Parkinson-White syndrome, acute coronary
syndrome (ACS), autoimmune cardiac disorders (pericarditis,
endocarditis, valvolitis, aortitis, cardiomyopathies), boxer
cardiomyopathy, aneurysms, shock such as cardiogenic shock, septic
shock and anaphylactic shock, furthermore for the treatment and/or
prophylaxis of thromboembolic disorders and ischaemias such as
myocardial ischaemia, myocardial infarction, stroke, cardiac
hypertrophy, transient and ischaemic attacks, preeclampsia,
inflammatory cardiovascular disorders, spasms of the coronary
arteries and peripheral arteries, oedema formation such as, for
example, pulmonary oedema, cerebral oedema, renal oedema or oedema
caused by heart failure, peripheral circulatory disturbances,
reperfusion damage, arterial and venous thromboses,
microalbuminuria, myocardial insufficiency, endothelial
dysfunction, micro- und macrovascular damage (vasculitis), and also
to prevent restenoses, for example after thrombolysis therapies,
percutaneous transluminal angioplasties (PTA), percutaneous
transluminal coronary angioplasties (PTCA), heart transplants and
bypass operations.
[0346] In the context of the present invention, the term "heart
failure" encompasses both acute and chronic forms of heart failure,
and also specific or related disease types thereof, such as acute
decompensated heart failure, right heart failure, left heart
failure, global failure, ischaemic cardiomyopathy, dilated
cardiomyopathy, hypertrophic cardiomyopathy, idiopathic
cardiomyopathy, congenital heart defects, heart valve defects,
heart failure associated with heart valve defects, mitral valve
stenosis, mitral valve insufficiency, aortic valve stenosis, aortic
valve insufficiency, tricuspid valve stenosis, tricuspid valve
insufficiency, pulmonary valve stenosis, pulmonary valve
insufficiency, combined heart valve defects, myocardial
inflammation (myocarditis), chronic myocarditis, acute myocarditis,
viral myocarditis, diabetic heart failure, alcoholic
cardiomyopathy, cardiac storage disorders and diastolic and
systolic heart failure.
[0347] The compounds according to the invention are also suitable
for the treatment and/or prevention of renal disorders, in
particular renal insufficiency and kidney failure. In the context
of the present invention, the terms "renal insufficiency" and
"kidney failure" encompass both acute and chronic manifestations
thereof and also underlying or related renal disorders such as
renal hypoperfusion, intradialytic hypotension, obstructive
uropathy, glomerulopathies, glomerulonephritis, acute
glomerulonephritis, glomerulosclerosis, tubulointerstitial
diseases, nephropathic disorders such as primary and congenital
kidney disease, nephritis, immunological kidney disorders such as
kidney transplant rejection and immunocomplex-induced kidney
disorders, nephropathy induced by toxic substances, nephropathy
induced by contrast agents, diabetic and non-diabetic nephropathy,
pyelonephritis, renal cysts, nephrosclerosis, hypertensive
nephrosclerosis and nephrotic syndrome which can be characterized
diagnostically, for example by abnormally reduced creatinine and/or
water excretion, abnormally elevated blood concentrations of urea,
nitrogen, potassium and/or creatinine, altered activity of renal
enzymes, for example glutamyl synthetase, altered urine osmolarity
or urine volume, elevated microalbuminuria, macroalbuminuria,
lesions on glomerulae and arterioles, tubular dilatation,
hyperphosphataemia and/or need for dialysis. The present invention
also comprises the use of the compounds according to the invention
for the treatment and/or prevention of sequelae of renal
insufficiency, for example hypertension, pulmonary oedema, heart
failure, uraemia, anaemia, electrolyte disturbances (for example
hyperkalaemia, hyponatraemia) and disturbances in bone and
carbohydrate metabolism.
[0348] In addition, the compounds according to the invention are
suitable for the treatment and/or prevention of disorders of the
urogenital system such as, for example, benign prostate syndrome
(BPS), benign prostate hyperplasia (BPH), benign prostate
enlargement (BPE), bladder outlet obstruction (BOO), lower urinary
tract syndromes (LUTS), neurogenic overactive bladder (OAB) and
(IC), incontinence such as, for example, mixed urinary
incontinence, urge urinary incontinence, stress urinary
incontinence or overflow urinary incontinence (MUI, UUI, SUI, OUI),
pelvic pain, and also erectile dysfunction and female sexual
dysfunction.
[0349] In addition, the compounds according to the invention have
antiinflammatory action and can therefore be used as
antiinflammatory agents for treatment and/or prevention of sepsis
(SIRS), multiple organ failure (MODS, MOF), inflammatory disorders
of the kidney, chronic intestinal inflammations (IBD, Crohn's
disease, ulcerative colitis), pancreatitis, peritonitis, cystitis,
urethritis, prostatitis, epidimytitis, oophoritis, salpingitis,
vulvovaginitis, rheumatoid disorders, inflammatory disorders of the
central nervous system, multiple sclerosis, inflammatory skin
disorders and inflammatory eye disorders.
[0350] Furthermore, the compounds according to the invention are
suitable for treatment and/or prevention of fibrotic disorders of
the internal organs, for example the lung, the heart, the kidney,
the bone marrow and in particular the liver, and also
dermatological fibroses and fibrotic eye disorders. In the context
of the present invention, the term "fibrotic disorders" includes in
particular disorders such as hepatic fibrosis, cirrhosis of the
liver, pulmonary fibrosis, endomyocardial fibrosis, nephropathy,
glomerulonephritis, interstitial renal fibrosis, fibrotic damage
resulting from diabetes, bone marrow fibrosis, peritoneal fibrosis
and similar fibrotic disorders, scleroderma, morphoea, keloids,
hypertrophic scarring, naevi, diabetic retinopathy, proliferative
vitroretinopathy and disorders of the connective tissue (for
example sarcoidosis). The compounds according to the invention can
also be used for promoting wound healing, for controlling
postoperative scarring, for example as a result of glaucoma
operations and cosmetically for ageing or keratinized skin.
[0351] The compounds according to the invention can also be
employed for the treatment and/or prevention of anaemias such as
haemolytic anaemias, in particular haemoglobinopathies such as
sickle cell anaemia and thalassaemias, megaloblastic anaemias, iron
deficiency anaemias, anaemias owing to acute blood loss,
displacement anaemias and aplastic anaemias.
[0352] Moreover, the compounds according to the invention are
suitable for the treatment of cancers such as, for example, skin
cancer, brain tumours, breast cancer, bone marrow tumours,
leukaemias, liposarcomas, carcinomas of the gastrointestinal tract,
of the liver, the pancreas, the lung, the kidney, the ureter, the
prostate and the genital tract and also of malignant tumours of the
lymphoproliferative system, for example Hodgkin- and
Non-Hodgkin-lymphoma.
[0353] In addition, the compounds according to the invention can be
used for the treatment and/or prevention of arteriosclerosis,
impaired lipid metabolism and dyslipidaemias (hypolipoproteinaemia,
hypertriglyceridaemias, hyperlipidaemia, combined hyperlipidaemias,
hypercholesterolaemia, abetalipoproteinaemia, sitosterolaemia),
xanthomatosis, Tangier disease, adiposity, obesity, metabolic
disorders (metabolic syndrome, hyperglycaemia, insulin-dependent
diabetes, non-insulin-dependent diabetes, gestation diabetes,
hyperinsulinaemia, insulin resistence, glucose intolerance and
diabetic sequelae, such as retinopathy, nephropathy and
neuropathy), of disorders of the gastrointestinal tract and the
abdomen (glossitis, gingivitis, periodontitis, oesophagitis,
eosinophilic gastroenteritis, mastocytosis, Crohn's disease,
colitis, proctitis, anus pruritis, diarrhoea, coeliac disease,
hepatitis, hepatic fibrosis, cirrhosis of the liver, pancreatitis
and cholecystitis), of disorders of the central nervous system and
neurodegenerative disorders (stroke, Alzheimer's disease,
Parkinson's disease, dementia, epilepsy, depressions, multiple
sclerosis), immune disorders, thyroid disorders (hyperthyreosis),
skin disorders (psoriasis, acne, eczema, neurodermitis, various
forms of dermatitis, such as, for example, dermatitis abacribus,
actinic dermatitis, allergic dermatitis, ammonia dermatitis,
facticial dermatitis, autogenic dermatitis, atopic dermatitis,
dermatitis calorica, dermatitis combustionis, dermatitis
congelationis, dermatitis cosmetica, dermatitis escharotica,
exfoliative dermatitis, dermatitis gangraenose, stasis dermatitis,
dermatitis herpetiformis, lichenoid dermatitis, dermatitis
linearis, dermatitis maligna, medicinal eruption dermatitis,
dermatitis palmaris and plantaris, parasitic dermatitis,
photoallergic contact dermatitis, phototoxic dermatitis, dermatitis
pustularis, seborrhoeic dermatitis, sunburn, toxic dermatitis,
Meleney's ulcer, dermatitis veneata, infectious dermatitis,
pyrogenic dermatitis and perioral dermatitis, and also keratitis,
bullosis, vasculitis, cellulitis, panniculitis, lupus
erythematosus, erythema, lymphomas, skin cancer, Sweet syndrome,
Weber-Christian syndrome, scar formation, wart formation,
chilblains), of inflammatory eye diseases (saccoidosis,
blepharitis, conjunctivitis, iritis, uveitis, chorioiditis,
ophthalmitis), viral diseases (caused by influenza, adeno and
corona viruses, such as, for example, HPV, HCMV, HIV, SARS), of
disorders of the skeletal bone and the joints and also the skeletal
muscle (multifarious forms of arthritis, such as, for example,
arthritis alcaptonurica, arthritis ankylosans, arthritis
dysenterica, arthritis exsudativa, arthritis fungosa, arthritis
gonorrhoica, arthritis mutilans, arthritis psoriatica, arthritis
purulenta, arthritis rheumatica, arthritis serosa, arthritis
syphilitica, arthritis tuberculosa, arthritis urica, arthritis
villonodularis pigmentosa, atypical arthritis, haemophilic
arthritis, juvenile chronic arthritis, rheumatoid arthritis and
metastatic arthritis, furthermore Still syndrome, Felty syndrome,
Sjorgen syndrome, Clutton syndrome, Poncet syndrome, Pott syndrome
and Reiter syndrome, multifarious forms of arthropathies, such as,
for example, arthropathia deformans, arthropathia neuropathica,
arthropathia ovaripriva, arthropathia psoriatica and arthropathia
tabica, systemic scleroses, multifarious forms of inflammatory
myopathies, such as, for example, myopathie epidemica, myopathie
fibrosa, myopathie myoglobinurica, myopathie ossificans, myopathie
ossificans neurotica, myopathie ossificans progressiva multiplex,
myopathie purulenta, myopathie rheumatica, myopathie trichinosa,
myopathie tropica and myopathie typhosa, and also the Giinther
syndrome and the Miinchmeyer syndrome), of inflammatory changes of
the arteries (multifarious forms of arteritis, such as, for
example, endarteritis, mesarteritis, periarteritis, panarteritis,
arteritis rheumatica, arteritis deformans, arteritis temporalis,
arteritis cranialis, arteritis gigantocellularis and arteritis
granulomatosa, and also Horton syndrome, Churg-Strauss syndrome and
Takayasu arteritis), of Muckle-Well syndrome, of Kikuchi disease,
of polychondritis, dermatosclerosis and also other disorders having
an inflammatory or immunological component, such as, for example,
cataract, cachexia, osteoporosis, gout, incontinence, lepra, Sezary
syndrome and paraneoplastic syndrome, for rejection reactions after
organ transplants and for wound healing and angiogenesis in
particular in the case of chronic wounds.
[0354] Owing to their property profile, the compounds according to
the invention are particularly suitable for the treatment and/or
prevention of interstitial lung diseases, especially idiopathic
pulmonary fibrosis (IPF), and also of pulmonary hypertension (PH),
bronchiolitis obliterans syndrome (BOS), chronic obstructive
pulmonary disease (COPD), asthma, cystic fibrosis (CF), myocardial
infarction, heart failure and haemoglobinopathies, in particular
sickle cell anemia.
[0355] The above-mentioned, well-characterized diseases in humans
can also occur with a comparable aetiology in other mammals and can
likewise be treated there with the compounds of the present
invention.
[0356] In the context of the present invention, the term
"treatment" or "treating" includes inhibition, retardation,
checking, alleviating, attenuating, restricting, reducing,
suppressing, repelling or healing of a disease, a condition, a
disorder, an injury or a health problem, or the development, the
course or the progression of such states and/or the symptoms of
such states. The term "therapy" is understood here to be synonymous
with the term "treatment".
[0357] The terms "prevention", "prophylaxis" or "preclusion" are
used synonymously in the context of the present invention and refer
to the avoidance or reduction of the risk of contracting,
experiencing, suffering from or having a disease, a condition, a
disorder, an injury or a health problem, or a development or
advancement of such states and/or the symptoms of such states.
[0358] The treatment or prevention of a disease, a condition, a
disorder, an injury or a health problem may be partial or
complete.
[0359] The present invention thus further provides for the use of
the compounds according to the invention for the treatment and/or
prevention of disorders, in particular the disorders mentioned
above.
[0360] The present invention further provides for the use of the
compounds according to the invention for producing a medicament for
the treatment and/or prevention of disorders, in particular the
disorders mentioned above.
[0361] The present invention further provides a medicament
comprising at least one of the compounds according to the
invention, for the treatment and/or prevention of disorders, in
particular the disorders mentioned above.
[0362] The present invention furthermore provides for the use of
the compounds according to the invention in a method for treatment
and/or prevention of disorders, in particular the disorders
mentioned above.
[0363] The present invention further provides a method for
treatment and/or prevention of disorders, in particular the
disorders mentioned above, using an effective amount of at least
one of the compounds according to the invention.
[0364] The compounds according to the invention can be used alone
or, if required, in combination with one or more other
pharmacologically active substances, provided that this combination
does not lead to undesirable and unacceptable side effects. The
present invention furthermore therefore provides medicaments
containing at least one of the compounds according to the invention
and one or more further active compounds, in particular for
treatment and/or prevention of the abovementioned disorders.
Preferred examples of active compounds suitable for combinations
include: [0365] organic nitrates and NO donors, for example sodium
nitroprusside, nitroglycerin, isosorbide mononitrate, isosorbide
dinitrate, molsidomine or SIN-1, and inhaled NO; [0366] compounds
which inhibit the degradation of cyclic guanosine monophosphate
(cGMP) and/or cyclic adenosine monophosphate (cAMP), for example
inhibitors of phosphodiesterases (PDE) 1, 2, 3, 4 and/or 5,
especially PDE 5 inhibitors such as sildenafil, vardenafil,
tadalafil, udenafil, dasantafil, avanafil, mirodenafil or
lodenafil; [0367] NO- and haem-independent activators of soluble
guanylate cyclase (sGC), such as in particular the compounds
described in WO 01/19355, WO 01/19776, WO 01/19778, WO 01/19780, WO
02/070462 and WO 02/070510; [0368] NO-independent but
haem-dependent stimulators of soluble guanylate cyclase (sGC), such
as in particular riociguat and the compounds described in WO
00/06568, WO 00/06569, WO 02/42301, WO 03/095451, WO 2011/147809,
WO 2012/004258, WO 2012/028647 and WO 2012/059549; [0369]
prostacyclin analogues and IP receptor agonists, by way of example
and with preference iloprost, beraprost, treprostinil, epoprostenol
or NS-304; [0370] edothelin receptor antagonists, by way of example
and with preference bosentan, darusentan, ambrisentan or
sitaxsentan; [0371] compounds which inhibit human neutrophile
elastase (HNE), by way of example and with preference sivelestat or
DX-890 (reltran); [0372] compounds which inhibit the signal
transduction cascade, by way of example and with preference from
the group of the kinase inhibitors, in particular from the group of
the tyrosine kinase and/or serine/threonine kinase inhibitors, by
way of example and with preference nintedanib, dasatinib,
nilotinib, bosutinib, regorafenib, sorafenib, sunitinib, cediranib,
axitinib, telatinib, imatinib, brivanib, pazopanib, vatalanib,
gefitinib, erlotinib, lapatinib, canertinib, lestaurtinib,
pelitinib, semaxanib or tandutinib; [0373] compounds which inhibit
the degradation and alteration of the extracellular matrix, by way
of example and with preference inhibitors of the matrix
metalloproteases (MMPs), especially inhibitors of stromelysin,
collagenases, gelatinases and aggrecanases (in this context
particularly of MMP-1, MMP-3, MMP-8, MMP-9, MMP-10, MMP-11 and
MMP-13) and of metalloelastase (MMP-12); [0374] compounds which
block the binding of serotonin to its receptor, by way of example
and with preference antagonists of the 5-HT.sub.2B receptor such as
PRX-08066; [0375] antagonists of growth factors, cytokines and
chemokines, by way of example and with preference antagonists of
TGF-.beta., CTGF, IL-1, IL-4, IL-5, IL-6, IL-8, IL-13 and
integrins; [0376] Rho kinase-inhibiting compounds, by way of
example and with preference fasudil, Y-27632, SLx-2119, BF-66851,
BF-66852, BF-66853, KI-23095 or BA-1049; [0377] compounds which
inhibit soluble epoxide hydrolase (sEH), for example
N,N'-dicyclohexylurea, 12-(3-adamantan-1-ylureido)dodecanoic acid
or 1-adamantan-1-yl-3-{5-[2-(2-ethoxyethoxy)ethoxy]pentyl}urea;
[0378] compounds which influence the energy metabolism of the
heart, by way of example and with preference etomoxir,
dichloroacetate, ranolazine or trimetazidine; [0379]
anti-obstructive agents as used, for example, for the therapy of
chronic obstructive pulmonary disease (COPD) or bronchial asthma,
by way of example and with preference from the group of the
inhalatively or systemically administered agonists of the
beta-adrenergic receptor (beta-mimetics) and the inhalatively
administered anti-muscarinergic substances; [0380]
antiinflammatory, immunomodulating, immunosuppressive and/or
cytotoxic agents, by way of example and with preference from the
group of the systemically or inhalatively administered
corticosteroids and also acetylcysteine, montelukast, azathioprine,
cyclophosphamide, hydroxycarbamide, azithromycin, IFN-.gamma.,
pirfenidone or etanercept; [0381] antifibrotic agents, by way of
example and with preference lysophosphatidic acid receptor 1
(LPA-1) antagonists, lysyl oxidase (LOX) inhibitors, lysyl
oxidase-like-2 inhibitors, vasoactive intestinal peptide (VIP), VIP
analogues, .alpha..sub.v.beta..sub.6-integrin antagonists,
cholchicine, IFN-.beta., D-penicillamine, inhibitors of the WNT
signal path or CCR2 antagonists; [0382] antithrombotic agents, by
way of example and with preference from the group of platelet
aggregation inhibitors, the anticoagulants and the profibrinolytic
substances; [0383] hypotensive active compounds, by way of example
and with preference from the group of the calcium antagonists,
angiotensin AII antagonists, ACE inhibitors, vasopeptidase
inhibitors, endothelin antagonists, renin inhibitors, alpha
receptor blockers, beta receptor blockers, mineralocorticoid
receptor antagonists and also the diuretics; [0384] lipid
metabolism modifiers, by way of example and with preference from
the group of the thyroid receptor agonists, cholesterol synthesis
inhibitors, by way of example and with preference HMG-CoA reductase
or squalene synthesis inhibitors, of the ACAT inhibitors, CETP
inhibitors, MTP inhibitors, PPAR-alpha, PPAR-gamma and/or
PPAR-delta agonists, cholesterol absorption inhibitors, lipase
inhibitors, polymeric bile acid adsorbents, bile acid reabsorption
inhibitors and lipoprotein(a) antagonists; and/or [0385]
chemotherapeutics like those employed, for example, for the therapy
of neoplasms in the lung or other organs.
[0386] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with a
beta-adrenergic receptor agonist, by way of example and with
preference albuterol, isoproterenol, metaproterenol, terbutalin,
fenoterol, formoterol, reproterol, salbutamol or salmeterol.
[0387] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with an
antimuscarinergic substance, by way of example and with preference
ipratropium bromide, tiotropium bromide or oxitropium bromide.
[0388] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with a
corticosteroid, by way of example and with preference prednisone,
prednisolone, methylprednisolone, triamcinolone, dexamethasone,
beclomethasone, betamethasone, flunisolide, budesonide or
fluticasone.
[0389] Antithrombotic agents are preferably understood to mean
compounds from the group of the platelet aggregation inhibitors,
the anticoagulants and the profibrinolytic substances.
[0390] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with a
platelet aggregation inhibitor, by way of example and with
preference aspirin, clopidogrel, ticlopidin or dipyridamole.
[0391] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with a
thrombin inhibitor, by way of example and with preference
ximelagatran, melagatran, dabigatran, bivalirudin or clexane.
[0392] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with a
GPIIb/IIIa antagonist such as, by way of example and with
preference tirofiban or abciximab.
[0393] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with a
factor Xa inhibitor, by way of example and with preference
rivaroxaban, apixaban, fidexaban, razaxaban, fondaparinux,
idraparinux, DU-176b, PMD-3112, YM-150, KFA-1982, EMD-503982,
MCM-17, MLN-1021, DX 9065a, DPC 906, JTV 803, SSR-126512 or
SSR-128428.
[0394] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with
heparin or with a low molecular weight (LMW) heparin
derivative.
[0395] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with a
vitamin K antagonist, by way of example and with preference
coumarin.
[0396] Hypotensive agents are preferably understood to mean
compounds from the group of the calcium antagonists, angiotensin
AII antagonists, ACE inhibitors, endothelin antagonists, renin
inhibitors, alpha-receptor blockers, beta-receptor blockers,
mineralocorticoid receptor antagonists, and the diuretics.
[0397] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with a
calcium antagonist, by way of example and with preference
nifedipine, amlodipine, verapamil or diltiazem.
[0398] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with an
alpha-1-receptor blocker, by way of example and with preference
prazosin.
[0399] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with a
beta-receptor blocker, by way of example and with preference
propranolol, atenolol, timolol, pindolol, alprenolol, oxprenolol,
penbutolol, bupranolol, metipranolol, nadolol, mepindolol,
carazalol, sotalol, metoprolol, betaxolol, celiprolol, bisoprolol,
carteolol, esmolol, labetalol, carvedilol, adaprolol, landiolol,
nebivolol, epanolol or bucindolol.
[0400] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with an
angiotensin AII antagonist, by way of example and with preference
losartan, candesartan, valsartan, telmisartan or embusartan.
[0401] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with an
ACE inhibitor, by way of example and with preference enalapril,
captopril, lisinopril, ramipril, delapril, fosinopril, quinopril,
perindopril or trandopril.
[0402] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with an
endothelin antagonist, by way of example and with preference
bosentan, darusentan, ambrisentan or sitaxsentan.
[0403] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with a
renin inhibitor, by way of example and with preference aliskiren,
SPP-600 or SPP-800.
[0404] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with a
mineralocorticoid receptor antagonist, by way of example and with
preference spironolactone or eplerenone.
[0405] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with a
diuretic, by way of example and with preference furosemide,
bumetanide, torsemide, bendroflumethiazide, chlorthiazide,
hydrochlorthiazide, hydroflumethiazide, methyclothiazide,
polythiazide, trichlormethiazide, chlorthalidone, indapamide,
metolazone, quinethazone, acetazolamide, dichlorophenamide,
methazolamide, glycerol, isosorbide, mannitol, amiloride or
triamterene.
[0406] Lipid metabolism modifiers are preferably understood to mean
compounds from the group of the CETP inhibitors, thyroid receptor
agonists, cholesterol synthesis inhibitors such as HMG-CoA
reductase inhibitors or squalene synthesis inhibitors, the ACAT
inhibitors, MTP inhibitors, PPAR-alpha, PPAR-gamma and/or
PPAR-delta agonists, cholesterol absorption inhibitors, polymeric
bile acid adsorbents, bile acid reabsorption inhibitors, lipase
inhibitors and the lipoprotein(a) antagonists.
[0407] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with a
CETP inhibitor, by way of example and with preference torcetrapib
(CP-529 414), JJT-705 or CETP vaccine (Avant).
[0408] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with a
thyroid receptor agonist, by way of example and with preference
D-thyroxin, 3,5,3'-triiodothyronin (T3), CGS 23425 or axitirome
(CGS 26214).
[0409] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with an
HMG-CoA reductase inhibitor from the class of statins, by way of
example and with preference lovastatin, simvastatin, pravastatin,
fluvastatin, atorvastatin, rosuvastatin or pitavastatin.
[0410] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with a
squalene synthesis inhibitor, by way of example and with preference
BMS-188494 or TAK-475.
[0411] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with an
ACAT inhibitor, by way of example and with preference avasimibe,
melinamide, pactimibe, eflucimibe or SMP-797.
[0412] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with an
MTP inhibitor, by way of example and with preference implitapide,
BMS-201038, R-103757 or JTT-130.
[0413] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with a
PPAR-gamma agonist, by way of example and with preference
pioglitazone or rosiglitazone.
[0414] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with a
PPAR-delta agonist, by way of example and with preference GW 501516
or BAY 68-5042.
[0415] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with a
cholesterol absorption inhibitor, by way of example and with
preference ezetimibe, tiqueside or pamaqueside.
[0416] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with a
lipase inhibitor, by way of example and with preference
orlistat.
[0417] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with a
polymeric bile acid adsorbent, by way of example and with
preference cholestyramine, colestipol, colesolvam, CholestaGel or
colestimide.
[0418] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with a
bile acid reabsorption inhibitor, by way of example and with
preference ASBT (=IBAT) inhibitors, for example AZD-7806, S-8921,
AK-105, BARI-1741, SC-435 or SC-635.
[0419] In a preferred embodiment of the invention, the compounds
according to the invention are administered in combination with a
lipoprotein(a) antagonist, by way of example and with preference
gemcabene calcium (CI-1027) or nicotinic acid.
[0420] Particular preference is given to combinations of the
compounds according to the invention with one or more further
active compounds selected from the group of the PDE 5 inhibitors,
sGC activators, sGC stimulators, prostacyclin analogs, endothelin
antagonists, of the antifibrotic agents, the antiinflammatory,
immunomodulating, immunosuppressive and/or cytotoxic agents and/or
the signal transduction cascade-inhibiting compounds.
[0421] The present invention further provides medicaments which
comprise at least one compound according to the invention,
typically together with one or more inert, nontoxic,
pharmaceutically suitable excipients, and the use thereof for the
aforementioned purposes.
[0422] The compounds according to the invention can act
systemically and/or locally. For this purpose, they can be
administered in a suitable manner, for example by the oral,
parenteral, pulmonal, nasal, sublingual, lingual, buccal, rectal,
dermal, transdermal, conjunctival or otic route, or as an implant
or stent.
[0423] The compounds according to the invention can be administered
in suitable administration forms for these administration
routes.
[0424] Suitable administration forms for oral administration are
those which work according to the prior art and release the
compounds according to the invention rapidly and/or in a modified
manner and which contain the compounds according to the invention
in crystalline and/or amorphized and/or dissolved form, for example
tablets (uncoated or coated tablets, for example with gastric
juice-resistant or retarded-dissolution or insoluble coatings which
control the release of the compound according to the invention),
tablets or films/oblates which disintegrate rapidly in the oral
cavity, films/lyophilizates or capsules (for example hard or soft
gelatin capsules), sugar-coated tablets, granules, pellets,
powders, emulsions, suspensions, aerosols or solutions.
[0425] Parenteral administration can bypass an absorption step
(e.g. intravenously, intraarterially, intracardially, intraspinally
or intralumbally) or include an absorption (e.g. inhalatively,
intramuscularly, subcutaneously, intracutaneously, percutaneously
or intraperitoneally). Suitable administration forms for parenteral
administration include injection and infusion formulations in the
form of solutions, suspensions, emulsions, lyophilizates or sterile
powders.
[0426] For the other administration routes, suitable examples are
inhalable medicament forms (including powder inhalers, nebulizers,
metered aerosols), nasal drops, solutions or sprays, tablets,
films/oblates or capsules for lingual, sublingual or buccal
administration, suppositories, ear or eye preparations, vaginal
capsules, aqueous suspensions (lotions, shaking mixtures),
lipophilic suspensions, ointments, creams, transdermal therapeutic
systems (e.g. patches), milk, pastes, foams, sprinkling powders,
implants or stents.
[0427] Oral and parenteral administration are preferred, especially
oral, intravenous and intrapulmonary (inhalative)
administration.
[0428] The compounds according to the invention can be converted to
the administration forms mentioned. This can be accomplished in a
manner known per se by mixing with inert, non-toxic,
pharmaceutically suitable excipients. These excipients include
carriers (for example microcrystalline cellulose, lactose,
mannitol), solvents (e.g. liquid polyethylene glycols), emulsifiers
and dispersing or wetting agents (for example sodium
dodecylsulphate, polyoxysorbitan oleate), binders (for example
polyvinylpyrrolidone), synthetic and natural polymers (for example
albumin), stabilizers (e.g. antioxidants, for example ascorbic
acid), colorants (e.g. inorganic pigments, for example iron oxides)
and flavour and/or odour correctants.
[0429] In general, it has been found to be advantageous in the case
of parenteral administration to administer amounts of from about
0.001 to 1 mg/kg, preferably about 0.01 to 0.5 mg/kg, of body
weight to achieve effective results. In the case of oral
administration the dosage is about 0.01 to 100 mg/kg, preferably
about 0.01 to 20 mg/kg and most preferably 0.1 to 10 mg/kg of body
weight. In the case of intrapulmonary administration, the amount is
generally about 0.1 to 50 mg per inhalation.
[0430] It may nevertheless be necessary where appropriate to
deviate from the stated amounts, specifically as a function of the
body weight, route of administration, individual response to the
active compound, nature of the preparation and time or interval
over which administration takes place. Thus, in some cases less
than the abovementioned minimum amount may be sufficient, while in
other cases the upper limit mentioned must be exceeded. In the case
of administration of greater amounts, it may be advisable to divide
them into several individual doses over the day.
[0431] The working examples which follow illustrate the invention.
The invention is not restricted to the examples.
A. EXAMPLES
Abbreviations and Acronyms
[0432] abs. absolute [0433] Ac acetyl [0434] AIBN
2,2'-azobis(2-methylpropionitrile) [0435] aq. aqueous, aqueous
solution [0436] br. broad (in NMR signal) [0437] Ex. Example [0438]
Bu butyl [0439] c concentration [0440] cat. catalytic [0441] CDI
N,N'-carbonyldiimidazole [0442] CI chemical ionization (in MS)
[0443] d doublet (in NMR) [0444] d day(s) [0445] DAST
N,N-diethylaminosulphur trifluoride [0446] TLC thin-layer
chromatography [0447] DCI direct chemical ionization (in MS) [0448]
dd doublet of doublets (in NMR) [0449] Deoxo-Fluor.RTM./.TM.
bis(2-methoxyethyl)aminosulphur trifluoride [0450] DIAD diisopropyl
azodicarboxylate [0451] DME 1,2-dimethoxyethane [0452] DMF
N,N-dimethylformamide [0453] DMSO dimethyl sulphoxide [0454] dq
doublet of quartets (in NMR) [0455] dt doublet of triplets (in NMR)
[0456] EDC N'-(3-dimethylaminopropyl)-N-ethylcarbodiimide
hydrochloride [0457] ee enantiomeric excess [0458] El electron
impact ionization (in MS) [0459] eq. equivalent(s) [0460] ESI
electrospray ionization (in MS) [0461] Et ethyl [0462] GC gas
chromatography [0463] GC/MS gas chromatography-coupled mass
spectrometry [0464] h hour(s) [0465] HATU
O-(7-azabenzotriazol-1-yl)-N,N,N,N'-tetramethyluronium
hexafluorophosphate [0466] HOBt 1-hydroxy-1H-benzotriazole hydrate
[0467] HPLC high-pressure high-performance liquid chromatography
[0468] iPr isopropyl [0469] conc. concentrated (in case of a
solution) [0470] LC liquid chromatography [0471] LC/MS liquid
chromatography-coupled mass spectrometry [0472] lit. literature
(reference) [0473] m multiplet (in NMR) [0474] Me methyl [0475] min
minute(s) [0476] MPLC medium-pressure liquid chromatography (on
silica gel; also referred to as flash chromatography) [0477] MS
mass spectrometry [0478] NBS N-bromosuccinimide [0479] NMM
N-methylmorpholine [0480] NMO N-methylmorpholine N-oxide [0481] NMP
N-methyl-2-pyrrolidinone [0482] NMR nuclear magnetic resonance
spectrometry [0483] Pd/C palladium on activated carbon [0484] PEG
polyethylene glycol [0485] Ph phenyl [0486] Pr propyl [0487] quant.
quantitative (in chemical yield) [0488] quart quartet (in NMR)
[0489] quint quintet (in NMR) [0490] Rf retention index (in TLC)
[0491] RP reversed phase (in HPLC) [0492] RT room temperature
[0493] R.sub.t retention time (in HPLC, LC/MS) [0494] s singlet (in
NMR) [0495] sept septet (in NMR) [0496] SFC supercritical fluid
chromatography [0497] t triplet (in NMR) [0498] TBAF
tetra-n-butylammonium fluoride [0499] TBME tert-butyl methyl ether
[0500] TBTU
N-[(1H-benzotriazol-1-yloxy)(dimethylamino)methylene]-N-methylmethanamini-
um tetrafluoroborate [0501] tBu tert-butyl [0502] TFA
trifluoroacetic acid [0503] THF tetrahydrofuran [0504] TMS
tetramethylsilane [0505] UV ultraviolet spectrometry [0506] v/v
ratio by volume (of a solution) [0507] tog. together
HPLC, LC/MS and GC/MS Methods:
Method 1 (LC/MS):
[0508] Instrument: Waters ACQUITY SQD UPLC System; column: Waters
Acquity UPLC HSS T3 1.8 .mu.m, 50 mm.times.1 mm; mobile phase A: 1
l of water+0.25 ml of 99% formic acid, eluent B: 1 l of
acetonitrile+0.25 ml of 99% formic acid; gradient: 0.0 min 90%
A.fwdarw.1.2 min 5% A.fwdarw.2.0 min 5% A; temperature: 50.degree.
C.; flow rate: 0.40 ml/min; UV detection: 210-400 nm.
Method 2 (LC/MS):
[0509] Instrument: Micromass Quattro Premier with Waters UPLC
Acquity; column: Thermo Hypersil GOLD 1.9 .mu.m, 50 mm.times.1 mm;
mobile phase A: 1 l of water+0.5 ml of 50% strength formic acid,
mobile phase B: 1 l of acetonitrile+0.5 ml of 50% formic acid;
gradient: 0.0 min 97% A.fwdarw.0.5 min 97% A.fwdarw.3.2 min 5%
A.fwdarw.4.0 min 5% A; temperature: 50.degree. C.; flow rate: 0.30
ml/min; UV detection: 210 nm.
Method 3 (LC/MS):
[0510] Instrument: Waters SQD with Waters UPLC; column: Zorbax
SB-Aq (Agilent) 1.8 .mu.m, 50 mm.times.2.1 mm; mobile phase A:
water+0.025% formic acid, mobile phase B: acetonitrile+0.025%
formic acid; gradient: 0.0 min 98% A.fwdarw.0.9 min 25%
A.fwdarw.1.0 min 5% A.fwdarw.1.4 min 5% A.fwdarw.1.41 min 98%
A.fwdarw.1.5 min 98% A; temperature: 40.degree. C.; flow rate: 0.60
ml/min; UV detection: DAD, 210 nm.
Method 4 (GC/MS):
[0511] Instrument: Thermo DFS, Trace GC Ultra; column: Restek
RTX-35, 15 m.times.200 .mu.m.times.0.33 .mu.m; constant helium flow
rate: 1.20 ml/min; oven: 60.degree. C.; inlet: 220.degree. C.;
gradient: 60.degree. C., 30.degree. C./min.fwdarw.300.degree. C.
(maintained for 3.33 min).
Method 5 (Preparative HPLC):
[0512] column: Chromatorex C18, 10 .mu.m, 125 mm.times.30 mm;
mobile phase: acetonitrile/water with 0.1% of formic acid;
gradient: 20:80.fwdarw.95:5 over 20 min.
Method 6 (Preparative HPLC):
[0513] column: Chromatorex C18, 10 .mu.m, 125 mm.times.30 mm;
mobile phase: acetonitrile/water with 0.1% of formic acid;
gradient: 30:70.fwdarw.95:5 over 20 min.
Method 7 (Preparative HPLC):
[0514] column: Chromatorex C18, 10 .mu.m, 125 mm.times.30 mm;
mobile phase: methanol/water with 0.1% of formic acid; gradient:
20:80.fwdarw.95:5 over 20 min.
Method 8 (Preparative HPLC with Mass Detection):
[0515] Instrument: Waters; column: Phenomenex Luna 5 .mu.m C18(2)
100A, AXIA Tech., 50 mm.times.21.2 mm; mobile phase A: water+0.05%
formic acid, mobile phase B: acetonitrile+0.05% formic acid;
gradient: 0.0 min 95% A.fwdarw.0.15 min 95% A.fwdarw.8.0 min 5%
A.fwdarw.9.0 min 5% A; flow rate: 40 ml/min; UV detection: DAD,
210-400 nm.
Method 9 (LC/MS):
[0516] Instrument: Agilent MS Quad 6150 with HPLC Agilent 1290;
column: Waters Acquity UPLC HSS T3 1.8 .mu.m, 50 mm.times.2.1 mm;
mobile phase A: 1 l of water+0.25 ml of 99% formic acid, eluent B:
1 l of acetonitrile+0.25 ml of 99% formic acid; gradient: 0.0 min
90% A.fwdarw.0.3 min 90% A.fwdarw.1.7 min 5% A.fwdarw.3.0 min 5% A;
flow rate: 1.20 ml/min, temperature: 50.degree. C.; UV detection:
205-305 nm.
Method 10 (LC/MS):
[0517] Instrument: Waters Synapt G2S with UPLC Waters Acquity
I-CLASS; column: Waters HSS T3 C18 1.8 .mu.m, 50 mm.times.2.1 mm;
mobile phase A: 1 l of water+0.01% formic acid, mobile phase B: 1 l
of acetonitrile+0.01% formic acid; gradient: 0.0 min 10%
B.fwdarw.0.3 min 10% B.fwdarw.1.7 min 95% B.fwdarw.2.5 min 95% B;
flow rate: 1.20 ml/min, temperature: 50.degree. C.; UV detection:
210 nm.
Method 11 (Preparative HPLC):
[0518] column: Chromatorex C18, 10 .mu.m, 125 mm.times.30 mm;
mobile phase: methanol/water with 0.1% of formic acid; gradient:
30:70.fwdarw.95:5 over 20 min.
Method 12 (Preparative HPLC):
[0519] column: Chromatorex C18, 10 .mu.m, 125 mm.times.30 mm;
mobile phase A: water+0.05% trifluoroacetic acid, mobile phase B:
acetonitrile+0.05% trifluoroacetic acid; gradient: 0.0 min 75%
A.fwdarw.5.0 min 75% A.fwdarw.8.5 min 53% A.fwdarw.15 min 53%
A.
Method 13 (Preparative HPLC):
[0520] column: Chromatorex C18, 10 .mu.m, 125 mm.times.30 mm;
mobile phase A: water+0.05% trifluoroacetic acid, mobile phase B:
acetonitrile+0.05% trifluoroacetic acid; gradient: 0.0 min 75%
A.fwdarw.5.0 min 75% A.fwdarw.7.0 min 60% A.fwdarw.16 min 45%
A.fwdarw.18 min 45% A.
Method 14 (Preparative HPLC):
[0521] column: Chromatorex C18, 10 .mu.m, 125 mm.times.30 mm;
mobile phase A: water+0.05% trifluoroacetic acid, mobile phase B:
acetonitrile+0.05% trifluoroacetic acid; gradient: 0.0 min 80%
A.fwdarw.5.0 min 80% A.fwdarw.8.0 min 55% A.fwdarw.15 min 55%
A.
Method 15 (Preparative HPLC):
[0522] column: Chromatorex C18, 10 .mu.m, 125 mm.times.30 mm;
mobile phase: acetonitrile/water with 0.1% of formic acid;
gradient: 40:60.fwdarw.95:5 over 20 min.
Method 16 (Preparative HPLC):
[0523] column: Chromatorex C18, 10 .mu.m, 125 mm.times.30 mm;
mobile phase: acetonitrile/water with 0.1% of formic acid;
gradient: 15:85.fwdarw.95:5 over 20 min.
Method 17 (LC/MS):
[0524] Instrument: Waters Acquity SQD UPLC System; column: Waters
Acquity UPLC HSS T3 1.8 .mu.m, 50 mm.times.1 mm; mobile phase A: 1
l of water+0.25 ml of 99% formic acid, eluent B: 1 l of
acetonitrile+0.25 ml of 99% formic acid; gradient: 0.0 min 95%
A.fwdarw.6.0 min 5% A.fwdarw.7.5 min 5% A; oven: 50.degree. C.;
flow rate: 0.35 ml/min; UV detection: 210-400 nm.
Method 18 (Preparative HPLC):
[0525] column: Reprosil-Pur C18, 10 .mu.m, 125 mm.times.30 mm;
mobile phase: acetonitrile/water with 0.05% of trifluoroacetic
acid; gradient: 50:50.fwdarw.100:0 over 12 min.
Method 19 (preparative HPLC):
[0526] column: Reprosil-Pur C18, 10 .mu.m, 125 mm.times.30 mm;
mobile phase: acetonitrile/water with 0.05% of trifluoroacetic
acid; gradient: 10:90.fwdarw.100:0 over 12 min.
Further Details:
[0527] The descriptions of the coupling patterns of .sup.1H NMR
signals below refer to the optical appearance of the signals in
question and do not necessarily correspond to a strict, physically
correct interpretation. In general, the stated chemical shift
refers to the centre of the signal in question; in the case of
broad multiplets, an interval is generally given.
[0528] Melting points and melting points ranges, if stated, are
uncorrected.
[0529] In cases where the reaction products were obtained by
trituration, stirring or recrystallization, it was frequently
possible to isolate further amounts of product from the respective
mother liquor by chromatography. However, a description of this
chromatography is dispensed with hereinbelow unless a large part of
the total yield could only be isolated in this step.
[0530] All reactants or reagents whose preparation is not described
explicitly hereinafter were purchased commercially from generally
accessible sources. For all other reactants or reagents whose
preparation likewise is not described hereinafter and which were
not commercially obtainable or were obtained from sources which are
not generally accessible, a reference is given to the published
literature in which their preparation is described.
Starting Materials and Intermediates
Example 1A
2-tert-Butyl 4-ethyl
5-amino-3-methylthiophene-2,4-dicarboxylate
##STR00085##
[0532] 10.0 g (63.2 mmol) of tert-butyl acetoacetate, 7.15 g (63.2
mmol) of ethyl cyanoacetate and 2.23 g (69.5 mmol) of sulphur were
initially charged in 15 ml of ethanol and warmed to 45.degree. C.
7.5 ml (72.7 mmol) of diethylamine were added dropwise to this
mixture. The reaction mixture was then stirred at 65.degree. C. for
8 h. All the volatile constituents were then removed on a rotary
evaporator. About 500 ml of water were added to the residue that
remained, and the mixture was extracted three times with in each
case about 200 ml of ethyl acetate. The combined organic extracts
were washed with about 200 ml of saturated sodium chloride solution
and dried over anhydrous magnesium sulphate. After filtration, the
mixture was evaporated to dryness. The crude product obtained was
purified by MPLC (about 300 g of silica gel, cyclohexane/ethyl
acetate 10:1). This gave, after combination of the product
fractions, evaporation and drying of the residue under high vacuum,
9.72 g (52% of theory) of the title compound.
[0533] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 6.44 (br. s,
2H), 4.31 (quart, 2H), 2.66 (s, 3H), 1.54 (s, 9H), 1.37 (t,
3H).
[0534] LC/MS (Method 1, ESIpos): R.sub.t=1.20 min, m/z=286
[M+H].sup.+.
Example 2A
2-tert-Butyl 4-ethyl
3-methyl-5-{[(2-phenylethyl)carbamoyl]amino}thiophene-2,4-dicarboxylate
##STR00086##
[0536] 10.0 g (35.0 mmol) of 2-tert-butyl 4-ethyl
5-amino-3-methylthiophene-2,4-dicarboxylate (Example 1A) were
dissolved in 500 ml of dichloromethane and 11.4 g (70.1 mmol) of
N,N'-carbonyldiimidazole (CDI) and 19.6 ml (140 mmol) of
triethylamine were added. The reaction mixture was stirred at RT
for 2 days, after which 8.8 ml (70.1 mmol) of 2-phenethylamine were
added. After a further 2 h of stirring at RT, the mixture was
evaporated to dryness on a rotary evaporator. The residue that
remained was purified by MPLC (silica gel, cyclohexane/ethyl
acetate 20:1.fwdarw.10:1). This gave, after evaporation of the
product fractions and drying of the residue under high vacuum, 14.4
g (95% of theory) of the title compound.
[0537] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 10.54 (s,
1H), 8.17 (t, 1H), 7.33-7.29 (m, 2H), 7.26-7.19 (m, 3H), 4.30
(quart, 2H), 3.36 (quart, 2H), 2.77 (t, 2H), 2.62 (s, 3H), 1.50 (s,
9H), 1.32 (t, 3H).
[0538] LC/MS (Method 1, ESIpos): R.sub.t=1.43 min, m/z=433
[M+H].sup.+.
Example 3A
2-tert-Butyl 4-ethyl
5-({[2-(2-fluorophenyl)ethyl]carbamoyl}amino)-3-methylthiophene-2,4-dicar-
boxylate
##STR00087##
[0540] Analogously to the process described in Ex. 2A, 2.0 g (7.01
mmol) of 2-tert-butyl 4-ethyl
5-amino-3-methylthiophene-2,4-dicarboxylate (Example 1A), 2.27 g
(14.0 mmol) of CDI, 3.9 ml (28.0 mmol) of triethylamine and 3.5 ml
(14.0 mmol) of 2-(2-fluorophenyl)ethylamine gave 1.82 g (55% of
theory, purity 95%) of the title compound. In deviation, MPLC
purification was carried out using the mobile phase
cyclohexane/ethyl acetate 10:1.
[0541] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 10.90 (br.
s, 1H), 7.24-7.19 (m, 2H), 7.10-7.01 (m, 2H), 5.18 (t, 1H), 4.32
(quart, 2H), 3.58 (quart, 2H), 2.94 (t, 2H), 2.71 (s, 3H), 1.55 (s,
9H), 1.39 (t, 3H).
[0542] LC/MS (Method 1, ESIpos): R.sub.t=1.38 min, m/z=451
[M+H].sup.+.
Example 4A
2-tert-Butyl 4-ethyl
5-({[2-(2-chlorophenyl)ethyl]carbamoyl}amino)-3-methylthiophene-2,4-dicar-
boxylate
##STR00088##
[0544] Analogously to the process described in Ex. 2A, 2.0 g (7.01
mmol) of 2-tert-butyl 4-ethyl
5-amino-3-methylthiophene-2,4-dicarboxylate (Example 1A), 2.27 g
(14.0 mmol) of CDI, 3.9 ml (28.0 mmol) of triethylamine and 2.18 g
(14.0 mmol) of 2-(2-chlorophenyl)ethylamine gave 2.49 g (72% of
theory, purity 95%) of the title compound. In deviation, MPLC
purification was carried out here using the mobile phase
cyclohexane/ethyl acetate 10:1.
[0545] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 10.91 (br.
s, 1H), 7.38-7.35 (m, 1H), 7.26-7.16 (m, 3H), 5.14 (t, 1H), 4.33
(quart, 2H), 3.60 (quart, 2H), 3.04 (t, 2H), 2.71 (s, 3H), 1.55 (s,
9H), 1.39 (t, 3H).
[0546] LC/MS (Method 1, ESIpos): R.sub.t=1.42 min, m/z=467/469
[M+H].sup.+.
Example 5A
2-tert-Butyl 4-ethyl
3-methyl-5-({[2-(pyridin-3-yl)ethyl]carbamoyl}amino)thiophene-2,4-dicarbo-
xylate
##STR00089##
[0548] Analogously to the process described in Ex. 2A, 2.0 g (7.01
mmol) of 2-tert-butyl 4-ethyl
5-amino-3-methylthiophene-2,4-dicarboxylate (Example 1A), 2.27 g
(14.0 mmol) of CDI, 3.9 ml (28.0 mmol) of triethylamine and 1.71 g
(14.0 mmol) of 2-(pyridin-3-yl)ethanamine gave 2.46 g (75% of
theory, purity 93%) of the title compound. In deviation, MPLC
purification was carried out here using the mobile phase
cyclohexane/ethyl acetate 1:2.
[0549] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 10.94 (br.
s, 1H), 8.50 (m, 1H), 8.46 (m, 1H), 7.56 (m, 1H), 7.24 (m, 1H),
5.42 (br. s, 1H), 4.31 (quart, 2H), 3.59 (quart, 2H), 2.92 (t, 2H),
2.70 (s, 3H), 1.55 (s, 9H), 1.39 (t, 3H).
[0550] LC/MS (Method 1, ESIpos): R.sub.t=0.99 min, m/z=434
[M+H].sup.+.
Example 6A
2-tert-Butyl 4-ethyl
5-[(ethylcarbamoyl)amino]-3-methylthiophene-2,4-dicarboxylate
##STR00090##
[0552] 6.0 g (21.0 mmol) of 2-tert-butyl 4-ethyl
5-amino-3-methylthiophene-2,4-dicarboxylate (Example 1A) were
dissolved in 300 ml of dichloromethane and 6.82 g (42.1 mmol) of
CDI and 11.7 ml (84.1 mmol) of triethylamine were added. The
reaction mixture was stirred at RT for 2 days, after which 42 ml
(84.1 mmol) of a 2 M solution of ethylamine in THF were added.
After a further 2 h of stirring at RT, the mixture was evaporated
to dryness on a rotary evaporator. The residue that remained was
purified by MPLC (Biotage cartridge with 340 g of silica gel,
cyclohexane/ethyl acetate 10:1.fwdarw.5:1). This gave, after
evaporation of the product fractions and drying of the residue
under high vacuum, 6.98 g (93% of theory) of the title
compound.
[0553] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 10.52 (br.
s, 1H), 8.06 (br. t, 1H), 4.31 (quart, 2H), 3.13 (dq, 2H), 2.77 (t,
2H), 2.62 (s, 3H), 1.50 (s, 9H), 1.32 (t, 3H), 1.07 (t, 3H).
[0554] LC/MS (Method 1, ESIpos): R.sub.t=1.26 min, m/z=357
[M+H].sup.+.
Example 7A
2-tert-Butyl 4-ethyl
5-{[(2,4-dimethoxybenzyl)carbamoyl]amino}-3-methylthiophene-2,4-dicarboxy-
late
##STR00091##
[0556] 8.78 g (30.8 mmol) of 2-tert-butyl 4-ethyl
5-amino-3-methylthiophene-2,4-dicarboxylate (Example 1A) were
dissolved in 300 ml of dichloromethane and 9.98 g (61.5 mmol) of
CDI and 17.2 ml (123 mmol) of triethylamine were added. The
reaction mixture was stirred at RT for 2 days, after which 9.3 ml
(61.5 mmol) of 2,4-dimethoxybenzylamine were added. After a further
2 h of stirring at RT, the mixture was diluted with 200 ml of
dichloromethane and washed successively with in each case about 200
ml of water and saturated sodium chloride solution. After drying
over anhydrous magnesium sulphate, the mixture was filtered and the
filtrate was evaporated. The residue that remained was taken up in
dichloromethane, insolubles being removed by filtration. The
filtrate was applied to silica gel and chromatographed on silica
gel using the mobile phase cyclohexane/ethyl acetate
2:1.fwdarw.1:1. This gave, after combination of the product
fractions, evaporation and drying of the residue under high vacuum,
12.8 g (87% of theory) of the title compound.
[0557] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 10.56 (s,
1H), 8.32 (t, 1H), 7.13 (d, 1H), 6.57 (d, 1H), 6.49 (dd, 1H), 4.30
(quart, 2H), 4.19 (d, 2H), 3.80 (s, 3H), 3.75 (s, 3H), 2.62 (s,
3H), 1.50 (s, 9H), 1.32 (t, 3H).
[0558] LC/MS (Method 1, ESIpos): R.sub.t=1.40 min, m/z=479
[M+H].sup.+.
Example 8A
tert-Butyl
5-methyl-2,4-dioxo-3-(2-phenylethyl)-1,2,3,4-tetrahydrothieno[2-
,3-d]pyrimidine-6-carboxylate
##STR00092##
[0560] 7.34 g (17.0 mmol) of the compound from Ex. 2A were
dissolved in 145 ml of ethanol, and 9.5 ml (25.4 mmol) of a 20%
solution of sodium ethoxide in ethanol were added. The reaction
mixture was stirred at RT for 2 h. The mixture was then poured into
about 400 ml of water and adjusted to a pH of about 5 using 5 M
acetic acid. In the course of this, the product precipitated out.
The product was filtered off with suction, washed neutral with
water and dried under a high vacuum. 5.89 g (91% of theory) of the
title compound were obtained.
[0561] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 12.44 (s,
1H), 7.33-7.29 (m, 2H), 7.25-7.20 (m, 3H), 4.01 (m, 2H), 2.83 (m,
2H), 2.72 (s, 3H), 1.52 (s, 9H).
[0562] LC/MS (Method 1, ESIpos): R.sub.t=1.28 min, m/z=387
[M+H].sup.+.
Example 9A
tert-Butyl
3-[2-(2-fluorophenyl)ethyl]-5-methyl-2,4-dioxo-1,2,3,4-tetrahyd-
rothieno[2,3-d]pyrimidine-6-carboxylate
##STR00093##
[0564] Analogously to the process described under Ex. 8A, 1.76 g
(3.90 mmol) of the compound from Ex. 3A gave 1.55 g (98% of theory)
of the title compound. Here, in deviation to the process described
above, the precipitated product was, after filtration with suction,
dissolved in ethyl acetate and once more washed with water. The
organic phase was then dried over anhydrous magnesium sulphate,
filtered and concentrated, and the residue was finally dried under
high vacuum.
[0565] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.28-7.24
(m, 1H, partially obscured by the CHCl.sub.3 signal), 7.22-7.17 (m,
1H), 7.08-6.99 (m, 2H), 4.25 (t, 2H), 3.03 (t, 2H), 2.82 (s, 3H),
1.58 (s, 9H).
[0566] LC/MS (Method 1, ESIpos): R.sub.t=1.25 min, m/z=405
[M+H].sup.+.
Example 10A
tert-Butyl
3-[2-(2-chlorophenyl)ethyl]-5-methyl-2,4-dioxo-1,2,3,4-tetrahyd-
rothieno[2,3-d]pyrimidine-6-carboxylate
##STR00094##
[0568] Analogously to the process described under Ex. 8A, 2.42 g
(5.17 mmol) of the compound from Ex. 4A gave 1.71 g (76% of theory,
purity 97%) of the title compound. Here, in deviation to the
process described above, the precipitated product was, after
filtration with suction, dissolved in ethyl acetate and once more
washed with water. The organic phase was then dried over anhydrous
magnesium sulphate, filtered and concentrated, and the residue was
finally dried under high vacuum.
[0569] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.35 (dd,
1H), 7.30 (dd, 1H), 7.20-7.14 (m, 2H), 4.26 (t, 2H), 3.13 (t, 2H),
2.83 (s, 3H), 1.58 (s, 9H).
[0570] LC/MS (Method 1, ESIpos): R.sub.t=1.30 min, m/z=421/422
[M+H].sup.+.
Example 11A
tert-Butyl
5-methyl-2,4-dioxo-3-[2-(pyridin-3-yl)ethyl]-1,2,3,4-tetrahydro-
thieno[2,3-d]pyrimidine-6-carboxylate
##STR00095##
[0572] Analogously to the process described under Ex. 8A, 2.41 g
(5.56 mmol) of the compound from Ex. 5A gave 1.89 g (87% of theory)
of the title compound. Here, in deviation to the process described
above, the precipitated product was, after filtration with suction,
dissolved in ethyl acetate and once more washed with water and
saturated sodium hydrogencarbonate solution. The organic phase was
then dried over anhydrous magnesium sulphate, filtered and
concentrated, and the residue was finally dried under high
vacuum.
[0573] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.42-8.40
(m, 2H), 7.64 (dt, 1H), 7.31 (dd, 1H), 4.01 (t, 2H), 2.81 (t, 2H),
2.67 (s, 3H), 1.49 (s, 9H).
[0574] LC/MS (Method 1, ESIpos): R.sub.t=0.82 min, m/z=388
[M+H].sup.+.
Example 12A
tert-Butyl
3-ethyl-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrim-
idine-6-carboxylate
##STR00096##
[0576] 6.98 g (19.6 mmol) of the compound from Ex. 6A were
dissolved in 130 ml of ethanol, and 11 ml (29.4 mmol) of a 20%
solution of sodium ethoxide in ethanol were added. The reaction
mixture was stirred at RT for 2 h. The mixture was then poured into
about 400 ml of water and adjusted to a pH of about 5 using 5 M
acetic acid. In the course of this, the product precipitated out.
The product was filtered off with suction, washed neutral with
water and dried under a high vacuum. 5.89 g (97% of theory) of the
title compound were obtained.
[0577] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 12.39 (s,
1H), 3.85 (quart, 2H), 2.71 (s, 3H), 1.51 (s, 9H), 1.11 (t,
3H).
[0578] LC/MS (Method 1, ESIpos): R.sub.t=1.06 min, m/z=311
[M+H].sup.+.
Example 13A
tert-Butyl
3-(2,4-dimethoxybenzyl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydroth-
ieno[2,3-d]pyrimidine-6-carboxylate
##STR00097##
[0580] 12.8 g (26.8 mmol) of the compound from Ex. 7A were
dissolved in 250 ml of ethanol, and 15 ml (40.2 mmol) of a 20%
solution of sodium ethoxide in ethanol were added. The reaction
mixture was stirred at RT for about 16 h. The mixture was then
poured into about 1.5 l of water and adjusted to a pH of about 5
using acetic acid. In the course of this, the product precipitated
out. The product was filtered off with suction, washed neutral with
water and dried under a high vacuum. 11.3 g (97% of theory) of the
title compound were obtained.
[0581] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 12.50 (s,
1H), 6.72 (d, 1H), 6.56 (d, 1H), 6.39 (dd, 1H), 4.89 (s, 2H), 3.82
(s, 3H), 3.72 (s, 3H), 2.69 (s, 3H), 1.52 (s, 9H).
[0582] LC/MS (Method 1, ESIpos): R.sub.t=1.20 min, m/z=433
[M+H]+.
Example 14A
1-(2-Phenylethyl)pyrimidine-2,4,6(1H,3H,5H)-trione
##STR00098##
[0584] 20.0 g (122 mmol) of 2-phenethylurea [commercially
available; lit. e.g.: L. De Luca, A. Porcheddu, G. Giacomelli, I.
Murgia, Synlett 2010 (16), 2439-2442] and 18.5 ml (122 mmol) of
diethyl malonate were dissolved in 70 ml of ethanol, and 45.5 ml
(122 mmol) of a 20% strength solution of sodium ethoxide in ethanol
were added. The mixture was heated under reflux for 16 h. Most of
the solvent was then removed on a rotary evaporator, and about 100
ml of water were added to the residue that remained. Insolubles
were filtered off and the filtrate was acidified with concentrated
hydrochloric acid to pH 3-4. This resulted in the precipitation of
the product, which was filtered off with suction and washed
initially with water and then with hexane/diethyl ether 1:1. Drying
under high vacuum gave 20.9 g (72% of theory) of the title
compound.
[0585] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 11.36 (s,
1H), 7.33-7.29 (m, 2H), 7.25-7.20 (m, 3H), 3.86 (dd, 2H), 3.62 (s,
2H), 2.77 (dd, 2H).
[0586] LC/MS (Method 1, ESIpos): R.sub.t=0.76 min, m/z=233
[M+H].sup.+.
Example 15A
1-Ethylpyrimidine-2,4,6(1H,3H, 5H)-trione
##STR00099##
[0588] 25.0 g (284 mmol) of ethylurea and 43 ml (284 mmol) of
diethyl malonate were dissolved in 150 ml of ethanol, and 106 ml
(284 mmol) of a 20% solution of sodium ethoxide in ethanol were
added. The mixture was heated under reflux for 1 h, resulting in
the formation of a precipitate. After cooling to RT, the
precipitate was separated off and the filtrate was freed from most
of the solvent on a rotary evaporator. About 500 ml of water were
added to the residue that remained, and the mixture was acidified
with 5 M hydrochloric acid to pH 3-4. The aqueous solution was then
extracted three times with about 100 ml of ethyl acetate each time.
Drying over anhydrous magnesium sulphate, filtration and
evaporation of the combined organic extracts gave a first fraction
of the title compound (14.1 g, 31% of theory). The aqueous phase
left earlier was concentrated to a volume of about 250 ml and
adjusted to pH 1 with 5 M hydrochloric acid, and solid sodium
chloride was added to saturation. The mixture was once more
extracted with ethyl acetate and the organic phase was dried over
magnesium sulphate, filtered and concentrated. At RT, the product
obtained in this manner was stirred with 200 ml of diethyl ether.
The mixture was then filtered and the residue was dried under high
vacuum. This gave a second fraction of the title compound (6.0 g,
13% of theory). A total of 20.1 g (45% of theory) of the title
compound were thus obtained.
[0589] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 11.30 (s,
1H), 3.70 (quart, 2H), 3.59 (s, 2H), 1.06 (t, 3H).
[0590] GC/MS (method 4, ESIpos): R.sub.t=4.28 min, m/z=156
[M].sup.+.
Example 16A
6-Chloro-3-(2-phenylethyl)pyrimidine-2,4(1H,3H)-dione
##STR00100##
[0592] At a temperature of 0.degree. C., 36.5 ml (392 mmol) of
phosphorus oxychloride were added carefully to 8.2 ml of 50%
strength aqueous ethanol. Then, likewise at 0.degree. C., 10.2 g
(43.9 mmol) of the compound from Ex. 14A were added a little at a
time. After the addition had ended, the reaction mixture was heated
first for 30 min at 50.degree. C. and then for 90 min at
100.degree. C. After the mixture had cooled to RT, it was poured
into about 100 ml of ice-water and stirred for 1 h. The
precipitated solid was filtered off with suction and washed
initially with water and then with hexane. The solid was then
stirred with a little dichloromethane at RT, once more filtered off
with suction and finally dried under high vacuum. This gave 3.16 g
(26% of theory, 93% pure) of the title compound.
[0593] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 12.38 (s,
1H), 7.32-7.28 (m, 2H), 7.23-7.19 (m, 3H), 5.91 (s, about 1H), 3.93
(dd, 2H), 2.80 (dd, 2H).
[0594] LC/MS (Method 1, ESIpos): R.sub.t=0.79 min, m/z=251/253
[M+H]+.
Example 17A
6-Chloro-3-ethylpyrimidine-2,4(1H,3H)-dione
##STR00101##
[0596] At a temperature of 0.degree. C., 28.8 ml (309 mmol) of
phosphorus oxychloride were added carefully to 6.6 ml of 50%
strength aqueous ethanol. Then, likewise at 0.degree. C., 5.4 g
(34.6 mmol) of the compound from Ex. 15A were added a little at a
time. After the addition had ended, the reaction mixture was heated
first for 30 min at 50.degree. C. and then for 2 h at 100.degree.
C. After the mixture had cooled to RT, it was poured into about 100
ml of ice-water. The precipitated solid was filtered off with
suction and washed with water. Drying under high vacuum gave 2.78 g
(46% of theory) of the title compound.
[0597] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 12.34 (s,
1H), 5.89 (s, about 1H), 3.76 (quart, 2H), 1.07 (t, 3H).
[0598] LC/MS (Method 1, ESIpos): R.sub.t=0.42 min, m/z=175/177
[M+H].sup.+.
Example 18A
1-[2,6-Dioxo-1-(2-phenylethyl)-4-(pyridinium-1-yl)-1,6-dihydropyrimidin-5(-
2H)-ylidene]-2,2,2-trifluoroethanolate
##STR00102##
[0600] At RT, 3.2 ml (39.9 mmol) of pyridine were added to a
suspension of 1.0 g (3.99 mmol) of the compound from Ex. 16A in 10
ml of acetonitrile. 2.3 ml (16.0 mmol) of trifluoroacetic anhydride
were then slowly added dropwise. After the addition had ended,
stirring of the mixture was continued at RT for 1 h. About 100 ml
of water were then added, and the mixture was extracted with about
100 ml of ethyl acetate. The organic extract was washed with
saturated aqueous sodium chloride solution. The solid, which was
finely suspended in the extract, was then filtered off with suction
and washed with a little ethyl acetate. The residue was dried under
high vacuum, thus giving a first fraction of the title compound
(659 mg, 42% of theory). The resulting filtrate was dried over
anhydrous magnesium sulphate, filtered and evaporated to dryness.
The solid that remained was stirred in a mixture of 25 ml of
diisopropyl ether and 11 ml of ethyl acetate at 40.degree. C. for
30 min. After cooling to RT, the solid present was filtered off
with suction and washed with a little diethyl ether. This gave,
after drying under high vacuum, a second fraction of the title
compound (499 mg, 32% of theory). A total of 1.16 g (74% of theory)
of the title compound were obtained in this manner.
[0601] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 9.28 (d,
2H), 8.81 (t, 1H), 8.28 (t, 2H), 7.36-7.28 (m, 4H), 7.25-7.21 (m,
1H), 4.03 (dd, 2H), 2.83 (dd, 2H).
[0602] LC/MS (Method 1, ESIpos): R.sub.t=0.85 min, m/z=390
[M+H].sup.+.
Example 19A
1-[1-Ethyl-2,6-dioxo-4-(pyridinium-1-yl)-1, 6-dihydropyrimidin-5
(2H)-ylidene]-2,2,2-trifluoroethanolate
##STR00103##
[0604] At RT, 4.6 ml (57.3 mmol) of pyridine were added to a
suspension of 1.0 g (5.73 mmol) of the compound from Ex. 17A in 15
ml of acetonitrile. 3.2 ml (22.9 mmol) of trifluoroacetic anhydride
were then slowly added dropwise. After the addition had ended,
stirring of the mixture was continued at RT for 1 h. About 100 ml
of water were then added, and the mixture was extracted twice with
about 100 ml of ethyl acetate each time. The organic extract was
washed with saturated aqueous sodium chloride solution and then
evaporated to dryness. The solid that remained was stirred in a
mixture of 25 ml of diisopropyl ether and 5 ml of ethyl acetate at
40.degree. C. for 30 min. After cooling to RT, the solid present
was filtered off with suction and washed with a little pentane.
Drying under high vacuum gave 1.54 g (86% of theory) of the title
compound.
[0605] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 9.28 (d,
2H), 8.80 (t, 1H), 8.26 (t, 2H), 3.87 (quart, 2H), 1.13 (t,
3H).
[0606] LC/MS (Method 1, ESIpos): R.sub.t=0.56 min, m/z=314
[M+H]+.
Example 20A
Ethyl
2,4-dioxo-3-(2-phenylethyl)-5-(trifluoromethyl)-1,2,3,4-tetrahydroth-
ieno[2,3-d]pyrimidine-6-carboxylate
##STR00104##
[0608] In a microwave oven (Biotage Initiator with dynamic control
of irradiation power), a mixture of 950 mg (2.44 mmol) of the
compound from Ex. 18A, 569 mg (5.37 mmol) of sodium carbonate and
535 .mu.l (4.88 mmol) of ethyl mercaptoacetate in 26 ml of ethanol
was heated at 120.degree. C. for 1 h. Then the mixture was
evaporated to dryness on a rotary evaporator. The residue that
remained was taken up in about 700 ml of ethyl acetate and the
mixture was washed successively with about 300 ml each of
semisaturated aqueous sodium chloride solution, water and saturated
sodium chloride solution. After drying over anhydrous magnesium
sulphate, the mixture was filtered and the filtrate was evaporated.
The crude product was purified by preparative HPLC (Method 5). This
gave, after combination and evaporation of the product fractions
and drying of the residue under high vacuum, 728 mg (72% of theory)
of the title compound.
[0609] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 12.61 (s,
1H), 7.33-7.29 (m, 2H), 7.26-7.20 (m, 3H), 4.33 (quart, 2H), 4.02
(m, 2H), 2.83 (m, 2H), 1.29 (t, 3H).
[0610] LC/MS (Method 1, ESIpos): R.sub.t=1.13 min, m/z=413
[M+H].sup.+.
Example 21A
Ethyl
3-ethyl-2,4-dioxo-5-(trifluoromethyl)-1,2,3,4-tetrahydrothieno[2,3-d-
]pyrimidine-6-carboxylate
##STR00105##
[0612] In a microwave oven (Biotage Initiator with dynamic control
of irradiation power), a mixture of 4.75 g (15.2 mmol) of the
compound from Ex. 19A, 3.54 g (33.4 mmol) of sodium carbonate and
3.3 ml (30.3 mmol) of ethyl mercaptoacetate in 39 ml of ethanol was
heated at 120.degree. C. for 1 h. Then the mixture was evaporated
to dryness on a rotary evaporator. About 200 ml of water were added
to the residue that remained, and the mixture was acidified
slightly with acetic acid (about pH 4). The mixture was extracted
three times with about 100 ml of dichloromethane each time. The
combined organic phases were washed with saturated sodium chloride
solution and dried over anhydrous magnesium sulphate and then
filtered and evaporated. The crude product was purified by MPLC
(Puriflash cartridge with 25 g of silica gel, cyclohexane/ethyl
acetate 3:1.fwdarw.1:1). This gave, after combination and
evaporation of the product fractions and drying of the residue
under high vacuum, 2.78 g (54% of theory) of the title
compound.
[0613] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 11.38 (s,
1H), 4.40 (quart, 2H), 4.10 (quart, 2H), 1.39 (t, 3H), 1.29 (t,
3H).
[0614] LC/MS (Method 2, ESIpos): R.sub.t=2.06 min, m/z=337
[M+H].sup.+.
Example 22A
1-[2,6-Dioxo-1-(2-phenylethyl)-4-(pyridinium-1-yl)-1,6-dihydropyrimidin-5(-
2H)-ylidene]-2,2-difluoroethanolate
##STR00106##
[0616] At RT, 16.1 ml (199 mmol) of pyridine were added to a
suspension of 5.0 g (19.9 mmol) of the compound from Ex. 16A in 50
ml of acetonitrile. 9.9 ml (79.8 mmol) of difluoroacetic anhydride
were then slowly added dropwise. After the addition had ended,
stirring was continued at RT for 1 h. About 500 ml of water were
then added, and the mixture was extracted twice with about 500 ml
of ethyl acetate each time. The organic extract was washed with
saturated aqueous sodium chloride solution. The solid, which was
finely suspended in the extract, was then filtered off with suction
and washed with a little ethyl acetate. The solid was dried under
high vacuum, thus giving a first fraction of the title compound
(2.8 g, 37% of theory). The filtrate was dried over anhydrous
magnesium sulphate, filtered and concentrated to dryness. The
residue that remained was initially stirred in a mixture of 20 ml
of diisopropyl ether and 8 ml of ethyl acetate at RT. Since the
solid obtained after filtration with suction was still slightly
contaminated, the product was for a second time stirred with a
mixture of 30 ml of diethyl ether and 10 ml of ethyl acetate. This
gave, after another filtration with suction and drying under high
vacuum, a second fraction of the title compound (2.3 g, 31% of
theory). In total, 5.1 g (68% of theory) of the title compound were
obtained in this manner.
[0617] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 9.22 (d,
2H), 8.81 (t, 1H), 8.27 (t, 2H), 7.36-7.28 (m, 4H), 7.26-7.22 (m,
1H), 6.97 (t, 1H), 4.04 (m, 2H), 2.84 (m, 2H).
[0618] LC/MS (Method 1, ESIpos): R.sub.t=0.82 min, m/z=372
[M+H].sup.+.
Example 23A
Ethyl
2,4-dioxo-3-(2-phenylethyl)-5-(difluoromethyl)-1,2,3,4-tetrahydrothi-
eno[2,3-d]pyrimidine-6-carboxylate
##STR00107##
[0620] In a microwave oven (Biotage Initiator with dynamic control
of irradiation power), a mixture of 4.0 g (10.8 mmol) of the
compound from Ex. 22A, 2.51 g (23.7 mmol) of sodium carbonate and
2.36 ml (21.5 mmol) of ethyl mercaptoacetate in 22.4 ml of ethanol
was heated at 120.degree. C. for 2 h. The reaction mixture was then
evaporated to dryness on a rotary evaporator. The residue that
remained was taken up in about 400 ml of water, acidified slightly
by addition of acetic acid and extracted three times with about 400
ml of dichloromethane each. The solid, which was finely suspended
in the combined organic extracts, was filtered off with suction and
stirred at RT with a mixture of 25 ml of pentane and 25 ml of
dichloromethane for 30 min. This gave, after another filtration
with suction and drying under high vacuum, a first fraction of the
title compound (1.76 g, 41% of theory). The filtrate from the
filtration of the combined organic extracts was washed with
saturated aqueous sodium chloride solution, dried over anhydrous
magnesium sulphate, filtered and concentrated. At RT, the solid
that remained was stirred in a mixture of 20 ml of pentane and 20
ml of dichloromethane for 30 min. This gave, after filtration with
suction and drying under high vacuum, a second fraction of the
title compound (1.14 g, 26% of theory). In total, 2.9 g (68% of
theory) of the title compound were obtained in this manner.
[0621] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 12.67 (s,
1H), 7.72 (t, 1H), 7.34-7.29 (m, 2H), 7.26-7.20 (m, 3H), 4.33
(quart, 2H), 4.02 (m, 2H), 2.84 (m, 2H), 1.31 (t, 3H).
[0622] LC/MS (Method 1, ESIpos): R.sub.t=1.06 min, m/z=395
[M+H].sup.+.
Example 24A
6-Chloro-2,4-dioxo-3-(2-phenylethyl)-1,2,3,4-tetrahydropyrimidine-5-carbal-
dehyde
##STR00108##
[0624] At a temperature of 0.degree. C., 31.7 ml (340 mmol) of
phosphorus oxychloride were added dropwise to 7.9 ml of DMF. After
the addition had ended, the cooling bath was removed and 3.95 g
(17.0 mmol) of the compound from Ex. 14A were added a little at a
time at RT. The mixture was then heated under reflux for 2 h. After
cooling, excess phosphorus oxychloride was removed on a rotary
evaporator. The residue that remained was, with vigorous stirring,
carefully poured into ice-water. The resulting precipitate was
filtered off with suction and then dissolved in ethyl acetate. The
mixture was extracted successively with water and saturated sodium
chloride solution. The combined aqueous wash phases were
re-extracted with dichloromethane, and the dichloromethane phase
was combined with the ethyl acetate phase. After concentration of
the combined organic phases, the crude product was suspended in
about 70 ml of ethyl acetate and stirred at RT for 30 min. This
gave, after the solid had been filtered off with suction and dried
under high vacuum, a first fraction of the title compound (1.08 g,
purity 91%, 20% of theory). The filtrate was concentrated and then
subjected to coarse purification by filtration with suction through
silica gel using the mobile phase ethyl acetate. After
re-evaporation, the solid that remained was stirred at RT in a
mixture of 10 ml of ethyl acetate and 3 ml of pentane for 3 h. This
gave, after filtration with suction and drying under high vacuum, a
second fraction of the title compound (0.91 g, purity 63%, 12% of
theory). Both fractions could be employed for further reactions
without further purification. This gave a total of 1.99 g (78%
purity, 33% of theory) of the title compound.
[0625] .sup.1H-NMR (500 MHz, CDCl.sub.3, .delta./ppm): 10.14 (s,
1H), 9.91 (br. s, 1H), 7.33-7.29 (m, 2H), 7.28-7.22 (m, 3H), 4.19
(m, 2H), 2.96 (m, 2H).
[0626] LC/MS (Method 1, ESIpos): R.sub.t=0.72 min, m/z=279/281
[M+H].sup.+.
Example 25A
Ethyl
2,4-dioxo-3-(2-phenylethyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-
e-6-carboxylate
##STR00109##
[0628] In a microwave oven (Biotage Initiator with dynamic control
of irradiation power), a mixture of 1.08 g (3.88 mmol) of the
compound from Ex. 24A, 411 mg (3.88 mmol) of sodium carbonate and
425 .mu.l (3.88 mmol) of ethyl mercaptoacetate in 15 ml of ethanol
was heated at 120.degree. C. for 90 min. The reaction mixture was
then evaporated to dryness on a rotary evaporator. The residue that
remained was taken up in ethyl acetate and washed twice with water
and once with saturated aqueous sodium chloride solution. After
drying over anhydrous magnesium sulphate, the mixture was filtered
and concentrated. The residue that remained with dissolved in a
little dichloromethane, a few drops of ethanol were added and the
material was then purified on a Biotage cartridge (50 g of silica
gel, mobile phase gradient: 5:1.fwdarw.1:2 cyclohexane/ethyl
acetate). This gave, after evaporation of the product fractions and
drying of the residue under high vacuum, 901 mg (67% of theory) of
the title compound.
[0629] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 12.54 (s,
1H), 7.77 (s, 1H), 7.33-7.28 (m, 2H), 7.24-7.20 (m, 3H), 4.29
(quart, 2H), 4.03 (m, 2H), 2.84 (m, 2H), 1.30 (t, 3H).
[0630] LC/MS (Method 1, ESIpos): R.sub.t=1.00 min, m/z=345
[M+H]+.
Example 26A
tert-Butyl
5-methyl-2,4-dioxo-3-(2-phenylethyl)-1-(3,3,3-trifluoropropyl)--
1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00110##
[0632] 5.55 g (17.0 mmol) of caesium carbonate were added to a
solution of 5.98 g (15.5 mmol) of the compound from Ex. 8A in 150
ml of DMF, and the mixture was stirred at RT for 15 min. 4.16 g
(18.6 mmol) of 3,3,3-trifluoro-1-iodopropane were then added, and
the mixture was heated at 100.degree. C. for 3 h. The mixture was
then evaporated to dryness on a rotary evaporator. The residue that
remained was taken up in ethyl acetate and washed successively with
water and saturated sodium chloride solution. After drying over
anhydrous magnesium sulphate, the mixture was filtered and the
filtrate was evaporated. The crude product was purified by MPLC
(Biotage cartridge with 340 g of silica gel, cyclohexane/ethyl
acetate 10:1). The product fractions were combined and
concentrated. The residue was then stirred in 50 ml of
pentane/dichloromethane (100:5) at RT. This gave, after another
filtration, evaporation and drying under high vacuum, 5.33 g (71%
of theory) of the title compound.
[0633] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.33-7.28
(m, 2H), 7.25-7.20 (m, 3H), 4.14 (t, 2H), 4.06 (m, 2H), 2.84 (m,
2H), 2.79-2.72 (m, 2H), 2.76 (s, 3H), 1.54 (s, 9H).
[0634] LC/MS (Method 1, ESIpos): R.sub.t=1.49 min, m/z=483
[M+H].sup.+.
Example 27A
tert-Butyl
1-(4,4-difluorobut-3-en-1-yl)-5-methyl-2,4-dioxo-3-(2-phenyleth-
yl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00111##
[0636] Analogously to the process described in Ex. 26A, 1.0 g (2.59
mmol) of the compound from Ex. 8A, 1.27 g (3.88 mmol) of caesium
carbonate and 664 mg (3.88 mmol) of 4-bromo-1,1-difluorobut-1-ene
gave 468 mg (37% of theory) of the title compound. In deviation
from the process described above, here, MPLC purification could be
dispensed with. The crude product was purified by stirring at RT
with a mixture of 20 ml of pentane and 0.5 ml of
dichloromethane.
[0637] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.32-7.29
(m, 4H), 7.26-7.20 (m, 1H), 4.28-4.24 (m, 1H), 4.24-4.18 (m, 2H),
3.97 (t, 2H), 2.96-2.92 (m, 2H), 2.86 (s, 3H), 2.47 (quart, 2H),
1.59 (s, 9H).
[0638] LC/MS (Method 1, ESIpos): R.sub.t=1.52 min, m/z=477
[M+H].sup.+.
Example 28A
tert-Butyl
1-(2-methoxyethyl)-5-methyl-2,4-dioxo-3-(2-phenylethyl)-1,2,3,4-
-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00112##
[0640] 1.85 g (5.69 mmol) of caesium carbonate were added to a
solution of 2.0 g (5.18 mmol) of the compound from Ex. 8A in 60 ml
of DMF, and the mixture was stirred at RT for 10 min. 863 mg (6.21
mmol) of 2-bromomethyl methyl ether were then added, and the
mixture was heated at 100.degree. C. for 30 min. The mixture was
then evaporated to dryness on a rotary evaporator. The residue that
remained was taken up in ethyl acetate and washed successively with
water and saturated sodium chloride solution. After drying over
anhydrous magnesium sulphate, the mixture was filtered and the
filtrate was evaporated. The crude product was purified by MPLC
(Puriflash column with 80 g of silica gel, cyclohexane/ethyl
acetate 10:1). Filtration, evaporation and drying of the residue
under high vacuum gave 2.22 g (96% of theory) of the title
compound.
[0641] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.32-7.28
(m, 2H), 7.24-7.20 (m, 3H), 4.09-4.04 (m, 4H), 3.61 (t, 2H), 3.24
(s, 3H), 2.84 (dd, 2H), 2.74 (s, 3H), 1.53 (s, 9H).
[0642] LC/MS (Method 1, ESIpos): R.sub.t=1.40 min, m/z=445
[M+H].sup.+.
Example 29A
tert-Butyl
3-[2-(2-fluorophenyl)ethyl]-5-methyl-2,4-dioxo-1-(3,3,3-trifluo-
ropropyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00113##
[0644] 665 mg (2.04 mmol) of caesium carbonate were added to a
solution of 750 mg (1.85 mmol) of the compound from Ex. 9A in 20 ml
of DMF, and the mixture was stirred at RT for 15 min. 498 mg (2.23
mmol) of 3,3,3-trifluoro-1-iodopropane were then added. The mixture
was heated at 100.degree. C. for a total of 17 h, with another 498
mg (2.23 mmol) of 3,3,3-trifluoro-1-iodopropane being added after a
reaction time of 5 h and a further 249 mg (1.12 mmol) of
3,3,3-trifluoro-1-iodopropane being added after a reaction time of
8 h. After the reaction had ended, the mixture was evaporated to
dryness on a rotary evaporator. The residue that remained was taken
up in ethyl acetate and washed successively with water and
saturated sodium chloride solution. After drying over anhydrous
magnesium sulphate, the mixture was filtered and the filtrate was
evaporated. The crude product was purified by MPLC (Puriflash
column with 200 g of silica gel, cyclohexane/ethyl acetate 5:1).
The product fractions were combined and concentrated. Finally, the
residue was stirred at RT in a mixture of 30 ml of pentane and 1 ml
of dichloromethane. This gave, after another filtration,
evaporation and drying under high vacuum, 430 mg (44% of theory,
purity 95%) of the title compound.
[0645] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.29-7.24
(m, 2H), 7.15-7.09 (m, 2H), 4.12 (t, 2H), 4.10 (t, 2H), 2.91 (t,
2H), 2.73 (s, 3H), 2.71 (t, 2H), 1.53 (s, 9H).
[0646] LC/MS (Method 1, ESIpos): R.sub.t=1.42 min, m/z=501
[M+H].sup.+.
Example 30A
tert-Butyl
1-(4,4-difluorobut-3-en-1-yl)-3-[2-(2-fluorophenyl)ethyl]-5-met-
hyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00114##
[0648] Analogously to the process described in Ex. 29A, 750 mg
(1.85 mmol) of the compound from Ex. 9A, 906 mg (2.78 mmol) of
caesium carbonate and 476 mg (2.78 mmol) of
4-bromo-1,1-difluorobut-1-ene gave 480 mg (52% of theory) of the
title compound. In deviation from the process described above, here
the reaction time was only 60 min, and during this time there was
no further addition of alkylating agent. Moreover, MPLC
purification could be dispensed with. The crude product was
purified by stirring in 20 ml of pentane at RT.
[0649] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.29-7.23
(m, 2H), 7.15-7.09 (m, 2H), 4.60 (d of t of d, 1H), 4.10 (t, 2H),
3.94 (t, 2H), 2.90 (t, 2H), 2.72 (s, 3H), 2.38-2.32 (m, 2H), 1.53
(s, 9H).
[0650] LC/MS (Method 1, ESIpos): R.sub.t=1.46 min, m/z=495
[M+H].sup.+.
Example 31A
tert-Butyl
3-[2-(2-chlorophenyl)ethyl]-5-methyl-2,4-dioxo-1-(3,3,3-trifluo-
ropropyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00115##
[0652] Analogously to the process described in Ex. 29A, 750 mg
(1.78 mmol) of the compound from Ex. 10A, 639 mg (1.69 mmol) of
caesium carbonate and initially 479 mg (2.14 mmol) of
3,3,3-trifluoro-1-iodopropane gave 440 mg (48% of theory) of the
title compound. In deviation from the process described above, here
the reaction time was 3 days in total, and the addition of further
alkylating agent was carried out after 6 h and 16 h (in each case
240 mg, 1.07 mmol).
[0653] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.36-7.33
(m, 1H), 7.27-7.23 (m, 1H, partially obscured by the CHCl.sub.3
signal), 7.19-7.14 (m, 2H), 4.28 (t, 2H), 4.13 (t, 2H), 3.11 (t,
2H), 2.84 (s, 3H), 2.59-2.47 (m, 2H), 1.59 (s, 9H).
[0654] LC/MS (Method 1, ESIpos): R.sub.t=1.46 min, m/z=517/519
[M+H].sup.+.
Example 32A
tert-Butyl
3-[2-(2-chlorophenyl)ethyl]-1-(4,4-difluorobut-3-en-1-yl)-5-met-
hyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00116##
[0656] Analogously to the process described in Ex. 29A, 750 mg
(1.85 mmol) of the compound from Ex. 10A, 871 mg (2.67 mmol) of
caesium carbonate and 457 mg (2.67 mmol) of
4-bromo-1,1-difluorobut-1-ene gave 543 mg (57% of theory) of the
title compound. In deviation from the process described above, here
the reaction time was only 60 min, and during this time there was
no further addition of alkylating agent. Moreover, MPLC
purification could be dispensed with. The crude product was
purified by stirring in 20 ml of pentane at RT.
[0657] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.42-7.38
(m, 1H), 7.30-7.22 (m, 3H), 4.60 (d of t of d, 1H), 4.12 (t, 2H),
3.93 (t, 2H), 2.99 (t, 2H), 2.72 (s, 3H), 2.37-2.31 (m, 2H), 1.53
(s, 9H).
[0658] LC/MS (Method 1, ESIpos): R.sub.t=1.50 min, m/z=511/513
[M+H]+.
Example 33A
tert-Butyl
5-methyl-2,4-dioxo-3-[2-(pyridin-3-yl)ethyl]-1-(3,3,3-trifluoro-
propyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00117##
[0660] 1.14 g (3.48 mmol) of caesium carbonate were added to a
solution of 900 mg (2.32 mmol) of the compound from Ex. 11A in 25
ml of DMF, and the mixture was stirred at RT for 15 min. 780 mg
(3.48 mmol) of 3,3,3-trifluoro-1-iodopropane were then added, and
the mixture was heated at 90.degree. C. for 6 h. The mixture was
then evaporated to dryness on a rotary evaporator. The residue that
remained was taken up in ethyl acetate and washed successively with
water and saturated sodium chloride solution. After drying over
anhydrous magnesium sulphate, the mixture was filtered and the
filtrate was evaporated. The crude product was purified by MPLC
(Biotage cartridge with 50 g of silica gel, cyclohexane/ethyl
acetate 5:1.fwdarw.1:1). The product fractions were combined and
concentrated. At RT, the residue was then stirred in a mixture of
20 ml of cyclohexane and 1 ml of dichloromethane for 2 h. This
gave, after another filtration, evaporation and drying under high
vacuum, a first fraction of the title compound (117 mg, 10% of
theory). After evaporation, the filtrate was purified further by
preparative HPLC (Method 5). This gave, after combination and
evaporation of the product fractions, a second fraction of the
title compound (381 mg, 33% of theory). A total of 498 mg (44% of
theory) of the title compound were thus obtained.
[0661] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.43-8.41
(m, 2H), 7.67-7.63 (m, 1H), 7.31 (dd, 1H), 4.13 (t, 2H), 4.10 (t,
2H), 2.89 (t, 2H), 2.80-2.69 (m, 2H), 2.73 (s, 3H), 1.53 (s,
9H).
[0662] LC/MS (Method 1, ESIpos): R.sub.t=1.07 min, m/z=484
[M+H].sup.+.
Example 34A
tert-Butyl
1-(4,4-difluorobut-3-en-1-yl)-5-methyl-2,4-dioxo-3-[2-(pyridin--
3-yl)ethyl]-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00118##
[0664] Analogously to the process described in Ex. 33A, 900 mg
(2.32 mmol) of the compound from Ex. 11A, 1.14 g (3.48 mmol) of
caesium carbonate and 596 mg (3.48 mmol) of
4-bromo-1,1-difluorobut-1-ene gave a total of 610 mg (55% of
theory) of the title compound.
[0665] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.43-8.40
(m, 2H), 7.67-7.64 (m, 1H), 7.31 (dd, 1H), 4.61 (d of t of d, 1H),
4.10 (t, 2H), 3.94 (t, 2H), 2.88 (t, 2H), 2.73 (s, 3H), 2.39-2.33
(m, 2H), 1.53 (s, 9H).
[0666] LC/MS (Method 1, ESIpos): R.sub.t=1.10 min, m/z=478
[M+H]+.
Example 35A
tert-Butyl
3-ethyl-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,2,3,4-te-
trahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00119##
[0668] 4.72 g (14.5 mmol) of caesium carbonate were added to a
solution of 3.0 g (9.67 mmol) of the compound from Ex. 12A in 100
ml of DMF, and the mixture was stirred at RT for 20 min. 2.57 g
(14.5 mmol) of 3,3,3-trifluoro-1-iodopropane were then added, and
the mixture was heated at 100.degree. C. for 5 h. The mixture was
then evaporated to dryness on a rotary evaporator. The residue that
remained was taken up in ethyl acetate and washed successively with
water and saturated sodium chloride solution. After drying over
anhydrous magnesium sulphate, the mixture was filtered and the
filtrate was evaporated. The crude product was purified by MPLC
(Puriflash column with 120 g of silica gel, cyclohexane/ethyl
acetate 10:1). The product fractions were combined and
concentrated, and the residue was dried under high vacuum. This
gave 3.24 g (76% of theory, 93% pure) of the title compound.
[0669] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.15 (t,
2H), 3.90 (quart, 2H), 2.84-2.74 (m, 2H), 2.76 (s, 3H), 1.53 (s,
9H), 1.13 (t, 3H).
[0670] LC/MS (Method 1, ESIpos): R.sub.t=1.36 min, m/z=407
[M+H].sup.+.
Example 36A
tert-Butyl
1-(4,4-difluorobut-3-en-1-yl)-3-ethyl-5-methyl-2,4-dioxo-1,2,3,-
4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00120##
[0672] Analogously to the process described in Ex. 35A, 800 mg
(2.58 mmol) of the compound from Ex. 12A, 1.26 g (3.87 mmol) of
caesium carbonate and 661 mg (3.87 mmol) of
4-bromo-1,1-difluorobut-1-ene gave 778 mg (76% of theory) of the
title compound. In deviation to the process described above, here
the reaction time was only 1 h. Also in deviation, a Puriflash
cartridge containing 40 g of silica gel was used for MPLC
purification, and the product was then purified by stirring in
pentane/dichloromethane (30:1).
[0673] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 4.25 (d of t
of d, 1H), 4.06 (quart, 2H), 3.98 (t, 2H), 2.85 (s, 3H), 2.51
(pseudo-quart, 2H), 1.59 (s, 9H), 1.25 (t, 3H).
[0674] LC/MS (Method 1, ESIpos): R.sub.t=1.39 min, m/z=401
[M+H].sup.+.
Example 37A
tert-Butyl
3-ethyl-1-(2-methoxyethyl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydr-
othieno[2,3-d]pyrimidine-6-carboxylate
##STR00121##
[0676] Analogously to the process described in Ex. 35A, 800 mg
(2.58 mmol) of the compound from Ex. 12A, 1.26 g (3.87 mmol) of
caesium carbonate and 537 mg (3.87 mmol) of 2-bromoethyl methyl
ether gave 680 mg (71% of theory) of the title compound. In
deviation to the process described above, here a Biotage cartridge
containing 50 g of silica gel was used for MPLC purification, and
the product was then purified by stirring in 31 ml of
pentane/dichloromethane (30:1).
[0677] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 4.13 (t,
2H), 4.07 (quart, 2H), 3.74 (t, 2H), 3.36 (s, 3H), 2.84 (s, 3H),
1.58 (s, 9H), 1.26 (t, 3H).
[0678] LC/MS (Method 1, ESIpos): R.sub.t=1.24 min, m/z=369
[M+H].sup.+.
Example 38A
Ethyl
2,4-dioxo-3-(2-phenylethyl)-5-(trifluoromethyl)-1-(3,3,3-trifluoropr-
opyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00122##
[0680] 719 mg (2.21 mmol) of caesium carbonate were added to a
solution of 700 mg (1.70 mmol) of the compound from Ex. 20A in 20
ml of DMF, and the mixture was stirred at RT for 15 min. 570 mg
(2.55 mmol) of 3,3,3-trifluoro-1-iodopropane were then added, and
the mixture was heated at 100.degree. C. for 60 min. 400 ml of
water were then added, and the mixture was extracted three times
with about 100 ml of diethyl ether each time. The combined organic
extracts were washed with saturated sodium chloride solution. After
drying over anhydrous magnesium sulphate, the mixture was filtered
and the filtrate was evaporated. At RT, the crude product was
triturated in a mixture of 25 ml of pentane and 0.5 ml of diethyl
ether for 1 h. The mixture was filtered and the residue was dried
under high vacuum. This gave a first fraction of the title compound
(497 mg, 57% of theory). A second fraction was isolated by
preparative HPLC (Method 6) from the mother liquor obtained after
stirring (138 mg, 16% of theory). A total of 635 mg (73% of theory)
of the title compound were thus obtained.
[0681] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.32-7.20
(m, 5H, partially obscured by the CHCl.sub.3 signal), 4.42 (quart,
2H), 4.26-4.22 (m, 2H), 4.16 (t, 2H), 2.98-2.94 (m, 2H), 2.64-2.53
(m, 2H), 1.41 (t, 3H).
[0682] LC/MS (Method 1, ESIpos): R.sub.t=1.30 min, m/z=509
[M+H].sup.+.
Example 39A
Ethyl
3-ethyl-2,4-dioxo-5-(trifluoromethyl)-1-(3,3,3-trifluoro9propyl)-1,2-
,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00123##
[0684] 1.39 g (13.1 mmol) of caesium carbonate were added to a
solution of 2.0 g (5.95 mmol) of the compound from Ex. 21A in 40 ml
of DMF, and the mixture was stirred at RT for 15 min. 2.66 g (11.9
mmol) of 3,3,3-trifluoro-1-iodopropane were then added, and the
mixture was heated at 60.degree. C. After 1 h, a further 2.66 g
(11.9 mmol) of 3,3,3-trifluoro-1-iodopropane were added. Stirring
at 60.degree. C. was continued for 16 h. After cooling to RT, about
160 ml of water were added and the mixture was extracted three
times with about 80 ml of diethyl ether each time. The combined
organic extracts were washed with saturated sodium chloride
solution. After drying over anhydrous magnesium sulphate, the
mixture was filtered and the filtrate was evaporated. The crude
product was purified by MPLC on a Puriflash cartridge (100 g of
silica gel, cyclohexane/ethyl acetate 7:1.fwdarw.1:1). The product
fractions were combined and concentrated, and the residue was dried
under high vacuum. This gave 1.86 g (72% of theory) of the title
compound.
[0685] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 4.41 (quart,
2H), 4.20 (t, 2H), 4.08 (quart, 2H), 2.73-2.61 (m, 2H), 1.40 (t,
3H), 1.26 (t, 3H).
[0686] LC/MS (Method 1, ESIpos): R.sub.t=1.15 min, m/z=433
[M+H].sup.+.
Example 40A
Ethyl
5-(difluoromethyl)-2,4-dioxo-3-(2-phenylethyl)-1-(3,3,3-trifluoropro-
pyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00124##
[0688] Analogously to the process described in Ex. 38A, 2.90 g
(7.35 mmol) of the compound from Ex. 23A and 1.72 ml (14.7 mmol) of
3,3,3-trifluoro-1-iodopropane gave 2.22 g (61% of theory) of the
title compound. Here, for purification the crude product was, at
RT, stirred successively with the following solvent mixtures: In
the first and second instance in each case with 100 ml of pentane
and 5 ml of diethyl ether, in the third instance with 50 ml of
pentane and 5 ml of diethyl ether.
[0689] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.74 (t,
1H), 7.33-7.29 (m, 2H), 7.26-7.21 (m, 3H), 4.36 (quart, 2H), 4.20
(t, 2H), 4.08 (m, 2H), 2.87-2.75 (m, 4H), 1.32 (t, 3H).
[0690] LC/MS (Method 1, ESIpos): R.sub.t=1.27 min, m/z=491
[M+H].sup.+.
Example 41A
Ethyl
2,4-dioxo-3-(2-phenylethyl)-1-(3,3,3-trifluoropropyl)-1,2,3,4-tetrah-
ydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00125##
[0692] 1.28 g (3.92 mmol) of caesium carbonate were added to a
solution of 900 mg (2.61 mmol) of the compound from Ex. 25A in 10
ml of DMF, and the mixture was stirred at RT for 20 min. 878 mg
(3.92 mmol) of 3,3,3-trifluoro-1-iodopropane were then added, and
the mixture was stirred in a microwave oven (Biotage Initiator with
dynamic control of irradiation power) at 100.degree. C. for 2 h 45
min. After cooling to RT, about 60 ml of water were added and the
mixture was extracted with ethyl acetate. The organic extract was
washed with water and saturated sodium chloride solution. After
drying over anhydrous magnesium sulphate, the mixture was filtered
and concentrated. At RT, the solid obtained was stirred in a
mixture of 20 ml of pentane and 1 ml of diethyl ether for about 16
h. This gave, after filtration with suction and drying under high
vacuum, 895 mg (77% of theory) of the title compound.
[0693] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.87 (s,
1H), 7.32-7.28 (m, 2H), 7.24-7.19 (m, 3H), 4.32 (quart, 2H), 4.17
(t, 2H), 4.09 (m, 2H), 2.89-2.73 (m, 4H), 1.31 (t, 3H).
[0694] LC/MS (Method 1, ESIpos): R.sub.t=1.24 min, m/z=441
[M+H].sup.+.
Example 42A
tert-Butyl
3-(2,4-dimethoxybenzyl)-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropr-
opyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00126##
[0696] 6.10 g (57.6 mmol) of caesium carbonate were added to a
solution of 11.3 g (26.2 mmol) of the compound from Ex. 13A in 250
ml of DMF, and the mixture was stirred at RT for 15 min. 11.7 g
(52.3 mmol) of 3,3,3-trifluoro-1-iodopropane were then added, and
the mixture was heated at 70.degree. C. After 6 h, a further 11.7 g
(52.3 mmol) of 3,3,3-trifluoro-1-iodopropane were added. Stirring
at 70.degree. C. was continued for 7 h. After cooling to RT, most
of the volatile components (including DMF) were removed on a rotary
evaporator. About 400 ml of ethyl acetate were added to the
residue, and the mixture was washed successively with water and
saturated sodium chloride solution. After drying of the organic
phase over anhydrous magnesium sulphate, the mixture was filtered
and evaporated. The crude product was purified by MPLC on a Biotage
cartridge (340 g of silica gel, cyclohexane/ethyl acetate 5:1). The
product fractions were combined and concentrated. Stirring of the
residue with pentane/dichloromethane (25:1), another filtration and
drying under high vacuum gave 8.78 g (63% of theory) of the title
compound.
[0697] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 6.75 (d,
1H), 6.57 (d, 1H), 6.39 (dd, 1H), 4.95 (s, 2H), 4.17 (t, 2H), 3.81
(s, 3H), 3.72 (s, 3H), 2.87-2.74 (m, 2H), 2.74 (s, 3H), 1.54 (s,
9H).
[0698] LC/MS (Method 1, ESIpos): R.sub.t=1.38 min, m/z=529
[M+H].sup.+.
Example 43A
5-Methyl-2,4-dioxo-3-(2-phenylethyl)-1-(3,3,3-trifluoropropyl)-1,2,3,4-tet-
rahydrothieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00127##
[0700] 80 ml of trifluoroacetic acid were added to a solution of
5.69 g (11.8 mmol) of the compound from Ex. 26A in 240 ml of
dichloromethane, and the mixture was stirred at RT for 2 h. The
reaction mixture was then evaporated to dryness on a rotary
evaporator. The residue that remained was stirred in diethyl ether
and filtered off with suction, and the solid was dried under high
vacuum. This gave 4.89 g (97% of theory) of the title compound.
[0701] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.47 (br.
s, 1H), 7.33-7.28 (m, 2H), 7.26-7.20 (m, 3H), 4.14 (t, 2H), 4.07
(m, 2H), 2.84 (m, 2H), 2.80-2.70 (m, 2H), 2.77 (s, 3H).
[0702] LC/MS (Method 1, ESIpos): R.sub.t=1.11 min, m/z=427
[M+H].sup.+.
Example 44A
1-(4,4-Difluorobut-3-en-1-yl)-5-methyl-2,4-dioxo-3-(2-phenylethyl)-1,2,3,4-
-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00128##
[0704] Analogously to the process described in Ex. 43A, 520 mg
(1.09 mmol) of the compound from Ex. 27A and 5 ml of
trifluoroacetic acid in 10 ml of dichloromethane gave 328 mg (71%
of theory) of the title compound.
[0705] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.42 (br.
s, 1H), 7.33-7.28 (m, 2H), 7.25-7.20 (m, 3H), 4.63 (d of t of d,
1H), 4.07 (m, 2H), 3.96 (t, 2H), 2.83 (m, 2H), 2.76 (s, 3H), 2.38
(m, 2H).
[0706] LC/MS (Method 1, ESIpos): R.sub.t=1.15 min, m/z=421
[M+H].sup.+.
Example 45A
1-(2-Methoxyethyl)-5-methyl-2,4-dioxo-3-(2-phenylethyl)-1,2,3,4-tetrahydro-
thieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00129##
[0708] 75 ml of trifluoroacetic acid were added to a solution of
5.0 g (11.2 mmol) of the compound from Ex. 28A in 225 ml of
dichloromethane, and the mixture was stirred at RT for 2 h. The
reaction mixture was then evaporated to dryness on a rotary
evaporator. The residue that remained was stirred in diethyl ether
and filtered off with suction, and the solid was dried under high
vacuum. 4.1 g (92% of theory) of the title compound were
obtained.
[0709] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.37 (br.
s, 1H), 7.33-7.29 (m, 2H), 7.25-7.20 (m, 3H), 4.09-4.04 (m, 4H),
3.62 (t, 2H), 3.25 (s, 3H), 2.84 (dd, 2H), 2.75 (s, 3H).
[0710] LC/MS (Method 1, ESIpos): R.sub.t=1.03 min, m/z=389
[M+H].sup.+.
Example 46A
3-[2-(2-Fluorophenyl)ethyl]-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1-
,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00130##
[0712] 10 ml of trifluoroacetic acid were added to a solution of
420 mg (0.84 mmol) of the compound from Ex. 29A in 20 ml of
dichloromethane, and the mixture was stirred at RT for 1 h. The
reaction mixture was then evaporated to dryness on a rotary
evaporator and the residue was subsequently dried under high
vacuum. 300 mg (79% of theory) of the title compound were
obtained.
[0713] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.47 (br.
s, 1H), 7.29-7.24 (m, 2H), 7.16-7.09 (m, 2H), 4.12 (t, 2H), 4.10
(t, 2H), 2.91 (t, 2H), 2.74 (s, 3H), 2.70 (t, 2H).
[0714] LC/MS (Method 1, ESIpos): R.sub.t=1.11 min, m/z=445
[M+H].sup.+.
Example 47A
1-(4,4-Difluorobut-3-en-1-yl)-3-[2-(2-fluorophenyl)ethyl]-5-methyl-2,4-dio-
xo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00131##
[0716] 15 ml of trifluoroacetic acid were added to a solution of
750 mg (1.52 mmol) of the compound from Ex. 30A in 30 ml of
dichloromethane, and the mixture was stirred at RT for 1 h. The
reaction mixture was then evaporated to dryness on a rotary
evaporator. The residue that remained was stirred in diethyl ether
and filtered off with suction, and the solid was dried under high
vacuum. 320 mg (47% of theory) of the title compound were thus
obtained. Since, except for the target compound, the mother liquor
did not contain any further impurities, it was evaporated
completely, and the residue that remained was likewise dried under
high vacuum (290 mg, 42% of theory). A total of 610 mg (90% of
theory) of the title compound were obtained in this manner.
[0717] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.42 (br.
s, 1H), 7.30-7.24 (m, 2H), 7.16-7.10 (m, 2H), 4.61 (d of t of d,
1H), 4.10 (t, 2H), 3.93 (t, 2H), 2.90 (t, 2H), 2.73 (s, 3H),
2.38-2.32 (m, 2H).
[0718] LC/MS (Method 1, ESIpos): R.sub.t=1.15 min, m/z=439
[M+H].sup.+.
Example 48A
3-[2-(2-Chlorophenyl)ethyl]-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1-
,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00132##
[0720] 7 ml of trifluoroacetic acid were added to a solution of 420
mg (0.81 mmol) of the compound from Ex. 31A in 15 ml of
dichloromethane, and the mixture was stirred at RT for 2 h. The
reaction mixture was then evaporated to dryness on a rotary
evaporator. The residue that remained was stirred in diethyl ether
and filtered off with suction, and the solid was dried under high
vacuum. 295 mg (79% of theory) of the title compound were
obtained.
[0721] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.46 (br.
s, 1H), 7.43-7.39 (m, 1H), 7.31-7.24 (m, 3H), 4.15-4.10 (m, 4H),
3.00 (t, 2H), 2.76-2.67 (m, 2H), 2.74 (s, 3H).
[0722] LC/MS (Method 1, ESIpos): R.sub.t=1.17 min, m/z=461/463
[M+H].sup.+.
Example 49A
3-[2-(2-Chlorophenyl)ethyl]-1-(4,4-difluorobut-3-en-1-yl)-5-methyl-2,4-dio-
xo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00133##
[0724] Analogously to the process described in Ex. 48A, 525 mg
(1.03 mmol) of the compound from Ex. 32A and 7 ml of
trifluoroacetic acid in 15 ml of dichloromethane gave 345 mg (73%
of theory) of the title compound.
[0725] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.41 (br.
s, 1H), 7.42-7.39 (m, 1H), 7.31-7.24 (m, 3H), 4.61 (d of t of d,
1H), 4.12 (t, 2H), 3.93 (t, 2H), 2.99 (t, 2H), 2.73 (s, 3H),
2.37-2.31 (m, 2H).
[0726] LC/MS (Method 1, ESIpos): R.sub.t=1.19 min, m/z=455/457
[M+H]+.
Example 50A
5-Methyl-2,4-dioxo-3-[2-(pyridin-3-yl)ethyl]-1-(3,3,3-trifluoropropyl)-1,2-
,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylic acid
hydrochloride
##STR00134##
[0728] 9.3 ml of a 4 M solution of hydrogen chloride in dioxane
were added to 450 mg (0.93 mmol) of the compound from Ex. 33A, and
the mixture was stirred at RT for about 16 h. The reaction mixture
was then evaporated to dryness on a rotary evaporator. The residue
that remained was stirred in 10 ml of diethyl ether at RT for 30
min and filtered off with suction, and the solid was dried under
high vacuum. 463 mg (91% of theory) of the title compound were
obtained.
[0729] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.50 (br.
s, 1H), 8.82 (s, 1H), 8.74 (d, 1H), 8.36 (d, 1H), 7.88 (t, 1H),
4.19 (t, 2H), 4.12 (t, 2H), 3.09 (t, 2H), 2.80-2.68 (m, 2H), 2.72
(s, 3H).
[0730] LC/MS (Method 1, ESIpos): R.sub.t=0.67 min, m/z=428
[M+H].sup.+.
Example 51A
1-(4,4-Difluorobut-3-en-1-yl)-5-methyl-2,4-dioxo-3-[2-(pyridin-3-yl)ethyl]-
-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylic acid
hydrochloride
##STR00135##
[0732] Analogously to the process described under Ex. 50A, 450 mg
(0.94 mmol) of the compound from Ex. 34A gave 365 mg (82% of
theory) of the title compound.
[0733] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.45 (br.
s, 1H), 8.82 (s, 1H), 8.73 (d, 1H), 8.35 (d, 1H), 7.87 (t, 1H),
4.61 (d of t of d, 1H), 4.19 (t, 2H), 3.92 (t, 2H), 3.08 (t, 2H),
2.72 (s, 3H), 2.37-2.30 (m, 2H).
[0734] LC/MS (Method 1, ESIpos): R.sub.t=0.70 min, m/z=422
[M+H].sup.+.
Example 52A
3-Ethyl-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,2,3,4-tetrahydrothi-
eno[2,3-d]pyrimidine-6-carboxylic acid
##STR00136##
[0735] Method A:
[0736] 80 ml of trifluoroacetic acid were added to a solution of
6.89 g (16.9 mmol) of the compound from Ex. 35A in 240 ml of
dichloromethane, and the mixture was stirred at RT for 2 h. The
reaction mixture was then evaporated to dryness on a rotary
evaporator. The residue that remained was stirred in diethyl ether
and filtered off with suction, and the solid was dried under high
vacuum. 5.13 g (86% of theory) of the title compound were
obtained.
[0737] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.46 (br.
s, 1H), 4.15 (t, 2H), 3.91 (quart, 2H), 2.85-2.73 (m, 2H), 2.76 (s,
3H), 1.13 (t, 3H).
[0738] LC/MS (Method 1, ESIpos): R.sub.t=0.94 min, m/z=351
[M+H]+.
Method B:
[0739] At about 2.degree. C., 926 mg (9.54 mmol) of sulphaminic
acid and 1.56 g (13.0 mmol) of sodium dihydrogenphosphate were
added to a solution of 2.9 g (8.67 mmol) of the compound from Ex.
167A in a mixture of 22 ml of acetone and 10 ml of water. A
solution of 1.03 g (9.11 mmol, content 80%) of sodium chlorite in 4
ml of water was then slowly added dropwise such that the
temperature of the reaction mixture did not rise above 6.degree. C.
After 30 min, the cooling bath was removed and stirring of the
mixture was continued overnight. The mixture was then diluted with
100 ml of water and extracted twice with 150 ml of ethyl acetate
each time. The organic extract was dried over anhydrous sodium
sulphate and then filtered, and the filtrate was concentrated to
dryness. The crude product was purified by chromatography (40 g of
silica gel, mobile phase: dichloromethane/methanol
100:0.fwdarw.90:10). This gave, after concentration of the product
fractions and drying of the residue, 2.60 g (85% of theory) of the
title compound.
Example 53A
1-(4,4-Difluorobut-3-en-1-yl)-3-ethyl-5-methyl-2,4-dioxo-1,2,3,4-tetrahydr-
othieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00137##
[0741] Analogously to the process described under Ex. 52A, 750 mg
(1.87 mmol) of the compound from Ex. 36A gave 528 mg (81% of
theory) of the title compound.
[0742] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.40 (br.
s, 1H), 4.64 (d of t of d, 1H), 3.96 (t, 2H), 3.90 (quart, 2H),
2.76 (s, 3H), 2.40 (pseudo-quart, 2H), 1.12 (t, 3H).
[0743] LC/MS (Method 1, ESIpos): R.sub.t=0.94 min, m/z=345
[M+H].sup.+.
Example 54A
3-Ethyl-1-(2-methoxyethyl)-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
-d]pyrimidine-6-carboxylic acid
##STR00138##
[0745] Analogously to the process described under Ex. 52A, 650 mg
(1.76 mmol) of the compound from Ex. 37A gave 469 mg (85% of
theory) of the title compound.
[0746] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.36 (br.
s, 1H), 4.07 (t, 2H), 3.90 (quart, 2H), 3.65 (t, 2H), 3.25 (s, 3H),
2.75 (s, 3H), 1.13 (t, 3H).
[0747] LC/MS (Method 1, ESIpos): R.sub.t=0.78 min, m/z=313
[M+H].sup.+.
Example 55A
2,4-Dioxo-3-(2-phenylethyl)-5-(trifluoromethyl)-1-(3,3,3-trifluoropropyl)--
1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00139##
[0749] A solution of 35 mg (1.46 mmol) of lithium hydroxide in 10
ml of water was added to a solution of 495 mg (0.970 mmol) of the
compound from Ex. 38A in 20 ml of ethanol, and the mixture was
stirred at RT for about 16 h. All the volatile constituents were
then removed on a rotary evaporator. The residue that remained was
taken up in water and acidified with 2 ml of 1 M hydrochloric acid.
The product precipitated out and was filtered off with suction,
washed with water and dried under high vacuum. 460 mg (95% of
theory) of the title compound were obtained.
[0750] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 14.50 (br.
s, 1H), 7.33-7.28 (m, 2H), 7.26-7.20 (m, 3H), 4.18 (t, 2H), 4.07
(m, 2H), 2.74-2.68 (m, 4H).
[0751] LC/MS (Method 2, ESIpos): R.sub.t=2.34 min, m/z=481
[M+H]+.
Example 56A
3-Ethyl-2,4-dioxo-5-(trifluoromethyl)-1-(3,3,3-trifluoropropyl)-1,2,3,4-te-
trahydrothieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00140##
[0753] Analogously to the process described under Ex. 55A, 231 mg
(0.540 mmol) of the compound from Ex. 39A gave 178 mg (82% of
theory) of the title compound.
[0754] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 14.51 (br.
s, 1H), 4.18 (t, 2H), 3.91 (quart, 2H), 2.87-2.75 (m, 2H), 1.13 (t,
3H).
[0755] LC/MS (Method 1, ESIpos): R.sub.t=0.76 min, m/z=405
[M+H]+.
Example 57A
5-(Difluoromethyl)-2,4-dioxo-3-(2-phenylethyl)-1-(3,3,3-trifluoropropyl)-1-
,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00141##
[0757] A solution of 59 mg (2.45 mmol) of lithium hydroxide in 17
ml of water was added to a solution of 800 mg (1.63 mmol) of the
compound from Ex. 40A in 33 ml of ethanol, and the mixture was
stirred at RT for 3 h. All the volatile constituents were then
removed on a rotary evaporator. The residue that remained was taken
up in water and acidified with 2 ml of 1 M hydrochloric acid. The
mixture was extracted three times with about 100 ml of
dichloromethane each time. The combined organic extracts were
washed once with saturated sodium chloride solution, dried over
anhydrous magnesium sulphate, filtered and concentrated. At RT, the
solid that remained was stirred in a mixture of 30 ml of pentane
and 3 ml of diethyl ether. This gave, after filtration with suction
and drying under high vacuum, 482 mg (63% of theory) of the title
compound.
[0758] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.79 (t,
1H), 7.34-7.29 (m, 2H), 7.26-7.20 (m, 3H), 4.19 (t, 2H), 4.07 (m,
2H), 2.87-2.73 (m, 4H).
[0759] LC/MS (Method 1, ESIpos): R.sub.t=1.01 min, m/z=463
[M+H].sup.+.
Example 58A
2,4-Dioxo-3-(2-phenylethyl)-1-(3,3,3-trifluoropropyl)-1,2,3,4-tetrahydroth-
ieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00142##
[0761] A solution of 65 mg (2.73 mmol) of lithium hydroxide in 8 ml
of water was added to a solution of 800 mg (1.82 mmol) of the
compound from Ex. 41A in 24 ml of ethanol. 2 ml of THF were then
added. The reaction mixture was stirred at RT for 3 h. All the
volatile constituents were then removed on a rotary evaporator. The
residue that remained was taken up in about 200 ml of water and
acidified with 3 ml of 1 M hydrochloric acid. The product
precipitated out and was filtered off with suction, washed with
water until neutral and dried under high vacuum. This gave 639 mg
(83% of theory, 97% pure) of the title compound.
[0762] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.63 (br.
s, 1H), 7.79 (s, 1H), 7.32-7.28 (m, 2H), 7.24-7.20 (m, 3H), 4.16
(t, 2H), 4.08 (m, 2H), 2.85 (m, 2H), 2.78 (m, 2H).
[0763] LC/MS (Method 1, ESIpos): R.sub.t=1.04 min, m/z=413
[M+H].sup.+.
Example 59A
5-Methyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,2,3,4-tetrahydrothieno[2,3--
d]pyrimidine-6-carboxylic acid
##STR00143##
[0765] 3.32 g (6.27 mmol) of the compound from Ex. 42A were
dissolved in 130 ml of toluene, and 5.02 g (37.6 mmol) of solid
aluminium trichloride were added at RT. The reaction mixture was
then stirred at 50.degree. C. for 90 min. After cooling to RT, 70
ml of water and 300 ml of ethyl acetate were added. After phase
separation, the organic phase was washed successively with water
and saturated sodium chloride solution. After drying over anhydrous
magnesium sulphate, the mixture was filtered and the filtrate was
evaporated. The crude product was stirred with 50 ml of
pentane/dichloromethane (20:1) at RT. Filtration with suction and
drying of the solid under high vacuum gave 1.93 g (87% of theory,
about 92% pure) of the title compound.
[0766] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.40
(broad, 1H), 11.63 (s, 1H), 4.09 (t, 2H), 2.83-2.69 (m, 2H), 2.72
(s, 3H).
[0767] LC/MS (Method 1, ESIpos): R.sub.t=0.65 min, m/z=323
[M+H].sup.+.
Example 60A
1-{[5-Methyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,2,3,4-tetrahydrothieno[-
2,3-d]pyrimidin-6-yl]carbonyl}piperidin-4-yl acetate
##STR00144##
[0769] 1.93 g (6.0 mmol) of the compound from Ex. 59A were
dissolved in 40 ml of DMF, and 2.74 g (7.20 mmol) of HATU, 1.29 g
(7.20 mmol) of piperidin-4-yl acetate hydrochloride [lit.: T.
Kikuchi et al., J. Med. Chem. 2005, 48 (7), 2577-2583] and 3.1 ml
(18.0 mmol) of N,N-diisopropylethylamine were successively added.
After the reaction mixture had been stirred at RT for about 16 h,
the mixture was poured onto water, resulting in the precipitation
of the product. The product was filtered off with suction, washed
with a little water and dried under a high vacuum. Stirring with
diethyl ether gave 2.35 g (80% of theory, purity about 92%) of the
title compound.
[0770] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 8.38 (s,
1H), 5.04 (m, 1H), 4.15 (t, 2H), 3.88-3.80 (m, 2H), 3.55-3.48 (m,
2H), 2.71-2.59 (m, 2H), 2.49 (s, 3H), 2.09 (s, 3H), 1.98-1.91 (m,
2H), 1.77-1.69 (m, 2H).
[0771] LC/MS (Method 1, ESIpos): R.sub.t=0.81 min, m/z=448
[M+H].sup.+.
Example 61A
3-Ethyl-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-car-
boxylic acid
##STR00145##
[0773] 149 ml of trifluoroacetic acid were added to a solution of
30.0 g (96.7 mmol) of the compound from Ex. 12A in 300 ml of
dichloromethane, and the mixture was stirred at RT for 12 h. The
reaction mixture was then evaporated to dryness on a rotary
evaporator. The residue that remained was stirred in diisopropyl
ether and filtered off with suction, and the solid was dried under
high vacuum. 22.80 g (92% of theory) of the title compound were
obtained.
[0774] LC/MS (Method 1, ESIpos): R.sub.t=0.61 min, m/z=255
[M+H].sup.+.
Example 62A
1-[(3-Ethyl-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6--
yl)carbonyl]piperidin-4-yl acetate
##STR00146##
[0776] 19.50 g (76.7 mmol) of the compound of Ex. 61A and 15.16 g
(84.4 mmol) of piperidin-4-yl acetate hydrochloride [lit.: T.
Kikuchi et al., J. Med. Chem. 2005, 48 (7), 2577-2583] were
dissolved in 390 ml of DMF, and 43.7 g (115 mmol) of HATU and 47 ml
(268 mmol) of N,N-diisopropylethylamine were added successively at
0.degree. C. After the reaction mixture had been stirred at RT for
about 16 h, it was diluted with about 400 ml of ethyl acetate and
washed successively with water, 1 M hydrochloric acid, water and
saturated aqueous sodium chloride solution. After drying over
anhydrous magnesium sulphate, the mixture was filtered and
evaporated to dryness. The residue obtained was purified by
filtration with suction through silica gel using a
cyclohexane/ethyl acetate gradient. This gave, after evaporation of
the product fraction and drying of the residue under high vacuum,
8.80 g (30% of theory) of the title compound.
[0777] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 12.23 (s,
1H), 4.90 (m, 1H), 3.86 (quart, 2H), 3.77-3.69 (m, 2H), 3.41-3.33
(m, 2H, partially obscured by the water signal), 2.35 (s, 3H), 2.02
(s, 3H), 1.90-1.83 (m, 2H), 1.58-1.49 (m, 2H), 1.11 (t, 3H).
[0778] LC/MS (Method 1, ESIpos): R.sub.t=0.72 min, m/z=380
[M+H]+.
Example 63A
1-({5-Methyl-3-[2-(2-methylphenyl)ethyl]-2,4-dioxo-1-(3,3,3-trifluoropropy-
l)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}carbonyl)piperidin-4-yl
acetate
##STR00147##
[0780] 70 mg (0.156 mmol) of the compound from Ex. 60A and 31.5
.mu.l (0.235 mmol) of 2-(2-methylphenyl)ethyl alcohol were
dissolved in 2 ml of anhydrous THF, and 62 mg (0.235 mmol) of
triphenylphosphine and 46.5 .mu.l (0.235 mmol) of diisopropyl
azodicarboxylate (DIAD) were added successively. After about 16 h
of stirring at RT, the reaction mixture, in two portions, was
separated by preparative HPLC into its components (Method 5). The
product fractions were combined and concentrated, and the residue
was dried under high vacuum. 66 mg (72% of theory) of the title
compound were obtained.
[0781] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.22-7.11
(m, 4H), 5.04 (m, 1H), 4.18-4.13 (m, 4H), 3.89-3.81 (m, 2H),
3.55-3.48 (m, 2H), 2.95 (m, 2H), 2.64-2.55 (m, 2H), 2.53 (s, 3H),
2.47 (s, 3H), 2.09 (s, 3H), 1.99-1.91 (m, 2H), 1.78-1.69 (m,
2H).
[0782] LC/MS (Method 1, ESIpos): R.sub.t=1.24 min, m/z=566
[M+H].sup.+.
Example 64A
1-({3-[2-(3-Fluorophenyl)ethyl]-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropy-
l)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}carbonyl)piperidin-4-yl
acetate
##STR00148##
[0784] Analogously to the process described in Ex. 63A, 70 mg
(0.156 mmol) of the compound from Ex. 60A and 29.3 .mu.l (0.235
mmol) of 2-(3-fluorophenyl)ethyl alcohol gave 65 mg (73% of theory)
of the title compound.
[0785] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.07 (d,
1H), 7.00 (d, 1H), 6.92 (dt, 1H), 5.04 (m, 1H), 4.23-4.13 (m, 4H),
3.89-3.81 (m, 2H), 3.56-3.48 (m, 2H), 2.94 (m, 2H), 2.66-2.55 (m,
2H), 2.51 (s, 3H), 2.09 (s, 3H), 1.99-1.91 (m, 2H), 1.78-1.69 (m,
2H).
[0786] LC/MS (Method 1, ESIpos): R.sub.t=1.19 min, m/z=570
[M+H].sup.+.
Example 65A
1-({3-[2-(3-Chlorophenyl)ethyl]-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropy-
l)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}carbonyl)piperidin-4-yl
acetate
##STR00149##
[0788] Analogously to the process described in Ex. 63A, 70 mg
(0.156 mmol) of the compound from Ex. 60A and 37 mg (0.235 mmol) of
2-(3-chlorophenyl)ethyl alcohol gave 74 mg (79% of theory) of the
title compound.
[0789] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.28-7.17
(m, 4H, partially obscured by the CHCl.sub.3 signal), 5.04 (m, 1H),
4.22-4.13 (m, 4H), 3.88-3.81 (m, 2H), 3.56-3.48 (m, 2H), 2.92 (m,
2H), 2.66-2.55 (m, 2H), 2.52 (s, 3H), 2.09 (s, 3H), 1.99-1.91 (m,
2H), 1.78-1.69 (m, 2H).
[0790] LC/MS (Method 1, ESIpos): R.sub.t=1.24 min, m/z=586/588
[M+H].sup.+.
Example 66A
1-({5-Methyl-3-[2-(3-methylphenyl)ethyl]-2,4-dioxo-1-(3,3,3-trifluoropropy-
l)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}carbonyl)piperidin-4-yl
acetate
##STR00150##
[0792] Analogously to the process described in Ex. 63A, 70 mg
(0.156 mmol) of the compound from Ex. 60A and 37 mg (0.235 mmol) of
2-(3-methylphenyl)ethyl alcohol gave 61 mg (66% of theory) of the
title compound.
[0793] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.20 (t,
1H), 7.13 (s, 1H), 7.10 (d, 1H), 7.05 (d, 1H), 5.04 (m, 1H),
4.21-4.14 (m, 4H), 3.89-3.81 (m, 2H), 3.56-3.48 (m, 2H), 2.89 (m,
2H), 2.67-2.55 (m, 2H), 2.53 (s, 3H), 2.34 (s, 3H), 2.09 (s, 3H),
1.99-1.91 (m, 2H), 1.78-1.69 (m, 2H).
[0794] LC/MS (Method 1, ESIpos): R.sub.t=1.23 min, m/z=566
[M+H].sup.+.
Example 67A
1-({3-[2-(4-Fluorophenyl)ethyl]-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropy-
l)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}carbonyl)piperidin-4-yl
acetate
##STR00151##
[0796] Analogously to the process described in Ex. 63A, 42 mg
(0.094 mmol) of the compound from Ex. 60A and 20 mg (0.141 mmol) of
2-(4-fluorophenyl)ethyl alcohol gave 39 mg (72% of theory) of the
title compound.
[0797] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.27-7.23
(m, 2H, partially obscured by the CHCl.sub.3 signal), 6.99 (t, 2H),
5.04 (m, 1H), 4.20-4.13 (m, 4H), 3.88-3.81 (m, 2H), 3.56-3.48 (m,
2H), 2.91 (m, 2H), 2.66-2.55 (m, 2H), 2.51 (s, 3H), 2.09 (s, 3H),
1.99-1.91 (m, 2H), 1.77-1.69 (m, 2H).
[0798] LC/MS (Method 1, ESIpos): R.sub.t=1.20 min, m/z=570
[M+H].sup.+.
Example 68A
1-({3-[2-(4-Chlorophenyl)ethyl]-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropy-
l)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}carbonyl)piperidin-4-yl
acetate
##STR00152##
[0800] Analogously to the process described in Ex. 63A, 70 mg
(0.156 mmol) of the compound from Ex. 60A and 37 mg (0.235 mmol) of
2-(4-chlorophenyl)ethyl alcohol gave 78 mg (85% of theory) of the
title compound.
[0801] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.27 (d,
2H), 7.22 (d, 2H), 5.04 (m, 1H), 4.20-4.13 (m, 4H), 3.89-3.80 (m,
2H), 3.56-3.48 (m, 2H), 2.91 (m, 2H), 2.65-2.53 (m, 2H), 2.51 (s,
3H), 2.09 (s, 3H), 1.99-1.91 (m, 2H), 1.78-1.69 (m, 2H).
[0802] LC/MS (Method 1, ESIpos): R.sub.t=1.23 min, m/z=586/588
[M+H].sup.+.
Example 69A
1-({3-[2-(4-Methoxyphenyl)ethyl]-5-methyl-2,4-dioxo-1-(3,3,3-trifluoroprop-
yl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}carbonyl)piperidin-4-yl
acetate
##STR00153##
[0804] Analogously to the process described in Ex. 63A, 70 mg
(0.156 mmol) of the compound from Ex. 60A and 36 mg (0.235 mmol) of
2-(4-methoxyphenyl)ethyl alcohol gave 72 mg (79% of theory) of the
title compound.
[0805] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.20 (d,
2H), 6.84 (d, 2H), 5.04 (m, 1H), 4.19-4.13 (m, 4H), 3.89-3.80 (m,
2H), 3.79 (s, 3H), 3.55-3.48 (m, 2H), 2.88 (m, 2H), 2.64-2.55 (m,
2H), 2.52 (s, 3H), 2.09 (s, 3H), 1.99-1.91 (m, 2H), 1.77-1.69 (m,
2H).
[0806] LC/MS (Method 1, ESIpos): R.sub.t=1.14 min, m/z=582
[M+H].sup.+.
Example 70A
1-({5-Methyl-2,4-dioxo-3-[2-(pyrazin-2-yl)ethyl]-1-(3,3,3-trifluoropropyl)-
-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}carbonyl)piperidin-4-yl
acetate
##STR00154##
[0808] Analogously to the process described in Ex. 63A, 70 mg
(0.156 mmol) of the compound from Ex. 60A and 29 mg (0.235 mmol) of
2-(2-hydroxyethyl)pyrazine [commercially available; lit. e.g.: U.S.
Pat. No. 5,344,830, Example 18/step A] gave two fractions of the
title compound: 14 mg (16% of theory, pure) and 93 mg of a mixture
of the title compound with triphenylphosphine oxide. In deviation
to the process in Ex. 63A, here the purification by preparative
HPLC was carried out according to Method 7.
[0809] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 8.51-8.42
(m, 3H), 5.04 (m, 1H), 4.41 (t, 2H), 4.13 (t, 2H), 3.89-3.80 (m,
2H), 3.55-3.47 (m, 2H), 3.18 (t, 2H), 2.65-2.54 (m, 2H), 2.48 (s,
3H), 2.09 (s, 3H), 1.99-1.91 (m, 2H), 1.78-1.68 (m, 2H).
[0810] LC/MS (Method 1, ESIpos): R.sub.t=0.93 min, m/z=554
[M+H].sup.+.
Example 71A
1-({5-Methyl-2,4-dioxo-3-[2-phenylpropyl]-1-(3,3,3-trifluoropropyl)-1,2,3,-
4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}carbonyl)piperidin-4-yl
acetate (Racemate)
##STR00155##
[0812] Analogously to the process described in Ex. 63A, 200 mg
(0.447 mmol) of the compound from Ex. 60A and 91 mg (0.670 mmol) of
racemic 2-phenylpropan-1-ol gave 238 mg (94% of theory) of the
title compound.
[0813] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.34-7.24
(m, 4H), 7.22-7.17 (m, 1H), 4.92 (m, 1H), 4.12-4.05 (m, 3H), 3.94
(m, 1H), 3.79-3.71 (m, 2H), 3.43-3.36 (m, 2H), 3.27-3.19 (m, 1H),
2.78-2.66 (m, 2H), 2.38 (s, 3H), 2.03 (s, 3H), 1.92-1.85 (m, 2H),
1.60-1.51 (m, 2H), 1.19 (d, 3H).
[0814] LC/MS (Method 1, ESIpos): R.sub.t=1.20 min, m/z=566
[M+H].sup.+.
Example 72A
1-{[3-(2-Methoxy-2-phenylethyl)-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropy-
l)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]carbonyl}piperidin-4-yl
acetate (Racemate)
##STR00156##
[0816] Analogously to the process described in Ex. 63A, 200 mg
(0.447 mmol) of the compound from Ex. 60A and 102 mg (0.670 mmol)
of racemic 2-methoxy-2-phenylethanol gave 256 mg (93% of theory,
purity 95%) of the title compound.
[0817] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.41-7.36
(m, 2H), 7.34-7.30 (m, 3H), 4.92 (m, 1H), 4.57 (dd, 1H), 4.35 (dd,
1H), 4.19-4.04 (m, 2H), 3.81 (dd, 1H), 3.79-3.72 (m, 2H), 3.44-3.37
(m, 2H), 3.07 (s, 3H), 2.79-2.67 (m, 2H), 2.39 (s, 3H), 2.03 (s,
3H), 1.93-1.84 (m, 2H), 1.61-1.52 (m, 2H).
[0818] LC/MS (Method 1, ESIpos): R.sub.t=1.15 min, m/z=582
[M+H].sup.+.
Example 73A
1-({5-Methyl-2,4-dioxo-3-[(1-phenylcyclopropyl)methyl]-1-(3,3,3-trifluorop-
ropyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}carbonyl)piperidin-4--
yl acetate
##STR00157##
[0820] Analogously to the process described in Ex. 63A, 100 mg
(0.223 mmol) of the compound from Ex. 60A and 50 mg (0.335 mmol) of
(1-phenylcyclopropyl)methanol [lit.: L. K. Sydnes, P. F. F.
Pereira, M. Sandberg, H. H. Oevreboe, J. Chem. Res. Miniprint 2001
(4), 464-474] gave 57 mg (42% of theory, purity 96%) of the title
compound.
[0821] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.26-7.19
(m, 4H), 7.17-7.13 (m, 1H), 4.91 (m, 1H), 4.16 (s, 2H), 4.00 (t,
2H), 3.78-3.70 (m, 2H), 3.43-3.35 (m, 2H), 2.63-2.51 (m, 2H, partly
obscured by DMSO signal), 2.32 (s, 3H), 2.03 (s, 3H), 1.91-1.85 (m,
2H), 1.60-1.51 (m, 2H), 0.95 (m, 2H), 0.72 (m, 2H).
[0822] LC/MS (Method 1, ESIpos): R.sub.t=1.22 min, m/z=578
[M+H].sup.+.
Example 74A
1-{[5-Methyl-3-(2-methyl-2-phenylpropyl)-2,4-dioxo-1-(3,3,3-trifluoropropy-
l)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]carbonyl}piperidin-4-yl
acetate
##STR00158##
[0824] Analogously to the process described in Ex. 63A, 150 mg
(0.335 mmol) of the compound from Ex. 60A and 76 mg (0.503 mmol) of
2-methyl-2-phenylpropan-1-ol [lit.: D. Coletta, B. di Giacomo, B.
Natalini, M.-H. Ni, R. Pellicciari, Farmaco 1999, 54 (9), 600-610]
gave 104 mg (51% of theory, purity 95%) of the title compound.
[0825] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.43 (d,
2H), 7.32 (t, 2H), 7.21 (t, 1H), 4.92 (m, 1H), 4.10-4.05 (m, 4H),
3.79-3.71 (m, 2H), 3.44-3.36 (m, 2H), 2.77-2.65 (m, 2H), 2.35 (s,
3H), 2.03 (s, 3H), 1.92-1.85 (m, 2H), 1.61-1.52 (m, 2H), 1.28 (s,
6H).
[0826] LC/MS (Method 1, ESIpos): R.sub.t=1.29 min, m/z=580
[M+H].sup.+.
Example 75A
1-({5-Methyl-2,4-dioxo-3-[2-(pyridin-2-yl)ethyl]-1-(3,3,3-trifluoropropyl)-
-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}carbonyl)piperidin-4-yl
acetate (Formic Acid Salt)
##STR00159##
[0828] Analogously to the process described in Ex. 63A, 70 mg
(0.156 mmol) of the compound from Ex. 60A and 29 mg (0.235 mmol) of
2-(2-hydroxyethyl)pyridine gave 112 mg (95% of theory, purity 80%)
of the title compound.
[0829] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.88 (s,
1H), 8.48 (d, 1H), 7.71 (dt, 1H), 7.28 (d, 1H), 7.23 (dd, 1H), 4.92
(m, 1H), 4.22 (t, 1H), 4.11 (t, 1H), 3.79-3.71 (m, 2H), 3.44-3.36
(m, 2H), 2.99 (t, 2H), 2.81-2.69 (m, 2H), 2.39 (s, 3H), 2.03 (s,
3H), 1.92-1.85 (m, 2H), 1.61-1.51 (m, 2H).
[0830] LC/MS (Method 1, ESIpos): R.sub.t=0.79 min, m/z=553
[M+H].sup.+.
Example 76A
1-({5-Methyl-2,4-dioxo-3-[2-(pyridin-4-yl)ethyl]-1-(3,3,3-trifluoropropyl)-
-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}carbonyl)piperidin-4-yl
acetate (Formic Acid Salt)
##STR00160##
[0832] Analogously to the process described in Ex. 63A, 70 mg
(0.156 mmol) of the compound from Ex. 60A and 29 mg (0.235 mmol) of
4-(2-hydroxyethyl)pyridine gave 54 mg (50% of theory, purity 80%)
of the title compound.
[0833] LC/MS (Method 1, ESIpos): R.sub.t=0.76 min, m/z=553
[M+H].sup.+.
Example 77A
1-({3-[2-(1H-Imidazol-1-yl)ethyl]-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropro-
pyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}carbonyl)piperidin-4-yl
acetate
##STR00161##
[0835] 182 mg (0.559 mmol) of caesium carbonate were added to a
solution of 100 mg (0.223 mmol) of the compound from Ex. 60A in 3
ml of DMF, and the mixture was stirred at RT for 10 min. 45 mg
(0.268 mmol) of 1-(2-chloroethyl)-1H-imidazole hydrochloride [lit.:
M. L. Burdeinyi, S. V. Popkov, M. V. Kharchevnikowa, Russ. Chem.
Bull. 2009, 58 (5), 936-939] were then added. After stirring at RT
overnight, conversion was incomplete. Therefore, the mixture was
heated at 70.degree. C. for another 1 h. After cooling to RT, the
reaction mixture was separated directly by preparative HPLC into
its components (Method 5). The product fractions were combined and
concentrated. The residue was dissolved in a little methanol and
the solution was passed over a bicarbonate cartridge (Polymerlabs,
Stratospheres SPE, PL-HCO.sub.3 MP SPE, capacity 0.9 mmol).
Subsequent evaporation and drying of the residue under high vacuum
gave 106 mg (87% of theory) of the title compound as the free
base.
[0836] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.58 (s,
1H), 7.12 (s, 1H), 6.85 (s, 1H), 4.92 (m, 1H), 4.23-4.17 (m, 4H),
4.09 (t, 2H), 3.79-3.71 (m, 2H), 3.43-3.36 (m, 2H), 2.80-2.68 (m,
2H), 2.36 (s, 3H), 2.02 (s, 3H), 1.92-1.84 (m, 2H), 1.60-1.52 (m,
2H).
[0837] LC/MS (Method 1, ESIpos): R.sub.t=0.67 min, m/z=542
[M+H].sup.+.
Example 78A
1-{[3-(But-3-yn-1-yl)-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,2,3,4-
-tetrahydrothieno[2,3-d]pyrimidin-6-yl]carbonyl}piperidin-4-yl
acetate
##STR00162##
[0839] 80 mg (0.246 mmol) of caesium carbonate were added to a
solution of 100 mg (0.223 mmol) of the compound from Ex. 60A in 3
ml of DMF, and the mixture was stirred at RT for 10 min. 37 mg
(0.268 mmol) of 4-bromobutyne were then added. The reaction mixture
was stirred at RT for about 16 h and then directly separated into
its components by means of preparative HPLC (Method 5). The product
fractions were combined and concentrated, and the residue was dried
under high vacuum. This gave 90 mg (80% of theory) of the title
compound.
[0840] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.92 (m,
1H), 4.13 (t, 2H), 4.01 (t, 2H), 3.79-3.71 (m, 2H), 3.43-3.36 (m,
2H), 2.88 (t, 1H), 2.85-2.73 (m, 2H), 2.49-2.44 (m, 2H), 2.39 (s,
3H), 2.02 (s, 3H), 1.92-1.84 (m, 2H), 1.60-1.51 (m, 2H).
[0841] LC/MS (Method 1, ESIpos): R.sub.t=0.99 min, m/z=500
[M+H].sup.+.
Example 79A
1-{[3-(2-Methoxyethyl)-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,2,3,-
4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]carbonyl}piperidin-4-yl
acetate
##STR00163##
[0843] Analogously to the process described in Ex. 78A, 100 mg
(0.223 mmol) of the compound from Ex. 60A and 37 mg (0.268 mmol) of
2-bromoethyl methyl ether gave 94 mg (83% of theory) of the title
compound.
[0844] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.92 (m,
1H), 4.13 (t, 2H), 4.06 (t, 2H), 3.79-3.71 (m, 2H), 3.50 (t, 2H),
3.44-3.36 (m, 2H), 3.24 (s, 3H), 2.85-2.73 (m, 2H), 2.39 (s, 3H),
2.02 (s, 3H), 1.91-1.84 (m, 2H), 1.60-1.51 (m, 2H).
[0845] LC/MS (Method 1, ESIpos): R.sub.t=0.93 min, m/z=506
[M+H].sup.+.
Example 80A
1-{[3-(2-Cyclopropylethyl)-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,-
2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]carbonyl}piperidin-4-yl
acetate
##STR00164##
[0847] Analogously to the process described in Ex. 63A, 100 mg
(0.223 mmol) of the compound from Ex. 60A and 29 mg (0.335 mmol) of
2-cyclopropylethanol gave 52 mg (45% of theory) of the title
compound.
[0848] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.91 (m,
1H), 4.12 (t, 2H), 3.95 (t, 2H), 3.78-3.71 (m, 2H), 3.43-3.34 (m,
2H, partially obscured by the water signal), 2.85-2.73 (m, 2H),
2.39 (s, 3H), 2.02 (s, 3H), 1.91-1.84 (m, 2H), 1.60-1.51 (m, 2H),
1.44 (quart, 2H), 0.72-0.65 (m, 1H), 0.41-0.37 (m, 2H), 0.02 (m,
2H, partially obscured by the TMS signal).
[0849] LC/MS (Method 1, ESIpos): R.sub.t=1.12 min, m/z=516
[M+H].sup.+.
Example 81A
1-{[3-Isobutyl-5-methyl-2,4-dioxo-1-(3,33-trifluoropropyl)-1,2,34-tetrahyd-
rothieno[2,3-d]pyrimidin-6-yl]carbonyl}piperidin-4-yl acetate
##STR00165##
[0851] Analogously to the process described in Ex. 63A, 100 mg
(0.223 mmol) of the compound from Ex. 60A and 25 mg (0.335 mmol) of
2-methylpropanol gave 95 mg (84% of theory) of the title
compound.
[0852] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.92 (m,
1H), 4.13 (t, 2H), 3.79-3.70 (m, 4H), 3.44-3.36 (m, 2H), 2.85-2.73
(m, 2H), 2.39 (s, 3H), 2.09-1.99 (m, 1H), 2.02 (s, 3H), 1.92-1.84
(m, 2H), 1.60-1.51 (m, 2H), 0.86 (d, 6H).
[0853] LC/MS (Method 1, ESIpos): R.sub.t=1.11 min, m/z=504
[M+H].sup.+.
Example 82A
1-{[3-(2-Methoxypropyl)-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,2,3-
,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]carbonyl}piperidin-4-yl
acetate (Racemate)
##STR00166##
[0855] Analogously to the process described in Ex. 63A, 80 mg
(0.179 mmol) of the compound from Ex. 60A and 24 mg (0.268 mmol) of
racemic 2-methoxypropanol gave 53 mg (57% of theory) of the title
compound. In deviation to the processes described above, here the
product obtained after preparative HPLC was chromatographed once
more on silica gel (mobile phase: 2:1 cyclohexane/ethyl
acetate).
[0856] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.92 (m,
1H), 4.13 (quart, 2H), 3.79-3.72 (m, 4H), 3.64 (m, 1H), 3.44-3.36
(m, 2H), 3.22 (s, 3H), 2.85-2.73 (m, 2H), 2.39 (s, 3H), 2.02 (s,
3H), 1.92-1.85 (m, 2H), 1.60-1.51 (m, 2H), 1.06 (d, 3H).
[0857] LC/MS (Method 1, ESIpos): R.sub.t=0.99 min, m/z=520
[M+H].sup.+.
Example 83A
1-({3-Ethyl-5-methyl-2,4-dioxo-1-[2-(trifluoromethoxy)ethyl]-1,2,3,4-tetra-
hydrothieno[2,3-d]pyrimidin-6-yl}carbonyl)piperidin-4-yl
acetate
##STR00167##
[0859] 97 mg (0.296 mmol) of caesium carbonate were added to a
solution of 75 mg (0.198 mmol) of the compound from Ex. 62A in 2 ml
of DMF, and the mixture was stirred at RT for 20 min. 57 mg (0.296
mmol) of 1-bromo-2-(trifluoromethoxy)ethane [commercially
available; lit.: P. E. Aldrich, W. A. Sheppard, J. Org. Chem. 1964,
29 (1), 11-15] were then added. In a microwave oven (Biotage
Initiator Sixty), the reaction mixture was heated at 100.degree. C.
for 15 min. After cooling to RT, the mixture was separated directly
by preparative HPLC into its components (Method 13). The product
fractions were combined and concentrated, and the residue was dried
under high vacuum. 66 mg (68% of theory) of the title compound were
obtained.
[0860] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.91 (m,
1H), 4.42 (t, 2H), 4.22 (t, 2H), 3.91 (quart, 2H), 3.78-3.70 (m,
2H), 3.43-3.38 (m, 2H, partially obscured by the water signal),
2.39 (s, 3H), 2.02 (s, 3H), 1.91-1.84 (m, 2H), 1.59-1.50 (m, 2H),
1.12 (t, 3H).
[0861] LC/MS (Method 1, ESIpos): R.sub.t=1.01 min, m/z=492
[M+H].sup.+.
Example 84A
1-[(3-Ethyl-5-methyl-2,4-dioxo-1-{2-[(trifluoromethyl)sulphanyl]ethyl}-1,2-
,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)carbonyl]piperidin-4-yl
acetate
##STR00168##
[0863] Analogously to the process described in Ex. 83A, 75 mg
(0.198 mmol) of the compound from Ex. 62A and 62 mg (0.296 mmol) of
2-bromoethyl trifluoromethyl sulphide gave 74 mg (74% of theory) of
the title compound.
[0864] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.91 (m,
1H), 4.16 (t, 2H), 3.91 (quart, 2H), 3.78-3.71 (m, 2H), 3.43-3.34
(m, 4H, partially obscured by the water signal), 2.39 (s, 3H), 2.02
(s, 3H), 1.92-1.84 (m, 2H), 1.59-1.51 (m, 2H), 1.12 (t, 3H).
[0865] LC/MS (Method 1, ESIpos): R.sub.t=1.07 min, m/z=508
[M+H].sup.+.
Example 85A
1-({3-Ethyl-5-methyl-2,4-dioxo-1-[2-(trifluoromethyl)prop-2-en-1-yl]-1,2,3-
,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}carbonyl)piperidin-4-yl
acetate
##STR00169##
[0867] Analogously to the process described in Ex. 83A, 75 mg
(0.198 mmol) of the compound from Ex. 62A and 56 mg (0.296 mmol) of
2-(bromomethyl)-3,3,3-trifluoropropene gave 77 mg (73% of theory,
purity 91%) of the title compound.
[0868] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 6.02 (s,
1H), 5.83 (s, 1H), 4.91 (m, 1H), 4.79 (s, 2H), 3.92 (quart, 2H),
3.77-3.69 (m, 2H), 3.43-3.37 (m, 2H, partially obscured by the
water signal), 2.40 (s, 3H), 2.02 (s, 3H), 1.91-1.83 (m, 2H),
1.59-1.50 (m, 2H), 1.13 (t, 3H).
[0869] LC/MS (Method 1, ESIpos): R.sub.t=1.03 min, m/z=488
[M+H].sup.+.
Example 86A
1-({1-[(2,2-Difluorocyclopropyl)methyl]-3-ethyl-5-methyl-2,4-dioxo-1,2,3,4-
-tetrahydrothieno[2,3-d]pyrimidin-6-yl}carbonyl)piperidin-4-yl
acetate (Racemate)
##STR00170##
[0871] Analogously to the process described in Ex. 83A, 75 mg
(0.198 mmol) of the compound from Ex. 62A and 51 mg (0.296 mmol) of
racemic 2-(bromomethyl)-1,1-difluorocyclopropane gave 68 mg (72% of
theory) of the title compound.
[0872] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.91 (m,
1H), 4.19-4.11 (m, 1H), 4.00-3.90 (m, 1H), 3.91 (quart, 2H),
3.79-3.71 (m, 2H), 3.43-3.36 (m, 2H, partially obscured by the
water signal), 2.40 (s, 3H), 2.29-2.17 (m, 1H), 2.02 (s, 3H),
1.91-1.84 (m, 2H), 1.77-1.67 (m, 1H), 1.60-1.45 (m, 3H), 1.13 (t,
3H).
[0873] LC/MS (Method 1, ESIpos): R.sub.t=1.08 min, m/z=470
[M+H].sup.+.
Example 87A
2-tert-Butyl 4-ethyl
5-{[(2,2-difluoro-2-phenylethyl)carbamoyl]amino}-3-methylthiophene-2,4-di-
carboxylate
##STR00171##
[0875] Analogously to the process described in Ex. 2A, 1.63 g (5.69
mmol) of 2-tert-butyl 4-ethyl
5-amino-3-methylthiophene-2,4-dicarboxylate (Example 1A), 1.85 g
(11.4 mmol) of N,N'-carbonyldiimidazole, 3.2 ml (22.8 mmol) of
triethylamine and 1.79 g (11.4 mmol) of
2,2-difluoro-2-phenylethanamine [lit.: K. D. Kreuter, M. R. Player
et al., Bioorg. Med. Chem. Lett. 2008, 18 (9), 2865-2870] gave 2.0
g (71% of theory, purity 95%) of the title compound. In deviation,
MPLC purification was carried out using the mobile phase
cyclohexane/ethyl acetate 5:1.
[0876] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 10.64 (s,
1H), 8.59 (t, 1H), 8.58-7.49 (m, 5H), 4.32 (quart, 2H), 3.92 (dt,
2H), 2.62 (s, 3H), 1.49 (s, 9H), 1.33 (t, 3H).
[0877] LC/MS (Method 1, ESIpos): R.sub.t=1.37 min, m/z=469
[M+H].sup.+.
Example 88A
2-tert-Butyl 4-ethyl
3-methyl-5-[(propylcarbamoyl)amino]thiophene-2,4-dicarboxylate
##STR00172##
[0879] Analogously to the process described in Ex. 2A, 15.0 g (52.6
mmol) of 2-tert-butyl 4-ethyl
5-amino-3-methylthiophene-2,4-dicarboxylate (Example 1A), 17.0 g
(105 mmol) of N,N'-carbonyldiimidazole, 29 ml (210 mmol) of
triethylamine and 17.3 ml (210 mmol) of propylamine gave 12.4 g
(63% of theory) of the title compound. In deviation, MPLC
purification was carried out using the mobile phase
cyclohexane/ethyl acetate 10:1.
[0880] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 10.54 (s,
1H), 8.05 (t, 1H), 4.31 (quart, 2H), 3.07 (quart, 2H), 2.62 (s,
3H), 1.50 (s, 9H), 1.50-1.41 (m, 2H), 1.32 (t, 3H), 0.88 (t,
3H).
[0881] LC/MS (Method 1, ESIpos): R.sub.t=1.30 min, m/z=371
[M+H].sup.+.
Example 89A
2-tert-Butyl 4-ethyl
3-methyl-5-{[(3,3,3-trifluoro-2-methoxypropyl)carbamoyl]amino}thiophene-2-
,4-dicarboxylate (Racemate)
##STR00173##
[0883] Analogously to the process described in Ex. 2A, 0.99 g (3.48
mmol) of 2-tert-butyl 4-ethyl
5-amino-3-methylthiophene-2,4-dicarboxylate (Example 1A), 1.13 g
(6.96 mmol) of N,N'-carbonyldiimidazole, 1.9 ml (13.9 mmol) of
triethylamine and 1.25 g (6.96 mmol) of racemic
3,3,3-trifluoro-2-methoxypropane-1-amine hydrochloride gave 1.39 g
(87% of theory) of the title compound. In deviation, here MPLC
purification was carried out using as mobile phase a
cyclohexane/ethyl acetate gradient 10:1.fwdarw.5:1.
[0884] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 10.64 (s,
1H), 8.39 (t, 1H), 4.32 (quart, 2H), 4.03-3.96 (m, 1H), 3.57-3.50
(m, 1H), 3.51 (s, 3H), 3.33-3.26 (m, 1H, partially obscured by
water signal), 2.63 (s, 3H), 1.50 (s, 9H), 1.33 (t, 3H).
[0885] LC/MS (Method 1, ESIpos): R.sub.t=1.35 min, m/z=455
[M+H].sup.+.
Example 90A
tert-Butyl
3-(2,2-difluoro-2-phenylethyl)-5-methyl-2,4-dioxo-1,2,3,4-tetra-
hydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00174##
[0887] Analogously to the process described under Ex. 8A, 1.96 g
(4.18 mmol) of the compound from Ex. 87A gave 1.64 g (92% of
theory) of the title compound.
[0888] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 12.57 (s,
1H), 7.56-7.49 (m, 5H), 4.56 (t, 2H), 2.69 (s, 3H), 1.52 (s,
9H).
[0889] LC/MS (Method 1, ESIpos): R.sub.t=1.20 min, m/z=421
[M-H].sup.-.
Example 91A
tert-Butyl
5-methyl-2,4-dioxo-3-propyl-1,2,3,4-tetrahydrothieno[2,3-d]pyri-
midine-6-carboxylate
##STR00175##
[0891] Analogously to the process described under Ex. 8A, 17.5 g
(47.1 mmol) of the compound from Ex. 88A gave 13.9 g (90% of
theory) of the title compound.
[0892] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 12.38 (s,
1H), 3.77 (dd, 2H), 2.71 (s, 3H), 1.60-1.49 (m, 2H), 1.52 (s, 9H),
0.87 (t, 3H).
[0893] LC/MS (Method 1, ESIpos): R.sub.t=1.11 min, m/z=325
[M+H].sup.+.
Example 92A
tert-Butyl
5-methyl-2,4-dioxo-3-(3,3,3-trifluoro-2-methoxypropyl)-1,2,3,4--
tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate (Racemate)
##STR00176##
[0895] Analogously to the process described under Ex. 8A, 1.38 g
(3.04 mmol) of the compound from Ex. 89A gave 1.19 g (96% of
theory) of the title compound.
[0896] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 12.56 (s,
1H), 4.24-4.16 (m, 2H), 4.00 (quart, 1H), 3.43 (s, 3H), 2.72 (s,
3H), 1.52 (s, 9H).
[0897] LC/MS (Method 9, ESIpos): R.sub.t=1.43 min, m/z=409
[M+H].sup.+.
Example 93A
tert-Butyl
3-(2,2-difluoro-2-phenylethyl)-5-methyl-2,4-dioxo-1-(3,3,3-trif-
luoropropyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00177##
[0899] 926 mg (2.84 mmol) of caesium carbonate were added to a
solution of 800 mg (1.89 mmol) of the compound from Ex. 90A in 20
ml of DMF, and the mixture was stirred at RT for 20 min. 636 mg
(2.84 mmol) of 3,3,3-trifluoro-1-iodopropane were then added, and
the mixture was stirred at 60.degree. C. for 5 h. After cooling to
RT, the mixture was diluted with ethyl acetate and washed
successively with water and saturated sodium chloride solution.
After drying over anhydrous magnesium sulphate, the mixture was
filtered and concentrated. The crude product was purified by MPLC
(Biotage cartridge with 50 g of silica gel, mobile phase
cyclohexane/ethyl acetate 10:1). The product fractions were
combined and concentrated. After the residue had been dried under
high vacuum, 625 mg (63% of theory) of the title compound were
obtained.
[0900] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.56-7.49
(m, 5H), 4.62 (t, 2H), 4.15 (t, 2H), 2.79-2.67 (m, 2H), 2.73 (s,
3H), 1.54 (s, 9H).
[0901] LC/MS (Method 1, ESIpos): R.sub.t=1.39 min, m/z=519
[M+H].sup.+.
Example 94A
tert-Butyl
3-(2,2-difluoro-2-phenylethyl)-1-(2-methoxyethyl)-5-methyl-2,4--
dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00178##
[0903] 926 mg (2.84 mmol) of caesium carbonate were added to a
solution of 800 mg (1.89 mmol) of the compound from Ex. 90A in 20
ml of DMF, and the mixture was stirred at RT for 10 min. 395 mg
(2.84 mmol) of 2-bromoethyl methyl ether were then added, and the
mixture was stirred at 65.degree. C. for 4 h. After cooling to RT,
the mixture was diluted with ethyl acetate and washed successively
with water and saturated sodium chloride solution. After drying
over anhydrous magnesium sulphate, the mixture was filtered and
concentrated. The crude product was purified by MPLC (Puriflash
cartridge with 50 g of silica gel, mobile phase cyclohexane/ethyl
acetate 10:1). The product fractions were combined and
concentrated. For further purification, the residue was stirred
with 20 ml of a mixture of pentane and dichloromethane (20:1) at
RT. This gave, after another filtration and drying under high
vacuum, 685 mg (75% of theory) of the title compound.
[0904] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.55-7.49
(m, 5H), 4.62 (t, 2H), 4.06 (t, 2H), 3.58 (t, 2H), 3.24 (s, 3H),
2.72 (s, 3H), 1.53 (s, 9H).
[0905] LC/MS (Method 1, ESIpos): R.sub.t=1.37 min, m/z=481
[M+H].sup.+.
Example 95A
tert-Butyl
5-methyl-2,4-dioxo-3-propyl-1-[2-(trifluoromethoxy)ethyl]-1,2,3-
,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00179##
[0907] 1.67 g (5.18 mmol) of caesium carbonate were added to a
solution of 1.12 g (3.46 mmol) of the compound from Ex. 91A in 30
ml of DMF, and the mixture was stirred at RT for 20 min. 1.0 g
(5.18 mmol) of 1-bromo-2-trifluoromethoxyethane were then added,
and the mixture was stirred at 80.degree. C. for 5 h. Subsequently,
the mixture was concentrated to dryness and the residue was taken
up in ethyl acetate. The mixture was washed successively with water
and saturated sodium chloride solution. After drying over anhydrous
magnesium sulphate, the mixture was filtered and concentrated. The
crude product was purified by MPLC (Biotage cartridge with 100 g of
silica gel, mobile phase cyclohexane/ethyl acetate
10:1.fwdarw.5:1). The product fractions were combined and
concentrated. Drying of the residue under high vacuum gave 1.28 g
(82% of theory, 97% pure) of the title compound.
[0908] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.42 (t,
2H), 4.25 (t, 2H), 3.83 (t, 2H), 2.75 (s, 3H), 1.61-1.51 (m, 2H),
1.53 (s, 9H), 0.86 (t, 3H).
[0909] LC/MS (Method 1, ESIpos): R.sub.t=1.37 min; no
ionization.
Example 96A
tert-Butyl
5-methyl-2,4-dioxo-3-(3,3,3-trifluoro-2-methoxypropyl)-1-(3,3,3-
-trifluoropropyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
(Racemate)
##STR00180##
[0911] 598 mg (1.84 mmol) of caesium carbonate were added to a
solution of 500 mg (1.22 mmol) of the compound from Ex. 92A in 5 ml
of DMF, and the mixture was stirred at RT for 20 min. 411 mg (1.84
mmol) of 3,3,3-trifluoro-1-iodopropane were then added. The mixture
was stirred in a microwave oven (Biotage Initiator with dynamic
control of irradiation power) at 100.degree. C. for 2 h. After
cooling to RT, about 50 ml of water were added and the mixture was
extracted with ethyl acetate. The organic extract was washed with
water and saturated sodium chloride solution. After drying over
anhydrous magnesium sulphate, the mixture was filtered and
concentrated. The residue obtained was purified by preparative HPLC
(Method 6). This gave, after combination of the product fractions,
concentration and drying under high vacuum, 495 mg (80% of theory)
of the title compound.
[0912] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.29-4.17
(m, 4H), 4.05 (dd, 1H), 3.42 (s, 3H), 2.87-2.76 (m, 2H), 2.76 (s,
3H), 1.54 (s, 9H).
[0913] LC/MS (Method 9, ESIpos): R.sub.t=1.38 min, m/z=505
[M+H].sup.+.
Example 97A
tert-Butyl
3-ethyl-5-methyl-2,4-dioxo-1-[2-(trifluoromethoxy)ethyl]-1,2,3,-
4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00181##
[0915] Analogously to the process described in Ex. 26A, 2.50 g
(8.06 mmol) of the compound from Ex. 12A and 2.33 g (12.1 mmol) of
1-bromo-2-trifluoromethoxyethane gave 1.93 g (56% of theory) of the
title compound. In deviation from the process described above, here
the reaction time at 100.degree. C. was 5 h. MPLC purification was
carried out via a Biotage cartridge containing 100 g of silica gel,
using a mobile phase gradient of cyclohexane/ethyl acetate
50:1.fwdarw.10:1. Final stirring of the product obtained in this
manner was carried out using a mixture of 30 ml of pentane and 0.5
ml of dichloromethane.
[0916] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.42 (t,
2H), 4.25 (t, 2H), 3.91 (quart, 2H), 2.75 (s, 3H), 1.53 (s, 9H),
1.13 (t, 3H).
[0917] LC/MS (Method 1, ESIpos): R.sub.t=1.30 min; poor
ionization.
Example 98A
tert-Butyl
5-methyl-2,4-dioxo-3-propyl-1-(3,3,3-trifluoropropyl)-1,2,3,4-t-
etrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00182##
[0919] 6.03 g (18.5 mmol) of caesium carbonate were added to a
solution of 4.0 g (12.3 mmol) of the compound from Ex. 91A in 120
ml of DMF, and the mixture was stirred at RT for 20 min. 4.14 g
(18.5 mmol) of 3,3,3-trifluoro-1-iodopropane were then added, and
the mixture was stirred at 70.degree. C. for 5 h. After this time,
a further 4.02 g (12.3 mmol) of caesium carbonate and 2.76 g (12.3
mmol) of 3,3,3-trifluoro-1-iodopropane were added, and the mixture
was stirred at 70.degree. C. for another 4 h. After cooling to RT,
the mixture was diluted with ethyl acetate and washed successively
with water and saturated sodium chloride solution. After drying
over anhydrous magnesium sulphate, the mixture was filtered and
concentrated. The crude product was purified by MPLC (Biotage
cartridge with 100 g of silica gel, mobile phase cyclohexane/ethyl
acetate 10:1). The product fractions were combined and
concentrated. Since the product obtained in this manner was still
contaminated, further purification was carried out by preparative
HPLC (Method 6). Another evaporation and drying under a high vacuum
gave 4.23 g (81% of theory) of the title compound.
[0920] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.15 (t,
2H), 3.83 (t, 2H), 2.85-2.73 (m, 2H), 2.75 (s, 3H), 1.62-1.51 (m,
2H), 1.53 (s, 9H), 0.87 (t, 3H).
[0921] LC/MS (Method 1, ESIpos): R.sub.t=1.37 min, m/z=421
[M+H].sup.+.
Example 99A
tert-Butyl
1-(2-methoxyethyl)-5-methyl-2,4-dioxo-3-propyl-1,2,3,4-tetrahyd-
rothieno[2,3-d]pyrimidine-6-carboxylate
##STR00183##
[0923] Analogously to the process described in Ex. 26A, 4.0 g (12.3
mmol) of the compound from Ex. 91A and 2.57 g (18.5 mmol) of
1-bromo-2-methoxyethane gave 3.59 g (76% of theory) of the title
compound. In deviation from the process described above, here the
reaction time at 100.degree. C. was 5 h.
[0924] MPLC purification was carried out via a Biotage cartridge
containing 100 g of silica gel, using a mobile phase gradient of
cyclohexane/ethyl acetate 10:1.fwdarw.5:1. Final stirring of the
product obtained in this manner was carried out using a mixture of
60 ml of pentane and 1.5 ml of dichloromethane.
[0925] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.07 (t,
2H), 3.82 (t, 2H), 3.65 (t, 2H), 3.24 (s, 3H), 2.74 (s, 3H),
1.61-1.50 (m, 2H), 1.53 (s, 9H), 0.87 (t, 3H).
[0926] LC/MS (Method 1, ESIpos): R.sub.t=1.29 min, m/z=383
[M+H].sup.+.
Example 100A
3-(2,2-Difluoro-2-phenylethyl)-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropyl-
)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00184##
[0928] Analogously to the process described in Ex. 43A, 614 mg
(1.18 mmol) of the compound from Ex. 93A and 10 ml of
trifluoroacetic acid in 20 ml of dichloromethane gave 543 mg (99%
of theory) of the title compound.
[0929] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.52 (s,
broad, 1H), 7.56-7.49 (m, 5H), 4.63 (t, 2H), 4.15 (t, 2H),
2.79-2.67 (m, 2H), 2.74 (s, 3H).
[0930] LC/MS (Method 1, ESIpos): R.sub.t=1.09 min, m/z=461
[M-H].sup.-.
Example 101A
3-(2,2-Difluoro-2-phenylethyl)-1-(2-methoxyethyl)-5-methyl-2,4-dioxo-1,2,3-
,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00185##
[0932] Analogously to the process described in Ex. 43A, 673 mg
(1.40 mmol) of the compound from Ex. 94A and 10 ml of
trifluoroacetic acid in 20 ml of dichloromethane gave 419 mg (67%
of theory, purity 96%) of the title compound.
[0933] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.41 (s,
broad, 1H), 7.56-7.49 (m, 5H), 4.62 (t, 2H), 4.06 (t, 2H), 3.59 (t,
2H), 3.24 (s, 3H), 2.73 (s, 3H).
[0934] LC/MS (Method 1, ESIpos): R.sub.t=0.98 min, m/z=425
[M+H].sup.+.
Example 102A
5-Methyl-2,4-dioxo-3-propyl-1-[2-(trifluoromethoxy)ethyl]-1,2,3,4-tetrahyd-
rothieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00186##
[0936] Analogously to the process described in Ex. 43A, 1.25 g
(2.86 mmol) of the compound from Ex. 95A and 15 ml of
trifluoroacetic acid in 30 ml of dichloromethane gave 1.06 g (95%
of theory, purity 97%) of the title compound.
[0937] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.40 (s,
broad, 1H), 4.41 (t, 2H), 4.25 (t, 2H), 3.83 (t, 2H), 2.75 (s, 3H),
1.57 (m, 2H), 0.87 (t, 3H).
[0938] LC/MS (Method 9, ESIpos): R.sub.t=1.25 min, m/z=381
[M+H]+.
Example 103A
5-Methyl-2,4-dioxo-3-(3,3,3-trifluoro-2-methoxypropyl)-1-(3,3,3-trifluorop-
ropyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylic acid
(Racemate)
##STR00187##
[0940] Analogously to the process described in Ex. 43A, 488 mg
(0.967 mmol) of the compound from Ex. 96A and 8 ml of
trifluoroacetic acid in 16 ml of dichloromethane gave 432 mg (99%
of theory) of the title compound.
[0941] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.50 (s,
broad, 1H), 4.29-4.16 (m, 4H), 4.05 (dd, 1H), 3.43 (s, 3H),
2.87-2.75 (m, 2H), 2.76 (s, 3H).
[0942] LC/MS (Method 1, ESIpos): R.sub.t=1.01 min, m/z=449
[M+H].sup.+.
Example 104A
3-Ethyl-5-methyl-2,4-dioxo-1-[2-(trifluoromethoxy)ethyl]-1,2,3,4-tetrahydr-
othieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00188##
[0944] 30 ml of trifluoroacetic acid were added to a solution of
2.31 g (5.47 mmol) of the compound from Ex. 97A in 60 ml of
dichloromethane, and the mixture was stirred at RT for 1 h. The
reaction mixture was then concentrated to dryness on a rotary
evaporator. The residue that remained was dissolved in about 400 ml
of ethyl acetate and washed twice with water and once with
saturated sodium chloride solution. After drying over anhydrous
magnesium sulphate, the mixture was filtered and concentrated, and
the residue was dried under high vacuum. 2.04 g (99% of theory) of
the title compound were obtained.
[0945] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.40 (s,
broad, 1H), 4.42 (t, 2H), 4.25 (t, 2H), 3.91 (quart, 2H), 2.76 (s,
3H), 1.13 (t, 3H).
[0946] LC/MS (Method 1, ESIpos): R.sub.t=0.91 min, m/z=367
[M+H].sup.+.
Example 105A
5-Methyl-2,4-dioxo-3-propyl-1-(3,3,3-trifluoropropyl)-1,2,3,4-tetrahydroth-
ieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00189##
[0948] Analogously to the process described in Ex. 43A, 4.20 g
(9.99 mmol) of the compound from Ex. 98A and 60 ml of
trifluoroacetic acid in 120 ml of dichloromethane gave 2.61 g (71%
of theory) of the title compound.
[0949] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.35 (s,
broad, 1H), 4.15 (t, 2H), 3.83 (t, 2H), 2.84-2.74 (m, 2H), 2.76 (s,
3H), 1.57 (m, 2H), 0.87 (t, 3H).
[0950] LC/MS (Method 1, ESIpos): R.sub.t=0.98 min, m/z=365
[M+H]+.
Example 106A
1-(2-Methoxyethyl)-5-methyl-2,4-dioxo-3-propyl-1,2,3,4-tetrahydrothieno[2,-
3-d]pyrimidine-6-carboxylic acid
##STR00190##
[0952] Analogously to the process described in Ex. 43A, 4.15 g
(10.8 mmol) of the compound from Ex. 99A and 60 ml of
trifluoroacetic acid in 120 ml of dichloromethane gave 3.44 g (97%
of theory) of the title compound.
[0953] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.32 (s,
broad, 1H), 4.07 (t, 2H), 3.82 (dd, 2H), 3.65 (t, 2H), 3.24 (s,
3H), 2.75 (s, 3H), 1.57 (m, 2H), 0.87 (t, 3H).
[0954] LC/MS (Method 1, ESIpos): R.sub.t=0.85 min, m/z=327
[M+H]+.
Example 107A
2-tert-Butyl 4-ethyl 5-amino-3-ethylthiophene-2,4-dicarboxylate
##STR00191##
[0956] 6.5 g (37.7 mmol) of tert-butyl 3-oxopentanoate [lit.: S.
Luedeke, M. Mueller, M. Richter, Adv. Synth. Catal. 2009, 351
(1-2), 253-259], 4.27 g (37.7 mmol) of ethyl cyanoacetate and 1.33
g (41.5 mmol) of sulphur were initially charged in 10 ml of ethanol
and heated to 45.degree. C. 3.8 ml (43.3 mmol) of morpholine were
added dropwise to this mixture. The reaction mixture was then
stirred at 60.degree. C. for 5 h. All the volatile constituents
were then removed on a rotary evaporator. About 250 ml of water
were added to the residue that remained, and the mixture was
extracted three times with in each case about 200 ml of ethyl
acetate. The combined organic extracts were washed with about 200
ml of saturated sodium chloride solution and then dried over
anhydrous magnesium sulphate. After filtration, the mixture was
concentrated to dryness. The crude product obtained in this manner
was purified by MPLC (Biotage cartridge, 340 g of silica gel,
mobile phase cyclohexane/ethyl acetate 20:1.fwdarw.10:1). This
gave, after combination of the product fractions, concentration and
drying under high vacuum, 4.06 g (35% of theory) of the title
compound.
[0957] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 6.45 (s,
broad, 2H), 4.32 (quart, 2H), 3.22 (quart, 2H), 1.54 (s, 9H), 1.37
(t, 3H), 1.16 (t, 3H).
[0958] LC/MS (Method 1, ESIpos): R.sub.t=1.23 min, m/z=300
[M+H].sup.+.
Example 108A
2-tert-Butyl 4-ethyl
3-ethyl-5-[(ethylcarbamoyl)amino]thiophene-2,4-dicarboxylate
##STR00192##
[0960] Analogously to the process described in Ex. 2A, 1.44 g (4.81
mmol) of the compound from Ex. 107A, 1.56 g (9.62 mmol) of
N,N'-carbonyldiimidazole (CDI), 2.7 ml (19.2 mmol) of triethylamine
and 9.6 ml (19.2 mmol) of a 2 M solution of ethylamine in THF gave
1.68 g (89% of theory, purity 95%) of the title compound. Here, the
reaction time for the reaction with CDI was 4 days, and MPLC
purification was carried out using the mobile phase
cyclohexane/ethyl acetate 10:1.fwdarw.5:1.
[0961] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 10.98 (s,
broad, 1H), 4.85 (t, 1H), 4.35 (quart, 2H), 3.37 (m, 2H), 3.27
(quart, 2H), 1.55 (s, 9H), 1.40 (t, 3H), 1.22 (t, 3H), 1.17 (t,
3H).
[0962] LC/MS (Method 1, ESIpos): R.sub.t=1.24 min, m/z=371
[M+H].sup.+.
Example 109A
tert-Butyl
3,5-diethyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-
-6-carboxylate
##STR00193##
[0964] Analogously to the process described under Ex. 8A, 1.60 g
(4.32 mmol) of the compound from Ex. 108A gave 1.34 g (88% of
theory, purity 92%) of the title compound.
[0965] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 10.49 (s,
broad, 1H), 4.08 (quart, 2H), 3.37 (quart, 2H), 1.58 (s, 9H), 1.29
(t, 3H), 1.23 (t, 3H).
[0966] LC/MS (Method 1, ESIpos): R.sub.t=1.07 min, m/z=325
[M+H].sup.+.
Example 110A
tert-Butyl
3,5-diethyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,2,3,4-tetrahy-
drothieno[2,3-d]pyrimidine-6-carboxylate
##STR00194##
[0968] 1.48 g (4.53 mmol) of caesium carbonate were added to a
solution of 980 mg (3.02 mmol) of the compound from Ex. 109A in 15
ml of DMF, and the mixture was stirred at RT for 20 min. 1.02 g
(4.53 mmol) of 3,3,3-trifluoro-1-iodopropane were then added, and
the mixture was stirred in a microwave oven (Biotage Initiator with
dynamic control of irradiation power) at 100.degree. C. for 2 h.
After cooling to RT, about 75 ml of water were added and the
mixture was extracted with ethyl acetate. The organic extract was
washed with water and saturated sodium chloride solution. After
drying over anhydrous magnesium sulphate, the mixture was filtered
and concentrated. The residue obtained was first prepurified
coarsely by MPLC (Biotage cartridge, 50 g of silica gel, mobile
phase cyclohexane/ethyl acetate 20:1). The product-containing
fractions were combined and concentrated to dryness. At RT, the
residue was stirred in a mixture of 20 ml of pentane and about 0.5
ml of dichloromethane for 16 h. After filtration with suction and
drying under high vacuum, a first fraction of 326 mg of the title
compound was obtained. The filtrate of stirring was concentrated
and the residue was purified by preparative HPLC (Method 6). This
gave, after concentration of the product fractions and drying under
high vacuum, a second fraction of 565 mg of the title compound. In
total, 891 mg (70% of theory) of the title compound were obtained
in this manner.
[0969] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 4.19 (m,
2H), 4.07 (quart, 2H), 3.38 (quart, 2H), 2.71-2.59 (m, 2H), 1.59
(s, 9H), 1.26 (t, 3H), 1.23 (t, 3H).
[0970] LC/MS (Method 1, ESIpos): R.sub.t=1.39 min, m/z=421
[M+H]+.
Example 111A
3,5-Diethyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,2,3,4-tetrahydrothieno[2-
,3-d]pyrimidine-6-carboxylic acid
##STR00195##
[0972] Analogously to the process described in Ex. 43A, 1.15 g
(2.73 mmol) of the compound from Ex. 110A and 20 ml of
trifluoroacetic acid in 60 ml of dichloromethane gave 851 mg (85%
of theory) of the title compound.
[0973] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.43 (s,
broad, 1H), 4.15 (t, 2H), 3.92 (quart, 2H), 3.35-3.29 (m, 2H,
partially obscured by water signal), 2.86-2.74 (m, 2H), 1.135 (t,
3H), 1.130 (t, 3H).
[0974] LC/MS (Method 10, ESIpos): R.sub.t=1.26 min, m/z=365
[M+H].sup.+.
Example 112A
3-Ethyl-5-methyl-6-[(3-methyl-4-oxopiperidin-1-yl)carbonyl]-1-(3,3,3-trifl-
uoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione (Racemate)
##STR00196##
[0976] Preparation of the Acid Chloride:
[0977] At RT, first 249 .mu.l (2.86 mmol) of oxalyl chloride and
then a small drop of DMF were added to a solution of 200 mg (0.571
mmol) of the compound from Ex. 52A in 4 ml of dichloromethane.
After the reaction mixture had been stirred at RT for 2.5 h, it was
concentrated to dryness on a rotary evaporator. The residue that
remained was dried under high vacuum and then reacted further in
the next partial step.
[0978] Preparation of the Amide:
[0979] The acid chloride obtained above was dissolved in 1 ml of
dichloromethane and added dropwise to a solution of 171 mg (1.14
mmol) of 3-methylpiperidin-4-one hydrochloride and 398 .mu.l (2.28
mmol) of N,N-diisopropylethylamine in 5 ml of dichloromethane. The
reaction mixture was stirred at RT for 2 h. After the mixture had
been concentrated to dryness on a rotary evaporator, the crude
product was purified by preparative HPLC (Method 6). This gave,
after combination of the product fractions, concentration and
drying under high vacuum, 236 mg (88% of theory, purity 95%) of the
title compound.
[0980] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.18-4.09
(m, 4H), 3.92 (quart, 2H), 3.53-3.45 (m, 1H), 3.19-3.12 (m, 1H),
2.86-2.74 (m, 2H), 2.71-2.63 (m, 1H), 2.61-2.52 (m, 1H, partially
obscured by the DMSO signal), 2.44 (s, 3H), 2.35 (dt, 1H), 1.13 (t,
3H), 0.92 (d, 3H).
[0981] LC/MS (Method 1, ESIpos): R.sub.t=0.93 min, m/z=446
[M+H].sup.+.
Example 113A
1-[1-Ethyl-2,6-dioxo-4-(pyridinium-1-yl)-1,6-dihydropyrimidin-5
(2H)-ylidene]-2,2-difluoroethanolate
##STR00197##
[0983] At RT, 35 ml (430 mmol) of pyridine were added to a
suspension of 7.5 g (43.0 mmol) of the compound from Ex. 17A in 110
ml of acetonitrile. 21.4 ml (172 mmol) of difluoroacetic anhydride
were then slowly added dropwise. After the addition had ended,
stirring was continued at RT for 1 h. About 300 ml of water were
then added, and the mixture was extracted four times with about 100
ml of ethyl acetate each time. The organic extract was washed with
saturated aqueous sodium chloride solution, dried over anhydrous
magnesium sulphate and then concentrated to dryness. At RT, the
solid that remained was stirred in a mixture of 50 ml of
diisopropyl ether and 50 ml of diethyl ether. This gave, after
filtration with suction and drying under high vacuum, 6.38 g (50%
of theory) of the title compound.
[0984] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 9.20 (d,
2H), 8.80 (t, 1H), 8.25 (t, 2H), 6.97 (t, 1H), 3.89 (quart, 2H),
1.14 (t, 3H).
[0985] LC/MS (Method 1, ESIpos): R.sub.t=0.46 min, m/z=296
[M+H].sup.+.
Example 114A
Ethyl
5-(difluoromethyl)-3-ethyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]-
pyrimidine-6-carboxylate
##STR00198##
[0987] 1.5 ml (13.8 mmol) of ethyl mercaptoacetate were added to a
suspension of 2.04 g (6.92 mmol) of the compound from Ex. 113A in
15 ml of ethanol, and the mixture was stirred at RT for 5 min. 1.61
g (15.2 mmol) of sodium carbonate were then added, and the mixture
was heated in a microwave oven (Biotage Initiator with dynamic
control of irradiation power) at 120.degree. C. for 1 h. Three such
batches were combined and concentrated to dryness on a rotary
evaporator. The residue that remained was taken up in about 300 ml
of water, acidified slightly by addition of acetic acid and
extracted three times with about 100 ml of dichloromethane each.
The organic extract was washed with saturated aqueous sodium
chloride solution, dried over anhydrous magnesium sulphate,
filtered and concentrated. The solid that remained was
chromatographed on a silica gel cartridge (Puriflash,
cyclohexane/ethyl acetate gradient 3:1.fwdarw.1:1). This gave,
after evaporation of the product fractions and drying of the
residue under high vacuum, 890 mg (12% of theory) of the title
compound.
[0988] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 12.59 (s,
1H), 7.71 (t, 1H), 4.32 (quart, 2H), 3.87 (quart, 2H), 1.30 (t,
3H), 1.13 (t, 3H).
[0989] LC/MS (Method 1, ESIpos): R.sub.t=0.87 min, m/z=319
[M+H].sup.+.
Example 115A
Ethyl
5-(difluoromethyl)-3-ethyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,2,3-
,4-tetrahydrothieno[2,3-d]-pyrimidine-6-carboxylate
##STR00199##
[0991] 1.35 g (4.15 mmol) of caesium carbonate were added to a
solution of 880 mg (2.76 mmol) of the compound from Ex. 114A in 12
ml of DMF, and the mixture was stirred at RT for 20 min. 929 mg
(4.15 mmol) of 3,3,3-trifluoro-1-iodopropane were then added, and
the mixture was heated at 80.degree. C. for 2 h. After cooling to
RT, the mixture was diluted with about 100 ml of ethyl acetate and,
in succession, washed twice with in each case about 100 ml of water
and once with about 100 ml of saturated sodium chloride solution.
After drying over anhydrous magnesium sulphate, the mixture was
filtered and concentrated. The crude product was purified by
preparative HPLC (Method 6). The product fractions were combined
and concentrated, and the residue was dried under high vacuum. 750
mg (63% of theory) of the title compound were obtained.
[0992] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.74 (t,
1H), 4.36 (quart, 2H), 4.20 (t, 2H), 3.92 (quart, 2H), 2.88-2.76
(m, 2H), 1.32 (t, 3H), 1.14 (t, 3H).
[0993] LC/MS (Method 1, ESIpos): R.sub.t=1.13 min, m/z=415
[M+H]+.
Example 116A
Ethyl
5-(difluoromethyl)-3-ethyl-2,4-dioxo-1-[2-(trifluoromethoxy)ethyl]-1-
,2,3,4-tetrahydrothieno-[2,3-d]pyrimidine-6-carboxylate
##STR00200##
[0995] Analogously to the process described in Ex. 115A, 500 mg
(1.57 mmol) of the compound from Ex. 114A and 455 mg (2.36 mmol) of
1-bromo-2-(trifluoromethoxy)ethane [commercially available; lit.:
P. E. Aldrich, W. A. Sheppard, J. Org. Chem. 1964, 29 (1), 11-15]
gave 385 mg (56% of theory) of the title compound. Here,
purification of the crude product by preparative HPLC was carried
out according to Method 5.
[0996] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.73 (t,
1H), 4.43 (t, 2H), 4.35 (quart, 2H), 4.32 (t, 2H), 3.93 (quart,
2H), 1.31 (t, 3H), 1.14 (t, 3H).
[0997] LC/MS (Method 1, ESIpos): R.sub.t=1.12 min, m/z=431
[M+H].sup.+.
Example 117A
tert-Butyl
5-methyl-2,4-dioxo-3-(2-phenylethyl)-1-[2-(trifluoromethoxy)eth-
yl]-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00201##
[0999] 1.26 g (3.88 mmol) of caesium carbonate were added to a
solution of 1.0 g (2.59 mmol) of the compound from Ex. 8A in 15 ml
of DMF, and the mixture was stirred at RT for 20 min. 749 mg (3.88
mmol) of 1-bromo-2-(trifluoromethoxy)ethane [commercially
available; lit.: P. E. Aldrich, W. A. Sheppard, J. Org. Chem. 1964,
29 (1), 11-15] were then added, and the mixture was heated at
80.degree. C. for 2 h. After cooling to RT, about 300 ml of water
were added and the mixture was extracted three times in succession
with in each case about 75 ml of diethyl ether. The combined
organic extract was washed in each case once with about 100 ml of
water and about 100 ml of saturated sodium chloride solution. After
drying over anhydrous magnesium sulphate, the mixture was filtered
and concentrated. At 0.degree. C., the crude product was stirred
with 30 ml of pentane, to which a few drops of dichloromethane had
been added. The solid was filtered off with suction, and gave,
after drying under high vacuum, a first fraction of 665 mg of the
title compound. The concentrated mother liquor gave, after
purification by preparative HPLC (Method 15), a second fraction of
402 mg of the title compound. A total of 1.07 g (82% of theory) of
the title compound were thus obtained.
[1000] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.30-7.20
(m, 5H, partially obscured by the CHCl.sub.3 signal), 4.28 (t, 2H),
4.22 (t, 2H), 4.21 (t, 2H), 2.97-2.93 (m, 2H), 2.85 (s, 3H), 1.59
(s, 9H).
[1001] LC/MS (Method 1, ESIpos): R.sub.t=1.43 min, m/z=499
[M+H].sup.+.
Example 118A
5-Methyl-2,4-dioxo-3-(2-phenylethyl)-1-[2-(trifluoromethoxy)ethyl]-1,2,3,4-
-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00202##
[1003] 12.5 ml of trifluoroacetic acid were added to a solution of
1.0 g (2.01 mmol) of the compound from Ex. 117A in 25 ml of
dichloromethane, and the mixture was stirred at RT for 1 h. The
reaction mixture was then concentrated to dryness on a rotary
evaporator. The residue that remained was stirred at RT in a
mixture of 40 ml of diethyl ether and 20 ml of pentane overnight.
After filtration with suction and drying under high vacuum, a first
fraction of 559 mg of the title compound was obtained. The
concentrated mother liquor gave, after purification by preparative
HPLC (Method 5), a second fraction of 266 mg of the title compound.
A total of 825 mg (92% of theory) of the title compound were thus
obtained.
[1004] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.42
(broad, 1H), 7.32-7.27 (m, 2H), 7.24-7.19 (m, 3H), 4.39 (t, 2H),
4.25 (t, 2H), 4.10-4.06 (m, 2H), 2.87-2.82 (m, 2H), 2.75 (s,
3H).
[1005] LC/MS (Method 1, ESIpos): R.sub.t=1.11 min, m/z=443
[M+H]+.
Example 119A
5-(Difluoromethyl)-3-ethyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,2,3,4-tet-
rahydrothieno[2,3-d]-pyrimidine-6-carboxylic acid
##STR00203##
[1007] Analogously to the process described under Ex. 55A, 733 mg
(1.77 mmol) of the compound from Ex. 115A gave 668 mg (95% of
theory) of the title compound.
[1008] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.77 (t,
1H), 4.19 (t, 2H), 3.92 (quart, 2H), 2.88-2.75 (m, 2H), 1.14 (t,
3H).
[1009] LC/MS (Method 1, ESIpos): R.sub.t=0.85 min, m/z=387
[M+H].sup.+.
Example 120A
5-(Difluoromethyl)-3-ethyl-2,4-dioxo-1-[2-(trifluoromethoxy)ethyl]-1,2,3,4-
-tetrahydrothieno[2,3-d]-pyrimidine-6-carboxylic acid
##STR00204##
[1011] Analogously to the process described under Ex. 55A, 365 mg
(0.848 mmol) of the compound from Ex. 116A gave 320 mg (91% of
theory) of the title compound. Here, the reaction time was 3 h.
[1012] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 14.38
(very broad, 1H), 7.77 (t, 1H), 4.43 (t, 2H), 4.30 (t, 2H), 3.92
(quart, 2H), 1.14 (t, 3H).
[1013] LC/MS (Method 1, ESIpos): R.sub.t=0.85 min, m/z=403
[M+H].sup.+.
Example 121A
1-{[5-Methyl-2,4-dioxo-3-(2-oxo-2-phenylethyl)-1-(3,3,3-trifluoropropyl)-1-
,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]carbonyl}piperidin-4-yl
acetate
##STR00205##
[1015] Analogously to the process described in Ex. 78A, 500 mg
(1.12 mmol) of the compound from Ex. 60A and 190 mg (1.23 mmol) of
2-chloroacetophenone gave 573 mg (88% of theory) of the title
compound. In this case, purification of the product was carried out
by MPLC (Biotage cartridge, 50 g of silica gel, cyclohexane/ethyl
acetate gradient 2:1.fwdarw.1:1).
[1016] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.10 (d,
2H), 7.74 (t, 1H), 7.60 (t, 2H), 5.43 (s, 2H), 4.94-4.90 (m, 1H),
4.19 (t, 2H), 3.80-3.74 (m, 2H), 3.44-3.40 (m, 2H), 2.86-2.78 (m,
2H), 2.38 (s, 3H), 2.03 (s, 3H), 1.92-1.87 (m, 2H), 1.60-1.54 (m,
2H).
[1017] LC/MS (Method 1, ESIpos): R.sub.t=1.06 min, m/z=566
[M+H].sup.+.
Example 122A
1-{[5-Methyl-2,4-dioxo-3-(3,3,3-trifluoro-2-phenylpropyl)-1-(3,3,3-trifluo-
ropropyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]carbonyl}piperidin-
-4-ylacetate (Racemate)
##STR00206##
[1019] Analogously to the process described in Ex. 63A, 100 mg
(0.223 mmol) of the compound from Ex. 60A and 64 mg (0.335 mmol) of
racemic 3,3,3-trifluoro-2-phenylpropanol [prepared analogously to
J. Y. Hamilton et al., Synthesis 2013, 45 (13), 1857-1862] gave 11
mg (7% of theory) of the title compound. A second batch of 200 mg
(0.447 mmol) of the compound from Ex. 60A gave 17 mg (6% of theory)
of the title compound.
[1020] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.37-7.30
(m, 5H), 5.06-5.00 (m, 1H), 4.62-4.50 (m, 2H), 4.16-3.98 (m, 3H),
3.87-3.79 (m, 2H), 3.54-3.46 (m, 2H), 2.52-2.40 (m, 2H), 2.47 (s,
3H), 2.09 (s, 3H), 1.98-1.90 (m, 2H), 1.77-1.68 (m, 2H).
[1021] LC/MS (Method 1, ESIpos): R.sub.t=1.19 min, m/z=620
[M+H].sup.+.
Example 123A
1-{[3-(4,4-Difluorobut-3-en-1-yl)-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropro-
pyl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]carbonyl}piperidin-4-yl-
acetate
##STR00207##
[1023] Analogously to the process described in Ex. 78A, 100 mg
(0.223 mmol) of the compound from Ex. 60A and 46 mg (0.268 mmol) of
4-bromo-1,1-difluorobutene gave 97 mg (80% of theory) of the title
compound.
[1024] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.95-4.89
(m, 1H), 4.53 (dtd, 1H), 4.13 (t, 2H), 3.93 (t, 2H), 3.79-3.71 (m,
2H), 3.44-3.37 (m, 2H, partially obscured by the water signal),
2.85-2.71 (m, 2H), 2.39 (s, 3H), 2.27 (quart, 2H), 2.02 (s, 3H),
1.92-1.85 (m, 2H), 1.60-1.52 (m, 2H).
[1025] LC/MS (Method 1, ESIpos): R.sub.t=1.10 min, m/z=538
[M+H].sup.+.
Example 124A
1-{[3-(2-Hydroxy-2-phenylethyl)-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropy-
l)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]carbonyl}piperidin-4-ylac-
etate (Racemate)
##STR00208##
[1027] At RT, a little at a time and over a period of about 2 h, a
total of 18 mg (0.476 mmol) of solid sodium borohydride was added
to a solution of 538 mg (0.951 mmol) of the compound from Ex. 121A
in 40 ml of methanol and 1 ml of dichloromethane. After a further
30 min at RT, water was added and the mixture was extracted
repeatedly with ethyl acetate. The combined organic extract was
washed with saturated sodium chloride solution, dried over
anhydrous magnesium sulphate, filtered and concentrated. The
residue obtained was purified by preparative HPLC (Method 16). This
gave, after evaporation of the product fractions and drying of the
residue under high vacuum, 435 mg (80% of theory) of the title
compound.
[1028] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.38-7.31
(m, 4H), 7.28-7.23 (m, 1H), 5.39 (d, 1H), 4.96-4.89 (m, 2H), 4.23
(dd, 1H), 4.11 (t, 2H), 3.82 (dd, 1H), 3.78-3.72 (m, 2H), 3.44-3.37
(m, 2H), 2.79-2.67 (m, 2H), 2.39 (s, 3H), 2.03 (s, 3H), 1.93-1.85
(m, 2H), 1.61-1.52 (m, 2H).
[1029] LC/MS (Method 1, ESIpos): R.sub.t=0.98 min, m/z=568
[M+H].sup.+.
Example 125A
1-{[3-(2-Hydroxy-2-phenylethyl)-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropy-
l)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]carbonyl}piperidin-4-ylac-
etate (Enantiomer 1)
##STR00209##
[1031] 452 mg (0.796 mmol) of the racemic compound from Ex. 124A
were dissolved in 20 ml of ethanol/acetonitrile (1:1) and, in 40
portions, separated into the enantiomers by preparative SFC-HPLC on
a chiral phase [column: Daicel Chiralpak IC 5 .mu.m 250 mm.times.20
mm; mobile phase: carbon dioxide/methanol 60:40; flow rate: 80
ml/min, temperature: 40.degree. C.; detection: 210 nm]. This gave,
after concentration of the product fractions and drying of the
residue under high vacuum, 210 mg (92% of theory) of enantiomer
1.
[1032] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.38-7.31
(m, 4H), 7.28-7.23 (m, 1H), 5.39 (d, 1H), 4.96-4.89 (m, 2H), 4.23
(dd, 1H), 4.11 (t, 2H), 3.82 (dd, 1H), 3.79-3.71 (m, 2H), 3.47-3.37
(m, 2H), 2.80-2.66 (m, 2H), 2.39 (s, 3H), 2.03 (s, 3H), 1.93-1.85
(m, 2H), 1.61-1.52 (m, 2H).
[1033] Chiral analytical SFC [column: Daicel Chiralpak IC 5 .mu.m
250 mm.times.4.6 mm; mobile phase: carbon dioxide/methanol 60:40;
flow rate: 3 ml/min, temperature: 40.degree. C.; detection: 210
nm]: R.sub.t=6.53 min; 99.9% ee.
Example 126A
1-{[3-(2-Hydroxy-2-phenylethyl)-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropy-
l)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]carbonyl}piperidin-4-ylac-
etate (Enantiomer 2)
##STR00210##
[1035] 452 mg (0.796 mmol) of the racemic compound from Ex. 124A
were dissolved in 20 ml of ethanol/acetonitrile (1:1) and, in 40
portions, separated into the enantiomers by preparative SFC-HPLC on
a chiral phase [column: Daicel Chiralpak IC 5 .mu.m 250 mm.times.20
mm; mobile phase: carbon dioxide/methanol 60:40; flow rate: 80
ml/min, temperature: 40.degree. C.; detection: 210 nm]. This gave,
after concentration of the product fractions and drying of the
residue under high vacuum, 206 mg (91% of theory) of enantiomer
2.
[1036] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.38-7.31
(m, 4H), 7.28-7.23 (m, 1H), 5.39 (d, 1H), 4.96-4.89 (m, 2H), 4.23
(dd, 1H), 4.11 (t, 2H), 3.82 (dd, 1H), 3.79-3.71 (m, 2H), 3.47-3.37
(m, 2H), 2.79-2.66 (m, 2H), 2.39 (s, 3H), 2.03 (s, 3H), 1.93-1.85
(m, 2H), 1.61-1.52 (m, 2H).
[1037] Chiral analytical SFC [column: Daicel Chiralpak IC 5 .mu.m
250 mm.times.4.6 mm; mobile phase: carbon dioxide/methanol 60:40;
flow rate: 3 ml/min, temperature: 40.degree. C.; detection: 210
nm]: R.sub.t=5.04 min; 99.9% ee.
Example 127A
1-{[3-(2-Fluoro-2-phenylethyl)-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropyl-
)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]carbonyl}piperidin-4-ylace-
tate (Enantiomer 1)
##STR00211##
[1039] At -20.degree. C., a solution of 28 .mu.l (0.211 mmol) of
diethylaminosulphur trifluoride (DAST) in 0.5 ml of dichloromethane
was added dropwise to a solution of 100 mg (0.176 mmol) of the
compound from Ex. 125A in 5 ml of dichloromethane. The reaction
mixture was then stirred at RT for 3 h. The same amount of DAST in
dichloromethane was then added again. After a further 4 h of
stirring, semisaturated aqueous sodium bicarbonate solution was
added and the mixture was extracted with dichloromethane. The
organic extract was dried over anhydrous magnesium sulphate,
filtered and concentrated. The residue was purified by preparative
HPLC (Method 5). This gave, after concentration of the product
fractions and drying of the residue under high vacuum, 84 mg (83%
of theory) of the title compound.
[1040] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.49-7.40
(m, 5H), 5.77 (ddd, 1H), 4.92 (m, 1H), 4.63 (m, 1H), 4.16 (t, 2H),
4.00 (ddd, 1H), 3.80-3.72 (m, 2H), 3.45-3.37 (m, 2H), 2.86-2.74 (m,
2H), 2.41 (s, 3H), 2.03 (s, 3H), 1.93-1.85 (m, 2H), 1.61-1.52 (m,
2H).
[1041] LC/MS (Method 1, ESIpos): R.sub.t=1.11 min, m/z=570
[M+H].sup.+.
Example 128A
1-{[3-(2-Fluoro-2-phenylethyl)-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropyl-
)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]carbonyl}piperidin-4-ylace-
tate (Enantiomer 2)
##STR00212##
[1043] At -20.degree. C., a solution of 20 .mu.l (0.148 mmol) of
diethylaminosulphur trifluoride (DAST) in 0.5 ml of dichloromethane
was added dropwise to a solution of 70 mg (0.123 mmol) of the
compound from Ex. 126A in 4 ml of dichloromethane. The reaction
mixture was subsequently stirred at -20.degree. C. for 1 h. The
same amount of DAST in dichloromethane was then added again. After
a further hour at -20.degree. C., the cooling bath was removed and
stirring was continued at RT. After 6 h at RT, semisaturated
aqueous sodium bicarbonate solution was added and the mixture was
extracted with dichloromethane. The organic extract was dried over
anhydrous magnesium sulphate, filtered and concentrated. The
residue was purified by preparative HPLC (Method 5). This gave,
after concentration of the product fractions and drying of the
residue under high vacuum, 62 mg (88% of theory) of the title
compound.
[1044] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.49-7.41
(m, 5H), 5.77 (ddd, 1H), 4.92 (m, 1H), 4.63 (m, 1H), 4.16 (t, 2H),
3.99 (ddd, 1H), 3.81-3.72 (m, 2H), 3.45-3.37 (m, 2H), 2.86-2.74 (m,
2H), 2.41 (s, 3H), 2.03 (s, 3H), 1.93-1.85 (m, 2H), 1.61-1.52 (m,
2H).
[1045] LC/MS (Method 1, ESIpos): R.sub.t=1.11 min, m/z=570
[M+H].sup.+.
Example 129A
1-{[3-(2-Hydroxy-2-phenylpropyl)-5-methyl-2,4-dioxo-1-(3,3,3-trifluoroprop-
yl)-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]carbonyl}piperidin-4-yla-
cetate (Racemate)
##STR00213##
[1047] 105 mg (0.186 mmol) of the compound from Ex. 121A were
dissolved in 3 ml of anhydrous THF, and 186 .mu.l (0.186 mmol) of a
1 M solution of methylmagnesium bromide in THF were added at
0.degree. C. After 3 h at 0.degree. C., an identical amount of
Grignard reagent was added. After a further 30 min, about 0.5 ml of
saturated aqueous ammonium chloride solution was added, the
reaction mixture was then diluted with ethyl acetate and finally
anhydrous magnesium sulphate was added in such an amount that the
aqueous phase was taken up completely. The mixture was then
filtered off with suction and the filtrate was evaporated. The
filtrate residue was purified by preparative HPLC (Method 5). This
gave, after combination of the product fractions, concentration and
drying under high vacuum, 55 mg (50% of theory) of the title
compound.
[1048] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.48 (d,
2H), 7.30 (t, 2H), 7.21 (t, 1H), 5.04 (s, 1H), 4.96-4.89 (m, 1H),
4.18 (quart, 2H), 4.12-4.03 (m, 2H), 3.79-3.72 (m, 2H), 3.44-3.37
(m, 2H), 2.76-2.64 (m, 2H), 2.36 (s, 3H), 2.03 (s, 3H), 1.93-1.85
(m, 2H), 1.61-1.52 (m, 2H), 1.42 (s, 3H).
[1049] LC/MS (Method 1, ESIpos): R.sub.t=1.10 min, m/z=582
[M+H].sup.+.
Example 130A
1-{[3-Ethyl-5-methyl-1-(3-methylbutyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[-
2,3-d]pyrimidin-6-yl]carbonyl}piperidin-4-yl acetate
##STR00214##
[1051] Analogously to the process described in Ex. 83A, 150 mg
(0.395 mmol) of the compound from Ex. 62A and 117 mg (0.593 mmol)
of 1-iodo-3-methylbutane gave 150 mg (84% of theory) of the title
compound. In deviation, the reaction time in the microwave oven was
60 min, and purification by preparative HPLC was carried out
according to Method 6.
[1052] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.91 (m,
1H), 3.92-3.87 (m, 2H), 3.91 (quart, 2H), 3.78-3.71 (m, 2H), 3.40
(m, 2H), 2.39 (s, 3H), 2.02 (s, 3H), 1.91-1.84 (m, 2H), 1.65 (sept,
1H), 1.60-1.54 (m, 4H), 1.12 (t, 3H), 0.95 (d, 6H).
[1053] LC/MS (Method 1, ESIpos): R.sub.t=1.10 min, m/z=450
[M+H].sup.+.
Example 131A
1-{[3-Ethyl-5-methyl-2,4-dioxo-1-(4,4,4-trifluorobutyl)-1,2,3,4-tetrahydro-
thieno[2,3-d]pyrimidin-6-yl]carbonyl}piperidin-4-yl acetate
##STR00215##
[1055] Analogously to the process described in Ex. 83A, 150 mg
(0.395 mmol) of the compound from Ex. 62A and 141 mg (0.593 mmol)
of 4,4,4-trifluoro-1-iodobutane gave 163 mg (84% of theory) of the
title compound. In deviation, the reaction time in the microwave
oven was 60 min, and purification by preparative HPLC was carried
out according to Method 6.
[1056] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.92 (m,
1H), 3.97 (t, 2H), 3.90 (quart, 2H), 3.79-3.71 (m, 2H), 3.40 (m,
2H), 2.47-2.38 (m, 2H), 2.39 (s, 3H), 2.02 (s, 3H), 1.95-1.85 (m,
4H), 1.60-1.51 (m, 2H), 1.13 (t, 3H).
[1057] LC/MS (Method 1, ESIpos): R.sub.t=1.01 min, m/z=490
[M+H].sup.+.
Example 132A
1-{[3-Ethyl-5-methyl-2,4-dioxo-1-(3,4,4-trifluorobut-3-en-1-yl)-1,2,3,4-te-
trahydrothieno[2,3-d]pyrimidin-6-yl]carbonyl}piperidin-4-yl
acetate
##STR00216##
[1059] Analogously to the process described in Ex. 83A, 150 mg
(0.395 mmol) of the compound from Ex. 62A and 140 mg (0.593 mmol)
of 1,1,2-trifluoro-4-iodobut-1-ene gave 72 mg (37% of theory) of
the title compound. In deviation, the reaction time in the
microwave oven was 90 min, and purification by preparative HPLC was
carried out according to Method 6.
[1060] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.91 (m,
1H), 4.10 (t, 2H), 3.91 (quart, 2H), 3.78-3.70 (m, 2H), 3.39 (m,
2H), 2.82 (m, 2H), 2.39 (s, 3H), 2.02 (s, 3H), 1.91-1.84 (m, 2H),
1.60-1.51 (m, 2H), 1.12 (t, 3H).
[1061] LC/MS (Method 1, ESIpos): R.sub.t=1.00 min, m/z=488
[M+H].sup.+.
Example 133A
6-Chloro-3-isobutylpyrimidine-2,4(1H,3H)-dione
##STR00217##
[1063] At a temperature of 0.degree. C., 18.8 ml (201 mmol) of
phosphorus oxychloride were added carefully to 4 ml of 50% strength
aqueous ethanol. Subsequently, likewise at 0.degree. C., 4.15 g
(22.6 mmol) of 1-isobutylpyrimidine-2,4,6(1H,3H,5H)-trione [lit.:
G. Bruckmann, S. D. Isaacs, J. Am. Chem. Soc. 1949, 71 (2),
390-392] were added a little at a time. After the addition had
ended, the reaction mixture was heated first for 30 min at
50.degree. C. and then for 2 h at 100.degree. C. After cooling to
RT, the reaction mixture was poured into about 80 ml of ice-water.
The precipitated solid was filtered off with suction and washed
with water. Drying under high vacuum gave 3.20 g (70% of theory) of
the title compound.
[1064] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 12.33 (br.
s, 1H), 5.89 (s, 1H), 3.56 (d, 2H), 1.99 (m, 1H), 0.83 (d, 6H).
[1065] LC/MS (Method 1, ESIpos): R.sub.t=0.64 min, m/z=203/205
[M+H].sup.+.
Example 134A
2,2-Difluoro-1-[1-isobutyl-2,6-dioxo-4-(pyridinium-1-yl)-1,6-dihydropyrimi-
din-5(2H)-ylidene]ethanolate
##STR00218##
[1067] At RT, 13 ml (158 mmol) of pyridine were added to a
suspension of 3.2 g (15.8 mmol) of the compound from Ex. 133A in 35
ml of ethyl acetate. 7.9 ml (63.2 mmol) of difluoroacetic anhydride
were then slowly added dropwise. After the dropwise addition had
ended, stirring was continued at RT for 1 h. The solid was then
filtered off with suction, washed with a little ethyl acetate and
pentane and dried under high vacuum. This gave 2.30 g (45% of
theory) of the title compound.
[1068] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 9.22 (d,
2H), 8.80 (t, 1H), 8.25 (t, 2H), 6.95 (t, 1H), 3.70 (d, 2H), 2.08
(m, 1H), 0.89 (d, 6H).
[1069] LC/MS (Method 1, ESIpos): R.sub.t=0.66 min, m/z=324
[M+H].sup.+.
Example 135A
Ethyl
5-(difluoromethyl)-3-isobutyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-
-d]pyrimidine-6-carboxylate
##STR00219##
[1071] 757 .mu.l (6.90 mmol) of ethyl mercaptoacetate were added to
a suspension of 1.11 g (3.45 mmol) of the compound from Ex. 134A in
14 ml of ethanol, and the mixture was stirred at RT for 5 min. 804
mg (7.59 mmol) of sodium carbonate were then added, and the mixture
was heated in a microwave oven (Biotage Initiator with dynamic
control of irradiation power) at 125.degree. C. for 2 h. Two such
batches were then combined and concentrated to dryness on a rotary
evaporator. The residue that remained was taken up in about 300 ml
of water, acidified slightly by addition of acetic acid and
extracted three times with about 100 ml of dichloromethane each.
The organic extract was washed with saturated aqueous sodium
chloride solution, dried over anhydrous magnesium sulphate,
filtered and concentrated. The residue was suspended in a little
dichloromethane and stirred at RT. The solid was then filtered off
with suction and dried under high vacuum. This gave a first
fraction of 1.59 g of the title compound. The filtrate was
concentrated to dryness and chromatographed on a silica gel
cartridge (Biotage, 100 g of silica gel, mobile phase
cyclohexane/ethyl acetate 3:1-1:1). Evaporation of the product
fractions and drying of the residue under high vacuum gave 355 mg
of a second fraction of the title compound. A total of 1.94 g (81%
of theory) of the title compound were thus obtained.
[1072] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 12.59 (s,
1H), 7.70 (t, 1H), 4.32 (quart, 2H), 3.68 (d, 2H), 2.03 (m, 1H),
1.30 (t, 3H), 0.86 (d, 6H).
[1073] LC/MS (Method 1, ESIpos): R.sub.t=0.98 min, m/z=347
[M+H].sup.+.
Example 136A
Ethyl
5-(difluoromethyl)-3-isobutyl-2,4-dioxo-1-[2-(trifluoromethoxy)ethyl-
]-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00220##
[1075] 847 mg (2.60 mmol) of caesium carbonate were added to a
solution of 600 mg (1.73 mmol) of the compound from Ex. 135A in 9
ml of DMF, and the mixture was stirred at RT for 20 min. 501 mg
(2.60 mmol) of 1-bromo-2-(trifluoromethoxy)ethane [commercially
available; lit.: P. E. Aldrich, W. A. Sheppard, J. Org. Chem. 1964,
29 (1), 11-15] were then added, and the mixture was heated in a
microwave oven (Biotage Initiator with dynamic control of
irradiation power) at 100.degree. C. for 1 h. After cooling to RT,
the mixture was diluted with about 80 ml of ethyl acetate and, in
succession, washed twice with in each case about 80 ml of water and
once with about 80 ml of saturated sodium chloride solution. After
drying over anhydrous magnesium sulphate, the mixture was filtered
and concentrated. The crude product was purified by preparative
HPLC (Method 5). The product fractions were combined and
concentrated, and the residue was dried under high vacuum. 553 mg
(69% of theory) of the title compound were obtained.
[1076] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.72 (t,
1H), 4.42 (t, 2H), 4.35 (quart, 2H), 4.32 (t, 2H), 3.74 (d, 2H),
2.03 (m, 1H), 1.31 (t, 3H), 0.86 (d, 6H).
[1077] LC/MS (Method 1, ESIpos): R.sub.t=1.23 min, m/z=459
[M+H].sup.+.
Example 137A
Ethyl
5-(difluoromethyl)-3-isobutyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,-
2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00221##
[1079] Analogously to the process described in Ex. 136A, 600 mg
(1.73 mmol) of the compound from Ex. 135A and 582 mg (2.60 mmol) of
3,3,3-trifluoro-1-iodopropane gave 570 mg (74% of theory) of the
title compound. Here, purification by preparative HPLC was carried
out according to Method 6.
[1080] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.73 (t,
1H), 4.36 (quart, 2H), 4.21 (t, 2H), 3.73 (d, 2H), 2.81 (m, 2H),
2.03 (m, 1H), 1.32 (t, 3H), 0.87 (d, 6H).
[1081] LC/MS (Method 1, ESIpos): R.sub.t=1.22 min, m/z=443
[M+H].sup.+.
Example 138A
5-(Difluoromethyl)-3-isobutyl-2,4-dioxo-1-[2-(trifluoromethoxy)ethyl]-1,2,-
3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00222##
[1083] 1.73 ml (1.73 mmol) of a 1 M solution of lithium hydroxide
in water were added to a solution of 530 mg (1.16 mmol) of the
compound from Ex. 136A in 12 ml of ethanol, and the mixture was
stirred at RT for 3 h. All the volatile constituents were then
removed on a rotary evaporator. The residue that remained was taken
up in water and acidified with about 1.5 ml of 1 M hydrochloric
acid. The product precipitated out and was filtered off with
suction, washed with water and dried under high vacuum. 466 mg (93%
of theory) of the title compound were obtained.
[1084] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 14.43
(very broad, about 1H), 7.76 (t, 1H), 4.42 (t, 2H), 4.30 (t, 2H),
3.74 (d, 2H), 2.03 (m, 1H), 0.86 (d, 6H).
[1085] LC/MS (Method 1, ESIpos): R.sub.t=0.99 min, m/z=431
[M+H].sup.+.
Example 139A
5-(Difluoromethyl)-3-isobutyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,2,3,4--
tetrahydrothieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00223##
[1087] Analogously to the process described under Ex. 138A, 540 mg
(1.22 mmol) of the compound from Ex. 137A gave 463 mg (91% of
theory) of the title compound.
[1088] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 14.39
(very broad, about 1H), 7.77 (t, 1H), 4.19 (t, 2H), 3.73 (d, 2H),
2.81 (m, 2H), 2.03 (m, 1H), 0.86 (d, 6H).
[1089] LC/MS (Method 1, ESIpos): R.sub.t=0.98 min, m/z=415
[M+H].sup.+.
Example 140A
tert-Butyl
5-(bromomethyl)-2,4-dioxo-3-propyl-1-(3,3,3-trifluoropropyl)-1,-
2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00224##
[1091] 200 mg (0.476 mmol) of the compound from Ex. 98A, 178 mg
(0.999 mmol) of N-bromosuccinimide (NBS) and 7.8 mg (0.048 mmol) of
2,2'-azobis(2-methylpropionitrile) (AIBN) in 5 ml of anhydrous
acetonitrile were heated under reflux for about 16 h. All the
volatile constituents were then substantially removed on a rotary
evaporator. The residue that remained was purified by means of
filtration with suction through silica gel using dichloromethane as
mobile phase. This gave, after combination of the product
fractions, concentration and drying under high vacuum, 213 mg (89%
of theory) of the title compound.
[1092] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 5.21 (s,
2H), 4.17 (t, 2H), 3.85 (t, 2H), 2.87-2.75 (m, 2H), 1.63-1.53 (m,
2H), 1.57 (s, 9H), 0.88 (t, 3H).
[1093] LC/MS (Method 1, ESIpos): R.sub.t=1.34 min, m/z=499/501
[M+H].sup.+.
Example 141A
tert-Butyl
5-(bromomethyl)-3-ethyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,2-
,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00225##
[1095] Analogously to the process described in Ex. 140A, 4.40 g
(10.8 mmol) of the compound from Ex. 35A, 2.02 g (11.4 mmol) of
N-bromosuccinimide (NBS) and 89 mg (0.541 mmol) of
2,2'-azobis(2-methylpropionitrile) (AIBN) gave 4.56 g (82% of
theory, purity 95%) of the title compound.
[1096] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 5.21 (s,
2H), 4.17 (t, 2H), 3.93 (quart, 2H), 2.88-2.76 (m, 2H), 1.57 (s,
9H), 1.15 (t, 3H).
[1097] LC/MS (Method 1, ESIpos): R.sub.t=1.31 min; no
ionization.
Example 142A
tert-Butyl
5-formyl-2,4-dioxo-3-propyl-1-(3,3,3-trifluoropropyl)-1,2,3,4-t-
etrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00226##
[1099] 385 mg of molecular sieve (4A) and, at a temperature of
-10.degree. C. and a little at a time, a total of 181 mg (1.54
mmol) of N-methylmorpholine N-oxide (NMO) were added to a solution
of 385 mg (0.771 mmol) of the compound from Ex. 140A in 5 ml of
anhydrous acetonitrile. The reaction mixture was then stirred at RT
for 4 h. The mixture was then filtered through a little kieselguhr
and the filtrate was concentrated to dryness. The residue obtained
was taken up in 20 ml of diisopropyl ether/ethyl acetate (1:1) and
washed successively twice with in each case 10 ml of aqueous citric
acid solution and once with 10 ml of saturated aqueous sodium
chloride solution. After drying over anhydrous magnesium sulphate,
the mixture was filtered and concentrated. Drying of the residue
under high vacuum gave 247 mg (73% of theory) of the title
compound.
[1100] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 10.36 (s,
1H), 4.19 (t, 2H), 3.81 (t, 2H), 2.88-2.76 (m, 2H), 1.61-1.51 (m,
2H), 1.50 (s, 9H), 0.86 (t, 3H).
[1101] LC/MS (Method 1, ESIpos): R.sub.t=1.22 min, m/z=435
[M+H]+.
Example 143A
tert-Butyl
3-ethyl-5-formyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,2,3,4-te-
trahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00227##
[1103] Analogously to the process described in Ex. 142A, 3.75 g
(7.73 mmol) of the compound from Ex. 141A and 1.81 g (15.4 mmol) of
N-methylmorpholine N-oxide (NMO) gave 2.38 g (73% of theory) of the
title compound. The reaction time in this case was 5 h.
[1104] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 10.36 (s,
1H), 4.19 (t, 2H), 3.88 (quart, 2H), 2.88-2.76 (m, 2H), 1.50 (s,
9H), 1.12 (t, 3H).
[1105] LC/MS (Method 1, ESIpos): R.sub.t=1.15 min, m/z=421
[M+H].sup.+.
Example 144A
tert-Butyl
5-(difluoromethyl)-2,4-dioxo-3-propyl-1-(3,3,3-trifluoropropyl)-
-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00228##
[1107] At 0.degree. C., 218 mg (1.35 mmol) of
N,N-diethylaminosulphur trifluoride (DAST) were added to a solution
of 235 mg (0.541 mmol) of the compound from Ex. 142A in 5 ml of
dichloromethane. The mixture was then stirred at RT for 3 h. 0.5 ml
of saturated aqueous sodium bicarbonate solution were then added,
and the mixture was stirred at RT for a few minutes. The mixture
was then diluted with 5 ml of ethyl acetate and solid anhydrous
magnesium sulphate was added in the amount required to take up the
aqueous phase completely. The mixture was filtered, the residue was
washed with a little ethyl acetate and the filtrate was
concentrated. The solid obtained was purified by preparative HPLC
(Method 6). This gave, after concentration of the product fractions
and drying under high vacuum, 198 mg (80% of theory) of the title
compound.
[1108] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.71 (t,
1H), 4.19 (t, 2H), 3.84 (t, 2H), 2.87-2.75 (m, 2H), 1.62-1.53 (m,
2H), 1.55 (s, 9H), 0.88 (t, 3H).
[1109] LC/MS (Method 1, ESIpos): R.sub.t=1.32 min, m/z=457
[M+H].sup.+.
Example 145A
tert-Butyl
3-ethyl-5-(fluoromethyl)-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,-
2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00229##
[1111] 400 mg of molecular sieve (4A) and 2 ml (1.98 mmol) of a 1 M
solution of tetra-n-butylammonium fluoride (TBAF) in THF were added
to a solution of 800 mg (1.65 mmol) of the compound from Ex. 141A
in 16 ml of anhydrous acetonitrile. After the mixture had been
stirred at RT for about 16 h, it was filtered and the filtrate was
concentrated to dryness. The residue obtained was purified by
preparative HPLC (Method 18). This gave, after concentration of the
product fractions and drying under high vacuum, 450 mg (60% of
theory, purity 94%) of the title compound.
[1112] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 5.93 (d,
2H), 4.19 (t, 2H), 3.93 (quart, 2H), 2.88-2.76 (m, 2H), 1.55 (s,
9H), 1.14 (t, 3H).
[1113] LC/MS (Method 1, ESIpos): R.sub.t=1.21 min, m/z=425
[M+H]+.
Example 146A
tert-Butyl
3-ethyl-5-(1-hydroxyethyl)-2,4-dioxo-1-(3,3,3-trifluoropropyl)--
1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
(Racemate)
##STR00230##
[1115] At 0.degree. C., 1.9 ml of a 1.4 M solution of
methylmagnesium bromide in a mixture of THF/toluene were added
dropwise to a solution of 1.0 g (2.38 mmol) of the compound from
Ex. 143A in 24 ml of anhydrous THF. After the reaction mixture had
been stirred at 0.degree. C. for 1 h, 5 ml of water were added at
this temperature. The mixture was allowed to warm to RT and then
extracted with ethyl acetate. The organic extract was washed
successively with water and saturated sodium chloride solution.
After drying over anhydrous sodium sulphate, the mixture was
filtered and concentrated. The residue obtained was purified by
preparative HPLC (Method 18). The product fractions were combined
and concentrated, and the residue was dried under high vacuum. 480
mg (46% of theory) of the title compound were obtained.
[1116] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 5.76
(broad, 1H), 4.18 (t, 2H), 3.97 (quart, 2H), 2.88-2.76 (m, 2H),
1.54 (s, 9H), 1.41 (d, 3H), 1.16 (t, 3H).
[1117] LC/MS (Method 1, ESIpos): R.sub.t=1.22 min, m/z=437
[M+H].sup.+.
Example 147A
tert-Butyl
3-ethyl-5-(1-fluoroethyl)-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1-
,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
(Racemate)
##STR00231##
[1119] At 0.degree. C., 405 mg (0.916 mmol) of a 50% strength
solution of bis(2-methoxyethyl)aminosulphur trifluoride
(Deoxo-Fluor.RTM.) in THF were added to a solution of 400 mg (0.916
mmol) of the compound from Ex. 146A in 9.2 ml of dichloromethane.
After stirring at RT for 30 min, a further 203 mg (0.458 mmol) of
Deoxo-Fluor.RTM. solution were added. After a further 30 min of
stirring, saturated aqueous sodium bicarbonate solution was added
and the mixture was extracted with ethyl acetate. The organic
extract was washed with water and dried over anhydrous sodium
sulphate. This gave, after filtration, concentration and drying
under high vacuum, 430 mg (90% of theory, purity 85%) of the title
compound.
[1120] LC/MS (Method 1, ESIpos): R.sub.t=1.28 min, m/z=439
[M+H].sup.+.
Example 148A
5-(Difluoromethyl)-2,4-dioxo-3-propyl-1-(3,3,3-trifluoropropyl)-1,2,3,4-te-
trahydrothieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00232##
[1122] 1 ml of trifluoroacetic acid were added to a solution of 190
mg (0.416 mmol) of the compound from Ex. 144A in 2 ml of
dichloromethane, and the mixture was stirred at RT for 3 h. The
reaction mixture was then concentrated to dryness on a rotary
evaporator. The residue that remained was twice dissolved in each
case 5 ml of dichloromethane and in each case concentrated again.
After drying under a high vacuum, 166 mg (97% of theory, 97%
purity) of the title compound were obtained.
[1123] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 14.43
(very broad, about 1H), 7.76 (t, 1H), 4.19 (t, 2H), 3.84 (t, 2H),
2.87-2.75 (m, 2H), 1.62-1.53 (m, 2H), 0.88 (t, 3H).
[1124] LC/MS (Method 1, ESIpos): R.sub.t=0.91 min, m/z=401
[M+H]+.
Example 149A
3-Ethyl-5-(fluoromethyl)-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,2,3,4-tetra-
hydrothieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00233##
[1126] Analogously to the process described under Ex. 148A, 450 mg
(1.06 mmol) of the compound from Ex. 145A gave 390 mg (92% of
theory, purity 93%) of the title compound.
[1127] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 14.04
(very broad, about 1H), 5.95 (d, 2H), 4.18 (t, 2H), 3.93 (quart,
2H), 2.87-2.75 (m, 2H), 1.14 (t, 3H).
[1128] LC/MS (Method 1, ESIpos): R.sub.t=0.86 min, m/z=369
[M+H].sup.+.
Example 150A
3-Ethyl-5-(1-fluoroethyl)-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,2,3,4-tetr-
ahydrothieno[2,3-d]pyrimidine-6-carboxylic acid (Racemate)
##STR00234##
[1130] Analogously to the process described under Ex. 148A, 430 mg
(0.834 mmol, purity 85%) of the compound from Ex. 147A gave 290 mg
(77% of theory, purity 85%) of the title compound.
[1131] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.91
(very broad, about 1H), 6.75 (d of quart, 1H), 4.17 (t, 2H), 3.92
(quart, 2H), 2.87-2.75 (m, 2H), 1.73 (dd, 3H), 1.14 (t, 3H).
[1132] LC/MS (Method 1, ESIpos): R.sub.t=0.89 min, m/z=383
[M+H].sup.+.
Example 151A
tert-Butyl
5-(bromomethyl)-2,4-dioxo-3-propyl-1-[2-(trifluoromethoxy)ethyl-
]-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00235##
[1134] Analogously to the process described in Ex. 140A, 2.0 g
(4.58 mmol) of the compound from Ex. 95A, 856 mg (4.81 mmol) of
N-bromosuccinimide (NBS) and 38 mg (0.229 mmol) of
2,2'-azobis(2-methylpropionitrile) (AIBN) gave 1.90 g (80% of
theory) of the title compound. The reaction time in this case was 1
h.
[1135] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 5.20 (s,
2H), 4.42 (t, 2H), 4.27 (t, 2H), 3.86 (t, 2H), 1.63-1.54 (m, 2H),
1.56 (s, 9H), 0.88 (t, 3H).
[1136] LC/MS (Method 1, ESIpos): R.sub.t=1.37 min, m/z=515/517
[M+H]+.
Example 152A
tert-Butyl
5-formyl-2,4-dioxo-3-propyl-1-[2-(trifluoromethoxy)ethyl]-1,2,3-
,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00236##
[1138] Analogously to the process described in Ex. 142A, 1.80 g
(3.49 mmol) of the compound from Ex. 151A and 818 mg (6.99 mmol) of
N-methylmorpholine N-oxide (NMO) gave 1.17 g (74% of theory) of the
title compound. The reaction time in this case was 5 h.
[1139] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 10.35 (s,
1H), 4.43 (t, 2H), 4.29 (t, 2H), 3.81 (t, 2H), 1.61-1.51 (m, 2H),
1.50 (s, 9H), 0.85 (t, 3H).
[1140] LC/MS (Method 1, ESIpos): R.sub.t=1.21 min, m/z=451
[M+H].sup.+.
Example 153A
tert-Butyl
5-(difluoromethyl)-2,4-dioxo-3-propyl-1-[2-(trifluoromethoxy)et-
hyl]-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00237##
[1142] Analogously to the process described in Ex. 144A, 1.11 g
(2.47 mmol) of the compound from Ex. 152A and 998 mg (6.19 mmol) of
N,N-diethylaminosulphur trifluoride (DAST) gave 935 mg (79% of
theory) of the title compound. Here, purification of the product
was carried out by chromatography on a silica gel cartridge
(Biotage, 50 g of silica gel, mobile phase: 5:1 cyclohexane/ethyl
acetate).
[1143] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.71 (t,
1H), 4.42 (t, 2H), 4.30 (t, 2H), 3.85 (t, 2H), 1.62-1.52 (m, 2H),
1.54 (s, 9H), 0.87 (t, 3H).
[1144] LC/MS (Method 1, ESIpos): R.sub.t=1.29 min, m/z=473
[M+H].sup.+.
Example 154A
5-(Difluoromethyl)-2,4-dioxo-3-propyl-1-[2-(trifluoromethoxy)ethyl]-1,2,3,-
4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00238##
[1146] Analogously to the process described under Ex. 148A, 916 mg
(1.94 mmol) of the compound from Ex. 153A gave 806 mg (98% of
theory) of the title compound.
[1147] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 14.34
(very broad, 1H), 7.76 (t, 1H), 4.42 (t, 2H), 4.30 (t, 2H), 3.85
(t, 2H), 1.62-1.53 (m, 2H), 0.87 (t, 3H).
[1148] LC/MS (Method 1, ESIpos): R.sub.t=0.88 min, m/z=417
[M+H]+.
Example 155A
tert-Butyl
1-ethyl-5-methyl-2,4-dioxo-3-propyl-1,2,3,4-tetrahydrothieno[2,-
3-d]pyrimidine-6-carboxylate
##STR00239##
[1150] 4.52 g (13.9 mmol) of caesium carbonate were added to a
solution of 3.0 g (9.25 mmol) of the compound from Ex. 91A in 36 ml
of DMF, and the mixture was stirred at RT for 10 min. 1.1 ml (13.9
mmol) of iodoethane were then added, and the mixture was stirred in
a microwave oven (Biotage Initiator with dynamic control of
irradiation power) at 100.degree. C. for 1 h. After cooling to RT,
the mixture was diluted with ethyl acetate and washed successively
with water and saturated sodium chloride solution. After drying
over anhydrous magnesium sulphate, the mixture was filtered and
concentrated. The crude product was purified by MPLC (Biotage
cartridge with 100 g of silica gel, mobile phase: 20:1
cyclohexane/ethyl acetate). The product fractions were combined and
concentrated. After the residue had been dried under high vacuum,
3.06 g (93% of theory) of the title compound were obtained.
[1151] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 3.94
(quart, 2H), 3.82 (m, 2H), 2.75 (s, 3H), 1.61-1.51 (m, 2H), 1.53
(s, 9H), 1.25 (t, 3H), 0.87 (t, 3H).
[1152] LC/MS (Method 1, ESIpos): R.sub.t=1.34 min, m/z=353
[M+H].sup.+.
Example 156A
tert-Butyl
5-(bromomethyl)-1-ethyl-2,4-dioxo-3-propyl-1,2,3,4-tetrahydroth-
ieno[2,3-d]pyrimidine-6-carboxylate
##STR00240##
[1154] Analogously to the process described in Ex. 140A, 2.0 g
(5.67 mmol) of the compound from Ex. 155A, 1.06 g (5.96 mmol) of
N-bromosuccinimide (NBS) and 47 mg (0.284 mmol) of
2,2'-azobis(2-methylpropionitrile) (AIBN) gave 2.22 g (90% of
theory) of the title compound. The reaction time in this case was 1
h.
[1155] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 5.21 (s,
2H), 3.96 (quart, 2H), 3.84 (m, 2H), 1.63-1.53 (m, 2H), 1.57 (s,
9H), 1.26 (t, 3H), 0.89 (t, 3H).
[1156] LC/MS (Method 1, ESIpos): R.sub.t=1.38 min, m/z=431/433
[M+H].sup.+.
Example 157A
tert-Butyl
1-ethyl-5-formyl-2,4-dioxo-3-propyl-1,2,3,4-tetrahydrothieno[2,-
3-d]pyrimidine-6-carboxylate
##STR00241##
[1158] Analogously to the process described in Ex. 142A, 2.15 g
(4.98 mmol) of the compound from Ex. 156A and 1.17 g (9.97 mmol) of
N-methylmorpholine N-oxide (NMO) gave 1.38 g (75% of theory) of the
title compound. Here, the reaction time was about 16 h.
[1159] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 10.35 (s,
1H), 3.97 (quart, 2H), 3.80 (m, 2H), 1.62-1.51 (m, 2H), 1.50 (s,
9H), 1.27 (t, 3H), 0.86 (t, 3H).
[1160] LC/MS (Method 1, ESIpos): R.sub.t=1.16 min, m/z=367
[M+H].sup.+.
Example 158A
tert-Butyl
5-(difluoromethyl)-1-ethyl-2,4-dioxo-3-propyl-1,2,3,4-tetrahydr-
othieno[2,3-d]pyrimidine-6-carboxylate
##STR00242##
[1162] Analogously to the process described in Ex. 144A, 1.32 g
(3.60 mmol) of the compound from Ex. 157A and 1.45 g (9.01 mmol) of
N,N-diethylaminosulphur trifluoride (DAST) gave 1.08 g (77% of
theory) of the title compound. Here, purification of the product
was carried out by chromatography on a silica gel cartridge
(Biotage, 100 g of silica gel, mobile phase: 5:1 cyclohexane/ethyl
acetate).
[1163] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.72 (t,
1H), 3.98 (quart, 2H), 3.83 (m, 2H), 1.62-1.53 (m, 2H), 1.55 (s,
9H), 1.27 (t, 3H), 0.88 (t, 3H).
[1164] LC/MS (Method 1, ESIpos): R.sub.t=1.25 min, m/z=389
[M+H].sup.+.
Example 159A
5-(Difluoromethyl)-1-ethyl-2,4-dioxo-3-propyl-1,2,3,4-tetrahydrothieno[2,3-
-d]pyrimidine-6-carboxylic acid
##STR00243##
[1166] Analogously to the process described under Ex. 148A, 1.0 g
(2.57 mmol) of the compound from Ex. 158A gave 855 mg (99% of
theory) of the title compound.
[1167] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 14.28
(very broad, about 1H), 7.76 (t, 1H), 3.98 (quart, 2H), 3.83 (m,
2H), 1.62-1.53 (m, 2H), 1.27 (t, 3H), 0.88 (t, 3H).
[1168] LC/MS (Method 1, ESIpos): R.sub.t=0.74 min, m/z=333
[M+H].sup.+.
Example 160A
3-Isobutyl-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,2,3,4-tetrahydro-
thieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00244##
[1170] 758 mg (2.33 mmol) of caesium carbonate were added to a
solution of 250 mg (0.776 mmol) of the compound from Ex. 59A in 7.5
ml of anhydrous DMF, and the mixture was stirred at RT for 10 min.
211 .mu.l (1.94 mmol) of 1-bromo-3-methylpropane were then added,
and the mixture was stirred initially at RT for 3 h and then at
60.degree. C. for 16 h. After cooling to RT, 2 ml of 2 M aqueous
sodium hydroxide solution were added and the reaction mixture was
stirred at RT for a further 2 h. The mixture was then poured onto
about 50 ml of water and extracted with dichloromethane. The
organic extract was discarded and the aqueous phase was brought to
a pH of about 4 with 1 M hydrochloric acid. The mixture was
extracted with ethyl acetate. The organic extract was dried over
anhydrous magnesium sulphate, filtered and concentrated. The
residue obtained was purified by preparative HPLC (Method 5). This
gave, after evaporation of the product fractions and drying of the
residue under high vacuum, 132 mg (44% of theory) of the title
compound.
[1171] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.42
(broad, 1H), 4.15 (t, 2H), 3.72 (d, 2H), 2.85-2.71 (m, 2H), 2.75
(s, 3H), 2.09-1.98 (m, 1H), 0.86 (d, 6H).
[1172] LC/MS (Method 1, ESIpos): R.sub.t=0.99 min, m/z=379
[M+H].sup.+.
Example 161A
3-(Cyclopropylmethyl)-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,2,3,4-
-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylic acid
##STR00245##
[1174] 758 mg (2.33 mmol) of caesium carbonate were added to a
solution of 250 mg (0.776 mmol) of the compound from Ex. 59A in 7.5
ml of anhydrous DMF, and the mixture was stirred at RT for 10 min.
262 mg (1.94 mmol) of (bromomethyl)cyclopropane were then added and
the mixture was stirred at RT for about 16 h. 2 ml of 2 M aqueous
sodium hydroxide solution were then added and the mixture was
stirred at RT for a further 3 h. The mixture was then poured onto
about 50 ml of water. The solid that precipitated out was filtered
off and discarded. The filtrate was adjusted to a pH of about 4-5
using 1 M hydrochloric acid. The product which precipitated out was
filtered off with suction, washed with a little water and dried
under high vacuum. This gave 160 mg (52% of theory, purity 95%) of
the title compound which was used further without further
purification.
[1175] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.44
(broad, about 1H), 4.16 (t, 2H), 3.77 (d, 2H), 2.86-2.73 (m, 2H),
2.76 (s, 3H), 1.20-1.13 (m, 1H), 0.45-0.40 (m, 2H), 0.36-0.32 (m,
2H).
[1176] LC/MS (Method 1, ESIpos): R.sub.t=0.95 min, m/z=377
[M+H].sup.+.
Example 162A
3-(2-Methoxypropyl)-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,2,3,4-t-
etrahydrothieno[2,3-d]pyrimidine-6-carboxylic acid (Racemate)
##STR00246##
[1177] 1st Step: 2-Methoxypropyl
3-(2-methoxypropyl)-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,2,3,4--
tetrahydrothieno[2,3-d]pyrimidine-6-carboxylate
##STR00247##
[1179] 1.52 g (4.66 mmol) of caesium carbonate were added to a
solution of 500 mg (1.55 mmol) of the compound from Ex. 59A in 15
ml of anhydrous DMF, and the mixture was stirred at RT for 10 min.
948 mg (3.88 mmol) of racemic 2-methoxypropyl-4-methylbenzene
sulphonate [prepared analogously to a published method starting
from racemic methyl 2-methoxypropionate; lit.: A. Terfort, H.
Brunner, J. Chem. Soc. Perkin Trans. 1, 1996 (12), 1467-1479] were
then added, and the mixture was stirred initially at RT for 16 h.
Since the reaction was still incomplete, the mixture was then
stirred at 80.degree. C. for another about 18 h. After cooling to
RT, about 100 ml of water were added and the mixture was extracted
with dichloromethane. The organic extract was dried over anhydrous
magnesium sulphate, filtered and concentrated. The residue obtained
was purified by preparative HPLC (Method 6). Concentration of the
product fractions gave 130 mg (18% of theory) of the title
compound.
[1180] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.31 (dd,
1H), 4.22-4.13 (m, 3H), 4.06 (dd, 1H), 3.77 (dd, 1H), 3.67-3.59 (m,
2H), 3.29 (s, 3H), 3.22 (s, 3H), 2.86-2.74 (m, 2H), 2.79 (s, 3H),
1.15 (d, 3H), 1.06 (d, 3H).
[1181] LC/MS (Method 1, ESIpos): R.sub.t=1.12 min, m/z=467
[M+H].sup.+.
2nd Step:
3-(2-Methoxypropyl)-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-
-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidino-6-carboxylic acid
(Racemate)
##STR00248##
[1183] 125 mg (0.268 mmol) of the compound from the preceding step
were dissolved in 5 ml of ethanol, 1.34 ml (1.34 mmol) of a 1 M
solution of lithium hydroxide in water were added and the mixture
was stirred at RT for 2 h. The ethanol was then removed on a rotary
evaporator and the residue was diluted with water and acidified by
addition of 1 M hydrochloric acid. It was then extracted with ethyl
acetate. The organic extract was dried over anhydrous magnesium
sulphate, filtered and concentrated. This gave 103 mg (63% of
theory, purity 66%) of the title compound which was reacted further
without further purification.
[1184] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 13.41
(broad, 1H), 4.19-4.13 (m, 2H), 4.05 (dd, 1H), 3.77 (dd, 1H),
3.67-3.59 (m, 1H), 3.22 (s, 3H), 2.85-2.73 (m, 2H), 2.76 (s, 3H),
1.06 (d, 3H).
[1185] LC/MS (Method 1, ESIpos): R.sub.t=0.84 min, m/z=395
[M+H].sup.+.
Example 163A
Ethyl 2-[(ethylcarbamoyl)amino]-4-methylthiophene-3-carboxylate
##STR00249##
[1187] 96 ml (1.21 mol) of ethyl isocyanate were added to a
solution of 150 g (0.810 mol) of ethyl
2-amino-4-methylthiophene-3-carboxylate and 113 ml (0.810 mol) of
triethylamine in 1.5 litres of THF. The reaction mixture was heated
under reflux for 2 days. After cooling to RT, the mixture was
poured into about 2 litres of water and extracted four times with a
total of 1.1 litres of dichloromethane. The organic extract was
dried over anhydrous sodium sulphate and then filtered and
concentrated to dryness. After the residue had been dried under
high vacuum, 200 g (89% of theory, purity about 93%) of the title
compound were obtained, this being employed in the next reaction
step without further purification.
[1188] .sup.1H-NMR (300 MHz, DMSO-d.sub.6, .delta./ppm): 10.28 (s,
1H), 7.83 (broad, 1H), 6.39 (s, 1H), 4.27 (quart, 2H), 3.13 (m,
2H), 2.26 (s, 3H), 1.31 (t, 3H), 1.06 (t, 3H).
[1189] LC/MS (Method 1, ESIpos): R.sub.t=0.92 min, m/z=257
[M+H].sup.+.
Example 164A
3-Ethyl-5-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00250##
[1191] 67 g (261 mmol) of the compound from Ex. 163A were dissolved
in 1.6 litres of ethanol and 141 ml (392 mmol) of a 21% strength
solution of sodium ethoxide in ethanol were added. After the
mixture had been stirred at RT for about 16 h, it was poured into
about 500 ml of cold water and adjusted to a pH of about 5 by
addition of glacial acetic acid. The resulting precipitate was
filtered off with suction, washed with water until neutral and
dried. 50 g (91% of theory) of the title compound were
obtained.
[1192] .sup.1H-NMR (300 MHz, DMSO-d.sub.6, .delta./ppm): 6.66 (s,
1H), 3.86 (quart, 2H), 2.35 (s, 3H), 1.11 (t, 3H).
[1193] LC/MS (Method 1, ESIpos): R.sub.t=0.67 min, m/z=211
[M+H].sup.+.
Example 165A
3-Ethyl-5-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-car-
baldehyde
##STR00251##
[1195] 4.5 ml (48.5 mmol) of phosphorus oxychloride were added
carefully to a solution of 850 mg (4.04 mmol) of the compound from
Ex. 164A in 3.1 ml (40.4 mmol) of DMF. After the strongly
exothermic reaction had subsided, the mixture was stirred for a
further 15 min. The reaction mixture was then carefully stirred
into 100 ml of ice-water. After 1 h of stirring, the precipitated
product was filtered off with suction, washed with water until
neutral and dried. 936 mg (97% of theory) of the title compound
were obtained.
[1196] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 12.58
(broad, 1H), 10.06 (s, 1H), 3.86 (quart, 2H), 2.76 (s, 3H), 1.12
(t, 3H).
[1197] LC/MS (Method 1, ESIpos): R.sub.t=0.68 min, m/z=239
[M+H].sup.+.
Example 166A
3-Ethyl-5-methyl-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3-
H)-dione
##STR00252##
[1199] 2.0 g (9.51 mmol) of the compound from Ex. 164A and 3.29 g
(23.8 mmol) of potassium carbonate in 50 ml of anhydrous DMF were
stirred at RT for 15 min, and 3.3 ml (28.5 mmol) of
1,1,1-trifluoro-3-iodopropane were then added. Since, after
stirring overnight at RT, conversion was incomplete, a further 1.31
g (9.51 mmol) of potassium carbonate and 1.1 ml (9.51 mmol) of
1,1,1-trifluoro-3-iodopropane were added and the mixture was
stirred at 60.degree. C. for 2 h. After cooling to RT, the mixture
was diluted with ethyl acetate and washed successively twice with
water and once with saturated sodium chloride solution. After
drying over anhydrous magnesium sulphate, the mixture was filtered
and the filtrate was evaporated to dryness. The crude product was
purified by chromatography on a silica gel cartridge (Biotage, 340
g of silica gel, mobile phase: cyclohexane/ethyl acetate
24:1.fwdarw.10:1). Concentration and drying of the product
fractions gave 2.06 g (70% of theory) of the title compound.
[1200] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 6.88 (s,
1H), 4.12 (t, 2H), 3.91 (quart, 2H), 2.84-2.71 (m, 2H), 2.39 (s,
3H), 1.12 (t, 3H).
[1201] LC/MS (Method 1, ESIpos): R.sub.t=1.02 min, m/z=307
[M+H].sup.+.
Example 167A
3-Ethyl-5-methyl-2,4-dioxo-1-(3,3,3-trifluoropropyl)-1,2,3,4-tetrahydrothi-
eno[2,3-d]pyrimidine-6-carbaldehyde
##STR00253##
[1202] Method A:
[1203] 5.0 g (21.0 mmol) of the compound from Ex. 165A and 7.25 g
(52.5 mmol) of potassium carbonate in a mixture of 95 ml of
acetonitrile and 15 ml of DMF were stirred at RT for 15 min, and
14.1 g (63.0 mmol) of 1,1,1-trifluoro-3-iodopropane were then
added. The reaction mixture was stirred at a temperature of
78.degree. C. for about 16 h. After cooling to RT, the mixture was
diluted with 500 ml of ethyl acetate and, in succession, washed
twice with in each case 100 ml of water and once with 50 ml of
saturated sodium chloride solution. After drying over anhydrous
sodium sulphate, the mixture was filtered and the filtrate was
evaporated to dryness. The crude product was purified by
chromatography (80 g of silica gel, mobile phase: heptane/ethyl
acetate 100:0.fwdarw.60:40). This gave, after concentration of the
product fractions and drying of the residue, 2.99 g (42% of theory)
of the title compound.
Method B:
[1204] 7.8 ml (83.2 mmol) of phosphorus oxychloride were added
carefully to a solution of 5.10 g (16.6 mmol) of the compound from
Ex. 166A in 25.6 ml (333 mmol) of DMF. After the strongly
exothermic reaction had almost subsided, the mixture was stirred
for a further 30 min at 100.degree. C. After cooling to RT, the
reaction mixture was carefully stirred into 100 ml of ice-water.
After 1 h of stirring, the precipitated product was filtered off
with suction, washed with water until neutral and dried. This gave
5.08 g (85% of theory, 94% pure) of the title compound.
[1205] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 10.11 (s,
1H), 4.18 (t, 2H), 3.91 (quart, 2H), 2.86-2.74 (m, 2H), 2.80 (s,
3H), 1.14 (t, 3H).
[1206] LC/MS (Method 1, ESIpos): R.sub.t=0.98 min, m/z=335
[M+H].sup.+.
WORKING EXAMPLES
Example 1
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-5-methyl-3-(2-phenylethyl)-1-(3,3,3--
trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00254##
[1208] Preparation of the Acid Chloride:
[1209] At RT, first 61 .mu.l (0.70 mmol) of oxalyl chloride and
then a small drop of DMF were added to a solution of 60 mg (0.140
mmol) of the compound from Ex. 43A in 2 ml of dichloromethane.
After the reaction mixture had been stirred at RT for 2 h, it was
evaporated to dryness on a rotary evaporator. The residue that
remained was dried under high vacuum and then reacted further in
the next partial step.
[1210] Preparation of the Amide:
[1211] The acid chloride obtained above was dissolved in 2 ml of
anhydrous THF, and this solution was added dropwise to a solution
of 17 mg (0.170 mmol) of 4-hydroxypiperidine and 49 .mu.l (0.280
mmol) of N,N-diisopropylethylamine in 2 ml of anhydrous THF. A few
drops of dichloromethane were then added, and the reaction mixture
was stirred at RT for 1 h. After the mixture had been evaporated to
dryness on a rotary evaporator, the crude product was purified by
preparative HPLC (Method 5). This gave, after combination of the
product fractions, evaporation and drying of the residue under high
vacuum, 69 mg (96% of theory) of the title compound.
[1212] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.32-7.21
(m, 5H, partially obscured by the CHCl.sub.3 signal), 4.22 (t, 2H),
4.14 (t, 2H), 4.03 (m, 1H), 3.98-3.90 (br. m, 2H), 3.45-3.37 (m,
2H), 2.94 (t, 2H), 2.64-2.52 (m, 2H), 2.51 (s, 3H), 1.98-1.91 (m,
2H), 1.65-1.55 (m, 2H, partially obscured by the water signal).
[1213] LC/MS (Method 1, ESIpos): R.sub.t=1.04 min, m/z=510
[M+H].sup.+.
Example 2
1-(4,4-Difluorobut-3-en-1-yl)-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-meth-
yl-3-(2-phenylethyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00255##
[1215] Analogously to the process described in Ex. 1, 70 mg (0.170
mmol) of the compound from Ex. 44A and 20 mg (0.20 mmol) of
4-hydroxypiperidine gave 42 mg (50% of theory) of the title
compound. In deviation to the process described above, the reaction
time in the second partial step (amide formation) was not 1 h but
about 16 h.
[1216] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.33-7.29
(m, 2H), 7.27-7.20 (m, 3H), 4.82 (d, 1H), 4.62 (d of t of d, 1H),
4.07 (dd, 2H), 3.93 (t, 2H), 3.82-3.71 (br. m, 3H), 3.24 (m, 2H),
2.83 (dd, 2H), 2.41-2.33 (m, 2H), 2.38 (s, 3H), 1.80-1.72 (m, 2H),
1.40-1.30 (m, 2H).
[1217] LC/MS (Method 1, ESIpos): R.sub.t=1.04 min, m/z=504
[M+H].sup.+.
Example 3
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-1-(2-methoxyethyl)-5-methyl-3-(2-phe-
nylethyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00256##
[1219] Analogously to the process described in Ex. 1, 100 mg (0.260
mmol) of the compound from Ex. 45A and 31 mg (0.310 mmol) of
4-hydroxypiperidine gave 102 mg (82% of theory) of the title
compound. In deviation to the process described above, the reaction
time in the second partial step (amide formation) was not 1 h but
about 16 h. Here, purification by preparative HPLC was carried out
according to Method 6.
[1220] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.33-7.29
(m, 2H), 7.26-7.20 (m, 3H), 4.82 (d, 1H), 4.09-4.02 (m, 4H),
3.82-3.71 (m, 3H), 3.62 (t, 2H), 3.27-3.19 (m, 2H), 2.25 (s, 3H),
2.84 (m, 2H), 2.37 (s, 3H), 1.80-1.73 (m, 2H), 1.40-1.30 (m,
2H).
[1221] LC/MS (Method 1, ESIpos): R.sub.t=0.93 min, m/z=472
[M+H].sup.+.
Example 4
3-[2-(2-Fluorophenyl)ethyl]-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methyl-
-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00257##
[1223] Analogously to the process described in Ex. 1, 95 mg (0.210
mmol) of the compound from Ex. 46A and 29 mg (0.287 mmol) of
4-hydroxypiperidine gave 112 mg (99% of theory) of the title
compound. In deviation to the process described above, the reaction
time in the second partial step (amide formation) was not 1 h but
about 16 h.
[1224] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.30-7.24
(m, 2H), 7.17-7.10 (m, 2H), 4.82 (d, 1H), 4.13-4.06 (m, 4H),
3.82-3.71 (m, 3H), 3.24 (m, 2H), 2.90 (t, 2H), 2.78-2.66 (m, 2H),
2.36 (s, 3H), 1.80-1.72 (m, 2H), 1.40-1.31 (m, 2H).
[1225] LC/MS (Method 1, ESIpos): R.sub.t=1.03 min, m/z=528
[M+H].sup.+.
Example 5
1-(4,4-Difluorobut-3-en-1-yl)-3-[2-(2-fluorophenyl)ethyl]-6-[(4-hydroxypip-
eridin-1-yl)carbonyl]-5-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00258##
[1227] Analogously to the process described in Ex. 1, 75 mg (0.170
mmol) of the compound from Ex. 47A and 41 mg (0.405 mmol) of
4-hydroxypiperidine gave 88 mg (99% of theory) of the title
compound. In deviation to the process described above, the reaction
time in the first partial step (acid chloride formation) was 3 h
and in the second partial step (amide formation) was about 16
h.
[1228] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.30-7.24
(m, 2H), 7.16-7.10 (m, 2H), 4.81 (d, 1H), 4.60 (d of t of d, 1H),
4.10 (m, 2H), 3.91 (m, 2H), 3.81-3.71 (m, 3H), 3.23 (m, 2H), 2.90
(m, 2H), 2.36 (s, 3H), 1.80-1.72 (m, 2H), 1.40-1.30 (m, 2H).
[1229] LC/MS (Method 1, ESIpos): R.sub.t=1.04 min, m/z=522
[M+H]+.
Example 6
3-[2-(2-Chlorophenyl)ethyl]-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methyl-
-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00259##
[1231] Preparation of the Acid Chloride:
[1232] At RT, first 71 .mu.l (0.810 mmol) of oxalyl chloride and
then a small drop of DMF were added to a solution of 75 mg (0.160
mmol) of the compound from Ex. 48A in 2.5 ml of dichloromethane.
After the reaction mixture had been stirred at RT for 2 h, it was
evaporated to dryness on a rotary evaporator. The residue that
remained was dried under high vacuum and then reacted further in
the next partial step.
[1233] Preparation of the Amide:
[1234] The acid chloride obtained above was dissolved in 2 ml of
dichloromethane, and this solution was added dropwise to a solution
of 25 mg (0.240 mmol) of 4-hydroxypiperidine and 57 .mu.l (0.330
mmol) of N,N-diisopropylethylamine in 2.5 ml of anhydrous THF. The
reaction mixture was then stirred at RT for about 16 h. After the
mixture had been evaporated to dryness on a rotary evaporator, the
crude product was purified by preparative HPLC (Method 5). This
gave, after combination of the product fractions, evaporation and
drying of the residue under high vacuum, 83 mg (94% of theory) of
the title compound.
[1235] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.43-7.40
(m, 1H), 7.31-7.24 (m, 3H), 4.82 (d, 1H), 4.15-4.07 (m, 4H),
3.82-3.71 (m, 3H), 3.24 (m, 2H), 2.99 (t, 2H), 2.78-2.66 (m, 2H),
2.36 (s, 3H), 1.80-1.73 (m, 2H), 1.40-1.31 (m, 2H).
[1236] LC/MS (Method 1, ESIpos): R.sub.t=1.08 min, m/z=544/546
[M+H].sup.+.
Example 7
3-[2-(2-Chlorophenyl)ethyl]-1-(4,4-difluorobut-3-en-1-yl)-6-[(4-hydroxypip-
eridin-1-yl)carbonyl]-5-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00260##
[1238] Analogously to the process described in Ex. 6, 75 mg (0.160
mmol) of the compound from Ex. 49A and 25 mg (0.250 mmol) of
4-hydroxypiperidine gave 85 mg (95% of theory) of the title
compound.
[1239] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.43-7.40
(m, 1H), 7.32-7.23 (m, 3H), 4.82 (d, 1H), 4.60 (d of t of d, 1H),
4.13 (m, 2H), 3.91 (t, 2H), 3.81-3.71 (m, 3H), 3.23 (m, 2H), 2.99
(t, 2H), 2.38-2.32 (m, 2H), 2.35 (s, 3H), 1.80-1.73 (m, 2H),
1.40-1.30 (m, 2H).
[1240] LC/MS (Method 1, ESIpos): R.sub.t=1.10 min, m/z=538/540
[M+H].sup.+.
Example 8
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-5-methyl-3-[2-(2-methylphenyl)ethyl]-
-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00261##
[1242] 59 mg (0.104 mmol) of the compound from Ex. 63A were
dissolved in 3 ml of ethanol, and 210 .mu.l (0.210 mmol) of a 1 M
solution of lithium hydroxide in water were added. After 1 h of
stirring at RT, the reaction mixture was separated directly by
preparative HPLC into its components (Method 5). The product
fractions were combined and concentrated, and the residue was dried
under high vacuum. 51 mg (93% of theory) of the title compound were
obtained.
[1243] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.22-7.10
(m, 4H), 4.19-4.12 (m, 4H), 4.03 (m, 1H), 3.98-3.90 (m, 2H),
3.44-3.37 (m, 2H), 2.94 (m, 2H), 2.65-2.54 (m, 2H), 2.52 (s, 3H),
2.47 (s, 3H), 1.98-1.90 (m, 2H), 1.65-1.57 (m, 2H, partially
obscured by the water signal).
[1244] LC/MS (Method 1, ESIpos): R.sub.t=1.06 min, m/z=524
[M+H].sup.+.
Example 9
3-[2-(3-Fluorophenyl)ethyl]-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methyl-
-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00262##
[1246] Analogously to the process described in Ex. 8, 53 mg (0.093
mmol) of the compound from Ex. 64 gave 37 mg (75% of theory) of the
title compound. In deviation to the process described above, here
the reaction time was 3 h.
[1247] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.07 (d,
1H), 7.00 (d, 1H), 6.92 (dt, 1H), 4.23-4.13 (m, 4H), 4.04 (m, 1H),
3.98-3.90 (m, 2H), 3.45-3.37 (m, 2H), 2.94 (m, 2H), 2.66-2.55 (m,
2H), 2.51 (s, 3H), 1.98-1.91 (m, 2H), 1.66-1.57 (m, 2H, partially
obscured by the water signal).
[1248] LC/MS (Method 1, ESIpos): R.sub.t=1.01 min, m/z=528
[M+H].sup.+.
Example 10
3-[2-(3-Chlorophenyl)ethyl]-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methyl-
-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00263##
[1250] Analogously to the process described in Ex. 8, 60 mg (0.10
mmol) of the compound from Ex. 65A gave 45 mg (77% of theory,
purity 95%) of the title compound. In deviation to the process
described above, here the reaction time was 3 h.
[1251] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.29-7.17
(m, 4H, partially obscured by the CHCl.sub.3 signal), 4.22-4.13 (m,
4H), 4.03 (m, 1H), 3.98-3.89 (m, 2H), 3.45-3.37 (m, 2H), 2.92 (m,
2H), 2.67-2.55 (m, 2H), 2.51 (s, 3H), 1.98-1.90 (m, 2H), 1.66-1.56
(m, 2H, partially obscured by the water signal).
[1252] LC/MS (Method 1, ESIpos): R.sub.t=1.06 min, m/z=544/546
[M+H]+.
Example 11
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-5-methyl-3-[2-(3-methylphenyl)ethyl]-
-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00264##
[1254] Analogously to the process described in Ex. 8, 55 mg (0.10
mmol) of the compound from Ex. 66A gave 44 mg (86% of theory) of
the title compound.
[1255] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.20 (t,
1H), 7.14 (s, 1H), 7.10 (d, 1H), 7.04 (d, 1H), 4.21-4.14 (m, 4H),
4.03 (m, 1H), 3.98-3.90 (m, 2H), 3.44-3.37 (m, 2H), 2.89 (m, 2H),
2.66-2.55 (m, 2H), 2.52 (s, 3H), 2.33 (s, 3H), 1.98-1.90 (m, 2H),
1.66-1.56 (m, 2H, partially obscured by the water signal).
[1256] LC/MS (Method 1, ESIpos): R.sub.t=1.09 min, m/z=524
[M+H]+.
Example 12
3-[2-(4-Fluorophenyl)ethyl]-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methyl-
-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00265##
[1258] Analogously to the process described in Ex. 8, 35 mg (0.061
mmol) of the compound from Ex. 67A gave 30 mg (93% of theory) of
the title compound. In deviation to the process described above,
here the reaction time was 2 h.
[1259] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.27-7.23
(m, 2H, partially obscured by the CHCl.sub.3 signal), 6.99 (t, 2H),
4.20-4.13 (m, 4H), 4.03 (m, 1H), 3.97-3.90 (m, 2H), 3.45-3.37 (m,
2H), 2.91 (m, 2H), 2.66-2.54 (m, 2H), 2.51 (s, 3H), 1.98-1.90 (m,
2H), 1.66-1.55 (m, 2H, partially obscured by the water signal).
[1260] LC/MS (Method 1, ESIpos): R.sub.t=1.02 min, m/z=528
[M+H].sup.+.
Example 13
3-[2-(4-Chlorophenyl)ethyl]-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methyl-
-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00266##
[1262] Analogously to the process described in Ex. 8, 74 mg (0.126
mmol) of the compound from Ex. 68A gave 60 mg (87% of theory) of
the title compound. In deviation to the process described above,
here the reaction time was 2 h.
[1263] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.27 (d,
2H), 7.22 (d, 2H), 4.20-4.13 (m, 4H), 4.04 (m, 1H), 3.97-3.90 (m,
2H), 3.45-3.37 (m, 2H), 2.91 (m, 2H), 2.65-2.53 (m, 2H), 2.51 (s,
3H), 1.98-1.90 (m, 2H), 1.66-1.56 (m, 2H, partially obscured by the
water signal).
[1264] LC/MS (Method 1, ESIpos): R.sub.t=1.10 min, m/z=544/546
[M+H]+.
Example 14
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-3-[2-(4-methoxyphenyl)ethyl]-5-methy-
l-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00267##
[1266] Analogously to the process described in Ex. 8, 66 mg (0.11
mmol) of the compound from Ex. 69A gave 54 mg (87% of theory) of
the title compound. In deviation to the process described above,
here the reaction time was 2 h.
[1267] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.20 (d,
2H), 6.84 (d, 2H), 4.19-4.12 (m, 4H), 4.03 (m, 1H), 3.98-3.90 (m,
2H), 3.79 (s, 3H), 3.44-3.37 (m, 2H), 2.88 (m, 2H), 2.64-2.54 (m,
2H), 2.51 (s, 3H), 1.98-1.91 (m, 2H), 1.65-1.55 (m, 2H, partially
obscured by the water signal).
[1268] LC/MS (Method 1, ESIpos): R.sub.t=0.98 min, m/z=540
[M+H]+.
Example 15
3-[2-(2-Chlorophenyl)ethyl]-1-(4,4-difluorobut-3-en-1-yl)-6-[(4-hydroxypip-
eridin-1-yl)carbonyl]-5-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00268##
[1270] Analogously to the process described in Ex. 6, 75 mg (0.160
mmol) of the compound from Ex. 50A and 25 mg (0.250 mmol) of
4-hydroxypiperidine gave 62 mg (70% of theory, purity 93%) of the
title compound. In addition to the process described above, here
the product obtained after preparative HPLC purification was
dissolved in a little methanol, and the solution was passed through
a bicarbonate cartridge (from Polymerlabs, Stratospheres SPE,
PL-HCO.sub.3 MP SPE, capacity 0.9 mmol) to yield, after subsequent
evaporation and drying of the residue under high vacuum, the free
base.
[1271] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.44-8.41
(m, 2H), 7.66 (d, 1H), 7.32 (dd, 1H), 4.82 (d, 1H), 4.13-4.08 (m,
4H), 3.82-3.71 (m, 3H), 3.24 (m, 2H), 2.88 (t, 2H), 2.81-2.68 (m,
2H), 2.36 (s, 3H), 1.80-1.72 (m, 2H), 1.41-1.31 (m, 2H).
[1272] LC/MS (Method 1, ESIpos): R.sub.t=0.60 min, m/z=511
[M+H].sup.+.
Example 16
1-(4,4-Difluorobut-3-en-1-yl)-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-meth-
yl-3-[2-(pyridin-3-yl)ethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00269##
[1274] Analogously to the process described in Ex. 6, 75 mg (0.160
mmol) of the compound from Ex. 51A and 25 mg (0.250 mmol) of
4-hydroxypiperidine gave 50 mg (61% of theory) of the title
compound. In addition to the process described above, here the
product obtained after preparative HPLC purification was dissolved
in a little methanol, and the solution was passed through a
bicarbonate cartridge (from Polymerlabs, Stratospheres SPE,
PL-HCO.sub.3 MP SPE, capacity 0.9 mmol) to yield, after subsequent
evaporation and drying of the residue under high vacuum, the free
base.
[1275] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.44-8.41
(m, 2H), 7.66 (d, 1H), 7.32 (dd, 1H), 4.82 (broad, 1H), 4.61 (d of
t of d, 1H), 4.10 (m, 2H), 3.92 (t, 2H), 3.81-3.72 (m, 3H), 3.24
(m, 2H), 2.88 (t, 2H), 2.39-2.33 (m, 2H), 2.36 (s, 3H), 1.80-1.72
(m, 2H), 1.40-1.31 (m, 2H).
[1276] LC/MS (Method 1, ESIpos): R.sub.t=0.63 min, m/z=505
[M+H].sup.+.
Example 17
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-5-methyl-3-[2-(pyrazin-2-yl)ethyl]-1-
-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00270##
[1278] Analogously to the process described in Ex. 8, 90 mg (0.08
mmol, purity about 50%) of the compound from Ex. 70A gave 35 mg
(85% of theory) of the title compound. In addition to the process
described above, here the product obtained after preparative HPLC
purification was dissolved in a little methanol, and the solution
was passed through a bicarbonate cartridge (from Polymerlabs,
Stratospheres SPE, PL-HCO.sub.3 MP SPE, capacity 0.9 mmol) to
yield, after subsequent evaporation and drying of the residue under
high vacuum, the free base.
[1279] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.50 (d,
1H), 8.49 (s, 1H), 8.43 (d, 1H), 4.42 (t, 2H), 4.13 (t, 2H), 4.04
(m, 1H), 3.98-3.90 (m, 2H), 3.44-3.37 (m, 2H), 3.18 (t, 2H),
2.65-2.53 (m, 2H), 2.48 (s, 3H), 1.98-1.90 (m, 2H), 1.66-1.56 (m,
2H, obscured by the water signal).
[1280] LC/MS (Method 1, ESIpos): R.sub.t=0.77 min, m/z=512
[M+H]+.
Example 18
3-Ethyl-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methyl-1-(3,3,3-trifluorop-
ropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00271##
[1282] Preparation of the Acid Chloride:
[1283] At RT, first 2.5 ml (28.6 mmol) of oxalyl chloride and then
a drop of DMF were added to a solution of 2.0 g (5.71 mmol) of the
compound from Ex. 52A in 60 ml of dichloromethane. After the
reaction mixture had been stirred at RT for 2 h, it was evaporated
to dryness on a rotary evaporator. The residue that remained was
dried under high vacuum and then reacted further in the next
partial step.
[1284] Preparation of the Amide:
[1285] The acid chloride obtained above was dissolved in 30 ml of
anhydrous THF, and this solution was added dropwise to a solution
of 693 mg (6.85 mmol) of 4-hydroxypiperidine and 2 ml (11.4 mmol)
of N,N-diisopropylethylamine in 30 ml of anhydrous THF. The
reaction mixture was then stirred at RT for about 16 h. After the
mixture had been evaporated to dryness on a rotary evaporator,
about 100 ml of water were added to the residue and the mixture was
extracted three times with in each case about 150 ml of ethyl
acetate. The combined organic extract was washed with saturated
aqueous sodium chloride solution, dried over anhydrous magnesium
sulphate, filtered and evaporated. At RT, the residue obtained in
this manner was stirred in a mixture of 30 ml of pentane and 0.5 ml
of diethyl ether for 2 h. The mixture was then filtered and the
solid was washed with a little pentane and dried under a high
vacuum. This gave 2.32 g (91% of theory) of the title compound.
[1286] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.81 (d,
1H), 4.13 (t, 2H), 3.91 (quart, 2H), 3.82-3.71 (m, 3H), 3.24 (m,
2H), 2.85-2.73 (m, 2H), 2.38 (s, 3H), 1.80-1.72 (m, 2H), 1.39-1.30
(m, 2H), 1.13 (t, 3H).
[1287] LC/MS (Method 1, ESIpos): R.sub.t=0.84 min, m/z=434
[M+H].sup.+.
Example 19
1-(4,4-Difluorobut-3-en-1-yl)-3-ethyl-6-[(4-hydroxypiperidin-1-yl)carbonyl-
]-5-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00272##
[1289] Analogously to the process described in Ex. 1, 70 mg (0.20
mmol) of the compound from Ex. 53A and 25 mg (0.240 mmol) of
4-hydroxypiperidine gave 70 mg (80% of theory) of the title
compound. In deviation to the process described above, the reaction
time in the first partial step (acid chloride formation) was only 1
h and in the second partial step (amide formation) was not 1 h but
about 16 h.
[1290] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.81 (d,
1H), 4.63 (d of t of d, 1H), 3.96-3.88 (m, 4H), 3.81-3.71 (m, 3H),
3.23 (m, 2H), 2.42-2.36 (m, 2H), 2.38 (s, 3H), 1.79-1.72 (m, 2H),
1.39-1.30 (m, 2H), 1.12 (t, 3H).
[1291] LC/MS (Method 1, ESIpos): R.sub.t=0.84 min, m/z=428
[M+H].sup.+.
Example 20
3-Ethyl-6-[(4-hydroxypiperidin-1-yl)carbonyl]-1-(2-methoxyethyl)-5-methylt-
hieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00273##
[1293] Analogously to the process described in Ex. 1, 75 mg (0.220
mmol) of the compound from Ex. 54A and 27 mg (0.270 mmol) of
4-hydroxypiperidine gave 57 mg (64% of theory) of the title
compound. In deviation to the process described above, the reaction
time in the first partial step (acid chloride formation) was only 1
h.
[1294] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.81 (d,
1H), 4.05 (t, 2H), 3.91 (quart, 2H), 3.82-3.70 (m, 3H), 3.65 (t,
2H), 3.26-3.19 (m, 2H), 3.25 (s, 3H), 2.37 (s, 3H), 1.79-1.72 (m,
2H), 1.39-1.30 (m, 2H), 1.12 (t, 3H).
[1295] LC/MS (Method 1, ESIpos): R.sub.t=0.72 min, m/z=396
[M+H].sup.+.
Example 21
3-Ethyl-6-[(4-hydroxy-4-methylpiperidin-1-yl)carbonyl]-5-methyl-1-(3,3,3-t-
rifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00274##
[1297] Preparation of the Acid Chloride:
[1298] At RT, first 125 .mu.l (1.43 mmol) of oxalyl chloride and
then a drop of DMF were added to a solution of 100 mg (0.290 mmol)
of the compound from Ex. 52A in 3 ml of dichloromethane. After the
reaction mixture had been stirred at RT for 1 h, it was evaporated
to dryness on a rotary evaporator. The residue that remained was
dried under high vacuum and then reacted further in the next
partial step.
[1299] Preparation of the Amide:
[1300] The acid chloride obtained above was dissolved in 3 ml of
anhydrous THF, and 40 mg (0.340 mmol) of 4-methylpiperidin-4-ol
[commercially available; lit. e.g.: J. M. McManus et al., J. Med
Chem. 1965, 8 (6), 766-776] and 100 .mu.l (0.570 mmol) of
N,N-diisopropylethylamine were added. The reaction mixture was then
stirred at RT for about 16 h. After the mixture had been evaporated
to dryness on a rotary evaporator, the crude product was purified
by preparative HPLC (Method 5). This gave, after combination of the
product fractions, evaporation and drying of the residue under high
vacuum, 113 mg (88% of theory) of the title compound.
[1301] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.47 (s,
1H), 4.12 (t, 2H), 3.91 (quart, 2H), 3.72 (broad, 2H), 3.36 (broad,
2H), 2.85-2.73 (m, 2H), 2.38 (s, 3H), 1.53-1.40 (m, 4H), 1.15 (s,
3H), 1.13 (t, 3H).
[1302] LC/MS (Method 1, ESIpos): R.sub.t=0.90 min, m/z=448
[M+H]+.
Example 22
3-Ethyl-6-{[4-hydroxy-4-(trifluoromethyl)piperidin-1-yl]carbonyl}-5-methyl-
-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00275##
[1304] Analogously to the process described in Ex. 21, 100 mg
(0.290 mmol) of the compound from Ex. 52A and 70 mg (0.340 mmol) of
4-trifluoromethylpiperidin-4-ol [commercially available; lit. e.g.:
WO 2005/103002-A2, intermediate product 1] gave 135 mg (94% of
theory) of the title compound.
[1305] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 6.19 (s,
1H), 4.13 (t, 2H), 4.02 (broad, 2H), 3.91 (quart, 2H), 3.22 (br. t,
2H), 2.86-2.73 (m, 2H), 2.40 (s, 3H), 1.76-1.61 (m, 4H), 1.12 (t,
3H).
[1306] LC/MS (Method 1, ESIpos): R.sub.t=0.97 min, m/z=502
[M+H]+.
Example 23
3-Ethyl-6-[(3-hydroxy-8-azabicyclo
[3.2.1]oct-8-yl)carbonyl]-5-methyl-1-(3,3,3-trifluoropropyl)thieno[2,3-d]-
pyrimidine-2,4(1H,3H)-dione
##STR00276##
[1308] In succession, solutions of 35 mg (0.10 mmol) of the
compound from Ex. 52A and 45.6 mg (0.120 mmol) of HATU in each case
300 .mu.l of DMF and 35 .mu.l (0.20 mmol) of
N,N-diisopropylethylamine were added to 12.7 mg (0.10 mmol) of
8-azabicyclo[3.2.1]octan-3-ol [G. B. Kok et al., J. Org. Chem.
2010, 75 (14), 4806-4811]. After a reaction time of about 16 h at
RT, the reaction mixture was separated directly by preparative HPLC
into its components (Method 8). The product fractions were combined
and concentrated, and the residue was dried under high vacuum. This
gave 29 mg (52% of theory, 80% pure) of the title compound.
[1309] LC/MS (Method 3, ESIpos): R.sub.t=0.98 min, m/z=460
[M+H].sup.+.
Example 24
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-3-(2-phenylethyl)-5-(trifluoromethyl-
)-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00277##
[1311] Preparation of the Acid Chloride:
[1312] At RT, first 67 .mu.l (0.760 mmol) of oxalyl chloride and
then a small drop of DMF were added to a solution of 75 mg (0.150
mmol) of the compound from Ex. 55A in 2.2 ml of dichloromethane.
After the reaction mixture had been stirred at RT for 2 h, it was
evaporated to dryness on a rotary evaporator. The residue that
remained was dried under high vacuum and then reacted further in
the next partial step.
[1313] Preparation of the Amide:
[1314] The acid chloride obtained above was dissolved in 2 ml of
anhydrous THF, and this solution was added dropwise to a solution
of 20 mg (0.20 mmol) of 4-hydroxypiperidine and 53 .mu.l (0.310
mmol) of N,N-diisopropylethylamine in 1 ml of dichloromethane. The
reaction mixture was then stirred at RT for 1 h. The mixture was
evaporated to dryness on a rotary evaporator, and the residue was
purified by preparative HPLC (Method 5). This gave, after
combination of the product fractions, evaporation and drying of the
residue under high vacuum, 72 mg (84% of theory) of the title
compound.
[1315] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.34-7.29
(m, 2H), 7.27-7.21 (m, 3H), 4.86 (d, 1H), 4.16 (m, 2H), 4.07 (m,
2H), 3.97 (broad, 1H), 3.76 (broad, 1H), 3.45 (broad, 1H),
3.35-3.21 (m, 1H), 3.16 (m, 1H), 2.87-2.73 (m, 4H), 1.84-1.65
(broad, 2H), 1.45-1.28 (broad, 2H).
[1316] LC/MS (Method 1, ESIpos): R.sub.t=1.07 min, m/z=564
[M+H].sup.+.
Example 25
3-Ethyl-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-(trifluoromethyl)-1-(3,3,3-
-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00278##
[1318] Analogously to the process described in Ex. 24, 55 mg (0.140
mmol) of the compound from Ex. 56A and 18 mg (0.180 mmol) of
4-hydroxypiperidine gave 64 mg (97% of theory) of the title
compound. In deviation to the process described above, the reaction
time in the second partial step (amide formation) was about 16
h.
[1319] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.85 (d,
1H), 4.16 (t, 2H), 4.02-3.88 (m, 3H), 3.76 (broad, 1H), 3.45 (m,
1H), 3.32-3.22 (br. m, 1H), 3.15 (m, 1H), 2.88-2.76 (m, 2H),
1.83-1.64 (broad, 2H), 1.43-1.25 (broad, 2H), 1.13 (t, 3H).
[1320] LC/MS (Method 1, ESIpos): R.sub.t=0.87 min, m/z=488
[M+H]+.
Example 26
5-Methyl-6-[(3-oxopiperazin-1-yl)carbonyl]-3-(2-phenylethyl)-1-(3,3,3-trif-
luoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00279##
[1322] Preparation of the Acid Chloride:
[1323] At RT, first 77 .mu.l (0.880 mmol) of oxalyl chloride and
then a small drop of DMF were added to a solution of 75 mg (0.180
mmol) of the compound from Ex. 43A in 2 ml of dichloromethane.
After the reaction mixture had been stirred at RT for 1 h, it was
evaporated to dryness on a rotary evaporator. The residue that
remained was dried under high vacuum and then reacted further in
the next partial step.
[1324] Preparation of the Amide:
[1325] The acid chloride obtained above was dissolved in 2 ml of
anhydrous THF, and 21 mg (0.210 mmol) of piperazin-2-one and 61
.mu.l (0.350 mmol) of N,N-diisopropylethylamine were added. The
reaction mixture was then stirred at RT for about 16 h. After the
mixture had been evaporated to dryness on a rotary evaporator, the
crude product was purified by preparative HPLC (Method 5). This
gave, after combination of the product fractions, evaporation and
drying of the residue under high vacuum, 85 mg (95% of theory) of
the title compound.
[1326] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.16 (s,
1H), 7.33-7.28 (m, 2H), 7.26-7.21 (m, 3H), 4.13 (t, 2H), 4.07 (m,
2H), 4.05 (s, 2H), 3.69 (m, 2H), 3.25 (m, 2H), 2.84 (m, 2H),
2.82-2.71 (m, 2H), 2.41 (s, 3H).
[1327] LC/MS (Method 1, ESIpos): R.sub.t=0.97 min, m/z=509
[M+H].sup.+.
Example 27
1-(4,4-Difluorobut-3-en-1-yl)-5-methyl-6-[(3-oxopiperazin-1-yl)carbonyl]-3-
-(2-phenylethyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00280##
[1329] Analogously to the process described in Ex. 26, 75 mg (0.180
mmol) of the compound from Ex. 44A and 21 mg (0.210 mmol) of
piperazin-2-one gave 88 mg (93% of theory) of the title
compound.
[1330] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.16 (s,
1H), 7.34-7.29 (m, 2H), 7.26-7.20 (m, 3H), 4.62 (d of t of d, 1H),
4.07 (m, 2H), 4.04 (s, 2H), 3.94 (t, 2H), 3.68 (m, 2H), 3.25 (m,
2H), 2.83 (m, 2H), 2.40 (s, 3H), 2.38 (m, 2H).
[1331] LC/MS (Method 1, ESIpos): R.sub.t=1.00 min, m/z=503
[M+H].sup.+.
Example 28
1-(2-Methoxyethyl)-5-methyl-6-[(3-oxopiperazin-1-yl)carbonyl]-3-(2-phenyle-
thyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00281##
[1333] Analogously to the process described in Ex. 26, 75 mg (0.190
mmol) of the compound from Ex. 45A and 23 mg (0.230 mmol) of
piperazin-2-one gave 82 mg (90% of theory) of the title
compound.
[1334] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.15 (s,
1H), 7.34-7.29 (m, 2H), 7.26-7.20 (m, 3H), 4.09-4.03 (m, 4H), 4.04
(s, 2H), 3.68 (m, 2H), 3.62 (t, 2H), 3.26-3.22 (m, 2H), 3.25 (s,
3H), 2.84 (m, 2H), 2.39 (s, 3H).
[1335] LC/MS (Method 1, ESIpos): R.sub.t=0.86 min, m/z=471
[M+H].sup.+.
Example 29
3-[2-(2-Fluorophenyl)ethyl]-5-methyl-6-[(3-oxopiperazin-1-yl)carbonyl]-1-(-
3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00282##
[1337] Preparation of the Acid Chloride:
[1338] At RT, first 74 .mu.l (0.840 mmol) of oxalyl chloride and
then a small drop of DMF were added to a solution of 75 mg (0.170
mmol) of the compound from Ex. 46A in 1.9 ml of dichloromethane.
After the reaction mixture had been stirred at RT for 1 h, it was
evaporated to dryness on a rotary evaporator. The residue that
remained was dried under high vacuum and then reacted further in
the next partial step.
[1339] Preparation of the Amide:
[1340] The acid chloride obtained above was dissolved in 1.9 ml of
anhydrous THF, and 20 mg (0.20 mmol) of piperazin-2-one and 59
.mu.l (0.340 mmol) of N,N-diisopropylethylamine were added. The
reaction mixture was then stirred at RT for about 16 h. After the
mixture had been evaporated to dryness on a rotary evaporator, the
crude product was purified by preparative HPLC (Method 5). This
gave, after combination of the product fractions, evaporation and
drying of the residue under high vacuum, 65 mg (73% of theory) of
the title compound.
[1341] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.16 (s,
1H), 7.29-7.24 (m, 2H), 7.17-7.10 (m, 2H), 4.13-4.07 (m, 4H), 4.04
(s, 2H), 3.68 (m, 2H), 3.25 (m, 2H), 2.91 (t, 2H), 2.78-2.66 (m,
2H), 2.38 (s, 3H).
[1342] LC/MS (Method 1, ESIpos): R.sub.t=0.98 min, m/z=527
[M+H].sup.+.
Example 30
1-(4,4-Difluorobut-3-en-1-yl)-3-[2-(2-fluorophenyl)ethyl]-5-methyl-6-[(3-o-
xopiperazin-1-yl)carbonyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00283##
[1344] Analogously to the process described in Ex. 29, 75 mg (0.170
mmol) of the compound from Ex. 47A and 21 mg (0.210 mmol) of
piperazin-2-one gave 60 mg (64% of theory, purity 95%) of the title
compound.
[1345] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.16 (s,
1H), 7.29-7.24 (m, 2H), 7.16-7.10 (m, 2H), 4.60 (d of t of d, 1H),
4.10 (t, 2H), 4.04 (s, 2H), 3.92 (t, 2H), 3.68 (m, 2H), 3.24 (m,
2H), 2.90 (t, 2H), 2.39-2.32 (m, 2H), 2.37 (s, 3H).
[1346] LC/MS (Method 1, ESIpos): R.sub.t=0.98 min, m/z=521
[M+H].sup.+.
Example 31
3-[2-(2-Chlorophenyl)ethyl]-5-methyl-6-[(3-oxopiperazin-1-yl)carbonyl]-1-(-
3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00284##
[1348] Preparation of the Acid Chloride:
[1349] At RT, first 71 .mu.l (0.810 mmol) of oxalyl chloride and
then a small drop of DMF were added to a solution of 75 mg (0.160
mmol) of the compound from Ex. 48A in 2.5 ml of dichloromethane.
After the reaction mixture had been stirred at RT for 2 h, it was
evaporated to dryness on a rotary evaporator. The residue that
remained was dried under high vacuum and then reacted further in
the next partial step.
[1350] Preparation of the Amide:
[1351] The acid chloride obtained above was dissolved in 2 ml of
dichloromethane, and this solution was added dropwise to a solution
of 24 mg (0.240 mmol) of piperazin-2-one and 57 .mu.l (0.330 mmol)
of N,N-diisopropylethylamine in 2.5 ml of anhydrous THF. The
reaction mixture was then stirred at RT for about 16 h. After the
mixture had been evaporated to dryness on a rotary evaporator, the
crude product was purified by preparative HPLC (Method 5). This
gave, after combination of the product fractions, evaporation and
drying of the residue under high vacuum, 75 mg (84% of theory) of
the title compound.
[1352] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.16 (s,
1H), 7.43-7.40 (m, 1H), 7.31-7.24 (m, 3H), 4.15-4.08 (m, 4H), 4.04
(s, 2H), 3.68 (m, 2H), 3.25 (m, 2H), 3.00 (t, 2H), 2.78-2.67 (m,
2H), 2.38 (s, 3H).
[1353] LC/MS (Method 1, ESIpos): R.sub.t=1.01 min, m/z=543/545
[M+H].sup.+.
Example 32
3-[2-(2-Chlorophenyl)ethyl]-1-(4,4-difluorobut-3-en-1-yl)-5-methyl-6-[(3-o-
xopiperazin-1-yl)carbonyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00285##
[1355] Analogously to the process described in Ex. 31, 75 mg (0.170
mmol) of the compound from Ex. 49A and 25 mg (0.250 mmol) of
piperazin-2-one gave 71 mg (80% of theory) of the title
compound.
[1356] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.15 (s,
1H), 7.43-7.39 (m, 1H), 7.32-7.23 (m, 3H), 4.60 (d of t of d, 1H),
4.13 (t, 2H), 4.04 (s, 2H), 3.91 (t, 2H), 3.68 (m, 2H), 3.25 (m,
2H), 2.99 (t, 2H), 2.39-2.32 (m, 2H), 2.37 (s, 3H).
[1357] LC/MS (Method 1, ESIpos): R.sub.t=1.03 min, m/z=537/539
[M+H].sup.+.
Example 33
5-Methyl-6-[(3-oxopiperazin-1-yl)carbonyl]-3-[2-(pyridin-3-yl)ethyl]-1-(3,-
3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00286##
[1359] Preparation of the Acid Chloride:
[1360] At RT, first 71 .mu.l (0.810 mmol) of oxalyl chloride and
then a small drop of DMF were added to a solution of 75 mg (0.160
mmol) of the compound from Ex. 50A in 2.5 ml of dichloromethane.
After the reaction mixture had been stirred at RT for 2 h, it was
evaporated to dryness on a rotary evaporator. The residue that
remained was dried under high vacuum and then reacted further in
the next partial step.
[1361] Preparation of the Amide:
[1362] The acid chloride obtained above was dissolved in 4 ml of
dichloromethane, and this solution was added dropwise to a solution
of 24 mg (0.240 mmol) of piperazin-2-one and 84 .mu.l (0.490 mmol)
of N,N-diisopropylethylamine in 2.5 ml of anhydrous THF. The
reaction mixture was then stirred at RT for about 16 h. After the
mixture had been evaporated to dryness on a rotary evaporator, the
crude product was purified by preparative HPLC (Method 5). After
combination and concentration of the product fractions, the residue
was dissolved in a little methanol and the solution was passed over
a bicarbonate cartridge (Polymerlabs, Stratospheres SPE,
PL-HCO.sub.3 MP SPE, capacity 0.9 mmol). Subsequent evaporation and
drying under high vacuum gave 86 mg (100% of theory) of the title
compound as the free base.
[1363] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.44-8.42
(m, 2H), 8.16 (s, 1H), 7.66 (m, 1H), 7.32 (m, 1H), 4.13-4.08 (m,
4H), 4.05 (s, 2H), 3.68 (m, 2H), 3.24 (m, 2H), 2.89 (t, 2H),
2.81-2.69 (m, 2H), 2.38 (s, 3H).
[1364] LC/MS (Method 1, ESIpos): R.sub.t=0.57 min, m/z=510
[M+H].sup.+.
Example 34
1-(4,4-Difluorobut-3-en-1-yl)-5-methyl-6-[(3-oxopiperazin-1-yl)carbonyl]-3-
-[2-(pyridin-3-yl)ethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00287##
[1366] Analogously to the process described in Ex. 33, 75 mg (0.160
mmol) of the compound from Ex. 51A and 25 mg (0.250 mmol) of
piperazin-2-one gave 52 mg (63% of theory) of the title
compound.
[1367] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.44-8.41
(m, 2H), 8.16 (s, 1H), 7.66 (m, 1H), 7.32 (m, 1H), 4.61 (d of t of
d, 1H), 4.11 (t, 2H), 4.04 (s, 2H), 3.92 (t, 2H), 3.68 (m, 2H),
3.24 (m, 2H), 2.88 (t, 2H), 2.40-2.33 (m, 2H), 2.38 (s, 3H).
[1368] LC/MS (Method 1, ESIpos): R.sub.t=0.59 min, m/z=504
[M+H].sup.+.
Example 35
3-Ethyl-5-methyl-6-[(3-oxopiperazin-1-yl)carbonyl]-1-(3,3,3-trifluoropropy-
l)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00288##
[1370] Analogously to the process described in Ex. 26, 100 mg
(0.290 mmol) of the compound from Ex. 52A and 34 mg (0.340 mmol) of
piperazin-2-one gave 49 mg (39% of theory) of the title
compound.
[1371] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.15 (s,
1H), 4.13 (t, 2H), 4.04 (s, 2H), 3.91 (quart, 2H), 3.68 (m, 2H),
3.24 (m, 2H), 2.85-2.73 (m, 2H), 2.40 (s, 3H), 1.13 (t, 3H).
[1372] LC/MS (Method 1, ESIpos): R.sub.t=0.76 min, m/z=433
[M+H].sup.+.
Example 36
1-(4,4-Difluorobut-3-en-1-yl)-3-ethyl-5-methyl-6-[(3-oxopiperazin-1-yl)car-
bonyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00289##
[1374] Analogously to the process described in Ex. 26, 75 mg (0.220
mmol) of the compound from Ex. 53A and 26 mg (0.260 mmol) of
piperazin-2-one gave 73 mg (74% of theory) of the title
compound.
[1375] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.15 (s,
1H), 4.63 (d of t of d, 1H), 4.04 (s, 2H), 3.96-3.88 (m, 4H), 3.68
(m, 2H), 3.23 (m, 2H), 2.43-2.37 (m, 2H), 2.40 (s, 3H), 1.12 (t,
3H).
[1376] LC/MS (Method 1, ESIpos): R.sub.t=0.81 min, m/z=427
[M+H].sup.+.
Example 37
3-Ethyl-1-(2-methoxyethyl)-5-methyl-6-[(3-oxopiperazin-1-yl)carbonyl]thien-
o[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00290##
[1378] Analogously to the process described in Ex. 26, 75 mg (0.240
mmol) of the compound from Ex. 54A and 29 mg (0.290 mmol) of
piperazin-2-one gave 84 mg (88% of theory) of the title
compound.
[1379] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.15 (s,
1H), 4.05 (t, 2H), 4.04 (s, 2H), 3.91 (quart, 2H), 3.69-3.63 (m,
4H), 3.25 (s, 3H), 3.25-3.21 (m, 2H), 2.39 (s, 3H), 1.13 (t,
3H).
[1380] LC/MS (Method 1, ESIpos): R.sub.t=0.63 min, m/z=395
[M+H].sup.+.
Example 38
6-[(2,2-Dimethyl-3-oxopiperazin-1-yl)carbonyl]-3-ethyl-5-methyl-1-(3,3,3-t-
rifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00291##
[1382] Analogously to the process described under Ex. 23, 12.8 mg
(0.10 mmol) of 3,3-dimethylpiperazin-2-one [A. Benjahad et al.,
Tetrahedron Lett. 1994, 35 (51), 9545-9548] and 35 mg (0.10 mmol)
of the compound from Ex. 52A gave 33 mg (53% of theory, purity 75%)
of the title compound.
[1383] LC/MS (Method 3, ESIpos): R.sub.t=0.97 min, m/z=461
[M+H].sup.+.
Example 39
3-Ethyl-5-methyl-6-[(2-methyl-3-oxopiperazin-1-yl)carbonyl]-1-(3,3,3-trifl-
uoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione (Racemate)
##STR00292##
[1385] Analogously to the process described under Ex. 23, 11.4 mg
(0.10 mmol) of 3-methylpiperazin-2-one [K. M. Beck et al., J. Amer.
Chem. Soc. 1952, 74 (3), 605-608] and 35 mg (0.10 mmol) of the
compound from Ex. 52A gave 20 mg (46% of theory) of the title
compound.
[1386] LC/MS (Method 3, ESIpos): R.sub.t=0.91 min, m/z=447
[M+H].sup.+.
Example 40
3-Ethyl-6-[(2-ethyl-3-oxopiperazin-1-yl)carbonyl]-5-methyl-1-(3,3,3-triflu-
oropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione (Racemate)
##STR00293##
[1388] Analogously to the process described under Ex. 23, 12.8 mg
(0.10 mmol) of 3-ethylpiperazin-2-one [S. R. Aspinall, J. Amer.
Chem. Soc. 1940, 62 (5), 1202-1204] and 35 mg (0.10 mmol) of the
compound from Ex. 52A gave 15 mg (32% of theory) of the title
compound.
[1389] LC/MS (Method 3, ESIpos): R.sub.t=0.94 min, m/z=461
[M+H].sup.+.
Example 41
6-[(3-Oxopiperazin-1-yl)carbonyl]-3-(2-phenylethyl)-5-(trifluoromethyl)-1--
(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00294##
[1391] Preparation of the Acid Chloride:
[1392] At RT, first 66 .mu.l (0.760 mmol) of oxalyl chloride and
then a small drop of DMF were added to a solution of 75 mg (0.150
mmol) of the compound from Ex. 55A in 2.2 ml of dichloromethane.
After the reaction mixture had been stirred at RT for 2 h, it was
evaporated to dryness on a rotary evaporator. The residue that
remained was dried under high vacuum and then reacted further in
the next partial step.
[1393] Preparation of the Amide:
[1394] The acid chloride obtained above was dissolved in 2.2 ml of
anhydrous THF, and this solution was added dropwise to a solution
of 20 mg (0.20 mmol) of piperazin-2-one and 53 .mu.l (0.310 mmol)
of N,N-diisopropylethylamine in 1 ml of dichloromethane. The
reaction mixture was then stirred at RT for about 16 h. After the
mixture had been evaporated to dryness on a rotary evaporator, the
crude product was purified by preparative HPLC (Method 5). This
gave, after combination of the product fractions, evaporation and
drying of the residue under high vacuum, 22 mg (24% of theory) of
the title compound.
[1395] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.20 (s,
1H), 7.34-7.29 (m, 2H), 7.27-7.21 (m, 3H), 4.17 (m, 2H), 4.11-4.04
(m, 3H), 3.89-3.76 (m, 2H), 3.51 (m, 1H), 3.30-3.12 (m, 2H),
2.88-2.74 (m, 4H).
[1396] LC/MS (Method 1, ESIpos): R.sub.t=1.02 min, m/z=563
[M+H]+.
Example 42
3-Ethyl-6-[(3-oxopiperazin-1-yl)carbonyl]-5-(trifluoromethyl)-1-(3,3,3-tri-
fluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00295##
[1398] Analogously to the process described in Ex. 41, 55 mg (0.140
mmol) of the compound from Ex. 56A and 18 mg (0.180 mmol) of
piperazin-2-one gave 56 mg (85% of theory) of the title
compound.
[1399] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.19 (s,
1H), 4.17 (m, 2H), 4.09 (broad, 1H), 3.92 (quart, 2H), 3.85 (broad,
1H), 3.79 (broad, 1H), 3.50 (m, 1H), 3.26 (broad, 1H), 3.18 (broad,
1H), 2.88-2.76 (m, 2H), 1.14 (t, 3H).
[1400] LC/MS (Method 1, ESIpos): R.sub.t=0.82 min, m/z=487
[M+H].sup.+.
Example 43
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-5-methyl-3-(2-phenylpropyl)-1-(3,3,3-
-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(Racemate)
##STR00296##
[1402] 230 mg (0.407 mmol) of the compound from Ex. 71A were
dissolved in 8 ml of ethanol, and 813 .mu.l (0.813 mmol) of a 1 M
solution of lithium hydroxide in water were added. After 1 h of
stirring at RT, the reaction mixture was separated directly by
preparative HPLC into its components (Method 5). The product
fractions were combined and concentrated, and the residue was dried
under high vacuum. 176 mg (82% of theory) of the title compound
were obtained.
[1403] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.31-7.24
(m, 4H), 7.22-7.18 (m, 1H), 4.82 (d, 1H), 4.12-4.05 (m, 3H), 3.95
(dd, 1H), 3.82-3.71 (m, 3H), 3.28-3.19 (m, 3H), 2.77-2.65 (m, 2H),
2.36 (s, 3H), 1.80-1.72 (m, 2H), 1.40-1.31 (m, 2H), 1.19 (d,
3H).
[1404] LC/MS (Method 1, ESIpos): R.sub.t=1.06 min, m/z=524
[M+H].sup.+.
Separation of the Enantiomers:
[1405] 168 mg (0.321 mmol) of the racemic compound from Ex. 43 were
dissolved in 2 ml of ethanol and, in 8 portions, separated into the
enantiomers by preparative HPLC on a chiral phase (see Examples 44
and 45) [column: Daicel Chiralpak AD-H, 5 .mu.m, 250 mm.times.20
mm; mobile phase: isohexane/ethanol 1:1; flow rate: 20 ml/min,
temperature: 23.degree. C.; detection: 220 nm]:
Example 44
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-5-methyl-3-(2-phenylpropyl)-1-(3,3,3-
-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(Enantiomer 1)
##STR00297##
[1407] Yield: 54 mg (64% of theory)
[1408] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.31-7.24
(m, 4H), 7.22-7.18 (m, 1H), 4.82 (s, broad, 1H), 4.12-4.05 (m, 3H),
3.95 (dd, 1H), 3.82-3.71 (m, 3H), 3.28-3.19 (m, 3H), 2.77-2.65 (m,
2H), 2.36 (s, 3H), 1.80-1.72 (m, 2H), 1.40-1.31 (m, 2H), 1.19 (d,
3H).
[1409] Analytical HPLC [column: Daicel Chiralpak AD-H, 5 .mu.m, 250
mm.times.4.6 mm; mobile phase: isohexane/ethanol 1:1; flow rate: 1
ml/min, temperature: 30.degree. C.; detection: 220 nm]:
R.sub.t=4.39 min, 99.9% ee.
Example 45
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-5-methyl-3-(2-phenylpropyl)-1-(3,3,3-
-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(Enantiomer 2)
##STR00298##
[1411] Yield: 58 mg (69% of theory)
[1412] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.31-7.24
(m, 4H), 7.22-7.18 (m, 1H), 4.82 (s, broad, 1H), 4.12-4.05 (m, 3H),
3.95 (dd, 1H), 3.82-3.71 (m, 3H), 3.28-3.19 (m, 3H), 2.77-2.65 (m,
2H), 2.36 (s, 3H), 1.80-1.72 (m, 2H), 1.40-1.31 (m, 2H), 1.19 (d,
3H).
[1413] Analytical HPLC [column: Daicel Chiralpak AD-H, 5 .mu.m, 250
mm.times.4.6 mm; mobile phase: isohexane/ethanol 1:1; flow rate: 1
ml/min, temperature: 30.degree. C.; detection: 220 nm]:
R.sub.t=6.76 min, 99.9% ee.
Example 46
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-3-(2-methoxy-2-phenylethyl)-5-methyl-
-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(Racemate)
##STR00299##
[1415] 249 mg (0.428 mmol) of the compound from Ex. 72A were
dissolved in 8 ml of ethanol, and 856 .mu.l (0.856 mmol) of a 1 M
solution of lithium hydroxide in water were added. After 1 h of
stirring at RT, the reaction mixture was separated directly by
preparative HPLC into its components (Method 5). The product
fractions were combined and concentrated, and the residue was dried
under high vacuum. 172 mg (74% of theory) of the title compound
were obtained.
[1416] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.41-7.37
(m, 2H), 7.34-7.30 (m, 3H), 4.82 (d, 1H), 4.58 (dd, 1H), 4.35 (dd,
1H), 4.18-4.04 (m, 2H), 3.84-3.71 (m, 4H), 3.28-3.20 (m, 2H), 3.07
(s, 3H), 2.79-2.67 (m, 2H), 2.37 (s, 3H), 1.80-1.73 (m, 2H),
1.41-1.31 (m, 2H).
[1417] LC/MS (Method 1, ESIpos): R.sub.t=1.00 min, m/z=540
[M+H].sup.+.
Separation of the Enantiomers:
[1418] 160 mg (0.298 mmol) of the racemic compound from Ex. 46 were
dissolved in 6 ml of ethanol and, in 6 portions, separated into the
enantiomers by preparative HPLC on a chiral phase (see Examples 47
and 48) [column: Daicel Chiralcel OZ-H, 5 .mu.m, 250 mm.times.20
mm; mobile phase: ethanol; flow rate: 25 ml/min, temperature:
50.degree. C.; detection: 220 nm]:
Example 47
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-3-(2-methoxy-2-phenylethyl)-5-methyl-
-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(Enantiomer 2)
##STR00300##
[1420] Yield: 68 mg (85% of theory)
[1421] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.41-7.37
(m, 2H), 7.34-7.30 (m, 3H), 4.82 (d, 1H), 4.57 (dd, 1H), 4.35 (dd,
1H), 4.18-4.04 (m, 2H), 3.84-3.71 (m, 4H), 3.28-3.20 (m, 2H), 3.07
(s, 3H), 2.79-2.67 (m, 2H), 2.37 (s, 3H), 1.80-1.73 (m, 2H),
1.41-1.31 (m, 2H).
[1422] Analytical HPLC [column: Daicel Chiralcel OZ-H, 5 .mu.m, 250
mm.times.4.6 mm; mobile phase: ethanol; flow rate: 1 ml/min,
temperature: 50.degree. C.; detection: 220 nm]: R.sub.t=14.25 min,
99.9% ee.
Example 48
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-3-(2-methoxy-2-phenylethyl)-5-methyl-
-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(Enantiomer 1)
##STR00301##
[1424] Yield: 70 mg (87% of theory)
[1425] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.41-7.37
(m, 2H), 7.34-7.30 (m, 3H), 4.82 (d, 1H), 4.58 (dd, 1H), 4.35 (dd,
1H), 4.18-4.04 (m, 2H), 3.84-3.71 (m, 4H), 3.28-3.20 (m, 2H), 3.07
(s, 3H), 2.79-2.67 (m, 2H), 2.37 (s, 3H), 1.80-1.73 (m, 2H),
1.41-1.31 (m, 2H).
[1426] Analytical HPLC [column: Daicel Chiralcel OZ-H, 5 .mu.m, 250
mm.times.4.6 mm; mobile phase: ethanol; flow rate: 1 ml/min,
temperature: 50.degree. C.; detection: 220 nm]: R.sub.t=6.54 min,
99.9% ee.
Example 49
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-5-methyl-3-[(1-phenylcyclopropyl)met-
hyl]-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00302##
[1428] Analogously to the process described in Ex. 43, 54 mg (0.094
mmol) of the compound from Ex. 73A gave 38 mg (75% of theory) of
the title compound.
[1429] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.26-7.19
(m, 4H), 7.17-7.12 (m, 1H), 4.82 (d, 1H), 4.16 (s, 2H), 3.99 (t,
2H), 3.81-3.71 (m, 3H), 3.26-3.20 (m, 2H), 2.63-2.52 (m, 2H,
partially obscured by DMSO signal), 2.31 (s, 3H), 1.80-1.73 (m,
2H), 1.40-1.31 (m, 2H), 0.95 (m, 2H), 0.72 (m, 2H).
[1430] LC/MS (Method 1, ESIpos): R.sub.t=1.08 min, m/z=536
[M+H].sup.+.
Example 50
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-5-methyl-3-(2-methyl-2-phenylpropyl)-
-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00303##
[1432] Analogously to the process described in Ex. 43, 96 mg (0.166
mmol) of the compound from Ex. 74A gave 68 mg (76% of theory) of
the title compound.
[1433] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.43 (d,
2H), 7.32 (t, 2H), 7.21 (t, 1H), 4.82 (d, 1H), 4.11-4.04 (m, 4H),
3.82-3.71 (m, 3H), 3.28-3.21 (m, 2H), 2.77-2.65 (m, 2H), 2.34 (s,
3H), 1.80-1.73 (m, 2H), 1.40-1.31 (m, 2H), 1.28 (s, 6H).
[1434] LC/MS (Method 1, ESIpos): R.sub.t=1.08 min, m/z=538
[M+H]+.
Example 51
3-(2,2-Difluoro-2-phenylethyl)-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-met-
hyl-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00304##
[1436] 21 mg (0.208 mmol) of 4-hydroxypiperidine, 39 .mu.l (0.225
mmol) of N,N-diisopropylethylamine and 79 mg (0.208 mmol) of HATU
were added successively to a solution of 80 mg (0.173 mmol) of the
compound from Ex. 100A in 2.5 ml of anhydrous DMF. After a reaction
time of about 16 h at RT, the reaction mixture was separated
directly by preparative HPLC into its components (Method 5). The
product fractions were combined and concentrated, and the residue
was dried under high vacuum. 88 mg (93% of theory) of the title
compound were obtained.
[1437] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.57-7.49
(m, 5H), 4.80 (broad, 1H), 4.62 (t, 2H), 4.12 (t, 2H), 2.82-2.72
(m, 3H), 3.29-3.21 (m, 2H), 2.79-2.67 (m, 2H), 2.36 (s, 3H),
1.81-1.73 (m, 2H), 1.41-1.31 (m, 2H).
[1438] LC/MS (Method 1, ESIpos): R.sub.t=0.98 min, m/z=546
[M+H].sup.+.
Example 52
3-(2,2-Difluoro-2-phenylethyl)-6-[(4-hydroxypiperidin-1-yl)carbonyl]-1-(2--
methoxyethyl)-5-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00305##
[1440] Analogously to the process described in Ex. 51, 80 mg (0.188
mmol) of the compound from Ex. 101A and 23 mg (0.226 mmol) of
4-hydroxypiperidine gave 90 mg (94% of theory) of the title
compound.
[1441] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.57-7.50
(m, 5H), 4.80 (d, 1H), 4.62 (t, 2H), 4.04 (t, 2H), 3.82-3.71 (m,
3H), 3.59 (t, 2H), 3.27-3.21 (m, 2H), 3.25 (s, 3H), 2.35 (s, 3H),
1.81-1.73 (m, 2H), 1.40-1.32 (m, 2H).
[1442] LC/MS (Method 1, ESIpos): R.sub.t=0.90 min, m/z=508
[M+H].sup.+.
Example 53
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-5-methyl-3-[2-(pyridin-2-yl)ethyl]-1-
-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00306##
[1444] Analogously to the process described in Ex. 43, 110 mg
(0.199 mmol) of the compound from Ex. 75A gave 35 mg (33% of
theory, purity 96%) of the title compound. In addition to the
process described above, here the product obtained after
preparative HPLC was dissolved once more in a little methanol, and
the solution was passed through a bicarbonate cartridge (from
Polymerlabs, Stratospheres SPE, PL-HCO.sub.3 MP SPE, capacity 0.9
mmol) to convert the formic acid salt into the free base.
[1445] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.47 (d,
1H), 7.71 (dt, 1H), 7.28 (d, 1H), 7.23 (dd, 1H), 4.82 (d, 1H), 4.22
(t, 1H), 4.11 (t, 1H), 3.82-3.72 (m, 3H), 3.28-3.21 (m, 2H), 2.99
(t, 2H), 2.81-2.69 (m, 2H), 2.38 (s, 3H), 1.80-1.73 (m, 2H),
1.40-1.31 (m, 2H).
[1446] LC/MS (Method 1, ESIpos): R.sub.t=0.63 min, m/z=511
[M+H].sup.+.
Example 54
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-5-methyl-3-[2-(pyridin-4-yl)ethyl]-1-
-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00307##
[1448] Analogously to the process described in Ex. 43, 54 mg (0.098
mmol) of the compound from Ex. 76A gave 24 mg (43% of theory,
purity 90%) of the title compound.
[1449] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.47 (d,
2H), 7.26 (d, 2H), 4.82 (d, 1H), 4.14-4.09 (m, 4H), 3.81-3.71 (m,
3H), 3.28-3.20 (m, 2H), 2.88 (t, 2H), 2.82-2.70 (m, 2H), 2.37 (s,
3H), 1.80-1.73 (m, 2H), 1.40-1.31 (m, 2H).
[1450] LC/MS (Method 1, ESIpos): R.sub.t=0.58 min, m/z=511
[M+H]+.
Example 55
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-3-[2-(1H-imidazol-1-yl)ethyl]-5-meth-
yl-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00308##
[1452] Analogously to the process described in Ex. 43, 100 mg
(0.185 mmol) of the compound from Ex. 77A gave 18 mg (19% of
theory) of the title compound. In addition to the process described
above, here the product obtained after preparative HPLC was
dissolved once more in a little methanol, and the solution was
passed through a bicarbonate cartridge (from Polymerlabs,
Stratospheres SPE, PL-HCO.sub.3 MP SPE, capacity 0.9 mmol) to
convert the formic acid salt into the free base.
[1453] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.56 (s,
1H), 7.11 (s, 1H), 6.84 (s, 1H), 4.82 (d, 1H), 4.22-4.17 (m, 4H),
4.08 (t, 2H), 3.81-3.71 (m, 3H), 3.27-3.20 (m, 2H), 2.80-2.68 (m,
2H), 2.34 (s, 3H), 1.80-1.73 (m, 2H), 1.40-1.31 (m, 2H).
[1454] LC/MS (Method 1, ESIpos): R.sub.t=0.49 min, m/z=500
[M+H].sup.+.
Example 56
3-Ethyl-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methyl-1-[2-(trifluorometh-
oxy)ethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00309##
[1456] Analogously to the process described in Ex. 43, 59 mg (0.121
mmol) of the compound from Ex. 83A gave 44 mg (80% of theory) of
the title compound. In this case, the reaction time was 2 h, and
purification by preparative HPLC was carried out according to
Method 12.
[1457] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.41 (t,
2H), 4.22 (t, 2H), 3.91 (quart, 2H), 3.80-3.71 (m, 3H), 3.26-3.19
(m, 2H), 2.37 (s, 3H), 1.79-1.71 (m, 2H), 1.39-1.29 (m, 2H), 1.12
(t, 3H).
[1458] LC/MS (Method 1, ESIpos): R.sub.t=0.83 min, m/z=450
[M+H].sup.+.
Example 57
3-Ethyl-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methyl-1-{2-[(trifluoromet-
hyl)sulphanyl]ethyl}thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00310##
[1460] Analogously to the process described in Ex. 43, 67 mg (0.133
mmol) of the compound from Ex. 84A gave 47 mg (76% of theory) of
the title compound. In this case, the reaction time was 2 h, and
purification by preparative HPLC was carried out according to
Method 12.
[1461] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.16 (t,
2H), 3.91 (quart, 2H), 3.81-3.71 (m, 3H), 3.37 (t, 2H), 3.26-3.20
(m, 2H), 2.38 (s, 3H), 1.79-1.72 (m, 2H), 1.39-1.30 (m, 2H), 1.12
(t, 3H).
[1462] LC/MS (Method 1, ESIpos): R.sub.t=0.90 min, m/z=466
[M+H].sup.+.
Example 58
3-Ethyl-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methyl-1-[2-(trifluorometh-
yl)prop-2-en-1-yl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00311##
[1464] Analogously to the process described in Ex. 43, 69 mg (0.142
mmol) of the compound from Ex. 85A gave 49 mg (78% of theory) of
the title compound. In this case, the reaction time was 2 h, and
purification by preparative HPLC was carried out according to
Method 14.
[1465] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 6.02 (s,
1H), 5.83 (s, 1H), 4.78 (s, 2H), 3.93 (quart, 2H), 3.80-3.70 (m,
3H), 3.26-3.19 (m, 2H), 2.38 (s, 3H), 1.78-1.71 (m, 2H), 1.38-1.29
(m, 2H), 1.13 (t, 3H).
[1466] LC/MS (Method 1, ESIpos): R.sub.t=0.84 min, m/z=446
[M+H].sup.+.
Example 59
1-[(2,2-Difluorocyclopropyl)methyl]-3-ethyl-6-[(4-hydroxypiperidin-1-yl)ca-
rbonyl]-5-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(Racemate)
##STR00312##
[1468] Analogously to the process described in Ex. 43, 62 mg (0.132
mmol) of the compound from Ex. 86A gave 57 mg (100% of theory) of
the title compound. In this case, the reaction time was 2 h, and
purification by preparative HPLC was carried out according to
Method 14.
[1469] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.15 (m,
1H), 4.00-3.88 (m, 4H), 3.81-3.70 (m, 3H), 3.27-3.20 (m, 2H), 2.38
(s, 3H), 2.28-2.17 (m, 1H), 1.79-1.67 (m, 3H), 1.53-1.44 (m, 1H),
1.39-1.30 (m, 2H), 1.13 (t, 3H).
[1470] LC/MS (Method 1, ESIpos): R.sub.t=0.80 min, m/z=428
[M+H].sup.+.
Example 60
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-5-methyl-3-propyl-1-[2-(trifluoromet-
hoxy)ethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00313##
[1472] 32 mg (0.316 mmol) of 4-hydroxypiperidine, 60 .mu.l (0.342
mmol) of N,N-diisopropylethylamine and 120 mg (0.316 mmol) of HATU
were added successively to a solution of 100 mg (0.263 mmol) of the
compound from Ex. 102A in 3 ml of anhydrous DMF. After a reaction
time of about 16 h at RT, the reaction mixture was separated
directly by preparative HPLC into its components (Method 5). The
product fractions were combined and concentrated, and the residue
was dried under high vacuum. 101 mg (82% of theory) of the title
compound were obtained.
[1473] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.79 (d,
1H), 4.41 (t, 2H), 4.22 (t, 2H), 3.84 (t, 2H), 3.80-3.70 (m, 3H),
3.26-3.19 (m, 2H), 2.37 (s, 3H), 1.79-1.71 (m, 2H), 1.57 (m, 2H),
1.39-1.30 (m, 2H), 0.87 (t, 3H).
[1474] LC/MS (Method 1, ESIpos): R.sub.t=0.88 min, m/z=464
[M+H].sup.+.
Example 61
3-(But-3-yn-1-yl)-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methyl-1-(3,3,3--
trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00314##
[1476] Analogously to the process described in Ex. 43, 81 mg (0.162
mmol) of the compound from Ex. 79A gave 48 mg (64% of theory) of
the title compound.
[1477] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.81 (d,
1H), 4.13 (t, 2H), 4.01 (t, 2H), 3.81-3.71 (m, 3H), 3.27-3.20 (m,
2H), 2.88 (t, 1H), 2.85-2.72 (m, 2H), 2.51-2.44 (m, 2H, partially
obscured by DMSO signal), 2.38 (s, 3H), 1.79-1.72 (m, 2H),
1.39-1.31 (m, 2H).
[1478] LC/MS (Method 1, ESIpos): R.sub.t=0.83 min, m/z=458
[M+H]+.
Example 62
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-3-(2-methoxyethyl)-5-methyl-1-(3,3,3-
-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00315##
[1480] Analogously to the process described in Ex. 43, 88 mg (0.174
mmol) of the compound from Ex. 79A gave 40 mg (49% of theory) of
the title compound. Here, the product obtained after preparative
HPLC was triturated again with pentane.
[1481] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.81 (d,
1H), 4.13 (t, 2H), 4.06 (t, 2H), 3.82-3.71 (m, 3H), 3.50 (t, 2H),
3.27-3.20 (m, 2H), 3.24 (s, 3H), 2.85-2.72 (m, 2H), 2.37 (s, 3H),
1.79-1.72 (m, 2H), 1.40-1.30 (m, 2H).
[1482] LC/MS (Method 1, ESIpos): R.sub.t=0.77 min, m/z=464
[M+H]+.
Example 63
3-(2-Cyclopropylethyl)-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methyl-1-(3-
,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00316##
[1484] Analogously to the process described in Ex. 43, 50 mg (0.097
mmol) of the compound from Ex. 80A gave 37 mg (80% of theory) of
the title compound.
[1485] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.81 (d,
1H), 4.12 (t, 2H), 3.95 (t, 2H), 3.81-3.71 (m, 3H), 3.27-3.20 (m,
2H), 2.85-2.73 (m, 2H), 2.37 (s, 3H), 1.79-1.72 (m, 2H), 1.44
(quart, 2H), 1.39-1.30 (m, 2H), 0.72-0.65 (m, 1H), 0.41-0.37 (m,
2H), 0.01 (m, 2H, substantially obscured by the TMS signal).
[1486] LC/MS (Method 1, ESIpos): R.sub.t=0.95 min, m/z=474
[M+H].sup.+.
Example 64
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-3-isobutyl-5-methyl-1-(3,3,3-trifluo-
ropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00317##
[1488] Analogously to the process described in Ex. 43, 87 mg (0.173
mmol) of the compound from Ex. 81A gave 65 mg (81% of theory) of
the title compound.
[1489] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.81 (d,
1H), 4.13 (t, 2H), 3.82-3.70 (m, 5H), 3.27-3.20 (m, 2H), 2.85-2.73
(m, 2H), 2.37 (s, 3H), 2.09-1.99 (m, 1H), 1.80-1.72 (m, 2H),
1.40-1.30 (m, 2H), 0.86 (d, 6H).
[1490] LC/MS (Method 1, ESIpos): R.sub.t=0.96 min, m/z=462
[M+H].sup.+.
Example 65
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-3-(2-methoxypropyl)-5-methyl-1-(3,3,-
3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(Racemate)
##STR00318##
[1492] Analogously to the process described in Ex. 43, 50 mg (0.096
mmol) of the compound from Ex. 82A gave 26 mg (51% of theory,
purity 90%) of the title compound.
[1493] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.81 (d,
1H), 4.13 (m, 2H), 4.06 (m, 1H), 3.82-3.71 (m, 4H), 3.64 (m, 1H),
3.28-3.23 (m, 2H), 3.22 (s, 3H), 2.85-2.73 (m, 2H), 2.38 (s, 3H),
1.80-1.72 (m, 2H), 1.40-1.30 (m, 2H), 1.06 (d, 3H).
[1494] LC/MS (Method 1, ESIpos): R.sub.t=0.81 min, m/z=478
[M+H].sup.+.
Example 66
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-5-methyl-3-(3,3,3-trifluoro-2-methox-
ypropyl)-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(Racemate)
##STR00319##
[1496] Analogously to the process described in Ex. 51, 140 mg
(0.312 mmol) of the compound from Ex. 103A and 38 mg (0.375 mmol)
of 4-hydroxypiperidine gave 162 mg (97% of theory) of the title
compound.
[1497] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.81 (d,
1H), 4.29-4.14 (m, 4H), 4.05 (dd, 1H), 3.82-3.71 (m, 3H), 3.43 (s,
3H), 3.28-3.21 (m, 2H), 2.87-2.75 (m, 2H), 2.38 (s, 3H), 1.80-1.73
(m, 2H), 1.41-1.32 (m, 2H).
[1498] LC/MS (Method 1, ESIpos): R.sub.t=0.92 min, m/z=532
[M+H].sup.+.
Example 67
6-[(4-Hydroxy-4-methylpiperidin-1-yl)carbonyl]-5-methyl-3-(2-phenylethyl)--
1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00320##
[1500] 26 mg (0.225 mmol) of 4-methylpiperidin-4-ol [commercially
available; lit. e.g.: J. M. McManus et al., J. Med. Chem. 1965, 8
(6), 766-776], 43 .mu.l (0.244 mmol) of N,N-diisopropylethylamine
and 86 mg (0.225 mmol) of HATU were added in succession to a
solution of 80 mg (0.188 mmol) of the compound from Ex. 43A in 2 ml
of anhydrous DMF. After a reaction time of about 16 h at RT, the
reaction mixture was separated directly by preparative HPLC into
its components (Method 6). The product fractions were combined and
concentrated, and the residue was dried under high vacuum. 79 mg
(80% of theory) of the title compound were obtained.
[1501] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.33-7.29
(m, 2H), 7.26-7.20 (m, 3H), 4.47 (broad, 1H), 4.12 (t, 2H), 4.06
(m, 2H), 3.79-3.65 (m, broad, 2H), 3.37-3.29 (m, broad, 2H,
substantially obscured by the water signal), 2.83 (m, 2H),
2.82-2.70 (m, 2H), 2.38 (s, 3H), 1.54-1.41 (m, 4H), 1.16 (s,
3H).
[1502] LC/MS (Method 1, ESIpos): R.sub.t=1.07 min, m/z=524
[M+H].sup.+.
Example 68
6-{[4-Hydroxy-4-(hydroxymethyl)piperidin-1-yl]carbonyl}-5-methyl-3-(2-phen-
ylethyl)-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00321##
[1504] 38 mg (0.225 mmol) of 4-(hydroxymethyl)piperidin-4-ol
hydrochloride [commercially available; lit. e.g.: WO
2005/103037-A2, Example A3b (free base); US 2011/288065-A1, Example
105/Step 1 (hydrochloride)], 43 .mu.l (0.244 mmol) of
N,N-diisopropylethylamine and 86 mg (0.225 mmol) of HATU were added
in succession to a solution of 80 mg (0.188 mmol) of the compound
from Ex. 43A in 2 ml of anhydrous DMF. After a reaction time of
about 16 h at RT, the reaction mixture was separated directly by
preparative HPLC into its components (Method 11). The product
fractions were combined and concentrated, and the residue was dried
under high vacuum. 84 mg (83% of theory) of the title compound were
obtained.
[1505] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.32-7.21
(m, 5H, partially obscured by the CHCl.sub.3 signal), 4.21 (m, 2H),
4.14 (m, 2H), 4.05 (broad, 2H), 3.52 (d, 2H), 3.49-3.40 (m, 2H),
2.96-2.92 (m, 2H), 2.64-2.52 (m, 2H), 2.51 (s, 3H), 2.15 (s, 1H),
1.86 (t, 1H), 1.76-1.70 (m, 2H), 1.57-1.51 (m, 2H, partially
obscured by the water signal).
[1506] LC/MS (Method 1, ESIpos): R.sub.t=0.94 min, m/z=540
[M+H].sup.+.
Example 69
6-{[4-Hydroxy-4-(trifluoromethyl)piperidin-1-yl]carbonyl}-5-methyl-3-(2-ph-
enylethyl)-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dio-
ne
##STR00322##
[1508] Analogously to the process described in Ex. 51, 80 mg (0.188
mmol) of the compound from Ex. 43A and 46 mg (0.225 mmol) of
4-(trifluoromethyl)piperidin-4-ol [commercially available; lit.
e.g.: WO 2005/103002-A2, intermediate 1] gave 90 mg (83% of theory)
of the title compound. In this case, preparative HPLC was carried
out according to Method 6.
[1509] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.34-7.29
(m, 2H), 7.26-7.21 (m, 3H), 6.20 (s, 1H), 4.13 (t, 2H), 4.07 (m,
2H), 4.00 (broad, 2H), 3.27-3.19 (m, 2H), 2.85-2.81 (m, 2H),
2.82-2.71 (m, 2H), 2.40 (s, 3H), 1.77-1.61 (m, 4H).
[1510] LC/MS (Method 1, ESIpos): R.sub.t=1.14 min, m/z=577
[M+H]+.
Example 70
3-(2,2-Difluoro-2-phenylethyl)-6-{[4-hydroxy-4-(hydroxymethyl)piperidin-1--
yl]carbonyl}-5-methyl-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4-
(1H,3H)-dione
##STR00323##
[1512] 35 mg (0.208 mmol) of 4-(hydroxymethyl)piperidin-4-ol
hydrochloride [commercially available; lit. e.g.: WO
2005/103037-A2, Example A3b (free base); US 2011/288065-A1, Example
105/Step 1 (hydrochloride)], 75 .mu.l (0.433 mmol) of
N,N-diisopropylethylamine and 79 mg (0.208 mmol) of HATU were added
in succession to a solution of 80 mg (0.173 mmol) of the compound
from Ex. 100A in 2.5 ml of anhydrous DMF. After a reaction time of
about 16 h at RT, the reaction mixture was separated directly by
preparative HPLC into its components (Method 5). The product
fractions were combined and concentrated, and the residue was dried
under high vacuum. This gave 73 mg (69% of theory, 95% pure) of the
title compound.
[1513] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.57-7.50
(m, 5H), 4.62 (t, 2H), 4.39 (broad, 1H), 4.12 (t, 2H), 3.92-3.78
(m, broad, 2H), 3.34-3.24 (m, 2H, partially obscured by the water
signal), 3.21 (s, 2H), 2.79-2.67 (m, 2H), 2.36 (s, 3H), 1.60-1.51
(m, 2H), 1.44-1.38 (m, 2H).
[1514] LC/MS (Method 1, ESIpos): R.sub.t=0.93 min, m/z=576
[M+H]+.
Example 71
3-(2,2-Difluoro-2-phenylethyl)-6-{[4-hydroxy-4-(hydroxymethyl)piperidin-1--
yl]carbonyl}-1-(2-methoxyethyl)-5-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-
-dione
##STR00324##
[1516] Analogously to the process described in Ex. 51, 80 mg (0.188
mmol) of the compound from Ex. 101A and 38 mg (0.226 mmol) of
4-(hydroxymethyl)piperidin-4-ol hydrochloride [commercially
available; lit. e.g.: WO 2005/103037-A2, Example A3b (free base);
US 2011/288065-A1, Example 105/Step 1 (hydrochloride)] gave 75 mg
(74% of theory) of the title compound.
[1517] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.56-7.51
(m, 5H), 4.62 (t, 2H), 4.36 (broad, 1H), 4.04 (t, 2H), 3.91-3.77
(m, broad, 2H), 3.31-3.25 (m, 2H, partially obscured by the water
signal), 3.25 (s, 3H), 3.21 (s, 2H), 2.35 (s, 3H), 1.59-1.51 (m,
2H), 1.44-1.38 (m, 2H).
[1518] LC/MS (Method 1, ESIpos): R.sub.t=0.86 min, m/z=538
[M+H].sup.+.
Example 72
3-Ethyl-6-[(9-hydroxy-3-azabicyclo
[3.3.1]non-3-yl)carbonyl]-5-methyl-1-(3,3,3-trifluoropropyl)thieno[2,3-d]-
pyrimidine-2,4(1H,3H)-dione (.alpha.-epimer)
##STR00325##
[1520] 48 mg (0.343 mmol) of 3-azabicyclo[3.3.1]nonan-9-ol [epimer
mixture, commercially available; lit. e.g.: A. I. Moskalenko, V. I.
Boev, Russ. J. Org. Chem. 2010, 46 (10), 1527-1533 (as
hydrochloride)], 114 .mu.l (0.657 mmol) of
N,N-diisopropylethylamine and 130 mg (0.343 mmol) of HATU were
added in succession to a solution of 100 mg (0.285 mmol) of the
compound from Ex. 52A in 3 ml of anhydrous DMF. After a reaction
time of about 16 h at RT, the reaction mixture was separated
directly by preparative HPLC into its components (Method 5). Two
fractions were obtained: 36 mg (26% of theory) of the title
compound (.alpha.-epimer, as shown) and 41 mg (29% of theory) of
the corresponding .beta.-epimer. The assignment was carried out
analogously to the literature cited above via the chemical shift of
the epimeric CHOH protons (.alpha.: 3.81 ppm, .beta.: 3.62 ppm; in
DMSO-d.sub.6).
[1521] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.89 (d,
1H), 4.70-3.60 (very broad, 2H), 4.13 (t, 2H), 3.91 (quart, 2H),
3.81 (m, 1H), 3.50-3.00 (very broad, 2H, partially obscured by the
water signal), 2.85-2.73 (m, 2H), 2.35 (s, 3H), 2.04-1.93 (m, 2H),
1.77-1.71 (m, 2H), 1.63-1.52 (m, 1H), 1.42-1.33 (m, 3H), 1.13 (t,
3H).
[1522] LC/MS (Method 9, ESIpos): R.sub.t=1.14 min, m/z=474
[M+H].sup.+.
Example 73
3-Ethyl-6-[(4-hydroxy-3-methylpiperidin-1-yl)carbonyl]-5-methyl-1-(3,3,3-t-
rifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione (Enantiomer
pair 1)
##STR00326##
[1524] 16 mg (0.427 mmol) of sodium borohydride were added to a
suspension of 190 mg (0.427 mmol) of the racemic compound from Ex.
112A in 20 ml of methanol, and the mixture was stirred at RT for 2
h. The reaction mixture was then concentrated on a rotary
evaporator to a small residual volume. This residue was then
subjected to coarse pre-purification by preparative HPLC (Method 5)
such that all four stereoisomers of the target product were
isolated together (185 mg). Separation of the stereoisomers was
then carried out by preparative HPLC on a chiral phase [column:
Daicel Chiralpak IC 5 .mu.m 250 mm.times.20 mm; mobile phase:
isohexane/ethanol 7:3; flow rate: 15 ml/min; temperature:
25.degree. C.; detection: 220 nm]. To this end, the stereoisomer
mixture obtained (185 mg) was dissolved in 3 ml of ethanol and
passed through the column in 10 portions. In this manner,
separation into the two diastereomeric enantiomer pairs was
achieved. Concentration of the respective product fractions and
drying under high vacuum gave 37 mg (18% of theory) of the title
compound (enantiomer pair 1) and 62 mg (30% of theory) of the
diastereomeric enantiomer pair 2. Retention times (R.sub.t) on an
analytic HPLC column on a chiral phase were 8.11 and 8.48 min
(enantiomer pair 1) and 9.82 and 10.06 min (enantiomer pair 2),
respectively [column: Daicel Chiralpak IC 5 .mu.m 250 mm.times.4.6
mm; mobile phase: isohexan/ethanol/diethylamine 70:30:0.2; flow
rate: 1 ml/min, temperature: 25.degree. C.; detection: 235 nm].
[1525] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.72
(broad, 1H), 4.12 (t, 2H), 3.91 (quart, 2H), 3.74 (m, 1H),
3.62-3.48 (m, broad, 2H), 3.43 (m, 1H, partially obscured by the
water signal), 3.17 (dd, 1H), 2.85-2.73 (m, 2H), 2.37 (s, 3H),
1.76-1.68 (m, 1H), 1.65-1.54 (m, 2H), 1.13 (t, 3H), 0.83 (d,
3H).
[1526] LC/MS (Method 1, ESIpos): R.sub.t=0.87 min, m/z=448
[M+H].sup.+.
Example 74
3-Ethyl-6-{[4-hydroxy-4-(hydroxymethyl)piperidin-1-yl]carbonyl}-5-methyl-1-
-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00327##
[1528] Analogously to the process described in Ex. 51, 100 mg
(0.285 mmol) of the compound from Ex. 52A and 57 mg (0.343 mmol) of
4-(hydroxymethyl)piperidin-4-ol hydrochloride [commercially
available; lit. e.g.: WO 2005/103037-A2, Example A3b (free base);
US 2011/288065-A1, Example 105/Step 1 (hydrochloride)] gave 88 mg
(66% of theory) of the title compound. In deviation from the
process described above, here the first preparative HPLC (according
to Method 5) was followed by a second HPLC purification (according
to Method 7).
[1529] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.65 (t,
1H), 4.38 (s, 1H), 4.12 (t, 2H), 3.91 (quart, 2H), 3.84 (broad,
2H), 3.27 (broad, 2H, partially obscured by the water signal), 3.20
(d, 2H), 2.85-2.73 (m, 2H), 2.38 (s, 3H), 1.59-1.50 (m, 2H),
1.43-1.37 (m, 2H), 1.12 (t, 3H).
[1530] LC/MS (Method 1, ESIpos): R.sub.t=0.78 min, m/z=464
[M+H].sup.+.
Example 75
3-Ethyl-6-{[4-hydroxy-4-(hydroxymethyl)piperidin-1-yl]carbonyl}-5-methyl-1-
-[2-(trifluoromethoxy)ethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00328##
[1532] 52 mg (0.311 mmol) of 4-(hydroxymethyl)piperidin-4-ol
hydrochloride [commercially available; lit. e.g.: WO
2005/103037-A2, Example A3b (free base); US 2011/288065-A1, Example
105/Step 1 (hydrochloride)], 113 .mu.l (0.648 mmol) of
N,N-diisopropylethylamine and 118 mg (0.311 mmol) of HATU were
added in succession to a solution of 100 mg (0.259 mmol, purity
95%) of the compound from Ex. 104A in 1.7 ml of anhydrous DMF.
After a reaction time of about 16 h at RT, the reaction mixture was
separated directly by preparative HPLC into its components (Method
7). The product fractions were combined and concentrated, and the
residue was dried under high vacuum. 103 mg (82% of theory) of the
title compound were obtained.
[1533] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.63 (t,
1H), 4.41 (t, 2H), 4.36 (s, 1H), 4.22 (t, 2H), 3.91 (quart, 2H),
3.82 (broad, 2H), 3.25 (broad, 2H, partially obscured by the water
signal), 3.20 (d, 2H), 2.37 (s, 3H), 1.54 (dt, 2H), 1.43-1.37 (m,
2H), 1.13 (t, 3H).
[1534] LC/MS (Method 9, ESIpos): R.sub.t=0.98 min, m/z=480
[M+H].sup.+.
Example 76
6-[(4-Hydroxy-4-methylpiperidin-1-yl)carbonyl]-5-methyl-3-propyl-1-(3,3,3--
trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00329##
[1536] 38 mg (0.329 mmol) of 4-methylpiperidin-4-ol [commercially
available; lit. e.g.: J. M. McManus et al., J. Med. Chem. 1965, 8
(6), 766-776], 62 .mu.l (0.357 mmol) of N,N-diisopropylethylamine
and 125 mg (0.329 mmol) of HATU were added in succession to a
solution of 100 mg (0.274 mmol) of the compound from Ex. 105A in 3
ml of anhydrous DMF. After a reaction time of about 16 h at RT, the
reaction mixture was separated directly by preparative HPLC into
its components (Method 5). The product fractions were combined and
concentrated, and the residue was dried under high vacuum. 95 mg
(75% of theory) of the title compound were obtained.
[1537] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.46 (s,
1H), 4.12 (t, 2H), 3.83 (t, 2H), 3.72 (broad, 2H), 3.34 (m, broad,
2H, partially obscured by the water signal), 2.85-2.72 (m, 2H),
2.68 (s, 3H), 1.61-1.41 (m, 6H), 1.15 (s, 3H), 0.87 (t, 3H).
[1538] LC/MS (Method 1, ESIpos): R.sub.t=0.93 min, m/z=462
[M+H].sup.+.
Example 77
6-{[4-Hydroxy-4-(hydroxymethyl)piperidin-1-yl]carbonyl}-5-methyl-3-propyl--
1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00330##
[1540] Analogously to the process described in Ex. 51, 100 mg
(0.274 mmol) of the compound from Ex. 105A and 55 mg (0.329 mmol)
of 4-(hydroxymethyl)piperidin-4-ol hydrochloride [commercially
available; lit. e.g.: WO 2005/103037-A2, Example A3b (free base);
US 2011/288065-A1, Example 105/Step 1 (hydrochloride)] gave 116 mg
(88% of theory) of the title compound.
[1541] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.63 (t,
1H), 4.36 (s, 1H), 4.12 (t, 2H), 3.85 (broad, 2H), 3.83 (t, 2H),
3.28 (broad, 2H, partially obscured by the water signal), 3.21 (d,
2H), 2.85-2.73 (m, 2H), 2.38 (s, 3H), 1.61-1.51 (m, 4H), 1.44-1.37
(m, 2H), 0.87 (t, 3H).
[1542] LC/MS (Method 1, ESIpos): R.sub.t=0.83 min, m/z=478
[M+H]+.
Example 78
6-{[4-Hydroxy-4-(hydroxymethyl)piperidin-1-yl]carbonyl}-1-(2-methoxyethyl)-
-5-methyl-3-propylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00331##
[1544] Analogously to the process described in Ex. 51, 100 mg
(0.306 mmol) of the compound from Ex. 106A and 62 mg (0.368 mmol)
of 4-(hydroxymethyl)piperidin-4-ol hydrochloride [commercially
available; lit. e.g.: WO 2005/103037-A2, Example A3b (free base);
US 2011/288065-A1, Example 105/Step 1 (hydrochloride)] gave 76 mg
(56% of theory) of the title compound. In deviation from the
process described above, here the first preparative HPLC (according
to Method 5) was followed by a second HPLC purification (according
to Method 7).
[1545] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.63 (t,
1H), 4.35 (s, 1H), 4.04 (t, 2H), 3.85 (broad, 2H), 3.83 (t, 2H),
3.65 (t, 2H), 3.26 (broad, 2H, partially obscured by the water
signal), 3.24 (s, 3H), 3.20 (d, 2H), 2.36 (s, 3H), 1.61-1.50 (m,
4H), 1.43-1.37 (m, 2H), 0.87 (t, 3H).
[1546] LC/MS (Method 1, ESIpos): R.sub.t=0.70 min, m/z=440
[M+H].sup.+.
Example 79
6-[(4-Hydroxy-4-methylpiperidin-1-yl)carbonyl]-5-methyl-3-propyl-1-[2-(tri-
fluoromethoxy)ethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00332##
[1548] 36 mg (0.316 mmol) of 4-methylpiperidin-4-ol [commercially
available; lit. e.g.: J. M. McManus et al., J. Med. Chem. 1965, 8
(6), 766-776], 59 .mu.l (0.342 mmol) of N,N-diisopropylethylamine
and 120 mg (0.316 mmol) of HATU were added in succession to a
solution of 100 mg (0.263 mmol) of the compound from Ex. 102A in 3
ml of anhydrous DMF. After a reaction time of about 16 h at RT, the
reaction mixture was separated directly by preparative HPLC into
its components (Method 5). The product fractions were combined and
concentrated, and the residue was dried under high vacuum. 108 mg
(86% of theory) of the title compound were obtained.
[1549] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.46 (s,
1H), 4.41 (t, 2H), 4.22 (t, 2H), 3.84 (t, 2H), 3.71 (broad, 2H),
3.34 (m, broad, 2H, partially obscured by the water signal), 2.37
(s, 3H), 1.62-1.40 (m, 6H), 1.15 (s, 3H), 0.87 (t, 3H).
[1550] LC/MS (Method 1, ESIpos): R.sub.t=0.94 min, m/z=478
[M+H].sup.+.
Example 80
6-{[4-Hydroxy-4-(hydroxymethyl)piperidin-1-yl]carbonyl}-5-methyl-3-propyl--
1-[2-(trifluoromethoxy)ethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00333##
[1552] 53 mg (0.316 mmol) of 4-(hydroxymethyl)piperidin-4-ol
hydrochloride [commercially available; lit. e.g.: WO
2005/103037-A2, Example A3b (free base); US 2011/288065-A1, Example
105/Step 1 (hydrochloride)], 114 .mu.l (0.657 mmol) of
N,N-diisopropylethylamine and 120 mg (0.316 mmol) of HATU were
added in succession to a solution of 100 mg (0.263 mmol) of the
compound from Ex. 102A in 3 ml of anhydrous DMF. After a reaction
time of about 16 h at RT, the reaction mixture was separated
directly by preparative HPLC into its components (Method 5). The
product fractions were combined and concentrated, and the residue
was dried under high vacuum. 78 mg (60% of theory) of the title
compound were obtained.
[1553] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.63 (t,
1H), 4.41 (t, 2H), 4.36 (s, 1H), 4.22 (t, 2H), 3.84 (t, 2H), 3.82
(broad, 2H), 3.27 (broad, 2H, partially obscured by the water
signal), 3.20 (d, 2H), 2.37 (s, 3H), 1.62-1.50 (m, 4H), 1.43-1.37
(m, 2H), 0.87 (t, 3H).
[1554] LC/MS (Method 1, ESIpos): R.sub.t=0.82 min, m/z=494
[M+H].sup.+.
Example 81
6-{[4-Hydroxy-4-(hydroxymethyl)piperidin-1-yl]carbonyl}-5-methyl-3-(3,3,3--
trifluoro-2-methoxypropyl)-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidin-
e-2,4(1H,3H)-dione (Racemate)
##STR00334##
[1556] Analogously to the process described in Ex. 51, 140 mg
(0.312 mmol) of the compound from Ex. 103A and 63 mg (0.375 mmol)
of 4-(hydroxymethyl)piperidin-4-ol hydrochloride [commercially
available; lit. e.g.: WO 2005/103037-A2, Example A3b (free base);
US 2011/288065-A1, Example 105/Step 1 (hydrochloride)] gave 140 mg
(79% of theory) of the title compound.
[1557] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.64 (t,
1H), 4.37 (s, 1H), 4.29-4.14 (m, 4H), 4.05 (dd, 1H), 3.85 (broad,
2H), 3.43 (s, 3H), 3.28 (broad, 2H, partially obscured by the water
signal), 3.21 (d, 2H), 2.87-2.75 (m, 2H), 2.38 (s, 3H), 1.56 (dt,
2H), 1.44-1.38 (m, 2H).
[1558] LC/MS (Method 1, ESIpos): R.sub.t=0.87 min, m/z=562
[M+H]+.
Example 82
3-Ethyl-6-[(4-hydroxy-4-methylpiperidin-1-yl)carbonyl]-5-(trifluoromethyl)-
-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00335##
[1560] 31 mg (0.272 mmol) of 4-methylpiperidin-4-ol [commercially
available; lit. e.g.: J. M. McManus et al., J. Med. Chem. 1965, 8
(6), 766-776], 56 .mu.l (0.322 mmol) of N,N-diisopropylethylamine
and 113 mg (0.297 mmol) of HATU were added in succession to a
solution of 100 mg (0.247 mmol) of the compound from Ex. 56A in 2
ml of anhydrous DMF. After a reaction time of about 16 h at RT, the
reaction mixture was separated directly by preparative HPLC into
its components (Method 5). The product fractions were combined and
concentrated, and the residue was dried under high vacuum. This
gave 96 mg (75% of theory, 97% pure) of the title compound.
[1561] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 4.38 (m,
broad, 1H), 4.24-4.06 (m, 2H), 4.09 (quart, 2H), 3.57-3.43 (m, 1H),
3.41-3.26 (m, 2H), 2.72-2.61 (m, 2H), 1.70-1.48 (m, 4H), 1.33 (s,
3H), 1.27 (t, 3H).
[1562] LC/MS (Method 1, ESIpos): R.sub.t=0.91 min, m/z=502
[M+H].sup.+.
Example 83
3-Ethyl-6-{[4-hydroxy-4-(hydroxymethyl)piperidin-1-yl]carbonyl}-5-(trifluo-
romethyl)-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dion-
e
##STR00336##
[1564] Analogously to the process described in Ex. 51, 100 mg
(0.247 mmol) of the compound from Ex. 56A and 46 mg (0.272 mmol) of
4-(hydroxymethyl)piperidin-4-ol hydrochloride [commercially
available; lit. e.g.: WO 2005/103037-A2, Example A3b (free base);
US 2011/288065-A1, Example 105/Step 1 (hydrochloride)] gave 79 mg
(61% of theory) of the title compound.
[1565] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.23 (d,
2H), 4.16 (t, 2H), 3.92 (m, 2H), 3.20 (s, 2H), 3.10 (t, 2H),
2.87-2.75 (m, 2H), 1.60-1.32 (m, 4H), 1.13 (t, 3H).
[1566] LC/MS (Method 1, ESIpos): R.sub.t=0.79 min, m/z=518
[M+H]+.
Example 84
5-(Difluoromethyl)-6-[(4-hydroxypiperidin-1-yl)carbonyl]-3-(2-phenylethyl)-
-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00337##
[1568] 17 mg (0.165 mmol) of 4-hydroxypiperidine, 29 .mu.l (0.165
mmol) of N,N-diisopropylethylamine and 58 mg (0.152 mmol) of HATU
were added successively to a solution of 60 mg (0.127 mmol, purity
97%) of the compound from Ex. 57A in 1.9 ml of anhydrous DMF. After
a reaction time of about 16 h at RT, the reaction mixture was
separated directly by preparative HPLC into its components (Method
6). The product fractions were combined and concentrated, and the
residue was dried under high vacuum. 60 mg (88% of theory) of the
title compound were obtained.
[1569] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.34 (t,
1H), 7.33-7.29 (m, 2H), 7.27-7.23 (m, 3H), 4.84 (d, 1H), 4.15 (t,
2H), 4.07 (m, 2H), 3.96 (broad, 1H), 3.79-3.71 (m, 1H), 3.49
(broad, 1H), 3.22 (broad, 2H), 2.87-2.72 (m, 4H), 1.74 (broad, 2H),
1.41-1.31 (m, 2H).
[1570] LC/MS (Method 2, ESIpos): R.sub.t=2.27 min, m/z=546
[M+H].sup.+.
Example 85
5-(Difluoromethyl)-6-[(4-hydroxy-4-methylpiperidin-1-yl)carbonyl]-3-(2-phe-
nylethyl)-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dion-
e
##STR00338##
[1572] 33 mg (0.274 mmol) of 4-methylpiperidin-4-ol [commercially
available; lit. e.g.: J. M. McManus et al., J. Med. Chem. 1965, 8
(6), 766-776], 48 .mu.l (0.274 mmol) of N,N-diisopropylethylamine
and 96 mg (0.253 mmol) of HATU were added in succession to a
solution of 100 mg (0.211 mmol, purity 97%) of the compound from
Ex. 57A in 3.2 ml of anhydrous DMF. After a reaction time of about
16 h at RT, the reaction mixture was separated directly by
preparative HPLC into its components (Method 6). The product
fractions were combined and concentrated, and the residue was dried
under high vacuum. 102 mg (86% of theory) of the title compound
were obtained.
[1573] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.33 (t,
1H), 7.32-7.29 (m, 2H), 7.26-7.21 (m, 3H), 4.48 (s, 1H), 4.15 (t,
2H), 4.08 (m, 2H), 4.08 (broad, 1H), 3.37-3.19 (m, broad, 3H,
partially obscured by the water signal), 2.89-2.72 (m, 4H),
1.56-1.40 (m, broad, 4H), 1.15 (s, 3H).
[1574] LC/MS (Method 1, ESIpos): R.sub.t=1.06 min, m/z=560
[M+H].sup.+.
Example 86
5-(Difluoromethyl)-6-{[4-hydroxy-4-(hydroxymethyl)piperidin-1-yl]carbonyl}-
-3-(2-phenylethyl)-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H-
,3H)-dione
##STR00339##
[1576] 31 mg (0.225 mmol) of 4-(hydroxymethyl)piperidin-4-ol
hydrochloride [commercially available; lit. e.g.: WO
2005/103037-A2, Example A3b (free base); US 2011/288065-A1, Example
105/Step 1 (hydrochloride)], 39 .mu.l (0.225 mmol) of
N,N-diisopropylethylamine and 79 mg (0.208 mmol) of HATU were added
in succession to a solution of 80 mg (0.173 mmol) of the compound
from Ex. 57A in 2.5 ml of anhydrous DMF. After a reaction time of
about 16 h at RT, the reaction mixture was separated directly by
preparative HPLC into its components (Method 6). The product
fractions were combined and concentrated, and the residue was dried
under high vacuum. Stirring with a mixture of 10 ml of pentane and
1 ml of diisopropyl ether for 20 min at RT, filtration with suction
and once more drying under high vacuum gave 55 mg (55% of theory,
purity 96%) of the title compound.
[1577] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.33 (t,
1H), 7.32-7.29 (m, 2H), 7.26-7.21 (m, 3H), 4.67 (t, 1H), 4.39 (s,
1H), 4.22 (broad, 1H), 4.15 (t, 2H), 4.08 (m, 2H), 3.39 (broad, 2H,
partially obscured by the water signal), 3.20 (d, 2H), 3.10 (broad,
1H), 2.88-2.73 (m, 4H), 1.54 (dt, 2H), 1.51-1.31 (broad, 2H).
[1578] LC/MS (Method 1, ESIpos): R.sub.t=0.96 min, m/z=576
[M+H].sup.+.
Example 87
3,5-Diethyl-6-[(4-hydroxypiperidin-1-yl)carbonyl]-1-(3,3,3-trifluoropropyl-
)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00340##
[1580] Analogously to the process described in Ex. 51, 80 mg (0.220
mmol) of the compound from Ex. 111A and 24 mg (0.242 mmol) of
4-hydroxypiperidine gave 96 mg (97% of theory) of the title
compound.
[1581] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.80 (d,
1H), 4.12 (t, 2H), 3.92 (quart, 2H), 3.82-3.71 (m, 3H), 3.23 (m,
2H), 2.86-2.74 (m, 4H), 1.79-1.72 (m, 2H), 1.39-1.29 (m, 2H), 1.13
(t, 3H), 1.12 (t, 3H).
[1582] LC/MS (Method 1, ESIpos): R.sub.t=0.86 min, m/z=448
[M+H]+.
Example 88
3,5-Diethyl-6-[(4-hydroxy-4-methylpiperidin-1-yl)carbonyl]-1-(3,3,3-triflu-
oropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00341##
[1584] 28 mg (0.242 mmol) of 4-methylpiperidin-4-ol [commercially
available; lit. e.g.: J. M. McManus et al., J. Med. Chem. 1965, 8
(6), 766-776], 96 .mu.l (0.549 mmol) of N,N-diisopropylethylamine
and 100 mg (0.263 mmol) of HATU were added in succession to a
solution of 80 mg (0.220 mmol) of the compound from Ex. 111A in 2
ml of anhydrous DMF. After a reaction time of about 16 h at RT, the
reaction mixture was separated directly by preparative HPLC into
its components (Method 5). The product fractions were combined and
concentrated, and the residue was dried under high vacuum. 96 mg
(95% of theory) of the title compound were obtained.
[1585] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.47 (s,
1H), 4.12 (t, 2H), 3.93 (quart, 2H), 3.72 (broad, 2H), 3.37-3.28
(m, broad, 2H, partially obscured by the water signal), 2.86-2.74
(m, 4H), 1.53-1.39 (m, 4H), 1.15 (s, 3H), 1.13 (t, 3H), 1.11 (t,
3H).
[1586] LC/MS (Method 1, ESIpos): R.sub.t=0.91 min, m/z=462
[M+H].sup.+.
Example 89
3,5-Diethyl-6-{[4-hydroxy-4-(hydroxymethyl)piperidin-1-yl]carbonyl}-1-(3,3-
,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00342##
[1588] 40 mg (0.242 mmol) of 4-(hydroxymethyl)piperidin-4-ol
hydrochloride [commercially available; lit. e.g.: WO
2005/103037-A2, Example A3b (free base); US 2011/288065-A1, Example
105/Step 1 (hydrochloride)], 96 .mu.l (0.549 mmol) of
N,N-diisopropylethylamine and 100 mg (0.263 mmol) of HATU were
added in succession to a solution of 80 mg (0.220 mmol) of the
compound from Ex. 111A in 2 ml of anhydrous DMF. After a reaction
time of about 16 h at RT, the reaction mixture was separated
directly by preparative HPLC into its components (Method 5). The
product fractions were combined and concentrated, and the residue
was dried under high vacuum. 89 mg (85% of theory) of the title
compound were obtained.
[1589] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.64 (t,
1H), 4.37 (s, 1H), 4.12 (t, 2H), 3.92 (quart, 2H), 3.85 (broad,
2H), 3.30-3.21 (m, broad, 2H, partially obscured by the water
signal), 3.21 (d, 2H), 2.86-2.74 (m, 4H), 1.54 (dt, 2H), 1.43-1.37
(m, 2H), 1.13 (t, 3H), 1.12 (t, 3H).
[1590] LC/MS (Method 1, ESIpos): R.sub.t=0.80 min, m/z=478
[M+H].sup.+.
Example 90
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-3-(2-phenylethyl)-1-(3,3,3-trifluoro-
propyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00343##
[1592] Analogously to the process described in Ex. 51, 85 mg (0.196
mmol, purity 96%) of the compound from Ex. 58A and 22 mg (0.215
mmol) of 4-hydroxypiperidine gave 79 mg (81% of theory) of the
title compound.
[1593] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.55 (s,
1H), 7.32-7.28 (m, 2H), 7.25-7.19 (m, 3H), 4.15 (t, 2H), 4.09 (m,
2H), 4.00-3.92 (m, 2H), 3.39 (broad, 2H), 2.85 (t, 2H), 2.84-2.71
(m, 2H), 1.84-1.77 (m, 2H), 1.45-1.36 (m, 2H).
[1594] LC/MS (Method 1, ESIpos): R.sub.t=0.99 min, m/z=496
[M+H].sup.+.
Example 91
6-[(4-Hydroxy-4-methylpiperidin-1-yl)carbonyl]-3-(2-phenylethyl)-1-(3,3,3--
trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00344##
[1596] Analogously to the process described in Ex. 51, 85 mg (0.196
mmol, purity 96%) of the compound from Ex. 58A and 22 mg (0.215
mmol) of 4-methylpiperidin-4-ol [commercially available; lit. e.g.:
J. M. McManus et al., J. Med. Chem. 1965, 8 (6), 766-776] gave 44
mg (44% of theory) of the title compound.
[1597] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.55 (s,
1H), 7.32-7.28 (m, 2H), 7.24-7.19 (m, 3H), 4.15 (t, 2H), 4.09 (m,
2H), 4.00-3.93 (m, 2H), 3.42 (broad, 2H), 2.85 (t, 2H), 2.83-2.71
(m, 2H), 1.57-1.47 (m, 4H), 1.17 (s, 3H).
[1598] LC/MS (Method 1, ESIpos): R.sub.t=1.02 min, m/z=510
[M+H].sup.+.
Example 92
6-{[4-Hydroxy-4-(hydroxymethyl)piperidin-1-yl]carbonyl}-3-(2-phenylethyl)--
1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00345##
[1600] Analogously to the process described in Ex. 51, 85 mg (0.196
mmol, purity 96%) of the compound from Ex. 58A and 36 mg (0.215
mmol) of 4-(hydroxymethyl)piperidin-4-ol hydrochloride
[commercially available; lit. e.g.: WO 2005/103037-A2, Example A3b
(free base); US 2011/288065-A1, Example 105/Step 1 (hydrochloride)]
gave 86 mg (83% of theory) of the title compound.
[1601] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.52 (s,
1H), 7.32-7.21 (m, 5H, partially obscured by the CHCl.sub.3
signal), 4.29 (broad, 2H), 4.24 (m, 2H), 4.17 (t, 2H), 3.53 (d,
2H), 3.50 (broad, 2H), 2.95 (t, 2H), 2.65-2.54 (m, 2H), 2.21
(broad, 1H), 1.94 (broad, 1H), 1.80-1.74 (m, 2H), 1.61 (m, 2H,
partially obscured by the water signal).
[1602] LC/MS (Method 1, ESIpos): R.sub.t=0.92 min, m/z=526
[M+H]+.
Example 93
3-(2,2-Difluoro-2-phenylethyl)-5-methyl-6-[(3-oxopiperazin-1-yl)carbonyl]--
1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00346##
[1604] 21 mg (0.208 mmol) of 2-oxopiperazine, 39 .mu.l (0.225 mmol)
of N,N-diisopropylethylamine and 79 mg (0.208 mmol) of HATU were
added successively to a solution of 80 mg (0.173 mmol) of the
compound from Ex. 100A in 2.5 ml of anhydrous DMF. After a reaction
time of about 16 h at RT, the reaction mixture was separated
directly by preparative HPLC into its components (Method 5). The
product fractions were combined and concentrated, and the residue
was dried under high vacuum. 80 mg (84% of theory) of the title
compound were obtained.
[1605] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.16 (s,
1H), 7.57-7.49 (m, 5H), 4.63 (t, 2H), 4.13 (t, 2H), 4.05 (s, 2H),
3.69 (t, 2H), 3.25 (m, 2H), 2.79-2.67 (m, 2H), 2.38 (s, 3H).
[1606] LC/MS (Method 1, ESIpos): R.sub.t=0.94 min, m/z=545
[M+H].sup.+.
Example 94
3-(2,2-Difluoro-2-phenylethyl)-1-(2-methoxyethyl)-5-methyl-6-[(3-oxopipera-
zin-1-yl)carbonyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00347##
[1608] Analogously to the process described in Ex. 51, 80 mg (0.188
mmol) of the compound from Ex. 101A and 23 mg (0.226 mmol) of
oxopiperazine gave 33 mg (32% of theory, purity 95%) of the title
compound. In this case, the product was purified by preparative
HPLC (twice, in each case Method 5) and finally by stirring with
pentane.
[1609] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.13 (s,
1H), 7.56-7.50 (m, 5H), 4.63 (t, 2H), 4.05 (s, 2H), 4.04 (t, 2H),
3.69 (t, 2H), 3.59 (t, 2H), 3.24 (s, 3H), 3.24 (m, 2H), 2.37 (s,
3H).
[1610] LC/MS (Method 1, ESIpos): R.sub.t=0.83 min, m/z=507
[M+H].sup.+.
Example 95
5-Methyl-6-[(3-oxopiperazin-1-yl)carbonyl]-3-propyl-1-(3,3,3-trifluoroprop-
yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00348##
[1612] Analogously to the process described in Ex. 51, 100 mg
(0.274 mmol) of the compound from Ex. 105A and 33 mg (0.329 mmol)
of 2-oxopiperazine gave 106 mg (86% of theory) of the title
compound.
[1613] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.13 (s,
1H), 4.13 (t, 2H), 4.05 (s, 2H), 3.83 (t, 2H), 3.69 (t, 2H), 3.24
(m, 2H), 2.84-2.74 (m, 2H), 2.40 (s, 3H), 1.57 (sext, 2H), 0.87 (t,
3H).
[1614] LC/MS (Method 1, ESIpos): R.sub.t=0.84 min, m/z=447
[M+H].sup.+.
Example 96
5-Methyl-6-[(3-oxopiperazin-1-yl)carbonyl]-3-propyl-1-[2-(trifluoromethoxy-
)ethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00349##
[1616] Analogously to the process described in Ex. 51, 100 mg
(0.263 mmol) of the compound from Ex. 102A and 32 mg (0.316 mmol)
of 2-oxopiperazine gave 78 mg (64% of theory) of the title
compound.
[1617] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.13 (s,
1H), 4.41 (t, 2H), 4.23 (t, 2H), 4.04 (s, 2H), 3.84 (t, 2H), 3.67
(t, 2H), 3.23 (m, 2H), 2.39 (s, 3H), 1.57 (sext, 2H), 0.87 (t,
3H).
[1618] LC/MS (Method 1, ESIpos): R.sub.t=0.83 min, m/z=463
[M+H]+.
Example 97
5-(Difluoromethyl)-6-[(3-oxopiperazin-1-yl)carbonyl]-3-(2-phenylethyl)-1-(-
3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00350##
[1620] 28 mg (0.281 mmol) of 2-oxopiperazine, 49 .mu.l (0.281 mmol)
of N,N-diisopropylethylamine and 99 mg (0.260 mmol) of HATU were
added successively to a solution of 100 mg (0.216 mmol) of the
compound from Ex. 57A in 3.1 ml of anhydrous DMF. After a reaction
time of about 16 h at RT, the reaction mixture was separated
directly by preparative HPLC into its components (Method 6). The
product fractions were combined and concentrated, and the residue
was dried under high vacuum. Stirring with a mixture of 10 ml of
pentane and 1 ml of diisopropyl ether for 20 min at RT, filtration
with suction and once more drying under high vacuum gave 78 mg (66%
of theory) of the title compound.
[1621] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.18 (s,
1H), 7.36 (t, 1H), 7.34-7.29 (m, 2H), 7.27-7.21 (m, 3H), 4.15 (t,
2H), 4.08 (m, 2H), 3.90 (broad, 1H), 3.77 (broad, 1H), 3.52 (broad,
2H), 3.22 (broad, 2H), 2.86-2.71 (m, 4H).
[1622] LC/MS (Method 1, ESIpos): R.sub.t=0.98 min, m/z=545
[M+H].sup.+.
Example 98
3,5-Diethyl-6-[(3-oxopiperazin-1-yl)carbonyl]-1-(3,3,3-trifluoropropyl)thi-
eno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00351##
[1624] Analogously to the process described in Ex. 51, 80 mg (0.220
mmol) of the compound from Ex. 111A and 24 mg (0.242 mmol) of
2-oxopiperazine gave 93 mg (95% of theory) of the title
compound.
[1625] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.14 (s,
1H), 4.13 (t, 2H), 4.04 (s, 2H), 3.93 (quart, 2H), 3.67 (t, 2H),
3.23 (m, 2H), 2.86-2.74 (m, 4H), 1.13 (t, 3H), 1.11 (t, 3H).
[1626] LC/MS (Method 1, ESIpos): R.sub.t=0.79 min, m/z=447
[M+H].sup.+.
Example 99
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-5-methyl-3-(2-phenylethyl)-1-[2-(tri-
fluoromethoxy)ethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00352##
[1628] Analogously to the process described in Ex. 51, 65 mg (0.147
mmol) of the compound from Ex. 118A and 17 mg (0.162 mmol) of
4-hydroxypiperidine gave 72 mg (93% of theory) of the title
compound.
[1629] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.32-7.28
(m, 2H), 7.25-7.20 (m, 3H), 4.80 (d, 1H), 4.39 (t, 2H), 4.22 (t,
2H), 4.08 (m, 2H), 3.80-3.71 (m, 3H), 3.23 (m, 2H), 2.84 (m, 2H),
2.37 (s, 3H), 1.79-1.72 (m, 2H), 1.40-1.30 (m, 2H).
[1630] LC/MS (Method 1, ESIpos): R.sub.t=1.05 min, m/z=526
[M+H].sup.+.
Example 100
3-(2-Hydroxy-2-phenylethyl)-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methyl-
-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(Enantiomer 1)
##STR00353##
[1632] Analogously to the process described in Ex. 43, 50 mg (0.088
mmol) of the compound from Ex. 125A gave 18 mg (38% of theory) of
the title compound.
[1633] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.37-7.31
(m, 4H), 7.28-7.23 (m, 1H), 5.40 (d, 1H), 4.96-4.91 (m, 1H), 4.80
(d, 1H), 4.23 (dd, 1H), 4.11 (t, 2H), 3.85-3.72 (m, 4H), 3.31-3.21
(m, 2H, partially obscured by the water signal), 2.77-2.66 (m, 2H),
2.38 (s, 3H), 1.80-1.73 (m, 2H), 1.41-1.31 (m, 2H).
[1634] LC/MS (Method 1, ESIpos): R.sub.t=0.86 min, m/z=526
[M+H].sup.+.
[1635] Chiral analytical HPLC [column: Daicel Chiralcel OD-H, 5
.mu.m, 250 mm.times.4.6 mm; eluent: isohexane/ethanol 1:1; flow
rate: 1 ml/min, temperature: 30.degree. C.; detection: 220 nm]:
R.sub.t=6.65 min; 98% ee.
Example 101
3-(2-Hydroxy-2-phenylethyl)-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methyl-
-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(Enantiomer 2)
##STR00354##
[1637] Analogously to the process described in Ex. 43, 50 mg (0.088
mmol) of the compound from Ex. 126A gave 13 mg (29% of theory) of
the title compound.
[1638] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.38-7.32
(m, 4H), 7.28-7.23 (m, 1H), 5.40 (d, 1H), 4.96-4.91 (m, 1H), 4.80
(d, 1H), 4.23 (dd, 1H), 4.11 (t, 2H), 3.85-3.72 (m, 4H), 3.31-3.21
(m, 2H, partially obscured by the water signal), 2.77-2.66 (m, 2H),
2.38 (s, 3H), 1.80-1.73 (m, 2H), 1.40-1.31 (m, 2H).
[1639] LC/MS (Method 1, ESIpos): R.sub.t=0.86 min, m/z=526
[M+H].sup.+.
[1640] Chiral analytical HPLC [column: Daicel Chiralcel OD-H, 5
.mu.m, 250 mm.times.4.6 mm; eluent: isohexane/ethanol 1:1; flow
rate: 1 ml/min, temperature: 30.degree. C.; detection: 220 nm]:
R.sub.t=4.98 min; >99% ee.
Example 102
3-(2-Fluoro-2-phenylethyl)-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methyl--
1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(Enantiomer 1)
##STR00355##
[1642] Analogously to the process described in Ex. 43, 75 mg (0.133
mmol) of the compound from Ex. 127A gave 57 mg (81% of theory) of
the title compound. In this case, the reaction time was 30 min.
[1643] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.49-7.40
(m, 5H), 5.77 (ddd, 1H), 4.80 (d, 1H), 4.63 (m, 1H), 4.15 (t, 2H),
4.00 (ddd, 1H), 3.83-3.72 (m, 3H), 3.29-3.22 (m, 2H), 2.86-2.74 (m,
2H), 2.40 (s, 3H), 1.81-1.73 (m, 2H), 1.41-1.32 (m, 2H).
[1644] LC/MS (Method 1, ESIpos): R.sub.t=0.98 min, m/z=528
[M+H].sup.+.
Example 103
3-(2-Fluoro-2-phenylethyl)-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methyl--
1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(Enantiomer 2)
##STR00356##
[1646] Analogously to the process described in Ex. 43, 58 mg (0.102
mmol) of the compound from Ex. 128A gave 41 mg (76% of theory) of
the title compound. In this case, the reaction time was 30 min.
[1647] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.49-7.40
(m, 5H), 5.77 (ddd, 1H), 4.82 (d, 1H), 4.63 (m, 1H), 4.16 (t, 2H),
3.99 (ddd, 1H), 3.82-3.71 (m, 3H), 3.29-3.21 (m, 2H), 2.86-2.74 (m,
2H), 2.40 (s, 3H), 1.80-1.73 (m, 2H), 1.41-1.32 (m, 2H).
[1648] LC/MS (Method 1, ESIpos): R.sub.t=0.98 min, m/z=528
[M+H]+.
Example 104
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-5-methyl-3-(3,3,3-trifluoro-2-phenyl-
propyl)-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(Racemate)
##STR00357##
[1650] Analogously to the process described in Ex. 43, 25 mg (0.040
mmol) of the compound from Ex. 122A gave 20 mg (81% of theory,
purity 95%) of the title compound.
[1651] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 7.37-7.31
(m, 5H), 4.62-4.50 (m, 2H), 4.16-4.08 (m, 2H), 4.06-3.98 (m, 2H),
3.95-3.88 (m, 2H), 3.43-3.36 (m, 2H), 2.51-2.40 (m, 2H), 2.47 (s,
3H), 1.97-1.90 (m, 2H), 1.65-1.56 (m, 2H), 1.51 (broad, 1H).
[1652] LC/MS (Method 1, ESIpos): R.sub.t=1.04 min, m/z=578
[M+H].sup.+.
Example 105
3-(2-Hydroxy-2-phenylpropyl)-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methy-
l-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(Racemate)
##STR00358##
[1654] Analogously to the process described in Ex. 43, 67 mg (0.115
mmol) of the compound from Ex. 129A gave 17 mg (27% of theory) of
the title compound.
[1655] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.48 (d,
2H), 7.30 (t, 2H), 7.21 (t, 1H), 5.05 (s, 1H), 4.81 (d, 1H), 4.18
(quart, 2H), 4.12-4.03 (m, 2H), 3.81-3.72 (m, 3H), 3.28-3.21 (m,
2H), 2.75-2.63 (m, 2H), 2.34 (s, 3H), 1.80-1.74 (m, 2H), 1.42 (s,
3H), 1.41-1.32 (m, 2H).
[1656] LC/MS (Method 1, ESIpos): R.sub.t=0.93 min, m/z=540
[M+H].sup.+.
Example 106
3-(4,4-Difluorobut-3-en-1-yl)-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-meth-
yl-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00359##
[1658] Analogously to the process described in Ex. 43, 90 mg (0.167
mmol) of the compound from Ex. 123A gave 66 mg (79% of theory) of
the title compound.
[1659] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.80 (d,
1H), 4.53 (dtd, 1H), 4.13 (t, 2H), 3.92 (t, 2H), 3.81-3.71 (m, 3H),
3.27-3.21 (m, 2H), 2.84-2.71 (m, 2H), 2.38 (s, 3H), 2.32-2.22 (m,
2H), 1.80-1.72 (m, 2H), 1.40-1.30 (m, 2H).
[1660] LC/MS (Method 1, ESIpos): R.sub.t=0.96 min, m/z=496
[M+H].sup.+.
Example 107
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-5-methyl-3-(3,3,3-trifluoro-2-methox-
ypropyl)-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(Enantiomer 1)
##STR00360##
[1662] 134 mg (0.252 mmol) of the racemic compound from Ex. 66 were
dissolved in 4 ml of isopropanol and, in 13 portions, separated
into the enantiomers by preparative HPLC on a chiral phase [column:
Daicel Chiralcel OX-H, 5 .mu.m, 250 mm.times.20 mm; mobile phase:
isohexane/isopropanol 65:35; flow rate: 15 ml/min, temperature:
40.degree. C.; detection: 220 nm]. This gave, after concentration
of the product fractions and drying of the residue under high
vacuum, 32 mg (47% of theory) of enantiomer 1.
[1663] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.81 (d,
1H), 4.29-4.14 (m, 4H), 4.05 (dd, 1H), 3.82-3.71 (m, 3H), 3.43 (s,
3H), 3.28-3.21 (m, 2H), 2.87-2.75 (m, 2H), 2.38 (s, 3H), 1.80-1.73
(m, 2H), 1.40-1.31 (m, 2H).
[1664] LC/MS (Method 1, ESIpos): R.sub.t=0.92 min, m/z=532
[M+H].sup.+.
[1665] Chiral analytical HPLC [column: LUX Cellulose 4, 5 .mu.m,
250 mm.times.4.6 mm; mobile phase: isohexane/isopropanol 60:40;
flow rate: 1 ml/min, temperature: 40.degree. C.; detection: 220
nm]: R.sub.t=7.47 min; 99.9% ee.
Example 108
6-[(4-Hydroxypiperidin-1-yl)carbonyl]-5-methyl-3-(3,3,3-trifluoro-2-methox-
ypropyl)-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(Enantiomer 2)
##STR00361##
[1667] 134 mg (0.252 mmol) of the racemic compound from Ex. 66 were
dissolved in 4 ml of isopropanol and, in 13 portions, separated
into the enantiomers by preparative HPLC on a chiral phase [column:
Daicel Chiralcel OX-H, 5 .mu.m, 250 mm.times.20 mm; mobile phase:
isohexane/isopropanol 65:35; flow rate: 15 ml/min, temperature:
40.degree. C.; detection: 220 nm]. This gave, after concentration
of the product fractions and drying of the residue under high
vacuum, 53 mg (79% of theory) of enantiomer 2.
[1668] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.81 (d,
1H), 4.29-4.14 (m, 4H), 4.05 (dd, 1H), 3.82-3.71 (m, 3H), 3.43 (s,
3H), 3.28-3.21 (m, 2H), 2.87-2.75 (m, 2H), 2.38 (s, 3H), 1.80-1.73
(m, 2H), 1.40-1.31 (m, 2H).
[1669] LC/MS (Method 1, ESIpos): R.sub.t=0.92 min, m/z=532
[M+H]+.
[1670] Chiral analytical HPLC [column: LUX Cellulose 4, 5 .mu.m,
250 mm.times.4.6 mm; mobile phase: isohexane/isopropanol 60:40;
flow rate: 1 ml/min, temperature: 40.degree. C.; detection: 220
nm]: R.sub.t=9.67 min; 99.9% ee.
Example 109
6-[(4-Hydroxy-4-methylpiperidin-1-yl)carbonyl]-5-methyl-3-(2-phenylethyl)--
1-[2-(trifluoromethoxy)ethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00362##
[1672] Analogously to the process described in Ex. 51, 65 mg (0.147
mmol) of the compound from Ex. 118A and 19 mg (0.162 mmol) of
4-methylpiperidin-4-ol [commercially available; lit. e.g.: J. M.
McManus et al., J. Med. Chem. 1965, 8 (6), 766-776] gave 65 mg (79%
of theory) of the title compound.
[1673] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.33-7.28
(m, 2H), 7.25-7.20 (m, 3H), 4.46 (s, 1H), 4.39 (t, 2H), 4.22 (t,
2H), 4.08 (m, 2H), 3.76-3.65 (broad, 2H), 3.37-3.29 (m, 2H,
partially obscured by the water signal), 2.84 (m, 2H), 2.37 (s,
3H), 1.54-1.40 (m, 4H), 1.15 (s, 3H).
[1674] LC/MS (Method 1, ESIpos): R.sub.t=1.10 min, m/z=540
[M+H].sup.+.
Example 110
6-{[4-Hydroxy-4-(hydroxymethyl)piperidin-1-yl]carbonyl}-5-methyl-3-(2-phen-
ylethyl)-1-[2-(trifluoromethoxy)ethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-d-
ione
##STR00363##
[1676] Analogously to the process described in Ex. 51, 65 mg (0.147
mmol) of the compound from Ex. 118A and 27 mg (0.162 mmol) of
4-(hydroxymethyl)piperidin-4-ol hydrochloride [commercially
available; lit. e.g.: WO 2005/103037-A2, Example A3b (free base);
US 2011/288065-A1, Example 105/Step 1 (hydrochloride)] gave 73 mg
(90% of theory) of the title compound.
[1677] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.32-7.28
(m, 2H), 7.25-7.20 (m, 3H), 4.63 (t, 1H), 4.39 (t, 2H), 4.36 (s,
1H), 4.22 (t, 2H), 4.08 (m, 2H), 3.89-3.77 (broad, 2H), 3.31-3.22
(m, 2H, partially obscured by the water signal), 3.21 (d, 2H), 2.84
(m, 2H), 2.38 (s, 3H), 1.59-1.51 (m, 2H), 1.43-1.37 (m, 2H).
[1678] LC/MS (Method 1, ESIpos): R.sub.t=0.99 min, m/z=556
[M+H]+.
Example 111
3-Ethyl-6-[(4-hydroxy-4-methylpiperidin-1-yl)carbonyl]-5-methyl-1-[2-(trif-
luoromethoxy)ethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00364##
[1680] Analogously to the process described in Ex. 51, 100 mg
(0.273 mmol) of the compound from Ex. 104A and 38 mg (0.328 mmol)
of 4-methylpiperidin-4-ol [commercially available; lit. e.g.: J. M.
McManus et al., J. Med. Chem. 1965, 8 (6), 766-776] gave 98 mg (77%
of theory) of the title compound. The reaction time in this case
was 1 h.
[1681] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.45 (s,
1H), 4.41 (t, 2H), 4.22 (t, 2H), 3.91 (quart, 2H), 3.75-3.65
(broad, 2H), 3.37-3.29 (m, 2H, partially obscured by the water
signal), 2.37 (s, 3H), 1.53-1.40 (m, 4H), 1.15 (s, 3H), 1.13 (t,
3H).
[1682] LC/MS (Method 1, ESIpos): R.sub.t=0.88 min, m/z=464
[M+H].sup.+.
Example 112
3-Ethyl-6-[(4-ethyl-4-hydroxypiperidin-1-yl)carbonyl]-5-methyl-1-[2-(trifl-
uoromethoxy)ethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00365##
[1684] Analogously to the process described in Ex. 51, 80 mg (0.218
mmol) of the compound from Ex. 104A and 44 mg (0.262 mmol) of
4-ethylpiperidin-4-ol hydrochloride [commercially available; lit.
e.g.: US 2004/0067931-A1, Example 3.232 (free base)] gave 97 mg
(93% of theory) of the title compound.
[1685] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.41 (t,
2H), 4.26 (s, 1H), 4.22 (t, 2H), 3.91 (quart, 2H), 3.82-3.72
(broad, 2H), 3.33-3.25 (m, 2H, partially obscured by the water
signal), 2.37 (s, 3H), 1.51-1.45 (m, 2H), 1.42-1.34 (m, 2H), 1.40
(quart, 2H), 1.13 (t, 3H), 0.83 (t, 3H).
[1686] LC/MS (Method 1, ESIpos): R.sub.t=0.94 min, m/z=478
[M+H].sup.+.
Example 113
3-Ethyl-6-[(4-ethyl-4-hydroxypiperidin-1-yl)carbonyl]-5-methyl-1-(3,3,3-tr-
ifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00366##
[1688] Analogously to the process described in Ex. 51, 80 mg (0.228
mmol) of the compound from Ex. 52A and 45 mg (0.274 mmol) of
4-ethylpiperidin-4-ol hydrochloride [commercially available; lit.
e.g.: US 2004/0067931-A1, Example 3.232 (free base)] gave 94 mg
(89% of theory) of the title compound.
[1689] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.26 (s,
1H), 4.12 (t, 2H), 3.91 (quart, 2H), 3.84-3.73 (broad, 2H),
3.33-3.25 (m, 2H, partially obscured by the water signal),
2.85-2.73 (m, 2H), 2.38 (s, 3H), 1.52-1.46 (m, 2H), 1.41 (quart,
2H), 1.41-1.35 (m, 2H), 1.13 (t, 3H), 0.84 (t, 3H).
[1690] LC/MS (Method 1, ESIpos): R.sub.t=0.90 min, m/z=462
[M+H].sup.+.
Example 114
6-{[4-Hydroxy-4-(hydroxymethyl)piperidin-1-yl]carbonyl}-5-methyl-3-(3,3,3--
trifluoro-2-methoxypropyl)-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidin-
e-2,4(1H,3H)-dione (Enantiomer 1)
##STR00367##
[1692] 120 mg (0.214 mmol) of the racemic compound from Ex. 81 were
dissolved in 4 ml of isopropanol and, in 13 portions, separated
into the enantiomers by preparative HPLC on a chiral phase [column:
Daicel Chiralcel OX-H, 5 .mu.m, 250 mm.times.20 mm; mobile phase:
isohexane/isopropanol 60:40; flow rate: 15 ml/min, temperature:
30.degree. C.; detection: 220 nm]. This gave, after concentration
of the product fractions and drying of the residue under high
vacuum, 54 mg (86% of theory, chem. purity 95%, >99% ee) of
enantiomer 1. Re-purification by preparative HPLC (Method 5) gave
44 mg (73% of theory) of the title compound in pure form.
[1693] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 4.46 (dd,
1H), 4.21-3.97 (m, 6H), 3.51 (s, 5H), 3.45 (br. t, 2H), 2.71-2.60
(m, 2H), 2.50 (s, 3H), 2.21 (broad, 1H), 1.95 (broad, 1H),
1.76-1.70 (m, 2H), 1.58-1.51 (m, 2H, partially obscured by the
water signal).
[1694] LC/MS (Method 1, ESIpos): R.sub.t=0.88 min, m/z=562
[M+H].sup.+.
[1695] Chiral analytical HPLC [column: LUX Cellulose 4, 5 .mu.m,
250 mm.times.4.6 mm; mobile phase: isohexane/isopropanol 60:40;
flow rate: 1 ml/min, temperature: 40.degree. C.; detection: 220
nm]: R.sub.t=8.11 min.
Example 115
6-{[4-Hydroxy-4-(hydroxymethyl)piperidin-1-yl]carbonyl}-5-methyl-3-(3,3,3--
trifluoro-2-methoxypropyl)-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidin-
e-2,4(1H,3H)-dione (Enantiomer 2)
##STR00368##
[1697] 120 mg (0.214 mmol) of the racemic compound from Ex. 81 were
dissolved in 4 ml of isopropanol and, in 13 portions, separated
into the enantiomers by preparative HPLC on a chiral phase [column:
Daicel Chiralcel OX-H, 5 .mu.m, 250 mm.times.20 mm; mobile phase:
isohexane/isopropanol 60:40; flow rate: 15 ml/min, temperature:
30.degree. C.; detection: 220 nm]. This gave, after concentration
of the product fractions and drying of the residue under high
vacuum, 58 mg (92% of theory, chem. purity 95%, >99% ee) of
enantiomer 2. Re-purification by preparative HPLC (Method 5) gave
45 mg (75% of theory) of the title compound in pure form.
[1698] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 4.46 (dd,
1H), 4.21-3.97 (m, 6H), 3.51 (s, 5H), 3.45 (br. t, 2H), 2.71-2.60
(m, 2H), 2.50 (s, 3H), 2.20 (broad, 1H), 1.94 (broad, 1H),
1.76-1.70 (m, 2H), 1.57-1.51 (m, 2H, partially obscured by the
water signal).
[1699] LC/MS (Method 1, ESIpos): R.sub.t=0.88 min, m/z=562
[M+H].sup.+.
[1700] Chiral analytical HPLC [column: LUX Cellulose 4, 5 .mu.m,
250 mm.times.4.6 mm; mobile phase: isohexane/isopropanol 60:40;
flow rate: 1 ml/min, temperature: 40.degree. C.; detection: 220
nm]: R.sub.t=10.96 min.
Example 116
6-[(3,4-Dihydroxypiperidin-1-yl)carbonyl]-3-ethyl-5-methyl-1-(3,3,3-triflu-
oropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(cis-racemate)
##STR00369##
[1702] Analogously to the process described in Ex. 51, 200 mg
(0.571 mmol) of the compound from Ex. 52A and 105 mg (0.685 mmol)
of racemic cis-3,4-dihydroxypiperidine hydrochloride [commercially
available; lit. e.g.: H. H. Jensen et al., Chemistry Eur. J. 2002,
8 (5), 1218-1226] gave 160 mg (62% of theory) of the title
compound. Purification was carried out by preparative HPLC (twice)
according to Method 5.
[1703] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 4.23-4.11
(m, 2H), 4.07 (quart, 2H), 3.97 (dt, 1H), 3.89-3.82 (m, 2H), 3.81
(t, 1H), 3.61-3.55 (m, 1H), 3.42-3.36 (m, 1H), 2.70-2.59 (m, 2H),
2.51 (s, 3H), 1.98-1.89 (m, 1H), 1.79-1.72 (m, 1H), 1.25 (t,
3H).
[1704] LC/MS (Method 1, ESIpos): R.sub.t=0.76 min, m/z=450
[M+H].sup.+.
Example 117
6-[(3,4-Dihydroxypiperidin-1-yl)carbonyl]-3-ethyl-5-methyl-1-(3,3,3-triflu-
oropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione (cis-enantiomer
1)
##STR00370##
[1706] 149 mg (0.332 mmol) of the racemic compound from Ex. 116
were dissolved in a mixture of 1 ml of methanol and 0.5 ml of
isopropanol and, in 6 portions, separated into the enantiomers by
preparative HPLC on a chiral phase [column: Daicel Chiralpak IC 5
.mu.m 250 mm.times.20 mm; mobile phase: isohexane/ethanol 50:50;
flow rate: 20 ml/min, temperature: 23.degree. C.; detection: 220
nm]. This gave, after concentration of the product fractions and
drying of the residue under high vacuum, 49 mg (63% of theory,
chem. purity 97%, 95% ee) of enantiomer 1. Subsequent stirring with
pentane gave 38 mg (51% of theory) of the title compound in pure
form.
[1707] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 4.23-4.11
(m, 2H), 4.07 (quart, 2H), 3.99-3.94 (m, 1H), 3.89-3.82 (m, 2H),
3.81 (t, 1H), 3.61-3.55 (m, 1H), 3.42-3.36 (m, 1H), 2.70-2.59 (m,
2H), 2.51 (s, 3H), 2.26 (d, 1H), 2.11 (d, 1H), 1.98-1.89 (m, 1H),
1.79-1.72 (m, 1H), 1.25 (t, 3H).
[1708] Chiral analytical HPLC [column: Daicel Chiralpak IE-3, 3
.mu.m 50 mm.times.4.6 mm; mobile phase: isohexane/ethanol 50:50;
flow rate: 1 ml/min, temperature: 40.degree. C.; detection: 220
nm]: R.sub.t=1.96 min.
Example 118
6-[(3,4-Dihydroxypiperidin-1-yl)carbonyl]-3-ethyl-5-methyl-1-(3,3,3-triflu-
oropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione (cis-enantiomer
2)
##STR00371##
[1710] 149 mg (0.332 mmol) of the racemic compound from Ex. 116
were dissolved in a mixture of 1 ml of methanol and 0.5 ml of
isopropanol and, in 6 portions, separated into the enantiomers by
preparative HPLC on a chiral phase [column: Daicel Chiralpak IC 5
.mu.m 250 mm.times.20 mm; mobile phase: isohexane/ethanol 50:50;
flow rate: 20 ml/min, temperature: 23.degree. C.; detection: 220
nm]. This gave, after concentration of the product fractions and
drying of the residue under high vacuum, 56 mg (74% of theory,
chem. purity 97%, 94% ee) of enantiomer 2. Subsequent stirring with
pentane gave 50 mg (67% of theory) of the title compound in pure
form.
[1711] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 4.23-4.11
(m, 2H), 4.07 (quart, 2H), 3.99-3.94 (m, 1H), 3.89-3.82 (m, 2H),
3.81 (t, 1H), 3.61-3.55 (m, 1H), 3.42-3.36 (m, 1H), 2.70-2.59 (m,
2H), 2.51 (s, 3H), 2.31 (broad, 1H), 2.14 (broad, 1H), 1.98-1.89
(m, 1H), 1.79-1.72 (m, 1H), 1.25 (t, 3H).
[1712] Chiral analytical HPLC [column: Daicel Chiralpak IE-3, 3
.mu.m 50 mm.times.4.6 mm; mobile phase: isohexane/ethanol 50:50;
flow rate: 1 ml/min, temperature: 40.degree. C.; detection: 220
nm]: R.sub.t=1.62 min.
Example 119
6-[(3,4-Dihydroxypiperidin-1-yl)carbonyl]-3-ethyl-5-methyl-1-(3,3,3-triflu-
oropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(cis-racemate)
##STR00372##
[1714] Analogously to the process described in Ex. 51, 200 mg
(0.571 mmol) of the compound from Ex. 52A and 105 mg (0.685 mmol)
of racemic trans-3,4-dihydroxypiperidine hydrochloride
[commercially available; lit. e.g.: H. H. Jensen et al., Chemistry
Eur. J. 2002, 8 (5), 1218-1226] gave 161 mg (62% of theory) of the
title compound. Purification was carried out by preparative HPLC
(twice) according to Method 5.
[1715] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 4.24-4.13
(m, 3H), 4.11-4.02 (m, 3H), 3.74-3.66 (m, 1H), 3.60-3.53 (m, 1H),
3.22-3.05 (m, 2H), 2.70-2.59 (m, 2H), 2.51 (s, 3H), 2.11-2.03 (m,
1H), 1.62-1.51 (m, 1H), 1.26 (t, 3H).
[1716] LC/MS (Method 1, ESIpos): R.sub.t=0.76 min, m/z=450
[M+H].sup.+.
Example 120
6-[(3,4-Dihydroxypiperidin-1-yl)carbonyl]-3-ethyl-5-methyl-1-(3,3,3-triflu-
oropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(trans-enantiomer 1)
##STR00373##
[1718] 146 mg (0.325 mmol) of the racemic compound from Ex. 119
were dissolved in 3 ml of isopropanol and, in 4 portions, separated
into the enantiomers by preparative HPLC on a chiral phase [column:
Daicel Chiralpak IC 5 .mu.m 250 mm.times.20 mm; mobile phase:
isohexane/isopropanol 40:60; flow rate: 15 ml/min, temperature:
35.degree. C.; detection: 220 nm]. This gave, after concentration
of the product fractions and drying of the residue under high
vacuum, 62 mg (84% of theory) of enantiomer 1.
[1719] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 4.20 (broad,
1H), 4.17 (m, 2H), 4.08 (broad, 1H), 4.07 (quart, 2H), 3.73-3.67
(m, 1H), 3.59-3.53 (m, 1H), 3.17 (t, 1H), 3.09 (dd, 1H), 2.70-2.59
(m, 2H), 2.51 (s, 3H), 2.48 (broad, 1H), 2.25 (broad, 1H),
2.10-2.04 (m, 1H), 1.61-1.51 (m, 1H, partially obscured by the
water signal), 1.25 (t, 3H).
[1720] Chiral analytical HPLC [column: Daicel Chiralpak IC 5 .mu.m
250 mm.times.4.6 mm; mobile phase: 40% isohexane/60% isopropanol
with 0.2% TFA and 1% water; flow rate: 1 ml/min, temperature:
40.degree. C.; detection: 220 nm]: R.sub.t=6.69 min; >99%
ee.
Example 121
6-[(3,4-Dihydroxypiperidin-1-yl)carbonyl]-3-ethyl-5-methyl-1-(3,3,3-triflu-
oropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(trans-enantiomer 2)
##STR00374##
[1722] 146 mg (0.325 mmol) of the racemic compound from Ex. 119
were dissolved in 3 ml of isopropanol and, in 4 portions, separated
into the enantiomers by preparative HPLC on a chiral phase [column:
Daicel Chiralpak IC 5 .mu.m 250 mm.times.20 mm; mobile phase:
isohexane/isopropanol 40:60; flow rate: 15 ml/min, temperature:
35.degree. C.; detection: 220 nm]. This gave, after concentration
of the product fractions and drying of the residue under high
vacuum, 62 mg (84% of theory) of enantiomer 2.
[1723] .sup.1H-NMR (400 MHz, CDCl.sub.3, .delta./ppm): 4.20 (broad,
1H), 4.17 (m, 2H), 4.08 (broad, 1H), 4.07 (quart, 2H), 3.73-3.67
(m, 1H), 3.59-3.53 (m, 1H), 3.17 (t, 1H), 3.09 (dd, 1H), 2.70-2.59
(m, 2H), 2.51 (br. s, 4H), 2.27 (broad, 1H), 2.10-2.04 (m, 1H),
1.61-1.51 (m, 1H, partially obscured by the water signal), 1.26 (t,
3H).
[1724] Chiral analytical HPLC [column: Daicel Chiralpak IC 5 .mu.m
250 mm.times.4.6 mm; mobile phase: 40% isohexane/60% isopropanol
with 0.2% TFA and 1% water; flow rate: 1 ml/min, temperature:
40.degree. C.; detection: 220 nm]: R.sub.t=5.74 min; >99%
ee.
Example 122
5-(Difluoromethyl)-3-ethyl-6-[(4-hydroxypiperidin-1-yl)carbonyl]-1-(3,3,3--
trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00375##
[1726] 23 mg (0.228 mmol) of 4-hydroxypiperidine, 95 mg (0.249
mmol) of HATU and 54 .mu.l (0.311 mmol) of
N,N-diisopropylethylamine were added successively to a solution of
80 mg (0.207 mmol) of the compound from Ex. 119A in 3 ml of
anhydrous DMF. After a reaction time of about 16 h at RT, the
reaction mixture was separated directly by preparative HPLC (Method
5) into its components. The product fractions were combined and
concentrated, and the residue was dried under high vacuum. 86 mg
(88% of theory) of the title compound were obtained.
[1727] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.33 (t,
1H), 4.81 (broad, 1H), 4.15 (t, 2H), 3.94 (broad, 1H), 3.92 (quart,
2H), 3.75 (m, 1H), 3.50 (broad, 1H), 3.21 (broad, 2H), 2.89-2.73
(m, 2H), 1.73 (broad, 2H), 1.36 (broad, 2H), 1.14 (t, 3H).
[1728] LC/MS (Method 1, ESIpos): R.sub.t=0.83 min, m/z=470
[M+H].sup.+.
Example 123
5-(Difluoromethyl)-3-ethyl-6-[(4-hydroxypiperidin-1-yl)carbonyl]-1-[2-(tri-
fluoromethoxy)ethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00376##
[1730] Analogously to the process described in Ex. 122, 100 mg
(0.249 mmol) of the compound from Ex. 120A and 30 mg (0.298 mmol)
of 4-hydroxypiperidine gave 70 mg (58% of theory) of the title
compound.
[1731] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.33 (t,
1H), 4.81 (broad, 1H), 4.43 (t, 2H), 4.26 (t, 2H), 3.96 (broad,
1H), 3.93 (quart, 2H), 3.74 (m, 1H), 3.46 (broad, 1H), 3.20 (broad,
2H), 1.72 (broad, 2H), 1.35 (broad, 2H), 1.14 (t, 3H).
[1732] LC/MS (Method 1, ESIpos): R.sub.t=0.84 min, m/z=486
[M+H].sup.+.
Example 124
5-(Difluoromethyl)-3-ethyl-6-[(4-hydroxy-4-methylpiperidin-1-yl)carbonyl]--
1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00377##
[1734] Analogously to the process described in Ex. 122, 80 mg
(0.207 mmol) of the compound from Ex. 119A and 26 mg (0.228 mmol)
of 4-methylpiperidin-4-ol [commercially available; lit. e.g.: J. M.
McManus et al., J. Med. Chem. 1965, 8 (6), 766-776] gave 87 mg (83%
of theory, purity 96%) of the title compound.
[1735] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.33 (t,
1H), 4.47 (broad, 1H), 4.15 (t, 2H), 4.06 (broad, 1H), 3.92 (quart,
2H), 3.24 (broad, 3H), 2.89-2.73 (m, 2H), 1.56-1.40 (broad, 4H),
1.15 (s, 3H), 1.14 (t, 3H).
[1736] LC/MS (Method 1, ESIpos): R.sub.t=0.88 min, m/z=484
[M+H].sup.+.
Example 125
5-(Difluoromethyl)-3-ethyl-6-[(4-ethyl-4-hydroxypiperidin-1-yl)carbonyl]-1-
-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00378##
[1738] Analogously to the process described in Ex. 122, 80 mg
(0.207 mmol) of the compound from Ex. 119A and 41 mg (0.249 mmol)
of 4-ethylpiperidin-4-ol hydrochloride [commercially available;
lit. e.g.: US 2004/0067931-A1, Example 3.232 (free base)] gave 86
mg (83% of theory) of the title compound.
[1739] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.33 (t,
1H), 4.27 (s, 1H), 4.16 (broad, 1H), 4.15 (t, 2H), 3.92 (quart,
2H), 3.36 (broad, 2H), 3.13 (broad, 1H), 2.87-2.75 (m, 2H), 1.50
(broad, 2H), 1.40 (quart, 2H), 1.39 (broad, 2H), 1.14 (t, 3H), 0.83
(t, 3H).
[1740] LC/MS (Method 1, ESIpos): R.sub.t=0.92 min, m/z=498
[M+H].sup.+.
Example 126
5-(Difluoromethyl)-3-ethyl-6-{[4-hydroxy-4-(hydroxymethyl)piperidin-1-yl]c-
arbonyl}-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00379##
[1742] Analogously to the process described in Ex. 122, 80 mg
(0.207 mmol) of the compound from Ex. 119A and 38 mg (0.228 mmol)
of 4-(hydroxymethyl)piperidin-4-ol hydrochloride [commercially
available; lit. e.g.: WO 2005/103037-A2, Example A3b (free base);
US 2011/288065-A1, Example 105/Step 1 (hydrochloride)] gave 88 mg
(85% of theory) of the title compound.
[1743] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.32 (t,
1H), 4.63 (broad, 1H), 4.36 (broad, 1H), 4.21 (broad, 1H), 4.15 (t,
2H), 3.92 (quart, 2H), 3.37 (broad, 2H), 3.20 (s, 2H), 3.10 (broad,
1H), 2.89-2.73 (m, 2H), 1.53 (dt, 2H), 1.40 (broad, 2H), 1.14 (t,
3H).
[1744] LC/MS (Method 1, ESIpos): R.sub.t=0.77 min, m/z=500
[M+H].sup.+.
Example 127
5-(Difluoromethyl)-3-ethyl-6-[(4-hydroxy-4-methylpiperidin-1-yl)carbonyl]--
1-[2-(trifluoromethoxy)ethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00380##
[1746] Analogously to the process described in Ex. 122, 100 mg
(0.249 mmol) of the compound from Ex. 120A and 34 mg (0.298 mmol)
of 4-methylpiperidin-4-ol [commercially available; lit. e.g.: J. M.
McManus et al., J. Med. Chem. 1965, 8 (6), 766-776] gave 82 mg (66%
of theory) of the title compound.
[1747] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.32 (t,
1H), 4.47 (s, 1H), 4.42 (t, 2H), 4.25 (t, 2H), 4.05 (broad, 1H),
3.92 (quart, 2H), 3.25 (broad, 3H), 1.57-1.38 (broad, 4H), 1.14 (s,
3H), 1.14 (t, 3H).
[1748] LC/MS (Method 1, ESIpos): R.sub.t=0.88 min, m/z=500
[M+H].sup.+.
Example 128
3,5-Diethyl-6-[(4-ethyl-4-hydroxypiperidin-1-yl)carbonyl]-1-(3,3,3-trifluo-
ropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00381##
[1750] Analogously to the process described in Ex. 122, 80 mg
(0.220 mmol) of the compound from Ex. 111A and 44 mg (0.263 mmol)
of 4-ethylpiperidin-4-ol hydrochloride [commercially available;
lit. e.g.: US 2004/0067931-A1, Example 3.232 (free base)] gave 100
mg (95% of theory) of the title compound.
[1751] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.27 (s,
1H), 4.12 (t, 2H), 3.92 (quart, 2H), 3.80 (broad, 2H), 3.27 (broad,
2H, partially obscured by water signal), 2.86-2.74 (m, 2H), 2.79
(quart, 2H), 1.49 (broad, 2H), 1.41 (quart, 2H), 1.38 (broad, 2H),
1.13 (t, 3H), 1.11 (t, 3H), 0.83 (t, 3H).
[1752] LC/MS (Method 1, ESIpos): R.sub.t=0.96 min, m/z=476
[M+H].sup.+.
Example 129
5-Methyl-6-[(3-oxopiperazin-1-yl)carbonyl]-3-(2-phenylethyl)-1-[2-(trifluo-
romethoxy)ethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00382##
[1754] 16 mg (0.162 mmol) of piperazin-2-one, 67 mg (0.176 mmol) of
HATU and 64 .mu.l (0.367 mmol) of N,N-diisopropylethylamine were
added successively to a solution of 65 mg (0.147 mmol) of the
compound from Ex. 118A in 2 ml of anhydrous DMF. After a reaction
time of about 16 h at RT, the reaction mixture was separated
directly by preparative HPLC (Method 5) into its components. The
product fractions were combined and concentrated, and the residue
was dried under high vacuum. 69 mg (77% of theory) of the title
compound were obtained.
[1755] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.14 (br.
s, 1H), 7.32-7.28 (m, 2H), 7.25-7.20 (m, 3H), 4.39 (t, 2H), 4.23
(t, 2H), 4.08 (m, 2H), 4.04 (s, 2H), 3.67 (t, 2H), 3.26-3.22 (m,
2H), 2.84 (m, 2H), 2.39 (s, 3H).
[1756] LC/MS (Method 1, ESIpos): R.sub.t=0.99 min, m/z=525
[M+H].sup.+.
Example 130
3-Ethyl-5-methyl-6-[(3-oxopiperazin-1-yl)carbonyl]-1-[2-(trifluoromethoxy)-
ethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00383##
[1758] 33 mg (0.328 mmol) of piperazin-2-one, 125 mg (0.328 mmol)
of HATU and 62 .mu.l (0.355 mmol) of N,N-diisopropylethylamine were
added successively to a solution of 100 mg (0.273 mmol) of the
compound from Ex. 104A in 3 ml of anhydrous DMF. After a reaction
time of 1 h at RT, the reaction mixture was separated directly by
preparative HPLC (Method 5) into its components. The product
fractions were combined and concentrated, and the residue was dried
under high vacuum. 95 mg (77% of theory) of the title compound were
obtained.
[1759] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.13 (br.
s, 1H), 4.42 (t, 2H), 4.23 (t, 2H), 4.03 (s, 2H), 3.92 (quart, 2H),
3.67 (t, 2H), 3.25-3.21 (m, 2H), 2.40 (s, 3H), 1.13 (t, 3H).
[1760] LC/MS (Method 1, ESIpos): R.sub.t=0.74 min, m/z=449
[M+H]+.
Example 131
5-(Difluoromethyl)-3-ethyl-6-[(3-oxopiperazin-1-yl)carbonyl]-1-(3,3,3-trif-
luoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00384##
[1762] Analogously to the process described in Ex. 122, 80 mg
(0.207 mmol) of the compound from Ex. 119A and 23 mg (0.228 mmol)
of piperazin-2-one gave 49 mg (50% of theory) of the title
compound. Purification was carried out by preparative HPLC (twice)
according to Method 5.
[1763] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.15 (br.
s, 1H), 7.35 (t, 1H), 4.16 (t, 2H), 4.05 (broad, 2H), 3.93 (quart,
2H), 3.75 (broad, 1H), 3.53 (broad, 1H), 3.21 (broad, 2H),
2.88-2.76 (m, 2H), 1.14 (t, 3H).
[1764] LC/MS (Method 1, ESIpos): R.sub.t=0.77 min, m/z=469
[M+H].sup.+.
Example 132
3-(2-Hydroxy-2-phenylpropyl)-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methy-
l-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(Enantiomer 1)
##STR00385##
[1766] 35 mg (0.065 mmol) of the racemic compound from Ex. 105 were
dissolved in 6 ml of isohexane/ethanol (1:1) and, in 3 portions,
separated into the enantiomers by preparative HPLC on a chiral
phase [column: Daicel Chiralpak ID 5 .mu.m 250 mm.times.20 mm;
mobile phase: isohexane/ethanol 50:50; flow rate: 20 ml/min,
temperature: 35.degree. C.; detection: 220 nm]. This gave, after
concentration of the product fractions and drying of the residue
under high vacuum, 11 mg (62% of theory) of enantiomer 1.
[1767] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.48 (d,
2H), 7.30 (t, 2H), 7.21 (t, 1H), 5.05 (s, 1H), 4.81 (d, 1H), 4.18
(quart, 2H), 4.12-4.03 (m, 2H), 3.81-3.72 (m, 3H), 3.28-3.21 (m,
2H), 2.76-2.63 (m, 2H), 2.34 (s, 3H), 1.80-1.73 (m, 2H), 1.42 (s,
3H), 1.41-1.32 (m, 2H).
[1768] Chiral analytical HPLC [column: Daicel Chiralpak IB-3, 3
.mu.m 50 mm.times.4.6 mm; mobile phase: isohexane/ethanol 50:50;
flow rate: 1 ml/min, temperature: 40.degree. C.; detection: 220
nm]: R.sub.t=1.23 min; >99% ee.
Example 133
3-(2-Hydroxy-2-phenylpropyl)-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methy-
l-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(Enantiomer 2)
##STR00386##
[1770] 35 mg (0.065 mmol) of the racemic compound from Ex. 105 were
dissolved in 6 ml of isohexane/ethanol (1:1) and, in 3 portions,
separated into the enantiomers by preparative HPLC on a chiral
phase [column: Daicel Chiralpak ID 5 .mu.m 250 mm.times.20 mm;
mobile phase: isohexane/ethanol 50:50; flow rate: 20 ml/min,
temperature: 35.degree. C.; detection: 220 nm]. This gave, after
concentration of the product fractions and drying of the residue
under high vacuum, 10 mg (57% of theory) of enantiomer 2.
[1771] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.48 (d,
2H), 7.30 (t, 2H), 7.21 (t, 1H), 5.05 (s, 1H), 4.81 (d, 1H), 4.18
(quart, 2H), 4.12-4.03 (m, 2H), 3.82-3.72 (m, 3H), 3.28-3.21 (m,
2H), 2.76-2.63 (m, 2H), 2.34 (s, 3H), 1.81-1.73 (m, 2H), 1.42 (s,
3H), 1.41-1.32 (m, 2H).
[1772] Chiral analytical HPLC [column: Daicel Chiralpak IB-3, 3
.mu.m 50 mm.times.4.6 mm; mobile phase: isohexane/ethanol 50:50;
flow rate: 1 ml/min, temperature: 40.degree. C.; detection: 220
nm]: R.sub.t=1.10 min; >99% ee.
Example 134
3-Ethyl-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methyl-1-(3-methylbutyl)th-
ieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00387##
[1774] 135 mg (0.300 mmol) of the compound from Ex. 130A were
dissolved in 5 ml of ethanol/THF (1:1), and 360 .mu.l (0.360 mmol)
of a 1 M solution of lithium hydroxide in water were added. After
stirring at RT for about 16 h, 250 .mu.l of glacial acetic acid
were added and the reaction mixture was diluted with about 200 ml
of ethyl acetate. The mixture was washed successively twice with
water and once with saturated sodium chloride solution. After
drying over anhydrous magnesium sulphate, the mixture was filtered
and concentrated to dryness. 115 mg (94% of theory) of the title
compound were obtained.
[1775] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.79 (d,
1H), 3.92-3.88 (m, 2H), 3.91 (quart, 2H), 3.81-3.70 (m, 3H), 3.23
(m, 2H), 2.37 (s, 3H), 1.79-1.72 (m, 2H), 1.65 (sept, 1H),
1.59-1.54 (m, 2H), 1.39-1.31 (m, 2H), 1.12 (t, 3H), 0.94 (d,
6H).
[1776] LC/MS (Method 1, ESIpos): R.sub.t=0.91 min, m/z=408
[M+H].sup.+.
Example 135
3-Ethyl-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methyl-1-(4,4,4-trifluorob-
utyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00388##
[1778] Analogously to the process described in Ex. 134, 150 mg
(0.306 mmol) of the compound from Ex. 131A gave 127 mg (92% of
theory) of the title compound. Here, at RT the product was stirred
with a mixture of 10 ml of pentane and 2 ml of diethyl ether for 10
min.
[1779] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.79 (d,
1H), 3.97 (t, 2H), 3.90 (quart, 2H), 3.81-3.71 (m, 3H), 3.23 (m,
2H), 2.46-2.40 (m, 2H), 2.38 (s, 3H), 1.91 (quint, 2H), 1.79-1.72
(m, 2H), 1.39-1.31 (m, 2H), 1.12 (t, 3H).
[1780] LC/MS (Method 1, ESIpos): R.sub.t=0.83 min, m/z=448
[M+H].sup.+.
Example 136
3-Ethyl-6-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methyl-1-(3,4,4-trifluorob-
ut-3-en-1-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00389##
[1782] 69 mg (0.143 mmol) of the compound from Ex. 132A were
dissolved in 2.5 ml of ethanol/THF (1:1), and 158 .mu.l (0.158
mmol) of a 1 M solution of lithium hydroxide in water were added.
After stirring at RT for 2 h, the reaction mixture was concentrated
to dryness. The residue was taken up in 3 ml of dichloromethane and
1 ml of water and stirred vigorously. The aqueous phase was then
separated off via an Extrelut.RTM.-NT3 cartridge. Concentration of
the organic phase and drying of the residue under high vacuum gave
57 mg (89% of theory, 98% pure) of the title compound.
[1783] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.80 (d,
1H), 4.10 (t, 2H), 3.91 (quart, 2H), 3.80-3.71 (m, 3H), 3.23 (m,
2H), 2.81 (m, 2H), 2.38 (s, 3H), 1.79-1.72 (m, 2H), 1.39-1.31 (m,
2H), 1.12 (t, 3H).
[1784] LC/MS (Method 1, ESIpos): R.sub.t=0.81 min, m/z=446
[M+H].sup.+.
Example 137
5-(Difluoromethyl)-6-[(4-hydroxypiperidin-1-yl)carbonyl]-3-isobutyl-1-[2-(-
trifluoromethoxy)ethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00390##
[1786] 28 mg (0.279 mmol) of 4-hydroxypiperidine, 106 mg (0.279
mmol) of HATU and 53 .mu.l (0.302 mmol) of
N,N-diisopropylethylamine were added successively to a solution of
100 mg (0.232 mmol) of the compound from Ex. 138A in 3 ml of
anhydrous DMF. After a reaction time of about 16 h at RT, the
reaction mixture was separated directly by preparative HPLC (Method
5) into its components. The product fractions were combined and
concentrated, and the residue was dried under high vacuum. 102 mg
(85% of theory) of the title compound were obtained.
[1787] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.32 (t,
1H), 4.81 (d, 1H), 4.42 (t, 2H), 4.26 (t, 2H), 3.95 (broad, 1H),
3.75 (m, 1H), 3.73 (d, 2H), 3.48 (broad, 1H), 3.20 (broad, 2H),
2.04 (m, 1H), 1.72 (broad, 2H), 1.35 (broad, 2H), 0.86 (d, 6H).
[1788] LC/MS (Method 1, ESIpos): R.sub.t=0.96 min, m/z=514
[M+H].sup.+.
Example 138
5-(Difluoromethyl)-6-[(4-hydroxy-4-methylpiperidin-1-yl)carbonyl]-3-isobut-
yl-1-[2-(trifluoromethoxy)ethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00391##
[1790] Analogously to the process described in Ex. 137, 100 mg
(0.232 mmol) of the compound from Ex. 138A and 32 mg (0.279 mmol)
of 4-methylpiperidin-4-ol [commercially available; lit. e.g.: J. M.
McManus et al., J. Med. Chem. 1965, 8 (6), 766-776] gave 55 mg (44%
of theory) of the title compound. In deviation from the process
described above, here the first preparative HPLC purification
(according to Method 5) was followed by a second HPLC purification
on [column: Kinetix C18, 5 .mu.m, 100 mm.times.21.5 mm; mobile
phase: 50% water, 45% acetonitrile, 5% formic acid (1% in water);
flow rate: 25 ml/min, temperature: 25.degree. C.; detection: 210
nm].
[1791] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.31 (t,
1H), 4.47 (s, 1H), 4.42 (t, 2H), 4.25 (t, 2H), 4.06 (broad, 1H),
3.73 (d, 2H), 3.22 (broad, 3H), 2.04 (m, 1H), 1.52 (broad, 1H),
1.43 (broad, 3H), 1.14 (s, 3H), 0.86 (d, 6H).
[1792] LC/MS (Method 1, ESIpos): R.sub.t=1.01 min, m/z=528
[M+H].sup.+.
Example 139
5-(Difluoromethyl)-6-[(4-hydroxypiperidin-1-yl)carbonyl]-3-isobutyl-1-(3,3-
,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00392##
[1794] Analogously to the process described in Ex. 137, 100 mg
(0.241 mmol) of the compound from Ex. 139A and 29 mg (0.290 mmol)
of 4-hydroxypiperidine gave 109 mg (90% of theory) of the title
compound.
[1795] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.32 (t,
1H), 4.81 (d, 1H), 4.15 (t, 2H), 3.96 (broad, 1H), 3.75 (m, 1H),
3.73 (d, 2H), 3.51 (broad, 1H), 3.21 (broad, 2H), 2.81 (m, 2H),
2.04 (m, 1H), 1.73 (broad, 2H), 1.36 (broad, 2H), 0.87 (d, 6H).
[1796] LC/MS (Method 1, ESIpos): R.sub.t=0.94 min, m/z=498
[M+H].sup.+.
Example 140
5-(Difluoromethyl)-6-[(4-hydroxy-4-methylpiperidin-1-yl)carbonyl]-3-isobut-
yl-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00393##
[1798] Analogously to the process described in Ex. 138, 100 mg
(0.241 mmol) of the compound from Ex. 139A and 33 mg (0.279 mmol)
of 4-methylpiperidin-4-ol [commercially available; lit. e.g.: J. M.
McManus et al., J. Med. Chem. 1965, 8 (6), 766-776] gave 47 mg (38%
of theory) of the title compound.
[1799] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.31 (t,
1H), 4.47 (s, 1H), 4.15 (t, 2H), 4.06 (broad, 1H), 3.73 (d, 2H),
3.35 (broad, 2H), 3.22 (broad, 1H), 2.81 (m, 2H), 2.04 (m, 1H),
1.52 (broad, 1H), 1.44 (broad, 3H), 1.15 (s, 3H), 0.87 (d, 6H).
[1800] LC/MS (Method 1, ESIpos): R.sub.t=1.00 min, m/z=512
[M+H].sup.+.
Example 141
5-(Difluoromethyl)-6-[(4-hydroxypiperidin-1-yl)carbonyl]-3-propyl-1-(3,3,3-
-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00394##
[1802] Analogously to the process described in Ex. 137, 55 mg
(0.137 mmol) of the compound from Ex. 148A and 17 mg (0.165 mmol)
of 4-hydroxypiperidine gave 54 mg (81% of theory) of the title
compound.
[1803] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.32 (t,
1H), 4.81 (broad, 1H), 4.15 (t, 2H), 3.95 (broad, 1H), 3.84 (t,
2H), 3.75 (broad, 1H), 3.50 (broad, 1H), 3.21 (broad, 2H),
2.89-2.75 (m, 2H), 1.73 (broad, 2H), 1.58 (m, 2H), 1.36 (broad,
2H), 0.88 (t, 3H).
[1804] LC/MS (Method 1, ESIpos): R.sub.t=0.88 min, m/z=484
[M+H]+.
Example 142
5-(Difluoromethyl)-6-[(4-hydroxy-4-methylpiperidin-1-yl)carbonyl]-3-propyl-
-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00395##
[1806] Analogously to the process described in Ex. 137, 55 mg
(0.137 mmol) of the compound from Ex. 148A and 19 mg (0.165 mmol)
of 4-methylpiperidin-4-ol [commercially available; lit. e.g.: J. M.
McManus et al., J. Med. Chem. 1965, 8 (6), 766-776] gave 56 mg (78%
of theory, purity 95%) of the title compound.
[1807] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.32 (t,
1H), 4.47 (broad, 1H), 4.15 (t, 2H), 4.05 (broad, 1H), 3.84 (t,
2H), 3.25 (broad, 3H), 2.87-2.75 (m, 2H), 1.58 (m, 2H), 1.55
(broad, 2H), 1.44 (broad, 2H), 1.15 (s, 3H), 0.88 (t, 3H).
[1808] LC/MS (Method 1, ESIpos): R.sub.t=0.94 min, m/z=498
[M+H]+.
Example 143
3-Ethyl-5-(fluoromethyl)-6-[(4-hydroxypiperidin-1-yl)carbonyl]-1-(3,3,3-tr-
ifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00396##
[1810] Analogously to the process described in Ex. 137, 40 mg
(0.109 mmol) of the compound from Ex. 149A and 13 mg (0.130 mmol)
of 4-hydroxypiperidine gave 46 mg (93% of theory) of the title
compound. In this case, the reaction time was 1 h, and purification
by preparative HPLC was carried out according to Method 19.
[1811] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 5.57 (d,
2H), 4.15 (t, 2H), 3.92 (quart, 2H), 3.87-3.58 (broad and m,
together 4H), 3.28-3.20 (m, 2H), 2.87-2.75 (m, 2H), 1.78-1.71 (m,
2H), 1.41-1.31 (m, 2H), 1.14 (t, 3H).
[1812] LC/MS (Method 1, ESIpos): R.sub.t=0.81 min, m/z=452
[M+H].sup.+.
Example 144
3-Ethyl-5-(fluoromethyl)-6-[(4-hydroxy-4-methylpiperidin-1-yl)carbonyl]-1--
(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00397##
[1814] Analogously to the process described in Ex. 137, 60 mg
(0.163 mmol) of the compound from Ex. 149A and 30 mg (0.195 mmol)
of 4-methylpiperidin-4-ol [commercially available; lit. e.g.: J. M.
McManus et al., J. Med. Chem. 1965, 8 (6), 766-776] gave 53 mg (69%
of theory) of the title compound. In this case, the reaction time
was 1 h, and purification by preparative HPLC was carried out
according to Method 19.
[1815] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 5.57 (d,
2H), 4.15 (t, 2H), 3.92 (quart, 2H), 3.36-3.27 (m, 2H), 2.87-2.75
(m, 2H), 1.52-1.40 (m, 4H), 1.15 (s, 3H), 1.14 (t, 3H).
[1816] LC/MS (Method 1, ESIpos): R.sub.t=0.84 min, m/z=466
[M+H].sup.+.
Example 145
3-Ethyl-5-(1-fluoroethyl)-6-[(4-hydroxypiperidin-1-yl)carbonyl]-1-(3,3,3-t-
rifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(Racemate)
##STR00398##
[1818] Analogously to the process described in Ex. 137, 11 mg
(0.029 mmol) of the compound from Ex. 150A and 3.5 mg (0.035 mmol)
of 4-hydroxypiperidine gave 13 mg (97% of theory) of the title
compound. In this case, the reaction time was 1 h, and purification
by preparative HPLC was carried out according to Method 19.
[1819] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 6.20 (d of
quart, 1H), 4.19-4.06 (m, 4H), 3.91 (quart, 2H), 3.76-3.70 (m, 1H),
3.25-3.11 (m, 2H), 2.86-2.74 (m, 2H), 1.76-1.66 (m, 2H), 1.61 (dd,
3H), 1.39-1.29 (m, 2H), 1.13 (t, 3H).
[1820] LC/MS (Method 1, ESIpos): R.sub.t=0.81 min, m/z=466
[M+H]+.
Example 146
3-Ethyl-5-(1-fluoroethyl)-6-[(4-hydroxy-4-methylpiperidin-1-yl)carbonyl]-1-
-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
(Racemate)
##STR00399##
[1822] Analogously to the process described in Ex. 137, 80 mg
(0.178 mmol, purity 85%) of the compound from Ex. 150A and 32 mg
(0.213 mmol) of 4-methylpiperidin-4-ol hydrochloride [commercially
available; lit. e.g.: J. M. McManus et al., J. Med. Chem. 1965, 8
(6), 766-776] gave 46 mg (53% of theory) of the title compound. In
this case, the reaction time was 1 h, and purification by
preparative HPLC was carried out according to Method 19.
[1823] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 6.20 (d of
quart, 1H), 4.44 (broad, 1H), 4.19-4.05 (m, 2H), 3.91 (quart, 2H),
3.24 (broad, 2H), 2.86-2.74 (m, 2H), 1.61 (dd, 3H), 1.52-1.37 (m,
4H), 1.14 (s, 3H), 1.13 (t, 3H).
[1824] LC/MS (Method 1, ESIpos): R.sub.t=0.89 min, m/z=480
[M+H].sup.+.
Example 147
3-Ethyl-5-(1-fluoroethyl)-6-[(3-oxopiperazin-1-yl)carbonyl]-1-(3,3,3-trifl-
uoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione (Racemate)
##STR00400##
[1826] Analogously to the process described in Ex. 137, 100 mg
(0.222 mmol, purity 85%) of the compound from Ex. 150A and 27 mg
(0.267 mmol) of 2-oxopiperazine gave 72 mg (66% of theory, purity
95%) of the title compound. In this case, the reaction time was 1
h, and purification by preparative HPLC was carried out according
to Method 19.
[1827] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.12 (s,
1H), 6.23 (d of quart, 1H), 4.19-4.07 (m, 2H), 3.91 (quart, 2H),
3.60-3.48 (broad, 4H), 3.22-3.18 (broad, 2H), 2.87-2.75 (m, 2H),
1.61 (dd, 3H), 1.13 (t, 3H).
[1828] LC/MS (Method 17, ESIpos): R.sub.t=2.09 min, m/z=465
[M+H].sup.+.
Example 148
3-Ethyl-5-(1-fluoroethyl)-6-[(3-oxopiperazin-1-yl)carbonyl]-1-(3,3,3-trifl-
uoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione (Enantiomer
1)
##STR00401##
[1830] 60 mg (0.123 mmol) of the racemic compound from Ex. 147 were
dissolved in 7 ml of methanol/ethanol/acetonitrile (1:1:1) and, in
4 portions, separated into the enantiomers by preparative SFC-HPLC
on a chiral phase [column: Daicel Chiralpak IC 5 .mu.m 250
mm.times.20 mm; mobile phase: carbon dioxide/ethanol 75:25; flow
rate: 60 ml/min, temperature: 40.degree. C.; detection: 210 nm].
This gave, after concentration of the product fractions and drying
of the residue under high vacuum, 12 mg (42% of theory) of
enantiomer 1.
[1831] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.12 (s,
1H), 6.23 (d of quart, 1H), 4.19-4.08 (m, 2H), 3.97 (broad, 2H),
3.91 (quart, 2H), 3.56 (broad, 2H), 3.20 (broad, 2H), 2.86-2.76 (m,
2H), 1.61 (dd, 3H), 1.13 (t, 3H).
[1832] LC/MS (Method 1, ESIpos): R.sub.t=0.78 min, m/z=465
[M+H].sup.+.
[1833] Chiral analytical SFC [column: Daicel Chiralpak IC 3 .mu.m
250 mm.times.4.6 mm; mobile phase: carbon dioxide/methanol
95:5.fwdarw.50:50; flow rate: 3 ml/min, temperature: 40.degree. C.;
detection: 210 nm]: R.sub.t=2.91 min; >99% ee.
Example 149
3-Ethyl-5-(1-fluoroethyl)-6-[(3-oxopiperazin-1-yl)carbonyl]-1-(3,3,3-trifl-
uoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione (Enantiomer
2)
##STR00402##
[1835] 60 mg (0.123 mmol) of the racemic compound from Ex. 147 were
dissolved in 7 ml of methanol/ethanol/acetonitrile (1:1:1) and, in
4 portions, separated into the enantiomers by preparative SFC-HPLC
on a chiral phase [column: Daicel Chiralpak IC 5 .mu.m 250
mm.times.20 mm; mobile phase: carbon dioxide/ethanol 75:25; flow
rate: 60 ml/min, temperature: 40.degree. C.; detection: 210 nm].
This gave, after concentration of the product fractions and drying
of the residue under high vacuum, 12 mg (42% of theory) of
enantiomer 2.
[1836] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 8.12 (s,
1H), 6.23 (d of quart, 1H), 4.18-4.08 (m, 2H), 3.96 (broad, 2H),
3.91 (quart, 2H), 3.57 (broad, 2H), 3.20 (broad, 2H), 2.86-2.76 (m,
2H), 1.61 (dd, 3H), 1.13 (t, 3H).
[1837] LC/MS (Method 1, ESIpos): R.sub.t=0.78 min, m/z=465
[M+H].sup.+.
[1838] Chiral analytical SFC [column: Daicel Chiralpak IC 3 .mu.m
250 mm.times.4.6 mm; mobile phase: carbon dioxide/methanol
95:5.fwdarw.50:50; flow rate: 3 ml/min, temperature: 40.degree. C.;
detection: 210 nm]: R.sub.t=3.48 min; >99% ee.
Example 150
5-(Difluoromethyl)-6-[(4-hydroxypiperidin-1-yl)carbonyl]-3-propyl-1-[2-(tr-
ifluoromethoxy)ethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00403##
[1840] Analogously to the process described in Ex. 137, 100 mg
(0.240 mmol) of the compound from Ex. 154A and 29 mg (0.288 mmol)
of 4-hydroxypiperidine gave 93 mg (77% of theory) of the title
compound.
[1841] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.32 (t,
1H), 4.81 (d, 1H), 4.42 (t, 2H), 4.25 (t, 2H), 3.95 (broad, 1H),
3.85 (t, 2H), 3.74 (m, 1H), 3.47 (broad, 1H), 3.20 (broad, 2H),
1.72 (broad, 2H), 1.58 (m, 2H), 1.35 (broad, 2H), 0.87 (t, 3H).
[1842] LC/MS (Method 1, ESIpos): R.sub.t=0.89 min, m/z=500
[M+H]+.
Example 151
5-(Difluoromethyl)-6-[(4-hydroxy-4-methylpiperidin-1-yl)carbonyl]-3-propyl-
-1-[2-(trifluoromethoxy)ethyl]thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00404##
[1844] Analogously to the process described in Ex. 137, 100 mg
(0.240 mmol) of the compound from Ex. 154A and 33 mg (0.165 mmol)
of 4-methylpiperidin-4-ol [commercially available; lit. e.g.: J. M.
McManus et al., J. Med. Chem. 1965, 8 (6), 766-776] gave 65 mg (52%
of theory) of the title compound. In deviation from the process
described above, here the first preparative HPLC purification
(according to Method 5) was followed by a second HPLC purification
on [column: XBridge C18, 5 .mu.m, 100 mm.times.30 mm; mobile phase:
water/acetonitrile/1% aq. ammonia 55:40:5; flow rate: 75 ml/min,
temperature: 40.degree. C.; detection: 210 nm].
[1845] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 7.31 (t,
1H), 4.48 (s, 1H), 4.42 (t, 2H), 4.25 (t, 2H), 4.05 (broad, 1H),
3.85 (t, 2H), 3.30 (broad, 1H), 3.21 (broad, 2H), 1.58 (m, 2H),
1.53 (broad, 2H), 1.43 (broad, 2H), 1.14 (s, 3H), 0.87 (t, 3H).
[1846] LC/MS (Method 1, ESIpos): R.sub.t=0.94 min, m/z=514
[M+H].sup.+.
Example 152
6-{[4-Hydroxy-4-(hydroxymethyl)piperidin-1-yl]carbonyl}-3-isobutyl-5-methy-
l-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
##STR00405##
[1848] Analogously to the process described in Ex. 122, 100 mg
(0.264 mmol) of the compound from Ex. 160A and 53 mg (0.317 mmol)
of 4-(hydroxymethyl)piperidin-4-ol hydrochloride [commercially
available; lit. e.g.: WO 2005/103037-A2, Example A3b (free base);
US 2011/288065-A1, Example 105/Step 1 (hydrochloride)] gave 106 mg
(81% of theory) of the title compound. In this case, the reaction
time was 30 min.
[1849] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.64 (t,
1H), 4.36 (s, 1H), 4.13 (t, 2H), 3.85 (broad, 2H), 3.72 (d, 2H),
3.28 (br. t, 2H), 3.21 (d, 2H), 2.85-2.73 (m, 2H), 2.37 (s, 3H),
2.04 (m, 1H), 1.55 (br. dt, 2H), 1.40 (br. d, 2H), 0.86 (d,
6H).
[1850] LC/MS (Method 1, ESIpos): R.sub.t=0.82 min, m/z=492
[M+H].sup.+.
Example 153
3-(Cyclopropylmethyl)-6-{[4-hydroxy-4-(hydroxymethyl)piperidin-1-yl]carbon-
yl}-5-methyl-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-d-
ione
##STR00406##
[1852] Analogously to the process described in Ex. 122, 100 mg
(0.266 mmol) of the compound from Ex. 161A and 53 mg (0.319 mmol)
of 4-(hydroxymethyl)piperidin-4-ol hydrochloride [commercially
available; lit. e.g.: WO 2005/103037-A2, Example A3b (free base);
US 2011/288065-A1, Example 105/Step 1 (hydrochloride)] gave 45 mg
(34% of theory) of the title compound. In this case, the reaction
time was 30 min.
[1853] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.64
(broad, 1H), 4.36 (br. s, 1H), 4.14 (t, 2H), 3.85 (broad, 2H), 3.77
(d, 2H), 3.27 (br. t, 2H), 3.21 (broad, 2H), 2.86-2.74 (m, 2H),
2.38 (s, 3H), 1.55 (br. dt, 2H), 1.40 (br. d, 2H), 1.17 (m, 1H),
0.45-0.40 (m, 2H), 0.36-0.32 (m, 2H).
[1854] LC/MS (Method 1, ESIpos): R.sub.t=0.78 min, m/z=490
[M+H].sup.+.
Example 154
6-{[4-Hydroxy-4-(hydroxymethyl)piperidin-1-yl]carbonyl}-3-(2-methoxypropyl-
)-5-methyl-1-(3,3,3-trifluoropropyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dio-
ne (Racemate)
##STR00407##
[1856] Analogously to the process described in Ex. 122, 99 mg
(0.166 mmol, purity 66%) of the compound from Ex. 162A and 33 mg
(0.199 mmol) of 4-(hydroxymethyl)piperidin-4-ol hydrochloride
[commercially available; lit. e.g.: WO 2005/103037-A2, Example A3b
(free base); US 2011/288065-A1, Example 105/Step 1 (hydrochloride)]
gave 37 mg (44% of theory) of the title compound. Here, the
reaction time was 30 min.
[1857] .sup.1H-NMR (400 MHz, DMSO-d.sub.6, .delta./ppm): 4.64 (t,
1H), 4.37 (s, 1H), 4.15-4.11 (m, 2H), 4.06 (dd, 1H), 3.85 (broad,
2H), 3.77 (dd, 1H), 3.68-3.60 (m, 1H), 3.28 (broad, 2H), 3.22 (s,
3H), 3.21 (d, 2H), 2.85-2.73 (m, 2H), 2.38 (s, 3H), 1.55 (br. dt,
2H), 1.40 (br. d, 2H), 1.06 (d, 3H).
[1858] LC/MS (Method 1, ESIpos): R.sub.t=0.75 min, m/z=508
[M+H].sup.+.
B. ASSESSMENT OF PHARMACOLOGICAL EFFICACY
[1859] The pharmacological activity of the compounds according to
the invention can be demonstrated by in vitro and in vivo studies,
as known to the person skilled in the art. The application examples
which follow describe the biological action of the compounds
according to the invention, without restricting the invention to
these examples.
B-1. Cellular In Vitro Tests for Determining A2b Receptor Activity
and Adenosine Receptor Selectivity
[1860] The identification of selective antagonists of the human
adenosine A2b receptor and the quantification of the efficacy and
selectivity of the compounds according to the invention was carried
out with the aid of recombinant cell lines for the human adenosine
receptors A1, A2a, A2b and A3. These cell lines were originally
derived from an ovarepithelial cell of the hamster (Chinese Hamster
Ovary, CHO-K1, American Type Culture Collection, Manassas, Va.
20108, USA). In addition to the respective recombinantly expressed
adenosine receptor for testing the efficacy at the A1, A2a and A2b
receptors, the cell lines contain a reporter gene construct where
expression of the firefly (Photinus pyralis) luciferase is under
the control of a promoter which can be activated via intracellular
signal cascades by stimulation of the receptors with the (not
subtype-selective) adenosine receptor agonist NECA
(5'-N-ethylcarboxamidoadenosine) [S. J. Hill, J. G. Baker, S.
Rhees, Curr. Opin. Pharmacol. 1, 526-532 (2001)].
[1861] In the case of the A2a and A2b cell lines, this is a minimal
promoter having a plurality of cAMP-responsive elements (CRE).
Stimulation of the G.sub.s-coupled A2b or A2a receptors by NECA
ultimately leads, via formation of cAMP, to CRE-dependent induction
of luciferase expression, which is detected 3 hours after the start
of the incubation with NECA using a detection solution in a
suitable luminometer. For testing the antagonists, initially, in a
pre-experiment, the concentration of NECA which, at the test day in
question, results in half-maximum stimulation of luciferase
expression (EC.sub.50 concentration) is determined. By joint
incubation of this EC.sub.50 concentration of NECA with the
substances to be tested, it is possible to determine their
antagonistic activity.
[1862] The cell line for testing the G.sub.i-coupled A1 receptor
contains a different reporter gene construct where expression of
the firefly luciferase is under the control of an NFAT (nuclear
factor of activated T-cells) promoter. This cell line was, in
addition to the A1 receptor and the NFAT reporter gene, also stably
transfected with a further gene coding for the promiscuous
G.alpha..sub.16 protein [T. T. Amatruda, D. A. Steele, V. Z.
Slepak, M. I. Simon, Proc. Natl. Acad. Sci. USA 88, 5587-5591
(1991)], either independently or as a fusion gene. The resulting
test cells react to stimulation of the usually G.sub.i-coupled A1
receptor with an increased intracellular calcium concentration
which then leads to a NFAT-dependent luciferase expression. The
procedure of the experiment for testing the antagonists at the A1
receptor corresponds to the procedure for testing with the A2a and
A2b cell lines.
[1863] During generation of the A3 receptor cell line,
co-transfection of the A3 receptor and the promiscuous
G.alpha..sub.16 protein were also carried out so that here, too,
stimulation of the receptor leads to an increased intracellular
calcium concentration. However, in the A3 receptor test, this
increase in calcium is measured directly via the calcium-sensitive
photoprotein Photina.RTM. [S. Bovolenta, M. Foti, S. Lohmer, S.
Corazza, J. Biomol. Screen. 12, 694-704 (2007)]. After
determination of the EC.sub.50 concentration of NECA, the effects
of the substance were measured after 5-10 minutes of pre-incubation
with substance by addition of this EC.sub.50 concentration in
measuring position in a suitable luminometer capable of
dispensing.
[1864] The IC.sub.50 values from the A2b receptor assay for
individual working examples are given in Table 1 below (in some
cases as means of a plurality of independent individual
determinations and rounded to two significant digits):
TABLE-US-00001 TABLE 1 A2b receptor Example No. IC.sub.50 [nmol/l]
1 37 2 44 3 290 4 25 5 52 6 13 7 110 8 20 9 52 10 310 11 510 12 65
13 100 14 190 15 32 16 38 17 350 18 57 19 92 20 340 21 25 22 67 23
43 24 13 25 49 26 17 27 41 28 150 29 21 30 53 31 16 32 110 33 67 34
120 35 120 36 200 37 340 38 140 39 220 40 230 41 26 42 88 43 6.3 44
4.6 45 150 46 7.9 47 4.4 48 59 49 68 50 150 51 16 52 210 53 170 54
76 55 250 56 19 57 130 58 380 59 370 60 12 61 17 62 120 63 210 64
45 65 96 66 280 67 13 68 20 69 60 70 28 71 420 72 17 73 53 74 110
75 33 76 27 77 75 78 350 79 8.0 80 27 81 170 82 23 83 56 84 19 85
9.5 86 12 87 26 88 8.7 89 35 90 440 91 260 92 370 93 36 94 490 95
140 96 65 97 7.0 98 100 99 10 100 29 101 1200 102 3.6 103 16 104
9.1 105 69 106 19 107 45 108 580 109 3.9 110 14 111 4.0 112 7.9 113
70 114 110 115 610 116 200 117 140 118 200 119 210 120 130 121 180
122 32 123 18 124 37 125 48 126 84 127 9.5 128 13 129 12 130 9.0
131 34 132 24 133 850 134 360 135 94 136 310 137 12 138 15 139 39
140 39 141 57 142 53 143 82 144 170 145 97 146 40 147 100 148 240
149 320 150 9.8 151 14
B-2. Measurement of NECA-Induced IL-6 Release by LL29
Fibroblasts
[1865] Stimulation of fibroblasts with adenosine or the adenosine
analog 5'-N-ethylcarboxamidoadenosine (NECA) leads to release of
the pro-inflammatory and pro-fibrotic cytokine IL-6 which can be
prevented by inhibition of the A2b receptor.
[1866] Accordingly, confluent cells of the human fibroblast cell
line LL29 were treated with the test substances and stimulated with
NECA (10 .mu.M). After an incubation time of 24 hours, the cell
supernatant is removed and human IL-6 in the cell supernatant is
determined by ELISA (Quantikine.RTM. IL6 ELISA, R&D Systems,
Minneapolis, USA).
[1867] The IC.sub.50 values from this assay for representative
working examples are given in Table 2 below (in some cases as means
of a plurality of independent individual determinations and rounded
to two significant digits):
TABLE-US-00002 TABLE 2 Example No. IC.sub.50 [nmol/l] 1 59 2 53 4
39 6 27 8 34 16 89 18 170 21 69 24 10 26 53 29 23 31 16 32 230 33
140 35 250 41 29 54 330 74 250 88 9 89 48
B-3. Animal Model of Monocrotaline-Induced Pulmonary
Hypertension
[1868] Monocrotaline-induced pulmonary hypertension of the rat is a
widely used animal model of pulmonary hypertension. The
pyrrolizidine alkaloid monocrotaline is, after subcutaneous
injection, metabolized in the liver to the toxic
monocrotalinepyrrole, and within a few days endothelium injury in
the pulmonary circulation results, followed by remodeling of the
small pulmonary arteries (mediahypertrophy, de novo
muscularization). A single subcutaneous injection suffices to
induce pronounced pulmonary hypertension in rats within 4 weeks
[Cowan et al., Nature Med. 6, 698-702 (2000)].
[1869] Male Sprague-Dawley rats are used for the model. On day 0,
the animals receive a subcutaneous injection of 60 mg of
monocrotaline/kg. Treatment of the animals with the test substance
(by gavage, by addition to the feed or drinking water, using an
osmotic minipump, by subcutaneous or intraperitoneal injection or
by inhalation) starts 14 days after the monocrotaline injection at
the earliest and extends over a period of at least 14 days. At the
end of the study, the animals are examined haemodynamically. For
the haemodynamic measurement, the rats are initially anaesthetized
with pentobarbital (60 mg/kg). The animals are then tracheotomized
and artificially ventilated (frequency: 60 breaths/min; ratio
inspiration to expiration: 50:50; positive end-expiratory pressure:
1 cm H.sub.2O; tidal volume: 10 ml/kg of body weight; FIO.sub.2:
0.5). Anaesthesia is maintained by inhalative isofluran
anaesthesia. The systemic blood pressure is determined in the left
carotid artery using a Millar microtip catheter. A polyethylene
catheter is advanced via the right jugular vein into the right
ventricle to determine the right-ventricular pressure. Following
the haemodynamic measurements, the heart is removed, the ratio of
right to left ventricle including septum is determined and the
tissue is deep-frozen for expression analyses. The lung is likewise
removed, the left half of the lung is fixed in formalin for
histopathological examination and the right half of the lung is
deep-frozen for expression analyses. Furthermore, plasma samples
are obtained to determine biomarkers (for example proBNP) and
plasma substance concentrations.
B-4. Animal Model of SU5416/Hypoxia-Induced Pulmonary
Hypertension
[1870] SU5416/hypoxia-induced pulmonary hypertension of the rat is
a widely used animal model of pulmonary hypertension. By injection
of the VEGF receptor antagonist SU5416 in combination with hypoxia,
the effect of the reduced oxygen content may be enhanced, leading
to changes in the endothelium in the form of plexiform lesions. A
single subcutaneous injection, generally of 20 mg/kg, is, in
combination with hypoxia, i.e. increased vascular shear forces by
vasoconstriction, sufficient to induce severe pulmonary
hypertension [Oka et al., Circ. Res. 100 (8), 923-929 (2007)].
[1871] Male Sprague-Dawley rats or Dahl-Salz rats are used for the
model. On day 0, the animals receive a subcutaneous injection of
SU5416 and are kept in a controlled hypoxic atmosphere (10%
oxygen). Corresponding control rats receive an injection of vehicle
and are kept under normoxic conditions. Chronic hypoxia of at least
14 days with subsequent normoxia of at least 28 days leads to the
development of pulmonary hypertension which can be demonstrated
both functionally and morphologically. Treatment of the animals
with the test substance (by gavage, by addition to the feed or
drinking water, using an osmotic minipump, by subcutaneous or
intraperitoneal injection or by inhalation) starts 14 days after
the SU5416 injection and at the beginning of the animals being kept
in a controlled hypoxic atmosphere at the earliest and extends over
a period of at least 14-28 days.
[1872] At the end of the study, the animals are examined
haemodynamically. For the haemodynamic measurement, the rats are
initially anaesthetized with pentobarbital (60 mg/kg). The animals
are then tracheotomized and artificially ventilated (frequency: 60
breaths/min; ratio inspiration to expiration: 50:50; positive
end-expiratory pressure: 1 cm H.sub.2O; tidal volume: 10 ml/kg of
body weight; FIO.sub.2: 0.5). Anaesthesia is maintained by
inhalative isofluran anaesthesia. The systemic blood pressure is
determined in the left carotid artery using a Millar microtip
catheter. A polyethylene catheter is advanced via the right jugular
vein into the right ventricle to determine the right-ventricular
pressure. Following the haemodynamic measurements, the heart is
removed, the ratio of right to left ventricle including septum is
determined and the tissue is deep-frozen for expression analyses.
The lung is likewise removed, the left half of the lung is fixed in
formalin for histopathological examination and the right half of
the lung is deep-frozen for expression analyses. Furthermore,
plasma samples are obtained to determine biomarkers (for example
proBNP) and plasma substance concentrations.
B-5. Animal Model of Bleomycin-Induced Pulmonary Fibrosis
[1873] Bleomycin-induced pulmonary fibrosis in the mouse or rat is
a widely used animal model of pulmonary fibrosis. Bleomycin is a
glycopeptide antibiotic employed in oncology for the therapy of
testicular tumours and Hodgkin- and Non-Hodgkin tumours. It is
eliminated renally, has a half-life of about 3 hours and, as
cytostatic, influences various phases of the division cycle [Lazo
et al., Cancer Chemother. Biol. Response Modif 15, 44-50 (1994)].
Its anti-neoplastic effect is based on an oxidatively damaging
action on DNA [Hay et al., Arch. Toxicol. 65, 81-94 (1991)]. Lung
tissue is at a particular risk when exposed to bleomycin since it
contains only a small number of cysteine hydrolases which, in other
tissues, lead to inactivation of bleomycin. Following
administration of bleomycin, the animals suffer an acute
respiratory distress syndrome (ARDS) with subsequent development of
pulmonary fibrosis.
[1874] Administration of bleomycin may be by single or repeat
intratracheal, inhalative, intravenous or intraperitoneal
administration. Treatment of the animals with the test substance
(by gavage, by addition to the feed or drinking water, using an
osmotic minipump, by subcutaneous or intraperitoneal injection or
by inhalation) starts at the day of the first bleomycin
administration or therapeutically 3-14 days later and extends over
a period of 2-6 weeks. At the end of the study, a bronchio-alveolar
lavage to determine the cell content and the pro-inflammatory and
pro-fibrotic markers and a histological assessment of pulmonary
fibrosis are carried out.
B-6. Animal Model of DQ12 Quartz-Induced Pulmonary Fibrosis
[1875] DQ12 quartz-induced pulmonary fibrosis in the mouse or rat
is a widely used animal model of pulmonary fibrosis [Shimbori et
al., Exp. Lung Res. 36, 292-301 (2010)]. DQ12 quartz is quartz
which is highly active owing to breaking or grinding. In mice and
rats, intratracheal or inhalative administration of DQ12 quartz
leads to alveolar proteinosis followed by interstitial pulmonary
fibrosis. The animals receive a single or repeat intratracheal or
inhalative instillation of DQ12 quartz. Treatment of the animals
with the test substance (by gavage, by addition to the feed or
drinking water, using an osmotic minipump, by subcutaneous or
intraperitoneal injection or by inhalation) starts at the day of
the first silicate instillation or therapeutically 3-14 days later
and extends over a period of 3-12 weeks. At the end of the study, a
bronchio-alveolar lavage to determine the cell content and the
pro-inflammatory and pro-fibrotic markers and a histological
assessment of pulmonary fibrosis are carried out.
B-7. Animal Model of DQ12 Quartz or FITC-Induced Pulmonary
Inflammation
[1876] In the mouse and the rat, intratracheal administration of
DQ12 quartz or fluorescein isothiocyanate (FITC) leads to an
inflammation in the lung [Shimbori et al., Exp. Lung Res. 36,
292-301 (2010)]. At the day of the instillation of DQ12 quartz or
FITC or a day later the animals are treated with the test substance
for a duration of 24 h up to 7 days (by gavage, by addition to the
feed or drinking water, using an osmotic minipump, by subcutaneous
or intraperitoneal injection or by inhalation). At the end of the
experiment, a bronchio-alveolar lavage to determine the cell
content and the pro-inflammatory and pro-fibrotic markers is
carried out.
B-8. Animal Model of the Elastase-Induced Pulmonary Emphysema
[1877] The elastase-induced pulmonary emphysema in the mouse, rat
or hamster is a widely used animal model of pulmonary emphysema
[Sawada et al., Exp. Lung Res. 33, 277-288 (2007)]. The animals
receive an orotracheal instillation of porcine pancreas elastase.
The treatment of the animals starts at the day of the instillation
of the porcine pancreas elastase and extends over a period of 3
weeks. At the end of the study, an alveolar morphometry is carried
out.
B-9. Animal Model of Permanent Coronary Ligature in Mouse and
Rat
[1878] Mice or rats are anaesthetized with 5% isoflurane in an
anaesthetization cage, intubated, connected to a ventilation pump
and ventilated with 2% of isoflurane/N.sub.2O/O.sub.2. The body
temperature is maintained at 37-38.degree. C. by a heating mat.
Temgesic.RTM. is administered as painkiller. The chest is opened
laterally between the third and fourth ribs, and the heart is
exposed. The coronary artery of the left ventricle (LAD) is
permanently ligated with an occlusion thread passed underneath
shortly below its origin (below the left atrium). The thorax is
closed again, and the muscle layers and the epidermis are sutured.
From the day of the operation or up to a week later the animals are
treated with the test substance over a period of 4-8 weeks (by
gavage, by addition of the test substance to the feed or drinking
water, using an osmotic minipump, by subcutaneous or
intraperitoneal injection or by inhalation). A further control
included is a sham group in which only the surgical procedure, but
not the LAD occlusion, was performed.
[1879] At the end of the experiment, the animals are anaesthetized
again [1.5% isoflurane (mouse), 2% isoflurane (rat)/N.sub.2O/air],
and a pressure catheter is introduced via the carotid artery into
the left ventricle. The heart rate, left-ventricular pressure
(LVP), left-ventricular end-diastolic pressure (LVEDP),
contractility (dp/dt) and relaxation rate (tau) are measured there
and analyzed with the aid of the Powerlab system (AD Instruments,
ADI-PWLB-4SP) and the ChartS software (SN 425-0586). A blood sample
is then taken to determine the blood levels of the substance and
plasma biomarkers, and the animals are sacrificed. The heart (heart
chambers, left ventricle plus septum, right ventricle), liver, lung
and kidney are removed and weighed.
C. WORKING EXAMPLES FOR PHARMACEUTICAL COMPOSITIONS
[1880] The compounds according to the invention can be converted to
pharmaceutical formulations as follows:
Tablet:
Composition:
[1881] 100 mg of the compound according to the invention, 50 mg of
lactose (monohydrate), 50 mg of corn starch (native), 10 mg of
polyvinylpyrrolidone (PVP 25) (BASF, Ludwigshafen, Germany) and 2
mg of magnesium stearate.
[1882] Tablet weight 212 mg, diameter 8 mm, radius of curvature 12
mm.
Production:
[1883] The mixture of compound according to the invention, lactose
and starch is granulated with a 5% solution (w/w) of the PVP in
water. The granules are dried and mixed with the magnesium stearate
for 5 minutes. This mixture is compressed in a conventional tablet
press (see above for format of the tablet). The guide value used
for the pressing is a pressing force of 15 kN.
Suspension which can be Administered Orally:
Composition:
[1884] 1000 mg of the compound according to the invention, 1000 mg
of ethanol (96%), 400 mg of Rhodigel.RTM. (xanthan gum from FMC,
Pennsylvania, USA) and 99 g of water.
[1885] 10 ml of oral suspension correspond to a single dose of 100
mg of the compound according to the invention.
Production:
[1886] The Rhodigel is suspended in ethanol; the compound according
to the invention is added to the suspension. The water is added
while stirring. The mixture is stirred for about 6 h before
swelling of the Rhodigel is complete.
Solution for Oral Administration:
Composition:
[1887] 500 mg of the compound according to the invention, 2.5 g of
polysorbate and 97 g of polyethylene glycol 400. 20 g of oral
solution correspond to a single dose of 100 mg of the compound
according to the invention.
Production:
[1888] The compound according to the invention is suspended in the
mixture of polyethylene glycol and polysorbate with stirring. The
stirring operation is continued until dissolution of the compound
according to the invention is complete.
i.v. Solution:
[1889] The compound according to the invention is dissolved in a
concentration below the saturation solubility in a physiologically
acceptable solvent (e.g. isotonic saline solution, glucose solution
5% and/or PEG 400 solution 30%). The solution is subjected to
sterile filtration and dispensed into sterile and pyrogen-free
injection vessels.
* * * * *